{"PMC3883635": [["IntroductionHepatitis C virus (HCV) has chronically infected about 170 million people worldwide and no prophylactic or therapeutic vaccine is available.", [["IntroductionHepatitis C", "DISEASE", 0, 23], ["IntroductionHepatitis C virus", "ORGANISM", 0, 29], ["HCV", "ORGANISM", 31, 34], ["people", "ORGANISM", 79, 85], ["C virus", "SPECIES", 22, 29], ["people", "SPECIES", 79, 85], ["HCV", "SPECIES", 31, 34], ["IntroductionHepatitis C virus (HCV)", "PROBLEM", 0, 35], ["prophylactic", "TREATMENT", 103, 115], ["therapeutic vaccine", "TREATMENT", 119, 138], ["virus", "OBSERVATION", 24, 29], ["chronically", "OBSERVATION_MODIFIER", 40, 51], ["infected", "OBSERVATION", 52, 60], ["no", "UNCERTAINTY", 100, 102]]], ["The p7 protein, encoded by HCV, is a small transmembrane (TM) protein 63 residues long and is found mainly at the endoplasmic reticulum (ER) membrane.", [["endoplasmic reticulum", "ANATOMY", 114, 135], ["ER) membrane", "ANATOMY", 137, 149], ["p7", "GENE_OR_GENE_PRODUCT", 4, 6], ["HCV", "ORGANISM", 27, 30], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 114, 135], ["ER", "CELLULAR_COMPONENT", 137, 139], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["p7 protein", "PROTEIN", 4, 14], ["small transmembrane (TM) protein", "PROTEIN", 37, 69], ["HCV", "SPECIES", 27, 30], ["The p7 protein", "TEST", 0, 14], ["HCV", "PROBLEM", 27, 30], ["a small transmembrane (TM) protein 63 residues long", "PROBLEM", 35, 86], ["HCV", "OBSERVATION", 27, 30], ["small", "OBSERVATION_MODIFIER", 37, 42], ["endoplasmic reticulum", "ANATOMY", 114, 135]]], ["Although p7 is not necessary for RNA replication [1], it is essential for infectivity, assembly, and release of infectious virions [2], [3].IntroductionOligomers formed by p7 show cation-selective channel activity [4]\u2013[6] which is blocked in some cases by amantadine, rimantadine, hexamethylene amiloride (HMA) and long-alkyl-chain imino sugar derivatives [4]\u2013[7].", [["[4]\u2013[6]", "CHEMICAL", 214, 221], ["amantadine", "CHEMICAL", 256, 266], ["rimantadine", "CHEMICAL", 268, 279], ["hexamethylene amiloride", "CHEMICAL", 281, 304], ["HMA", "CHEMICAL", 306, 309], ["amantadine", "CHEMICAL", 256, 266], ["rimantadine", "CHEMICAL", 268, 279], ["hexamethylene amiloride", "CHEMICAL", 281, 304], ["HMA", "CHEMICAL", 306, 309], ["long-alkyl-chain imino sugar", "CHEMICAL", 315, 343], ["p7", "GENE_OR_GENE_PRODUCT", 9, 11], ["cation", "SIMPLE_CHEMICAL", 180, 186], ["[4]\u2013[6]", "SIMPLE_CHEMICAL", 214, 221], ["amantadine", "SIMPLE_CHEMICAL", 256, 266], ["rimantadine", "SIMPLE_CHEMICAL", 268, 279], ["hexamethylene amiloride", "SIMPLE_CHEMICAL", 281, 304], ["HMA", "SIMPLE_CHEMICAL", 306, 309], ["long-alkyl-chain imino sugar derivatives [4]\u2013[7]", "SIMPLE_CHEMICAL", 315, 363], ["p7", "PROTEIN", 9, 11], ["p7", "PROTEIN", 172, 174], ["RNA replication", "TREATMENT", 33, 48], ["infectivity", "PROBLEM", 74, 85], ["infectious virions", "PROBLEM", 112, 130], ["cation-selective channel activity", "TREATMENT", 180, 213], ["amantadine", "TREATMENT", 256, 266], ["rimantadine", "TREATMENT", 268, 279], ["hexamethylene amiloride (HMA)", "TREATMENT", 281, 310], ["long-alkyl-chain imino sugar derivatives", "TREATMENT", 315, 355]]], ["Recently, membrane permeabilization to protons was found to be crucial for the production of infectious viruses, and was observed in intracellular vesicles harboring p7 [8].", [["membrane", "ANATOMY", 10, 18], ["intracellular vesicles", "ANATOMY", 133, 155], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["protons", "SIMPLE_CHEMICAL", 39, 46], ["intracellular vesicles", "CELLULAR_COMPONENT", 133, 155], ["p7 [8]", "PROTEIN", 166, 172], ["membrane permeabilization to protons", "TREATMENT", 10, 46], ["infectious viruses", "PROBLEM", 93, 111], ["infectious", "OBSERVATION", 93, 103]]], ["Additionally, p7 is involved in the capsid assembly and envelopment and localization of several viral proteins, possibly via channel-independent mechanisms [9]\u2013[11].IntroductionThe p7 protein is predicted to have two \u03b1-helical TM domains, but details on its three dimensional structure are limited.", [["p7", "GENE_OR_GENE_PRODUCT", 14, 16], ["p7", "PROTEIN", 14, 16], ["viral proteins", "PROTEIN", 96, 110], ["p7 protein", "PROTEIN", 181, 191], ["\u03b1-helical TM domains", "PROTEIN", 217, 237], ["several viral proteins", "PROBLEM", 88, 110], ["The p7 protein", "TEST", 177, 191], ["two \u03b1-helical TM domains", "TREATMENT", 213, 237]]], ["Solution NMR data has been obtained for synthetic p7 (C27A mutant) in 50% TFE [12], a helix inducer, and for recombinant p7 (C27S mutant) in DHPC micelles [13].", [["TFE", "CHEMICAL", 74, 77], ["TFE", "CHEMICAL", 74, 77], ["p7", "GENE_OR_GENE_PRODUCT", 121, 123], ["p7", "PROTEIN", 50, 52], ["C27A mutant", "PROTEIN", 54, 65], ["recombinant p7", "PROTEIN", 109, 123], ["C27S mutant", "PROTEIN", 125, 136], ["Solution NMR data", "TEST", 0, 17], ["synthetic p7", "TREATMENT", 40, 52], ["a helix inducer", "TREATMENT", 84, 99]]], ["Both papers report a similar percentage of \u03b1-helix, 60\u201370%, and predict an \u03b1-helical hairpin with two \u03b1-helical TMs kinked in the middle [12], [14], where the N-terminal TM helix (TM1) would face the lumen of a channel [15]\u2013[17] formed by either six or seven monomers [4], [12], [18], [19].", [["\u03b1-helix", "GENE_OR_GENE_PRODUCT", 43, 50], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 200, 205], ["[15]\u2013[17]", "SIMPLE_CHEMICAL", 219, 228], ["[4]", "SIMPLE_CHEMICAL", 268, 271], ["[12], [18], [19]", "SIMPLE_CHEMICAL", 273, 289], ["\u03b1-helix", "PROTEIN", 43, 50], ["\u03b1-helical hairpin", "PROTEIN", 75, 92], ["\u03b1-helical TMs", "PROTEIN", 102, 115], ["N-terminal TM helix", "PROTEIN", 159, 178], ["TM1", "PROTEIN", 180, 183], ["an \u03b1-helical hairpin", "TREATMENT", 72, 92], ["middle", "ANATOMY_MODIFIER", 130, 136], ["lumen", "ANATOMY_MODIFIER", 200, 205]]], ["Recently, a model formed mostly of \u03b1-helical domains has been reported in DPC micelles and electron microscopy [20].IntroductionAlternative topologies and conformations of p7 have been reported in the literature.", [["DPC micelles", "SIMPLE_CHEMICAL", 74, 86], ["p7", "GENE_OR_GENE_PRODUCT", 172, 174], ["\u03b1-helical domains", "PROTEIN", 35, 52], ["p7", "PROTEIN", 172, 174], ["\u03b1-helical domains", "PROBLEM", 35, 52], ["electron microscopy", "TEST", 91, 110]]], ["For example, using ectodomain CD4 or myc epitope tags [15] both N- and C-termini of p7 were exposed extracellularly, consistent with an \u03b1-helical hairpin formed by two TM domains.", [["N", "CHEMICAL", 64, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["myc", "GENE_OR_GENE_PRODUCT", 37, 40], ["p7", "GENE_OR_GENE_PRODUCT", 84, 86], ["ectodomain CD4", "PROTEIN", 19, 33], ["N- and C-termini", "PROTEIN", 64, 80], ["p7", "PROTEIN", 84, 86], ["\u03b1-helical hairpin", "PROTEIN", 136, 153], ["TM domains", "PROTEIN", 168, 178], ["ectodomain CD4", "TEST", 19, 33], ["myc epitope tags", "TEST", 37, 53], ["N", "TEST", 64, 65], ["C-termini of p7", "TREATMENT", 71, 86], ["an \u03b1-helical hairpin", "TREATMENT", 133, 153], ["consistent with", "UNCERTAINTY", 117, 132], ["hairpin", "OBSERVATION", 146, 153]]], ["However, a non-tagged p7 showed cytoplasmic orientation for its C-terminus, compatible with a form with only one TM domain [21], [22].", [["cytoplasmic", "ANATOMY", 32, 43], ["C", "CHEMICAL", 64, 65], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["non-tagged p7", "PROTEIN", 11, 24], ["C-terminus", "PROTEIN", 64, 74], ["TM domain", "PROTEIN", 113, 122], ["a non-tagged p7", "TEST", 9, 24], ["its C-terminus", "PROBLEM", 60, 74], ["cytoplasmic orientation", "OBSERVATION", 32, 55], ["compatible with", "UNCERTAINTY", 76, 91]]], ["More recently, two very different CD spectra (SRCD), one consistent with an \u03b1-helical form, and another that was not assigned to any particular structure, both showing some channel activity, were obtained when p7 protein was reconstituted in membranes with varying PC\u2236PE ratios [23].", [["membranes", "ANATOMY", 242, 251], ["membranes", "CELLULAR_COMPONENT", 242, 251], ["PE", "SIMPLE_CHEMICAL", 268, 270], ["\u03b1-helical form", "PROTEIN", 76, 90], ["p7 protein", "PROTEIN", 210, 220], ["two very different CD spectra (SRCD)", "PROBLEM", 15, 51], ["some channel activity", "PROBLEM", 168, 189], ["p7 protein", "TEST", 210, 220], ["varying PC\u2236PE ratios", "TEST", 257, 277], ["consistent with", "UNCERTAINTY", 57, 72], ["PE", "OBSERVATION", 268, 270]]], ["Overall, the above data indicate that the topology and conformation of p7 may not be unique.IntroductionIn addition to its ion and proton channel activity, p7 has also been shown previously to permeabilize liposomes inducing release of carboxyfluorescein (CF) when added to CF-loaded liposomes [7], [24].", [["carboxyfluorescein", "CHEMICAL", 236, 254], ["carboxyfluorescein", "CHEMICAL", 236, 254], ["p7", "GENE_OR_GENE_PRODUCT", 71, 73], ["liposomes", "SIMPLE_CHEMICAL", 206, 215], ["carboxyfluorescein", "SIMPLE_CHEMICAL", 236, 254], ["CF", "SIMPLE_CHEMICAL", 274, 276], ["p7", "PROTEIN", 71, 73], ["p7", "PROTEIN", 156, 158], ["the above data", "TEST", 9, 23], ["IntroductionIn", "TREATMENT", 92, 106], ["its ion and proton channel activity", "TREATMENT", 119, 154], ["carboxyfluorescein (CF", "TREATMENT", 236, 258], ["CF-loaded liposomes", "TREATMENT", 274, 293]]], ["The claimed sensitivity of this procedure to inhibitors such as rimantadine, which also has been proposed by some authors to inhibit p7 ion channel activity, has resulted in this method being proposed as a functional assay to test p7 mutants or discover p7 channel activity inhibitors [25], [26].IntroductionHowever, the presumed dual ability of an oligomer formed by \u03b1-helical hairpins to serve both as a channel for small ions or protons, and as facilitator for large molecules like CF, is puzzling.", [["rimantadine", "CHEMICAL", 64, 75], ["rimantadine", "CHEMICAL", 64, 75], ["rimantadine", "SIMPLE_CHEMICAL", 64, 75], ["[26]", "SIMPLE_CHEMICAL", 291, 295], ["protons", "SIMPLE_CHEMICAL", 432, 439], ["p7", "PROTEIN", 133, 135], ["p7 mutants", "PROTEIN", 231, 241], ["p7 channel", "PROTEIN", 254, 264], ["\u03b1-helical hairpins", "PROTEIN", 368, 386], ["this procedure", "TREATMENT", 27, 41], ["inhibitors", "TREATMENT", 45, 55], ["rimantadine", "TREATMENT", 64, 75], ["p7 channel activity inhibitors", "TREATMENT", 254, 284], ["an oligomer", "TREATMENT", 346, 357], ["\u03b1-helical hairpins", "TREATMENT", 368, 386], ["small ions or protons", "TREATMENT", 418, 439], ["large molecules like CF", "PROBLEM", 464, 487], ["CF", "OBSERVATION", 485, 487]]], ["Thus, we hypothesized that the conformation of p7 in these two cases is not the same.", [["p7", "GENE_OR_GENE_PRODUCT", 47, 49], ["p7", "PROTEIN", 47, 49]]], ["Yet, that both activities can be inhibited by similar small molecules indicates that the binding mode of these drugs to p7 in the two instances must be similar, and that inhibition of the two activities must be based on a similar mechanism.IntroductionThus, to establish a correlation between p7 conformation and its diverse activities, we have studied the effect of solvents and type of reconstitution on the structural features of p7 protein.", [["p7", "GENE_OR_GENE_PRODUCT", 433, 435], ["p7", "PROTEIN", 293, 295], ["p7 protein", "PROTEIN", 433, 443], ["these drugs", "TREATMENT", 105, 116], ["solvents", "TREATMENT", 367, 375], ["reconstitution", "TREATMENT", 388, 402]]], ["We have used attenuated total reflection Fourier Transform infrared (ATR-FTIR) spectroscopy, a technique that is especially suitable for studies in lipid bilayers.", [["lipid bilayers", "ANATOMY", 148, 162], ["lipid bilayers", "SIMPLE_CHEMICAL", 148, 162], ["a technique", "TEST", 93, 104], ["studies in lipid bilayers", "TEST", 137, 162]]], ["We have used three methods of reconstitution in lipidic membranes.", [["lipidic membranes", "ANATOMY", 48, 65], ["lipidic membranes", "CELLULAR_COMPONENT", 48, 65], ["reconstitution in lipidic membranes", "TREATMENT", 30, 65], ["reconstitution", "OBSERVATION", 30, 44], ["lipidic membranes", "OBSERVATION", 48, 65]]], ["The first two methods co-reconstitute p7, after the protein is dried from a solvent, with lipids, either with the aid of detergent \u2013 \u2018dialysis\u2019 method \u2013 or without detergent \u2013 \u2018direct\u2019 method \u2013.", [["lipids", "SIMPLE_CHEMICAL", 90, 96], ["lipids", "TREATMENT", 90, 96], ["dialysis", "TREATMENT", 134, 142]]], ["These two procedures may be followed by a freeze-thawing and extrusion protocol.", [["a freeze-thawing and extrusion protocol", "TREATMENT", 40, 79]]], ["In the third method, \u2013 \u2018addition\u2019 method \u2013 p7 is added directly from solvent to preformed liposomes, as in the CF-release assay [7], [24].", [["liposomes", "SIMPLE_CHEMICAL", 90, 99]]], ["All of these methods have been used previously in the literature.", [["these methods", "TREATMENT", 7, 20]]], ["The ability of p7 to elicit CF release and proton transport has been tested in the controled conditions where the p7 conformation was known, which allowed to infer that the \u2018\u03b1-helical hairpin\u2019 form is responsible for proton transport, but not of CF release.Cloning of p7 gene ::: Materials and MethodsThe nucleotide sequence corresponding to p7 (HCV subtype 1a, strain H77) was obtained from NCBI (accession number NCBI ID: ACH61709).", [["nucleotide", "CHEMICAL", 305, 315], ["nucleotide", "CHEMICAL", 305, 315], ["p7", "GENE_OR_GENE_PRODUCT", 15, 17], ["proton", "SIMPLE_CHEMICAL", 43, 49], ["proton", "SIMPLE_CHEMICAL", 217, 223], ["p7", "GENE_OR_GENE_PRODUCT", 268, 270], ["HCV subtype 1a", "ORGANISM", 346, 360], ["p7", "PROTEIN", 15, 17], ["\u03b1", "PROTEIN", 174, 175], ["p7 gene", "DNA", 268, 275], ["p7", "DNA", 342, 344], ["proton transport", "TREATMENT", 43, 59], ["proton transport", "TREATMENT", 217, 233], ["The nucleotide sequence", "TEST", 301, 324]]], ["The p7 gene was synthesized and the purity was determined by agarose gel electrophoresis.", [["p7", "GENE_OR_GENE_PRODUCT", 4, 6], ["agarose", "SIMPLE_CHEMICAL", 61, 68], ["p7 gene", "DNA", 4, 11], ["agarose gel electrophoresis", "TEST", 61, 88]]], ["The p7 gene was cloned into pTBMalE vector with MBP as fusion partner carrying a His-tag at the N-terminus, forming the construct His-MBP-p7.", [["His", "CHEMICAL", 81, 84], ["N", "CHEMICAL", 96, 97], ["p7", "GENE_OR_GENE_PRODUCT", 4, 6], ["pTBMalE", "GENE_OR_GENE_PRODUCT", 28, 35], ["MBP", "GENE_OR_GENE_PRODUCT", 48, 51], ["His-MBP-p7", "GENE_OR_GENE_PRODUCT", 130, 140], ["p7 gene", "DNA", 4, 11], ["pTBMalE vector", "DNA", 28, 42], ["MBP", "PROTEIN", 48, 51], ["His-tag", "DNA", 81, 88], ["N-terminus", "PROTEIN", 96, 106], ["MBP", "PROTEIN", 134, 137], ["p7", "PROTEIN", 138, 140], ["MBP", "TREATMENT", 48, 51], ["MBP", "TEST", 134, 137]]], ["For some of the experiments, an additional FLAG tag was added N-terminally to p7 by insertional mutagenesis using an appropriate set of primers [27], forming the construct His-MBP-FLAG-p7.Over-expression of the MBP-p7 construct ::: Materials and MethodsThe DNA plasmid containing the p7 gene was transformed into an E. coli competent cell strain BL-21 (DE3) CodonPlus-RIL (Stratagene) for protein over-expression.", [["cell", "ANATOMY", 334, 338], ["N", "CHEMICAL", 62, 63], ["FLAG", "GENE_OR_GENE_PRODUCT", 43, 47], ["p7", "GENE_OR_GENE_PRODUCT", 78, 80], ["FLAG", "GENE_OR_GENE_PRODUCT", 180, 184], ["MBP-p7", "GENE_OR_GENE_PRODUCT", 211, 217], ["DNA", "CELLULAR_COMPONENT", 257, 260], ["p7", "GENE_OR_GENE_PRODUCT", 284, 286], ["E. coli", "ORGANISM", 316, 323], ["cell", "CELL", 334, 338], ["BL-21", "GENE_OR_GENE_PRODUCT", 346, 351], ["DE3", "CELL", 353, 356], ["CodonPlus-RIL", "GENE_OR_GENE_PRODUCT", 358, 371], ["FLAG tag", "PROTEIN", 43, 51], ["p7", "PROTEIN", 78, 80], ["His-MBP", "PROTEIN", 172, 179], ["FLAG", "PROTEIN", 180, 184], ["p7", "PROTEIN", 185, 187], ["MBP", "PROTEIN", 211, 214], ["p7 construct", "DNA", 215, 227], ["DNA plasmid", "DNA", 257, 268], ["p7 gene", "DNA", 284, 291], ["BL-21 (DE3) CodonPlus-RIL (Stratagene", "DNA", 346, 383], ["E. coli", "SPECIES", 316, 323], ["E. coli", "SPECIES", 316, 323], ["an additional FLAG tag", "TREATMENT", 29, 51], ["insertional mutagenesis", "TREATMENT", 84, 107], ["an appropriate set of primers", "TREATMENT", 114, 143], ["the construct His-MBP", "TEST", 158, 179], ["FLAG", "TEST", 180, 184], ["the MBP", "TEST", 207, 214], ["Materials", "TREATMENT", 232, 241], ["Methods", "TREATMENT", 246, 253], ["The DNA plasmid", "TREATMENT", 253, 268], ["an E. coli", "TEST", 313, 323], ["CodonPlus", "TEST", 358, 367], ["RIL (Stratagene)", "TREATMENT", 368, 384], ["E. coli competent cell strain", "OBSERVATION", 316, 345]]], ["Cells from a single colony were picked to inoculate 10 mL LB media with 100 \u00b5g/ml ampicillin and 34 \u00b5g/ml chloramphenicol, and grown overnight at 37\u00b0C with shaking.", [["Cells", "ANATOMY", 0, 5], ["colony", "ANATOMY", 20, 26], ["ampicillin", "CHEMICAL", 82, 92], ["chloramphenicol", "CHEMICAL", 106, 121], ["ampicillin", "CHEMICAL", 82, 92], ["chloramphenicol", "CHEMICAL", 106, 121], ["Cells", "CELL", 0, 5], ["ampicillin", "SIMPLE_CHEMICAL", 82, 92], ["chloramphenicol", "SIMPLE_CHEMICAL", 106, 121], ["a single colony", "PROBLEM", 11, 26], ["ampicillin", "TREATMENT", 82, 92], ["chloramphenicol", "TREATMENT", 106, 121], ["shaking", "PROBLEM", 156, 163]]], ["A volume of 8 mL of the overnight culture was transferred to 800 mL Terrific Broth (TB) media with 1\u2236100 dilutions and grown at 37\u00b0C with shaking to an OD600 of 0.6\u20130.7.", [["the overnight culture", "TEST", 20, 41], ["shaking", "PROBLEM", 138, 145], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["The cells were induced with 0.4 mM isopropyl-\u03b2-thiogalactoside (IPTG) and grown at 30\u00b0C overnight with shaking.", [["cells", "ANATOMY", 4, 9], ["isopropyl-\u03b2-thiogalactoside", "CHEMICAL", 35, 62], ["IPTG", "CHEMICAL", 64, 68], ["isopropyl-\u03b2-thiogalactoside", "CHEMICAL", 35, 62], ["IPTG", "CHEMICAL", 64, 68], ["cells", "CELL", 4, 9], ["isopropyl-\u03b2-thiogalactoside", "SIMPLE_CHEMICAL", 35, 62], ["IPTG", "SIMPLE_CHEMICAL", 64, 68], ["0.4 mM isopropyl-\u03b2-thiogalactoside (IPTG", "TREATMENT", 28, 68], ["shaking", "PROBLEM", 103, 110]]], ["For the 15N-labeled sample, cells were harvested when an OD600 of 0.6\u20130.7 was reached, and washed with M9 minimal media once.", [["sample", "ANATOMY", 20, 26], ["cells", "ANATOMY", 28, 33], ["15N", "CHEMICAL", 8, 11], ["15N", "SIMPLE_CHEMICAL", 8, 11], ["cells", "CELL", 28, 33]]], ["The cells were transferred to M9 minimal media containing 15N ammonium chloride.", [["cells", "ANATOMY", 4, 9], ["15N ammonium chloride", "CHEMICAL", 58, 79], ["15N ammonium chloride", "CHEMICAL", 58, 79], ["cells", "CELL", 4, 9], ["15N ammonium chloride", "SIMPLE_CHEMICAL", 58, 79], ["15N ammonium chloride", "TREATMENT", 58, 79]]], ["A high cell density strategy was employed by concentrating 4L of culture to 1L media to enhance expression level in minimal media.", [["cell", "ANATOMY", 7, 11], ["cell", "CELL", 7, 11], ["A high cell density strategy", "TREATMENT", 0, 28], ["culture", "TEST", 65, 72], ["1L media", "TREATMENT", 76, 84], ["expression level", "TEST", 96, 112], ["high cell density", "OBSERVATION", 2, 19], ["minimal media", "OBSERVATION_MODIFIER", 116, 129]]], ["After induction, cells were harvested and resuspended in Ni2+-NTA binding buffer containing 20 mM Tris-HCl, 500 mM NaCl, and 5 mM imidazole, pH 8.0, and then kept frozen at \u221220\u00b0C overnight.", [["cells", "ANATOMY", 17, 22], ["Ni2+-NTA", "CHEMICAL", 57, 65], ["Tris-HCl", "CHEMICAL", 98, 106], ["NaCl", "CHEMICAL", 115, 119], ["imidazole", "CHEMICAL", 130, 139], ["Ni2+-NTA", "CHEMICAL", 57, 65], ["Tris-HCl", "CHEMICAL", 98, 106], ["NaCl", "CHEMICAL", 115, 119], ["imidazole", "CHEMICAL", 130, 139], ["cells", "CELL", 17, 22], ["Ni2+-NTA", "SIMPLE_CHEMICAL", 57, 65], ["Tris-HCl", "SIMPLE_CHEMICAL", 98, 106], ["imidazole", "SIMPLE_CHEMICAL", 130, 139], ["20 mM Tris-HCl", "TREATMENT", 92, 106], ["500 mM NaCl", "TREATMENT", 108, 119], ["5 mM imidazole", "TREATMENT", 125, 139], ["pH", "TEST", 141, 143]]], ["Thawed cells were incubated with 0.2 mg/ml lysozyme and 0.02 mg/ml benzonase for 10 min.", [["cells", "ANATOMY", 7, 12], ["benzonase", "CHEMICAL", 67, 76], ["benzonase", "CHEMICAL", 67, 76], ["cells", "CELL", 7, 12], ["benzonase", "SIMPLE_CHEMICAL", 67, 76], ["Thawed cells", "CELL_TYPE", 0, 12], ["lysozyme", "TREATMENT", 43, 51]]], ["Then, Triton-X100 was added to the sample to a final concentration of 1%.", [["Triton-X100", "CHEMICAL", 6, 17], ["Triton-X100", "CHEMICAL", 6, 17], ["Triton-X100", "SIMPLE_CHEMICAL", 6, 17], ["Triton", "TREATMENT", 6, 12]]], ["The cells were lysed with a microfluidizer at 15 kPSI pressure and supernatant was collected after centrifugation at 20,000 g for 30 min and loaded to an Econo column (BioRad) packed with Ni2+-NTA agarose resin (QIAGENE) that was pre-equilibrated with binding buffer.", [["cells", "ANATOMY", 4, 9], ["supernatant", "ANATOMY", 67, 78], ["Ni2+-NTA", "CHEMICAL", 188, 196], ["Ni2+-NTA", "CHEMICAL", 188, 196], ["cells", "CELL", 4, 9], ["Ni2+-NTA agarose resin", "SIMPLE_CHEMICAL", 188, 210], ["QIAGENE", "SIMPLE_CHEMICAL", 212, 219], ["a microfluidizer", "TREATMENT", 26, 42], ["centrifugation", "TREATMENT", 99, 113], ["an Econo column (BioRad)", "TREATMENT", 151, 175], ["Ni2+-NTA agarose resin (QIAGENE)", "TREATMENT", 188, 220], ["binding buffer", "TREATMENT", 252, 266]]], ["The fusion proteins were allowed to bind to the resin with gentle shaking at 4\u00b0C, overnight.", [["fusion proteins", "PROTEIN", 4, 19], ["The fusion proteins", "TREATMENT", 0, 19], ["gentle shaking", "PROBLEM", 59, 73], ["fusion", "OBSERVATION", 4, 10]]], ["The nickel resin with bound fusion protein was washed with 20 column volumes of buffer containing 20 mM Tris-HCl, 500 mM NaCl, and 20 mM imidazole, pH 8.0, to remove unbound proteins.", [["nickel", "CHEMICAL", 4, 10], ["Tris-HCl", "CHEMICAL", 104, 112], ["NaCl", "CHEMICAL", 121, 125], ["imidazole", "CHEMICAL", 137, 146], ["nickel", "CHEMICAL", 4, 10], ["Tris-HCl", "CHEMICAL", 104, 112], ["NaCl", "CHEMICAL", 121, 125], ["imidazole", "CHEMICAL", 137, 146], ["nickel resin", "SIMPLE_CHEMICAL", 4, 16], ["Tris-HCl", "SIMPLE_CHEMICAL", 104, 112], ["imidazole", "SIMPLE_CHEMICAL", 137, 146], ["bound fusion protein", "PROTEIN", 22, 42], ["The nickel resin", "TREATMENT", 0, 16], ["bound fusion protein", "TREATMENT", 22, 42], ["NaCl", "TREATMENT", 121, 125], ["20 mM imidazole", "TREATMENT", 131, 146], ["pH", "TEST", 148, 150], ["unbound proteins", "PROBLEM", 166, 182]]], ["The bound proteins were eluted with elution buffer containing 20 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 8.0, and 5 mM C14-betaine (C14SB).", [["Tris-HCl", "CHEMICAL", 68, 76], ["NaCl", "CHEMICAL", 85, 89], ["imidazole", "CHEMICAL", 98, 107], ["C14-betaine", "CHEMICAL", 126, 137], ["C14SB", "CHEMICAL", 139, 144], ["Tris-HCl", "CHEMICAL", 68, 76], ["NaCl", "CHEMICAL", 85, 89], ["imidazole", "CHEMICAL", 98, 107], ["C14-betaine", "CHEMICAL", 126, 137], ["C14SB", "CHEMICAL", 139, 144], ["Tris-HCl", "SIMPLE_CHEMICAL", 68, 76], ["imidazole", "SIMPLE_CHEMICAL", 98, 107], ["C14-betaine", "SIMPLE_CHEMICAL", 126, 137], ["C14SB", "SIMPLE_CHEMICAL", 139, 144], ["The bound proteins", "TEST", 0, 18], ["elution buffer", "TREATMENT", 36, 50], ["NaCl", "TREATMENT", 85, 89], ["pH", "TEST", 109, 111]]], ["All fractions collected were stored at 4\u00b0C. The fractions containing the fusion protein were checked by SDS-PAGE.Expression and purification of TEV protease ::: Materials and MethodsExpression and purification of TEV protease was done in a similar way for p7 protein except no detergent was added to the sample as it is a soluble protein.", [["fractions", "ANATOMY", 4, 13], ["sample", "ANATOMY", 304, 310], ["TEV", "GENE_OR_GENE_PRODUCT", 144, 147], ["TEV protease", "GENE_OR_GENE_PRODUCT", 213, 225], ["fusion protein", "PROTEIN", 73, 87], ["TEV protease", "PROTEIN", 144, 156], ["TEV protease", "PROTEIN", 213, 225], ["p7 protein", "PROTEIN", 256, 266], ["soluble protein", "PROTEIN", 322, 337], ["All fractions", "TEST", 0, 13], ["the fusion protein", "TEST", 69, 87], ["Materials", "TREATMENT", 161, 170], ["MethodsExpression", "TREATMENT", 175, 192], ["purification of TEV protease", "TREATMENT", 197, 225], ["p7 protein", "TREATMENT", 256, 266], ["detergent", "TREATMENT", 277, 286], ["a soluble protein", "PROBLEM", 320, 337], ["fusion protein", "OBSERVATION", 73, 87]]], ["TEV was stored at \u221220\u00b0C in buffer containing 50% glycerol, 10 mM Tris-HCl, 250 mM NaCl, 250 mM imidazole, 1 mM EDTA, and 5 mM DTT, pH 8.0.Purification of recombinant p7 protein ::: Materials and MethodsAfter purification using Ni2+-NTA resin, the construct was subjected to TEV enzymatic cleavage in order to remove MBP.", [["glycerol", "CHEMICAL", 49, 57], ["Tris-HCl", "CHEMICAL", 65, 73], ["NaCl", "CHEMICAL", 82, 86], ["imidazole", "CHEMICAL", 95, 104], ["Ni2+-NTA", "CHEMICAL", 227, 235], ["glycerol", "CHEMICAL", 49, 57], ["Tris-HCl", "CHEMICAL", 65, 73], ["NaCl", "CHEMICAL", 82, 86], ["imidazole", "CHEMICAL", 95, 104], ["EDTA", "CHEMICAL", 111, 115], ["DTT", "CHEMICAL", 126, 129], ["Ni2+-NTA", "CHEMICAL", 227, 235], ["MBP", "CHEMICAL", 316, 319], ["TEV", "GENE_OR_GENE_PRODUCT", 0, 3], ["C", "SIMPLE_CHEMICAL", 22, 23], ["glycerol", "SIMPLE_CHEMICAL", 49, 57], ["Tris-HCl", "SIMPLE_CHEMICAL", 65, 73], ["imidazole", "SIMPLE_CHEMICAL", 95, 104], ["EDTA", "SIMPLE_CHEMICAL", 111, 115], ["DTT", "SIMPLE_CHEMICAL", 126, 129], ["Ni2+-NTA", "SIMPLE_CHEMICAL", 227, 235], ["MBP", "GENE_OR_GENE_PRODUCT", 316, 319], ["recombinant p7 protein", "PROTEIN", 154, 176], ["MBP", "PROTEIN", 316, 319], ["TEV", "SPECIES", 0, 3], ["TEV", "TEST", 0, 3], ["glycerol", "TREATMENT", 49, 57], ["NaCl", "TREATMENT", 82, 86], ["imidazole", "TREATMENT", 95, 104], ["1 mM EDTA", "TREATMENT", 106, 115], ["5 mM DTT", "TEST", 121, 129], ["pH", "TEST", 131, 133], ["MethodsAfter purification", "TREATMENT", 195, 220], ["Ni2+-NTA resin", "TREATMENT", 227, 241], ["TEV enzymatic cleavage", "TREATMENT", 274, 296], ["MBP", "TEST", 316, 319]]], ["TEV protease was added to the fusion protein at a mass ratio of 1\u22365 (TEV: fusion protein).", [["TEV protease", "GENE_OR_GENE_PRODUCT", 0, 12], ["TEV", "GENE_OR_GENE_PRODUCT", 69, 72], ["TEV protease", "PROTEIN", 0, 12], ["fusion protein", "PROTEIN", 30, 44], ["1\u22365", "PROTEIN", 64, 67], ["TEV: fusion protein", "PROTEIN", 69, 88], ["TEV", "SPECIES", 0, 3], ["TEV protease", "TREATMENT", 0, 12], ["the fusion protein", "TEST", 26, 44], ["a mass ratio", "TEST", 48, 60]]], ["The digestion was performed at room temperature with gentle shaking, and the progress of the reaction was monitored by SDS-PAGE.", [["SDS", "CHEMICAL", 119, 122], ["The digestion", "PROBLEM", 0, 13], ["gentle shaking", "PROBLEM", 53, 67], ["the reaction", "PROBLEM", 89, 101]]], ["The digestion was stopped by addition of trichloroacetic acid (TCA) at a final concentration of 6% in volume, and the precipitate was collected by centrifugation at 18,000 g for 30 min.", [["trichloroacetic acid", "CHEMICAL", 41, 61], ["TCA", "CHEMICAL", 63, 66], ["trichloroacetic acid", "CHEMICAL", 41, 61], ["TCA", "CHEMICAL", 63, 66], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 41, 61], ["TCA", "SIMPLE_CHEMICAL", 63, 66], ["The digestion", "PROBLEM", 0, 13], ["trichloroacetic acid (TCA", "TREATMENT", 41, 66]]], ["The pellet was washed with water twice followed by lyophilization. p7 was extracted by methanol (10 ml methanol per 1L culture), mixing gently for 2 hours at room temperature.", [["pellet", "ANATOMY", 4, 10], ["methanol", "CHEMICAL", 87, 95], ["methanol", "CHEMICAL", 87, 95], ["methanol", "CHEMICAL", 103, 111], ["methanol", "SIMPLE_CHEMICAL", 87, 95], ["p7", "PROTEIN", 67, 69], ["water", "TREATMENT", 27, 32], ["lyophilization", "TREATMENT", 51, 65], ["methanol", "TREATMENT", 87, 95], ["methanol", "TREATMENT", 103, 111], ["pellet", "OBSERVATION", 4, 10]]], ["After removal of the insoluble fraction by centrifugation at 18,000 g for 30 min, the supernatant, contained mostly p7 protein.", [["supernatant", "ANATOMY", 86, 97], ["p7 protein", "PROTEIN", 116, 126], ["removal", "TREATMENT", 6, 13], ["the insoluble fraction", "TREATMENT", 17, 39]]], ["The p7 protein was further purified by injecting the supernatant onto a Zorbax C3-300 \u00c5 column connected to HPLC system.", [["supernatant", "ANATOMY", 53, 64], ["Zorbax", "CHEMICAL", 72, 78], ["p7", "GENE_OR_GENE_PRODUCT", 4, 6], ["p7 protein", "PROTEIN", 4, 14], ["The p7 protein", "TEST", 0, 14], ["a Zorbax C3", "TREATMENT", 70, 81]]], ["The p7 protein was eluted with a linear gradient of solvent A (water/TFA, 99.9\u22360.1, v/v) and solvent B (isopropanol/acetonitrile/TFA, 80\u223619.9\u22360.1, v/v/v).", [["solvent B (isopropanol/acetonitrile", "CHEMICAL", 93, 128], ["TFA", "CHEMICAL", 69, 72], ["isopropanol", "CHEMICAL", 104, 115], ["acetonitrile", "CHEMICAL", 116, 128], ["TFA", "CHEMICAL", 129, 132], ["water", "SIMPLE_CHEMICAL", 63, 68], ["TFA", "SIMPLE_CHEMICAL", 69, 72], ["solvent B", "SIMPLE_CHEMICAL", 93, 102], ["isopropanol", "SIMPLE_CHEMICAL", 104, 115], ["acetonitrile", "SIMPLE_CHEMICAL", 116, 128], ["TFA", "SIMPLE_CHEMICAL", 129, 132], ["p7 protein", "PROTEIN", 4, 14], ["The p7 protein", "TEST", 0, 14], ["TFA", "TEST", 69, 72], ["solvent B (isopropanol", "TREATMENT", 93, 115], ["acetonitrile", "TREATMENT", 116, 128], ["TFA", "TEST", 129, 132], ["linear", "OBSERVATION_MODIFIER", 33, 39]]], ["Pooled fractions were lyophilized and the purity was assessed by mass spectrometry.", [["Pooled fractions", "PROBLEM", 0, 16], ["fractions", "OBSERVATION_MODIFIER", 7, 16], ["lyophilized", "OBSERVATION_MODIFIER", 22, 33]]], ["The TEV cleavage results in additional N-terminal SNA residues, as described [28].", [["N-", "CHEMICAL", 39, 41], ["TEV", "GENE_OR_GENE_PRODUCT", 4, 7], ["N-terminal SNA residues", "PROTEIN", 39, 62], ["The TEV cleavage", "PROBLEM", 0, 16], ["additional N-terminal SNA residues", "PROBLEM", 28, 62], ["terminal", "OBSERVATION_MODIFIER", 41, 49], ["SNA residues", "OBSERVATION", 50, 62]]], ["An N-terminal methionine was also included as an alternative cleavage point with CNBr, in case the enzymatic cleavage was not successful.", [["N-terminal methionine", "CHEMICAL", 3, 24], ["N", "CHEMICAL", 3, 4], ["methionine", "CHEMICAL", 14, 24], ["CNBr", "GENE_OR_GENE_PRODUCT", 81, 85], ["CNBr", "PROTEIN", 81, 85], ["An N-terminal methionine", "TREATMENT", 0, 24], ["CNBr", "TREATMENT", 81, 85], ["the enzymatic cleavage", "PROBLEM", 95, 117]]], ["The channel activity of p7 protein was tested in black lipid membranes (Fig. S1 in File S1).Peptide synthesis and purification ::: Materials and MethodsThe synthetic peptides p71-63, p71-26 and p727-63 were obtained by solid-phase synthesis using FMOC chemistry.", [["lipid membranes", "ANATOMY", 55, 70], ["p71-63, p71-26 and p727-63", "CHEMICAL", 175, 201], ["FMOC", "CHEMICAL", 247, 251], ["FMOC", "CHEMICAL", 247, 251], ["p7", "GENE_OR_GENE_PRODUCT", 24, 26], ["lipid membranes", "CELLULAR_COMPONENT", 55, 70], ["File S1", "GENE_OR_GENE_PRODUCT", 83, 90], ["p71-63", "SIMPLE_CHEMICAL", 175, 181], ["p71-26", "SIMPLE_CHEMICAL", 183, 189], ["p727-63", "SIMPLE_CHEMICAL", 194, 201], ["FMOC", "SIMPLE_CHEMICAL", 247, 251], ["p7 protein", "PROTEIN", 24, 34], ["S1", "PROTEIN", 77, 79], ["p7 protein", "TEST", 24, 34], ["black lipid membranes", "PROBLEM", 49, 70], ["The synthetic peptides", "TEST", 152, 174], ["p71", "TEST", 183, 186], ["FMOC chemistry", "TEST", 247, 261], ["lipid membranes", "OBSERVATION", 55, 70], ["S1", "ANATOMY", 88, 90]]], ["Synthetic p71-63 was purified by RP-HPLC as described above for recombinant p7.", [["p71-63", "CHEMICAL", 10, 16], ["p71-63", "GENE_OR_GENE_PRODUCT", 10, 16], ["p71", "PROTEIN", 10, 13], ["recombinant p7", "PROTEIN", 64, 78], ["Synthetic p71", "TEST", 0, 13]]], ["The p7 protein from hepatitis C virus (HCV) used here has 63 amino acids [6].", [["hepatitis C", "DISEASE", 20, 31], ["amino acids", "CHEMICAL", 61, 72], ["amino acids", "CHEMICAL", 61, 72], ["p7", "GENE_OR_GENE_PRODUCT", 4, 6], ["hepatitis C virus", "ORGANISM", 20, 37], ["HCV", "ORGANISM", 39, 42], ["amino acids", "AMINO_ACID", 61, 72], ["p7 protein", "PROTEIN", 4, 14], ["hepatitis C virus", "SPECIES", 20, 37], ["hepatitis C virus", "SPECIES", 20, 37], ["HCV", "SPECIES", 39, 42], ["The p7 protein", "TEST", 0, 14], ["hepatitis C virus", "PROBLEM", 20, 37], ["amino acids", "TEST", 61, 72]]], ["Fragment p71-26 was synthesized manually on a 4-methyl-benzhydrylamine (MBHA) resin using standard tert-butoxycarbonyl (Boc) chemistry.", [["4-methyl-benzhydrylamine", "CHEMICAL", 46, 70], ["MBHA", "CHEMICAL", 72, 76], ["tert-butoxycarbonyl", "CHEMICAL", 99, 118], ["Boc", "CHEMICAL", 120, 123], ["4-methyl-benzhydrylamine", "CHEMICAL", 46, 70], ["MBHA", "CHEMICAL", 72, 76], ["tert-butoxycarbonyl", "CHEMICAL", 99, 118], ["Boc", "CHEMICAL", 120, 123], ["4-methyl-benzhydrylamine", "SIMPLE_CHEMICAL", 46, 70], ["MBHA", "SIMPLE_CHEMICAL", 72, 76], ["tert-butoxycarbonyl", "SIMPLE_CHEMICAL", 99, 118], ["Boc", "SIMPLE_CHEMICAL", 120, 123], ["p71-26", "DNA", 9, 15], ["Fragment p71", "TEST", 0, 12], ["a 4-methyl-benzhydrylamine (MBHA) resin", "TREATMENT", 44, 83], ["standard tert-butoxycarbonyl (Boc)", "TREATMENT", 90, 124]]], ["The thioester group was incorporated in the resin before chain elongation.", [["thioester", "CHEMICAL", 4, 13], ["The thioester group", "TREATMENT", 0, 19], ["thioester", "OBSERVATION_MODIFIER", 4, 13], ["elongation", "OBSERVATION_MODIFIER", 63, 73]]], ["Deprotection was done in 30% trifluoroacetic acid (TFA).", [["trifluoroacetic acid", "CHEMICAL", 29, 49], ["TFA", "CHEMICAL", 51, 54], ["trifluoroacetic acid", "CHEMICAL", 29, 49], ["TFA", "CHEMICAL", 51, 54], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 29, 49], ["TFA", "SIMPLE_CHEMICAL", 51, 54], ["Deprotection", "TREATMENT", 0, 12], ["30% trifluoroacetic acid", "TREATMENT", 25, 49]]], ["To monitor each coupling and deprotection step, we used a ninhydrin test.", [["ninhydrin", "CHEMICAL", 58, 67], ["deprotection step", "TREATMENT", 29, 46], ["a ninhydrin test", "TEST", 56, 72]]], ["Final peptide cleavage from the resin was achieved by hydrogen fluoride (HF).", [["hydrogen fluoride", "CHEMICAL", 54, 71], ["hydrogen fluoride", "CHEMICAL", 54, 71], ["hydrogen fluoride", "SIMPLE_CHEMICAL", 54, 71], ["Final peptide cleavage", "TREATMENT", 0, 22], ["the resin", "TREATMENT", 28, 37], ["hydrogen fluoride (HF", "TREATMENT", 54, 75], ["peptide cleavage", "OBSERVATION", 6, 22]]], ["Fragment p727-63 was synthesized by microwave assisted solid phase fluorenylmethyloxycarbonyl (FMOC) chemistry using an Odyssey microwave peptide synthesizer (CEM Corporation).", [["p727-63", "CHEMICAL", 9, 16], ["fluorenylmethyloxycarbonyl", "CHEMICAL", 67, 93], ["FMOC", "CHEMICAL", 95, 99], ["fluorenylmethyloxycarbonyl", "CHEMICAL", 67, 93], ["FMOC", "CHEMICAL", 95, 99], ["fluorenylmethyloxycarbonyl", "SIMPLE_CHEMICAL", 67, 93], ["FMOC", "SIMPLE_CHEMICAL", 95, 99], ["Fragment p727", "TEST", 0, 13], ["microwave assisted solid phase fluorenylmethyloxycarbonyl (FMOC", "TREATMENT", 36, 99], ["an Odyssey microwave peptide synthesizer", "TREATMENT", 117, 157]]], ["Both fragments were purified by RP-HPLC on a C4-semipreparative column with a linear acetonitrile gradient and purity was checked by SDS electrophoresis (Fig. S2 in File S1) and MALDI (Fig. S3 in File S1).", [["fragments", "ANATOMY", 5, 14], ["acetonitrile", "CHEMICAL", 85, 97], ["acetonitrile", "CHEMICAL", 85, 97], ["acetonitrile", "SIMPLE_CHEMICAL", 85, 97], ["File S1", "GENE_OR_GENE_PRODUCT", 196, 203], ["S2", "PROTEIN", 159, 161], ["S3", "PROTEIN", 190, 192], ["Both fragments", "PROBLEM", 0, 14], ["RP", "TEST", 32, 34], ["a C4-semipreparative column", "TREATMENT", 43, 70], ["a linear acetonitrile gradient", "TREATMENT", 76, 106], ["SDS electrophoresis", "PROBLEM", 133, 152], ["fragments", "OBSERVATION", 5, 14], ["linear", "OBSERVATION_MODIFIER", 78, 84], ["acetonitrile gradient", "OBSERVATION", 85, 106], ["S1", "ANATOMY", 170, 172], ["S1", "ANATOMY", 201, 203]]], ["The two peptides were ligated in 8 M urea, 48 mM DPC, 20 mM TCEP, 90 mM MESNA (catalyzer), and 20 mM phosphate buffer at pH 8.0.", [["urea", "CHEMICAL", 37, 41], ["DPC", "CHEMICAL", 49, 52], ["TCEP", "CHEMICAL", 60, 64], ["MESNA", "CHEMICAL", 72, 77], ["phosphate", "CHEMICAL", 101, 110], ["urea", "CHEMICAL", 37, 41], ["DPC", "CHEMICAL", 49, 52], ["TCEP", "CHEMICAL", 60, 64], ["MESNA", "CHEMICAL", 72, 77], ["phosphate", "CHEMICAL", 101, 110], ["urea", "SIMPLE_CHEMICAL", 37, 41], ["DPC", "SIMPLE_CHEMICAL", 49, 52], ["TCEP", "SIMPLE_CHEMICAL", 60, 64], ["MESNA", "SIMPLE_CHEMICAL", 72, 77], ["mM DPC", "TEST", 46, 52], ["20 mM TCEP", "TREATMENT", 54, 64], ["90 mM MESNA (catalyzer", "TREATMENT", 66, 88], ["20 mM phosphate buffer", "TREATMENT", 95, 117], ["pH", "TEST", 121, 123]]], ["After 36 h, the HPLC chromatogram showed fragment A consumed by the reaction, and SDS electrophoresis shows the band corresponding to full length p7 after 5 h of reaction (Fig. S4 in File S1).", [["File S1", "GENE_OR_GENE_PRODUCT", 183, 190], ["S4", "PROTEIN", 177, 179], ["the HPLC chromatogram", "TEST", 12, 33], ["fragment A", "PROBLEM", 41, 51], ["the reaction", "PROBLEM", 64, 76], ["SDS electrophoresis", "TEST", 82, 101], ["the band", "PROBLEM", 108, 116], ["reaction", "PROBLEM", 162, 170], ["fragment", "OBSERVATION", 41, 49], ["S1", "ANATOMY", 188, 190]]], ["The MALDI mass spectrum of the reaction mixture (Fig. S5 in File S1) shows the presence of the ligated p7 polypeptide.Gel electrophoresis ::: Materials and MethodsStandard SDS-PAGE was performed with DTT in 15% Tris-Glycine gel with TGS running buffer or in NuPAGE under non-reducing conditions (4\u201312% Bis-Tris gel with MES-SDS running buffer) according to the manufacturer's protocol (Invitrogen).", [["DTT", "CHEMICAL", 200, 203], ["Tris-Glycine", "CHEMICAL", 211, 223], ["Bis-Tris", "CHEMICAL", 302, 310], ["DTT", "CHEMICAL", 200, 203], ["NuPAGE", "CHEMICAL", 258, 264], ["Bis-Tris gel", "CHEMICAL", 302, 314], ["File S1", "GENE_OR_GENE_PRODUCT", 60, 67], ["DTT", "SIMPLE_CHEMICAL", 200, 203], ["Tris-Glycine", "SIMPLE_CHEMICAL", 211, 223], ["Bis-Tris gel", "SIMPLE_CHEMICAL", 302, 314], ["S5", "PROTEIN", 54, 56], ["p7 polypeptide", "PROTEIN", 103, 117], ["The MALDI mass", "PROBLEM", 0, 14], ["the reaction mixture", "PROBLEM", 27, 47], ["the ligated p7 polypeptide", "TREATMENT", 91, 117], ["MethodsStandard SDS", "TREATMENT", 156, 175], ["DTT", "TEST", 200, 203], ["Glycine gel", "TREATMENT", 216, 227], ["TGS running buffer", "TREATMENT", 233, 251], ["% Bis-Tris gel", "TREATMENT", 300, 314], ["MES-SDS running buffer", "TREATMENT", 320, 342], ["the manufacturer's protocol", "TREATMENT", 357, 384], ["mass", "OBSERVATION", 10, 14], ["ligated", "OBSERVATION", 95, 102]]], ["The sample, 5 \u00b5g, (final concentration of 2 \u00b5g/\u00b5l) was mixed with sample buffer for 1 min followed by heating at 95\u00b0C for 5 min before loading into the gel.", [["sample", "ANATOMY", 4, 10], ["The sample", "TEST", 0, 10], ["sample buffer", "TREATMENT", 66, 79]]], ["The standard SDS-PAGE gels were stained with Coomassie blue while the NuPAGE gels were stained with SimplyBlue SafeStain (Invitrogen) or silver stain (Bio-Rad).Infrared spectroscopy ::: Materials and MethodsATR-FTIR spectra were recorded as described previously [29].", [["silver", "CHEMICAL", 137, 143], ["Coomassie blue", "CHEMICAL", 45, 59], ["NuPAGE", "CHEMICAL", 70, 76], ["silver", "CHEMICAL", 137, 143], ["Coomassie blue", "SIMPLE_CHEMICAL", 45, 59], ["Invitrogen", "SIMPLE_CHEMICAL", 122, 132], ["silver stain", "SIMPLE_CHEMICAL", 137, 149], ["Coomassie blue", "SPECIES", 45, 59], ["The standard SDS-PAGE gels", "TREATMENT", 0, 26], ["Coomassie blue", "TREATMENT", 45, 59], ["the NuPAGE gels", "TREATMENT", 66, 81], ["SimplyBlue SafeStain (Invitrogen", "TREATMENT", 100, 132], ["silver stain", "TEST", 137, 149], ["Infrared spectroscopy", "TEST", 160, 181], ["MethodsATR-FTIR spectra", "TEST", 200, 223]]], ["Approximately 100 \u00b5l of sample in water with 50\u22361 lipid/protein molar ratio were applied onto a trapezoidal (50 mm\u00d72 mm\u00d720 mm) Ge internal reflection element (IRE).", [["sample", "ANATOMY", 24, 30], ["Ge", "CHEMICAL", 127, 129], ["water", "SIMPLE_CHEMICAL", 34, 39], ["lipid", "SIMPLE_CHEMICAL", 50, 55], ["IRE", "DNA", 159, 162], ["50\u22361 lipid/protein molar ratio", "TREATMENT", 45, 75], ["a trapezoidal (50 mm\u00d72 mm\u00d720 mm) Ge internal reflection element (IRE", "TREATMENT", 94, 162], ["trapezoidal", "ANATOMY_MODIFIER", 96, 107]]], ["The area of the amide I (C = O stretching) were obtained by peak integration from 1600 to 1700 cm\u22121, and the area of amide II (N-H bending, centered at \u223c1550 cm\u22121) were obtained by peak integration from 1510 cm\u22121 to 1580 cm\u22121.", [["amide II", "CHEMICAL", 117, 125], ["N-H", "CHEMICAL", 127, 130], ["amide I", "CHEMICAL", 16, 23], ["C = O", "CHEMICAL", 25, 30], ["amide II", "CHEMICAL", 117, 125], ["N-H", "CHEMICAL", 127, 130], ["C = O", "SIMPLE_CHEMICAL", 25, 30], ["1580 cm", "OBSERVATION_MODIFIER", 216, 223]]], ["No difference in band area was observed employing other means of peak size estimation such as peak fitting and Fourier self-deconvolution.", [["difference in band area", "PROBLEM", 3, 26], ["peak size estimation", "PROBLEM", 65, 85], ["peak fitting", "PROBLEM", 94, 106], ["Fourier self-deconvolution", "PROBLEM", 111, 137], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["band area", "OBSERVATION", 17, 26], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["For the hydrogen-deuterium exchange experiment, the exchange was calculated by measuring the relative area of amide II relative to amide I band, before and after addition of D2O, according to Equation 1.Equation 1.", [["hydrogen-deuterium", "CHEMICAL", 8, 26], ["amide II", "CHEMICAL", 110, 118], ["hydrogen", "CHEMICAL", 8, 16], ["deuterium", "CHEMICAL", 17, 26], ["amide II", "CHEMICAL", 110, 118], ["amide", "CHEMICAL", 131, 136], ["D2O", "CHEMICAL", 174, 177], ["hydrogen", "SIMPLE_CHEMICAL", 8, 16], ["D2O", "SIMPLE_CHEMICAL", 174, 177], ["amide II", "PROTEIN", 110, 118], ["the hydrogen-deuterium exchange experiment", "TREATMENT", 4, 46], ["the exchange", "TREATMENT", 48, 60], ["amide I band", "TREATMENT", 131, 143], ["D2O", "TREATMENT", 174, 177]]], ["Formula to calculate the percentage of non-exchanged amino acids, as described previously [29].p7 reconstitution in lipids ::: Materials and MethodsWe used three methods for p7 reconstitution, which started from recombinant or synthetic p7 samples solubilized in a suitable solvent, e.g., methanol or HFIP.", [["amino acids", "CHEMICAL", 53, 64], ["methanol", "CHEMICAL", 289, 297], ["HFIP", "CHEMICAL", 301, 305], ["amino acids", "CHEMICAL", 53, 64], ["methanol", "CHEMICAL", 289, 297], ["HFIP", "CHEMICAL", 301, 305], ["amino acids", "AMINO_ACID", 53, 64], ["lipids", "SIMPLE_CHEMICAL", 116, 122], ["methanol", "SIMPLE_CHEMICAL", 289, 297], ["HFIP", "SIMPLE_CHEMICAL", 301, 305], ["Formula", "TREATMENT", 0, 7], ["non-exchanged amino acids", "TREATMENT", 39, 64], ["MethodsWe", "TREATMENT", 141, 150], ["p7 reconstitution", "TREATMENT", 174, 191], ["a suitable solvent", "TREATMENT", 263, 281], ["methanol", "TREATMENT", 289, 297], ["HFIP", "TREATMENT", 301, 305]]], ["In the first \u2018dialysis\u2019 method, the solubilized p7 in organic solvent was first dried under N2 gas, followed by overnight lyophilization.", [["N2", "CHEMICAL", 92, 94], ["the first \u2018dialysis\u2019 method", "TREATMENT", 3, 30], ["the solubilized p7 in organic solvent", "TREATMENT", 32, 69], ["N2 gas", "TREATMENT", 92, 98], ["overnight lyophilization", "TREATMENT", 112, 136], ["N2 gas", "OBSERVATION", 92, 98]]], ["Reconstitution of p7 into DMPC lipid bilayers was performed by solubilizing the protein in 30 mM 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC), followed by mixing with DMPC lipids.", [["1,2-dihexanoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 97, 139], ["DHPC", "CHEMICAL", 141, 145], ["DMPC lipids", "CHEMICAL", 172, 183], ["DMPC", "CHEMICAL", 26, 30], ["1,2-dihexanoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 97, 139], ["DHPC", "CHEMICAL", 141, 145], ["DMPC", "CHEMICAL", 172, 176], ["DMPC lipid bilayers", "SIMPLE_CHEMICAL", 26, 45], ["1,2-dihexanoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 97, 139], ["DHPC", "SIMPLE_CHEMICAL", 141, 145], ["DMPC lipids", "SIMPLE_CHEMICAL", 172, 183], ["p7", "PROTEIN", 18, 20], ["DMPC lipid bilayers", "TEST", 26, 45], ["the protein", "TEST", 76, 87], ["dihexanoyl", "TEST", 101, 111], ["glycero", "TREATMENT", 115, 122], ["phosphocholine (DHPC", "TREATMENT", 125, 145], ["DMPC lipids", "TREATMENT", 172, 183]]], ["The mixture was left at room temperature for 1 h, followed by detergent removal with Biobeads (BioRad).", [["Biobeads", "SIMPLE_CHEMICAL", 85, 93], ["detergent removal", "TREATMENT", 62, 79], ["Biobeads (BioRad)", "TREATMENT", 85, 102]]], ["This last step was repeated three times in order to completely remove the detergent.", [["the detergent", "TREATMENT", 70, 83]]], ["If indicated, the mixture was then extruded through a 400 nm pore size membrane.p7 reconstitution in lipids ::: Materials and MethodsIn the second \u2018direct\u2019 method, this solution was mixed with a chloroform solution containing 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti Polar Lipids).", [["pore", "ANATOMY", 61, 65], ["membrane", "ANATOMY", 71, 79], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 226, 269], ["DMPC", "CHEMICAL", 271, 275], ["chloroform", "CHEMICAL", 195, 205], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 226, 269], ["DMPC", "CHEMICAL", 271, 275], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["lipids", "SIMPLE_CHEMICAL", 101, 107], ["1,2-dimyristoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 226, 269], ["DMPC", "SIMPLE_CHEMICAL", 271, 275], ["Avanti Polar Lipids", "SIMPLE_CHEMICAL", 278, 297], ["a 400 nm pore size membrane", "TREATMENT", 52, 79], ["MethodsIn", "TREATMENT", 126, 135], ["this solution", "TREATMENT", 164, 177], ["a chloroform solution", "TREATMENT", 193, 214], ["dimyristoyl", "TREATMENT", 230, 241], ["sn-glycero", "TREATMENT", 242, 252], ["phosphocholine (DMPC) (Avanti Polar Lipids", "TREATMENT", 255, 297], ["size", "OBSERVATION_MODIFIER", 66, 70]]], ["The mixture was dried to remove all solvent, and the dry residue was hydrated with 20 mM phosphate buffer pH 7.0 to form the liposomes.", [["phosphate", "CHEMICAL", 89, 98], ["phosphate", "CHEMICAL", 89, 98], ["liposomes", "SIMPLE_CHEMICAL", 125, 134], ["The mixture", "TREATMENT", 0, 11], ["all solvent", "TREATMENT", 32, 43], ["the dry residue", "PROBLEM", 49, 64], ["20 mM phosphate buffer pH", "TREATMENT", 83, 108], ["liposomes", "ANATOMY", 125, 134]]], ["Where indicated, the suspension was subsequently vortexed, freeze-thawed 3 times and extruded through a 400 nm pore size membrane.", [["membrane", "ANATOMY", 121, 129], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["the suspension", "TREATMENT", 17, 31], ["a 400 nm pore size membrane", "TREATMENT", 102, 129], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["Other than DMPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) \u2013 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPE) lipid mixtures at 1\u22364 and 4\u22361 w/w ratio have also been used.p7 reconstitution in lipids ::: Materials and MethodsIn the third \u2018addition\u2019 method, liposomes were extruded first with a 400 nm pore size membrane to get small unilamellar liposomes.", [["membrane", "ANATOMY", 322, 330], ["DMPC", "CHEMICAL", 11, 15], ["1,2-dioleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 17, 57], ["DOPC", "CHEMICAL", 59, 63], ["1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 67, 115], ["POPE", "CHEMICAL", 117, 121], ["DMPC", "CHEMICAL", 11, 15], ["1,2-dioleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 17, 57], ["DOPC", "CHEMICAL", 59, 63], ["1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine", "CHEMICAL", 67, 115], ["POPE", "CHEMICAL", 117, 121], ["DMPC", "SIMPLE_CHEMICAL", 11, 15], ["1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) \u2013 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine", "SIMPLE_CHEMICAL", 17, 115], ["POPE", "SIMPLE_CHEMICAL", 117, 121], [") lipid mixtures", "SIMPLE_CHEMICAL", 121, 137], ["lipids", "SIMPLE_CHEMICAL", 204, 210], ["liposomes", "SIMPLE_CHEMICAL", 268, 277], ["membrane", "CELLULAR_COMPONENT", 322, 330], ["unilamellar liposomes", "SIMPLE_CHEMICAL", 344, 365], ["DMPC", "TEST", 11, 15], ["dioleoyl", "TEST", 21, 29], ["glycero", "TEST", 33, 40], ["phosphocholine (DOPC", "TREATMENT", 43, 63], ["palmitoyl", "TEST", 69, 78], ["oleoyl", "TREATMENT", 81, 87], ["glycero", "TREATMENT", 91, 98], ["phosphocholine (POPE) lipid mixtures", "TREATMENT", 101, 137], ["Materials", "TREATMENT", 215, 224], ["MethodsIn", "TREATMENT", 229, 238], ["a 400 nm pore size membrane", "TREATMENT", 303, 330], ["small unilamellar liposomes", "TREATMENT", 338, 365], ["small", "OBSERVATION_MODIFIER", 338, 343], ["unilamellar liposomes", "OBSERVATION", 344, 365]]], ["The protein stock in organic solvent (\u223c10 mg/ml solution) was added to the liposome solution to a protein to lipid molar ratio of 1\u223650.Liposome carboxyfluorescein (CF) release assay ::: Materials and MethodsTwo variants of the liposome CF release assay were performed.", [["Liposome carboxyfluorescein", "CHEMICAL", 135, 162], ["carboxyfluorescein", "CHEMICAL", 144, 162], ["liposome", "SIMPLE_CHEMICAL", 75, 83], ["Liposome carboxyfluorescein", "SIMPLE_CHEMICAL", 135, 162], ["CF", "SIMPLE_CHEMICAL", 164, 166], ["The protein stock in organic solvent", "TREATMENT", 0, 36], ["the liposome solution", "TREATMENT", 71, 92], ["lipid molar ratio", "TEST", 109, 126], ["Liposome carboxyfluorescein (CF)", "TREATMENT", 135, 167], ["the liposome CF release assay", "TEST", 223, 252]]], ["In the first case (a), p7 was added to preformed CF-loaded liposomes.", [["liposomes", "SIMPLE_CHEMICAL", 59, 68], ["p7", "PROTEIN", 23, 25], ["preformed CF-loaded liposomes", "TREATMENT", 39, 68]]], ["An appropriate volume (1 mL) of buffer (60 mM KH2PO4, 60 mM K2HPO4, 75 mM NaCl and 10 mM KCl, pH 7.0) containing carboxyfluorescein (CF) at self-quenching concentration (50 mM) was used to re-hydrate dry lipid at 5 mg/ml.", [["NaCl", "CHEMICAL", 74, 78], ["KCl", "CHEMICAL", 89, 92], ["carboxyfluorescein", "CHEMICAL", 113, 131], ["KH2PO4", "CHEMICAL", 46, 52], ["K2HPO4", "CHEMICAL", 60, 66], ["NaCl", "CHEMICAL", 74, 78], ["KCl", "CHEMICAL", 89, 92], ["carboxyfluorescein", "CHEMICAL", 113, 131], ["carboxyfluorescein", "SIMPLE_CHEMICAL", 113, 131], ["buffer (60 mM KH2PO4", "TREATMENT", 32, 52], ["NaCl", "TREATMENT", 74, 78], ["10 mM KCl, pH", "TREATMENT", 83, 96], ["carboxyfluorescein (CF)", "TREATMENT", 113, 136], ["self-quenching concentration", "TREATMENT", 140, 168], ["dry lipid", "TREATMENT", 200, 209]]], ["This was followed by three freeze-thawing cycles and extrusion through a 0.2 \u00b5m membrane filter to produce unilamellar liposomes.", [["membrane", "ANATOMY", 80, 88], ["unilamellar", "ANATOMY", 107, 118], ["unilamellar liposomes", "SIMPLE_CHEMICAL", 107, 128], ["three freeze-thawing cycles", "TREATMENT", 21, 48], ["extrusion", "TREATMENT", 53, 62], ["a 0.2 \u00b5m membrane filter", "TREATMENT", 71, 95], ["unilamellar liposomes", "TREATMENT", 107, 128], ["unilamellar liposomes", "OBSERVATION", 107, 128]]], ["Non-incorporated CF dye was removed using an Econo-Pac\u00ae 10 DG column (Biorad).", [["CF dye", "SIMPLE_CHEMICAL", 17, 23], ["Non-incorporated CF dye", "PROBLEM", 0, 23], ["an Econo-Pac\u00ae 10 DG column", "TREATMENT", 42, 68]]], ["To initiate the liposome CF release assay, the liposome solution was diluted 5\u00d7 with the buffer above and aliquoted to a microtiter plate (100 \u00b5L/well).", [["liposome", "SIMPLE_CHEMICAL", 47, 55], ["the liposome CF release assay", "TREATMENT", 12, 41], ["the liposome solution", "TREATMENT", 43, 64], ["a microtiter plate", "TREATMENT", 119, 137]]], ["Typically 5 \u00b5g of protein, dissolved in either 1 \u00b5l HFIP (1% final volume) or 2.5 \u00b5l methanol (2.5% final volume), were added to the liposome solution.", [["HFIP", "CHEMICAL", 52, 56], ["methanol", "CHEMICAL", 85, 93], ["liposome", "SIMPLE_CHEMICAL", 133, 141], ["1 \u00b5l HFIP", "TREATMENT", 47, 56], ["2.5 \u00b5l methanol", "TREATMENT", 78, 93], ["the liposome solution", "TREATMENT", 129, 150]]], ["Fluorescence values were read every minute for \u223c40 min.", [["Fluorescence values", "TEST", 0, 19]]], ["Rimantadine was prepared in ethanol, 1% v/v, and added to the liposome solution at a final concentration of up to 100 \u00b5M.", [["Rimantadine", "CHEMICAL", 0, 11], ["ethanol", "CHEMICAL", 28, 35], ["Rimantadine", "CHEMICAL", 0, 11], ["ethanol", "CHEMICAL", 28, 35], ["Rimantadine", "SIMPLE_CHEMICAL", 0, 11], ["ethanol", "SIMPLE_CHEMICAL", 28, 35], ["liposome", "SIMPLE_CHEMICAL", 62, 70], ["Rimantadine", "TREATMENT", 0, 11], ["ethanol", "TREATMENT", 28, 35], ["the liposome solution", "TREATMENT", 58, 79]]], ["In the second case (b), p7 was added to the dried lipid prior to hydration.", [["the dried lipid", "TREATMENT", 40, 55], ["hydration", "TREATMENT", 65, 74]]], ["The protein-lipid suspension was subsequently freeze-thawed, extruded, and separated from non-incorporated CF in the same manner described above.", [["The protein-lipid suspension", "TREATMENT", 0, 28]]], ["Fluorescence values were read immediately, and after one hour.", [["Fluorescence values", "TEST", 0, 19]]], ["Fluorescence measurements were performed in a TECAN Microplate Reader (Model Infinite M200 Pro) with excitation and emission at 485 nm and 520 nm, respectively.", [["Fluorescence measurements", "TEST", 0, 25]]], ["Baseline fluorescence was determined with samples identical as those described; except that no protein was added.", [["samples", "ANATOMY", 42, 49], ["Baseline fluorescence", "TEST", 0, 21], ["protein", "PROBLEM", 95, 102]]], ["Addition of Triton X-100 to a final concentration of 1% (v/v) was used as a positive control for CF release.", [["Triton X-100", "CHEMICAL", 12, 24], ["Triton X-100", "CHEMICAL", 12, 24], ["Triton X-100", "SIMPLE_CHEMICAL", 12, 24], ["Triton", "TREATMENT", 12, 18], ["a final concentration", "TREATMENT", 28, 49], ["a positive control", "TREATMENT", 74, 92]]], ["Melittin from honey bee venom, also used as a control, was purchased from Sigma-Aldrich and used without further treatment.Liposome based proton transport assay ::: Materials and MethodsThe p7 polypeptide was solubilized in either HFIP or methanol prior mixing with E. coli lipids (Avanti Polar Lipids) or a lipid mixture PAESC, i.e., PA/PE/PS/PC (5\u22362\u22362\u22361 w/w), in chloroform at protein to lipid molar ratio 1\u2236125.", [["venom", "ANATOMY", 24, 29], ["Melittin", "CHEMICAL", 0, 8], ["HFIP", "CHEMICAL", 231, 235], ["methanol", "CHEMICAL", 239, 247], ["PAESC", "CHEMICAL", 322, 327], ["PE", "CHEMICAL", 338, 340], ["chloroform", "CHEMICAL", 365, 375], ["Melittin", "CHEMICAL", 0, 8], ["HFIP", "CHEMICAL", 231, 235], ["methanol", "CHEMICAL", 239, 247], ["chloroform", "CHEMICAL", 365, 375], ["Melittin", "SIMPLE_CHEMICAL", 0, 8], ["honey bee", "ORGANISM_SUBSTANCE", 14, 23], ["venom", "ORGANISM_SUBSTANCE", 24, 29], ["Sigma-Aldrich", "ORGANISM", 74, 87], ["Liposome", "SIMPLE_CHEMICAL", 123, 131], ["proton", "SIMPLE_CHEMICAL", 138, 144], ["HFIP", "SIMPLE_CHEMICAL", 231, 235], ["methanol", "SIMPLE_CHEMICAL", 239, 247], ["E. coli lipids", "SIMPLE_CHEMICAL", 266, 280], ["Avanti Polar Lipids", "SIMPLE_CHEMICAL", 282, 301], ["PAESC", "SIMPLE_CHEMICAL", 322, 327], ["PA", "SIMPLE_CHEMICAL", 335, 337], ["PE", "SIMPLE_CHEMICAL", 338, 340], ["PS/PC", "SIMPLE_CHEMICAL", 341, 346], ["chloroform", "SIMPLE_CHEMICAL", 365, 375], ["honey bee venom", "SPECIES", 14, 29], ["E. coli", "SPECIES", 266, 273], ["honey bee venom", "SPECIES", 14, 29], ["E. coli", "SPECIES", 266, 273], ["Melittin", "TREATMENT", 0, 8], ["honey bee venom", "TREATMENT", 14, 29], ["further treatment", "TREATMENT", 105, 122], ["Materials", "TREATMENT", 165, 174], ["Methods", "TREATMENT", 179, 186], ["The p7 polypeptide", "TREATMENT", 186, 204], ["methanol prior mixing", "TREATMENT", 239, 260], ["E. coli lipids", "TREATMENT", 266, 280], ["Avanti Polar Lipids", "TREATMENT", 282, 301], ["a lipid mixture PAESC", "TREATMENT", 306, 327], ["PA/PE/PS/PC", "TREATMENT", 335, 346], ["lipid molar ratio", "TEST", 390, 407], ["PE", "OBSERVATION", 338, 340]]], ["The mixture was dried with nitrogen gas.", [["nitrogen", "CHEMICAL", 27, 35], ["nitrogen", "SIMPLE_CHEMICAL", 27, 35], ["The mixture", "TREATMENT", 0, 11], ["nitrogen gas", "TEST", 27, 39]]], ["Liposomes were formed with a strong buffer (60 mM KH2PO4, 60 mM K2HPO4, 150 mM NaCl and 20 mM KCl, pH 7.0) to a lipid concentration of 10 mg/ml, and extruded 21 times through 0.2 \u00b5m polycarbonate membranes.", [["membranes", "ANATOMY", 196, 205], ["NaCl", "CHEMICAL", 79, 83], ["KCl", "CHEMICAL", 94, 97], ["KH2PO4", "CHEMICAL", 50, 56], ["K2HPO4", "CHEMICAL", 64, 70], ["NaCl", "CHEMICAL", 79, 83], ["KCl", "CHEMICAL", 94, 97], ["polycarbonate", "CHEMICAL", 182, 195], ["Liposomes", "SIMPLE_CHEMICAL", 0, 9], ["lipid", "SIMPLE_CHEMICAL", 112, 117], ["Liposomes", "TREATMENT", 0, 9], ["a strong buffer (60 mM KH2PO4", "TREATMENT", 27, 56], ["60 mM K2HPO4", "TREATMENT", 58, 70], ["150 mM NaCl", "TREATMENT", 72, 83], ["20 mM KCl", "TREATMENT", 88, 97], ["pH", "TEST", 99, 101], ["a lipid concentration", "TREATMENT", 110, 131], ["0.2 \u00b5m polycarbonate membranes", "TREATMENT", 175, 205]]], ["The external solution was exchanged to a weaker buffer (190 mM Na2SO4, 0.1 mM KH2PO4 and 0.1 mM K2HPO4, pH 7.0) over an Econo-Pac\u00ae 10 DG column (Biorad).", [["Na2SO4", "CHEMICAL", 63, 69], ["KH2PO4", "CHEMICAL", 78, 84], ["K2HPO4", "CHEMICAL", 96, 102], ["The external solution", "TREATMENT", 0, 21], ["a weaker buffer", "TREATMENT", 39, 54], ["mM K2HPO4", "TEST", 93, 102], ["pH", "TEST", 104, 106], ["an Econo-Pac\u00ae", "TREATMENT", 117, 130]]], ["The column was pre-equilibrated with weakly buffered external buffer and 2 ml of the same buffer was used to elute the liposome fraction from the column.", [["liposome", "SIMPLE_CHEMICAL", 119, 127], ["weakly buffered external buffer", "TREATMENT", 37, 68], ["the same buffer", "TREATMENT", 81, 96], ["column", "OBSERVATION_MODIFIER", 4, 10], ["liposome fraction", "OBSERVATION", 119, 136], ["column", "ANATOMY", 146, 152]]], ["The liposome fraction was then further diluted with weak external buffer to approximately 1\u20132 mg/ml prior the assay.Liposome based proton transport assay ::: Materials and MethodsA highly sensitive pH probe (Mettler Toledo InLab\u00aeMicro) was placed in the experimental cuvette containing 3 mL of liposome solution in weak buffer.", [["liposome", "SIMPLE_CHEMICAL", 4, 12], ["Liposome", "SIMPLE_CHEMICAL", 116, 124], ["proton", "SIMPLE_CHEMICAL", 131, 137], ["liposome", "SIMPLE_CHEMICAL", 294, 302], ["The liposome fraction", "TREATMENT", 0, 21], ["weak external buffer", "TREATMENT", 52, 72], ["the assay", "TEST", 106, 115], ["Materials", "TEST", 158, 167], ["MethodsA", "TREATMENT", 172, 180], ["the experimental cuvette", "TREATMENT", 250, 274], ["liposome solution", "TREATMENT", 294, 311], ["liposome fraction", "OBSERVATION", 4, 21], ["weak buffer", "OBSERVATION_MODIFIER", 315, 326]]], ["The experiment was initiated by lowering the external buffer pH to \u223c5.5\u20136 by addition of HCl.", [["HCl", "CHEMICAL", 89, 92], ["HCl", "CHEMICAL", 89, 92], ["HCl", "SIMPLE_CHEMICAL", 89, 92], ["the external buffer pH", "TREATMENT", 41, 63], ["HCl", "TREATMENT", 89, 92]]], ["After the pH baseline was stable for 2\u20133 min, the potassium ionophore valinomycin (final concentration 25 nM) was added to the solution.", [["potassium", "CHEMICAL", 50, 59], ["valinomycin", "CHEMICAL", 70, 81], ["potassium", "CHEMICAL", 50, 59], ["valinomycin", "CHEMICAL", 70, 81], ["potassium ionophore", "SIMPLE_CHEMICAL", 50, 69], ["valinomycin", "SIMPLE_CHEMICAL", 70, 81], ["the pH baseline", "TEST", 6, 21], ["the potassium ionophore valinomycin", "TREATMENT", 46, 81]]], ["After 5 min, the proton ionophore carbonyl cyanide m-chlorophenylhydrazone, CCCP, (final concentration 0.5 \u00b5M) was added to terminate the assay by allowing influx of protons to reach equilibrium.", [["carbonyl cyanide", "CHEMICAL", 34, 50], ["m-chlorophenylhydrazone", "CHEMICAL", 51, 74], ["CCCP", "CHEMICAL", 76, 80], ["carbonyl cyanide m-chlorophenylhydrazone", "CHEMICAL", 34, 74], ["CCCP", "CHEMICAL", 76, 80], ["proton ionophore carbonyl cyanide m-chlorophenylhydrazone", "SIMPLE_CHEMICAL", 17, 74], ["CCCP", "SIMPLE_CHEMICAL", 76, 80], ["protons", "SIMPLE_CHEMICAL", 166, 173], ["the proton ionophore carbonyl cyanide m-chlorophenylhydrazone", "TREATMENT", 13, 74], ["CCCP", "TREATMENT", 76, 80], ["influx of protons", "TREATMENT", 156, 173]]], ["Finally, the solution was back-titrated after 3\u20135 minutes with HCl.", [["HCl", "CHEMICAL", 63, 66], ["HCl", "CHEMICAL", 63, 66], ["HCl", "SIMPLE_CHEMICAL", 63, 66], ["the solution", "TREATMENT", 9, 21], ["HCl", "TREATMENT", 63, 66]]], ["Inhibition of p7-mediated proton transport was monitored with addition of 5 \u00b5M rimantadine.", [["rimantadine", "CHEMICAL", 79, 90], ["rimantadine", "CHEMICAL", 79, 90], ["p7", "GENE_OR_GENE_PRODUCT", 14, 16], ["proton", "SIMPLE_CHEMICAL", 26, 32], ["rimantadine", "SIMPLE_CHEMICAL", 79, 90], ["p7", "PROTEIN", 14, 16], ["p7-mediated proton transport", "TREATMENT", 14, 42], ["5 \u00b5M rimantadine", "TREATMENT", 74, 90]]], ["The inhibitor was added from concentrated stock solutions in ethanol 5 minutes before initiation of the proton transport assay with HCl.", [["ethanol", "CHEMICAL", 61, 68], ["HCl", "CHEMICAL", 132, 135], ["ethanol", "CHEMICAL", 61, 68], ["HCl", "CHEMICAL", 132, 135], ["ethanol", "SIMPLE_CHEMICAL", 61, 68], ["proton", "SIMPLE_CHEMICAL", 104, 110], ["HCl", "SIMPLE_CHEMICAL", 132, 135], ["The inhibitor", "TREATMENT", 0, 13], ["the proton transport assay", "TREATMENT", 100, 126], ["HCl", "TREATMENT", 132, 135]]], ["For comparison, a similar assay for influenza A M2 protein (18-60) (protein-to-lipid molar ratio 1\u22361000) was also performed.", [["influenza A M2", "GENE_OR_GENE_PRODUCT", 36, 50], ["influenza A M2 protein", "PROTEIN", 36, 58], ["a similar assay", "TEST", 16, 31], ["influenza", "PROBLEM", 36, 45], ["A M2 protein", "TEST", 46, 58], ["protein", "TEST", 68, 75], ["lipid molar ratio", "TEST", 79, 96]]], ["M2(18-60) fragment was pre-solubilized in either methanol or HFIP and results did not change (not shown).", [["methanol", "CHEMICAL", 49, 57], ["HFIP", "CHEMICAL", 61, 65], ["methanol", "CHEMICAL", 49, 57], ["HFIP", "CHEMICAL", 61, 65], ["methanol", "SIMPLE_CHEMICAL", 49, 57], ["HFIP", "SIMPLE_CHEMICAL", 61, 65], ["M2(18-60) fragment", "DNA", 0, 18], ["fragment", "PROBLEM", 10, 18]]], ["For the duration of the experiment, the solution was constantly stirred.Liposome flotation assay ::: Materials and MethodsIn the flotation assay, proteoliposomes were prepared by either the \u2018dyalisis\u2019 method after extrusion, or by the \u2018addition\u2019 method.", [["proteoliposomes", "ANATOMY", 146, 161], ["Liposome", "SIMPLE_CHEMICAL", 72, 80], ["proteoliposomes", "SIMPLE_CHEMICAL", 146, 161], ["the solution", "TREATMENT", 36, 48], ["Methods", "TREATMENT", 115, 122], ["the flotation assay", "TEST", 125, 144]]], ["Briefly, an appropriate volume of liposome sample containing 50 \u00b5g of p7 peptide obtained by either method of incorporation in the modified assay buffer (60 mM NaH2PO4, 60 mM Na2HPO4, 85 mM NaCl, pH 7.0), was mixed with sucrose to 20% (w/v) and Na2CO3 to 0.1 M. This sample was layered at the bottom of a 5-ml centrifuge tube.", [["liposome sample", "ANATOMY", 34, 49], ["sample", "ANATOMY", 267, 273], ["NaCl", "CHEMICAL", 190, 194], ["sucrose", "CHEMICAL", 220, 227], ["Na2CO3", "CHEMICAL", 245, 251], ["NaH2PO4", "CHEMICAL", 160, 167], ["Na2HPO4", "CHEMICAL", 175, 182], ["NaCl", "CHEMICAL", 190, 194], ["sucrose", "CHEMICAL", 220, 227], ["Na2CO3", "CHEMICAL", 245, 251], ["sucrose", "SIMPLE_CHEMICAL", 220, 227], ["Na2CO3", "SIMPLE_CHEMICAL", 245, 251], ["tube", "TISSUE", 321, 325], ["an appropriate volume of liposome sample", "TREATMENT", 9, 49], ["p7 peptide", "TREATMENT", 70, 80], ["NaH2PO4", "TEST", 160, 167], ["Na2HPO4", "TEST", 175, 182], ["NaCl", "TEST", 190, 194], ["pH", "TEST", 196, 198], ["sucrose", "TREATMENT", 220, 227], ["Na2CO3", "TREATMENT", 245, 251], ["a 5-ml centrifuge tube", "TREATMENT", 303, 325]]], ["Successively, 1 ml of 10% (w/v) sucrose solution in assay buffer and 1 ml of assay buffer was layered on top of the sample.", [["sample", "ANATOMY", 116, 122], ["sucrose", "CHEMICAL", 32, 39], ["sucrose", "CHEMICAL", 32, 39], ["w/v) sucrose solution in assay buffer", "TREATMENT", 27, 64], ["assay buffer", "TREATMENT", 77, 89]]], ["Liposome-containing fractions were diluted and centrifuged at 150,000\u00d7 g for 1 h at 25\u00b0C and resuspended in water, or desalted by passing through Econo-Pac\u00ae 10 DG column (Bio-Rad), to remove salt and sucrose.", [["Liposome", "CHEMICAL", 0, 8], ["sucrose", "CHEMICAL", 200, 207], ["sucrose", "CHEMICAL", 200, 207], ["Liposome", "SIMPLE_CHEMICAL", 0, 8], ["C", "SIMPLE_CHEMICAL", 87, 88], ["salt", "SIMPLE_CHEMICAL", 191, 195], ["sucrose", "SIMPLE_CHEMICAL", 200, 207], ["Liposome-containing fractions", "TREATMENT", 0, 29], ["Pac\u00ae", "TREATMENT", 152, 156], ["salt and sucrose", "TREATMENT", 191, 207]]], ["Subsequently, the sample was deposited onto a Germanium trapezoidal plate for p7 detection and secondary structure determination.", [["sample", "ANATOMY", 18, 24], ["a Germanium trapezoidal plate", "TREATMENT", 44, 73], ["p7 detection", "TEST", 78, 90], ["secondary structure determination", "PROBLEM", 95, 128], ["secondary structure", "OBSERVATION", 95, 114]]], ["To estimate the quantity of p7 protein in the liposome fraction, a calibration plot was obtained using increasing amounts of p7 (dissolved in HFIP) and dried onto a Ge plate.", [["Ge", "CHEMICAL", 165, 167], ["p7 protein", "PROTEIN", 28, 38], ["p7", "PROTEIN", 125, 127], ["a calibration plot", "TEST", 65, 83], ["increasing amounts of p7 (dissolved in HFIP", "TREATMENT", 103, 146], ["a Ge plate", "TREATMENT", 163, 173], ["increasing", "OBSERVATION_MODIFIER", 103, 113], ["amounts", "OBSERVATION_MODIFIER", 114, 121]]], ["The amount of p7 was correlated against amide I peak area (1700\u20131600 cm\u22121) and used to construct a calibration line.", [["amide I", "CHEMICAL", 40, 47], ["p7", "PROTEIN", 14, 16], ["a calibration line", "TREATMENT", 97, 115], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["calibration line", "OBSERVATION", 99, 115]]], ["For gel-based quantification purposes, dialyzed samples were TCA precipitated, dissolved with NuPAGE sample buffer and electrophoresed as described in the previous section.", [["samples", "ANATOMY", 48, 55], ["TCA", "CHEMICAL", 61, 64], ["TCA", "CHEMICAL", 61, 64], ["NuPAGE", "CHEMICAL", 94, 100], ["TCA", "SIMPLE_CHEMICAL", 61, 64], ["dialyzed samples", "TEST", 39, 55], ["TCA", "PROBLEM", 61, 64], ["NuPAGE sample buffer", "TREATMENT", 94, 114]]], ["The PAESC component densities and molecular weights were calculated from egg PA-brain PE-brain PS-egg PC 5\u22362\u22362\u22361, values obtained from Avanti website (www.avantilipids.com).", [["brain", "ANATOMY", 80, 85], ["brain", "ANATOMY", 89, 94], ["egg", "ORGANISM_SUBDIVISION", 73, 76], ["PA", "GENE_OR_GENE_PRODUCT", 77, 79], ["brain", "ORGAN", 80, 85], ["brain", "ORGAN", 89, 94], ["The PAESC component densities", "PROBLEM", 0, 29], ["molecular weights", "TEST", 34, 51], ["egg PA", "TEST", 73, 79], ["brain PE", "TEST", 80, 88], ["brain PS", "TEST", 89, 97], ["egg PC", "TEST", 98, 104], ["component", "OBSERVATION_MODIFIER", 10, 19], ["densities", "OBSERVATION", 20, 29], ["brain", "ANATOMY", 80, 85], ["PE", "OBSERVATION", 86, 88], ["brain", "ANATOMY", 89, 94]]], ["The p7 and sucrose buffer density was calculated using SEDNTERP [30].", [["sucrose", "CHEMICAL", 11, 18], ["sucrose", "CHEMICAL", 11, 18], ["sucrose", "SIMPLE_CHEMICAL", 11, 18], ["The p7 and sucrose buffer density", "TREATMENT", 0, 33]]], ["For the calculation of PAESC lipid area, the egg yolk PC area was used as a reference [31].Purity of synthetic and recombinant p7 protein ::: Results and DiscussionDye release assays have been previously performed with tagged p7 protein, either with FLAG [32], [33] or flu-antigen [25].", [["egg yolk PC area", "ANATOMY", 45, 61], ["egg yolk PC", "MULTI-TISSUE_STRUCTURE", 45, 56], ["Dye", "SIMPLE_CHEMICAL", 164, 167], ["p7", "GENE_OR_GENE_PRODUCT", 226, 228], ["FLAG", "GENE_OR_GENE_PRODUCT", 250, 254], ["[33]", "SIMPLE_CHEMICAL", 261, 265], ["flu-antigen [25]", "SIMPLE_CHEMICAL", 269, 285], ["p7 protein", "PROTEIN", 127, 137], ["p7 protein", "PROTEIN", 226, 236], ["FLAG", "PROTEIN", 250, 254], ["PAESC lipid area", "TREATMENT", 23, 39], ["the egg yolk PC area", "TREATMENT", 41, 61], ["Dye release assays", "TEST", 164, 182], ["tagged p7 protein", "TEST", 219, 236], ["FLAG", "TEST", 250, 254]]], ["In our experiments we have used essentially tag-free p7, either synthetic or recombinant.", [["p7", "GENE_OR_GENE_PRODUCT", 53, 55], ["tag", "PROTEIN", 44, 47], ["p7", "PROTEIN", 53, 55]]], ["The sequence of recombinant p7 protein used in the present work is shown in Fig. 1A, which includes 4 extra N-terminal residues (SNAM) [28], whereas the sequence for the synthetic peptide started at Met (residue \u20180\u2019, Fig. 1A).Purity of synthetic and recombinant p7 protein ::: Results and DiscussionThe fusion protein 6His-MBP-p7 was expressed at moderate levels after IPTG induction (Fig. 1B).", [["IPTG", "CHEMICAL", 369, 373], ["N", "CHEMICAL", 108, 109], ["Met", "CHEMICAL", 199, 202], ["IPTG", "CHEMICAL", 369, 373], ["p7", "GENE_OR_GENE_PRODUCT", 28, 30], ["Met", "GENE_OR_GENE_PRODUCT", 199, 202], ["6His-MBP-p7", "GENE_OR_GENE_PRODUCT", 318, 329], ["recombinant p7 protein", "PROTEIN", 16, 38], ["N-terminal residues", "PROTEIN", 108, 127], ["recombinant p7 protein", "PROTEIN", 250, 272], ["6His", "PROTEIN", 318, 322], ["MBP", "PROTEIN", 323, 326], ["p7", "PROTEIN", 327, 329], ["recombinant p7 protein", "TREATMENT", 16, 38], ["4 extra N-terminal residues", "TREATMENT", 100, 127], ["the synthetic peptide", "TREATMENT", 166, 187], ["The fusion protein", "TEST", 299, 317], ["MBP", "TEST", 323, 326], ["IPTG induction", "TREATMENT", 369, 383]]], ["After purification using Ni2+-NTA resin (Fig. 1C), the fusion protein was subjected to tobacco-etch virus (TEV) protease cleavage to remove 6His-MBP.", [["Ni2+-NTA", "CHEMICAL", 25, 33], ["Ni2+-NTA", "CHEMICAL", 25, 33], ["6His-MBP", "CHEMICAL", 140, 148], ["Ni2+-NTA", "SIMPLE_CHEMICAL", 25, 33], ["tobacco-etch virus", "ORGANISM", 87, 105], ["TEV", "ORGANISM", 107, 110], ["6His-MBP", "GENE_OR_GENE_PRODUCT", 140, 148], ["fusion protein", "PROTEIN", 55, 69], ["tobacco-etch virus (TEV) protease", "PROTEIN", 87, 120], ["6His", "PROTEIN", 140, 144], ["MBP", "PROTEIN", 145, 148], ["tobacco-etch virus", "SPECIES", 87, 105], ["TEV", "SPECIES", 107, 110], ["purification", "TEST", 6, 18], ["Ni2+-NTA resin (Fig. 1C", "TREATMENT", 25, 48], ["the fusion protein", "TEST", 51, 69], ["etch virus", "PROBLEM", 95, 105], ["protease cleavage", "TREATMENT", 112, 129]]], ["Approximately 80% cleavage was achieved in 4 h (Fig. 1D), and no further changes were observed after overnight reaction.", [["further changes", "PROBLEM", 65, 80], ["overnight reaction", "PROBLEM", 101, 119]]], ["The protein was successfully purified by RP-HPLC using an isopropanol gradient (Fig. 1E).", [["isopropanol", "CHEMICAL", 58, 69], ["isopropanol", "SIMPLE_CHEMICAL", 58, 69], ["The protein", "TEST", 0, 11], ["RP", "TEST", 41, 43], ["an isopropanol gradient", "TREATMENT", 55, 78]]], ["Pooled fractions were lyophilized and the purity was assessed by MALDI-TOF MS (Fig. 2A).", [["Pooled fractions", "PROBLEM", 0, 16], ["the purity", "TEST", 38, 48], ["fractions", "OBSERVATION_MODIFIER", 7, 16]]], ["Synthetic p7 was also purified by RP-HPLC (not shown) and the mass spectrum of the relevant fraction also shows one peak with the expected mass (Fig. 2B).", [["p7", "GENE_OR_GENE_PRODUCT", 10, 12], ["RP-HPLC", "TEST", 34, 41], ["the mass spectrum", "TEST", 58, 75], ["the relevant fraction", "TEST", 79, 100], ["the expected mass", "PROBLEM", 126, 143], ["mass", "OBSERVATION", 62, 66], ["peak", "OBSERVATION_MODIFIER", 116, 120], ["mass", "OBSERVATION", 139, 143]]], ["Both synthetic and recombinant p7 were subsequently lyophilized, and further resolubilized in methanol, HFIP, or other solvents, as indicated, prior to reconstitution in lipid bilayers.Dialysis method ::: Effect of reconstitution protocol on p7 secondary structure ::: Results and DiscussionWhen recombinant p7 was first dried from HFIP, solubilized in detergent and reconstituted in DMPC lipid bilayers, the amide I spectrum showed that most of the protein is \u03b1-helical (trace H in Fig. 3A, henceforth referred to as form A), with a peak centered at 1658 cm\u22121.", [["lipid bilayers", "ANATOMY", 170, 184], ["HFIP", "CHEMICAL", 104, 108], ["HFIP", "CHEMICAL", 332, 336], ["methanol", "CHEMICAL", 94, 102], ["HFIP", "CHEMICAL", 104, 108], ["DMPC", "CHEMICAL", 384, 388], ["amide", "CHEMICAL", 409, 414], ["H", "CHEMICAL", 478, 479], ["methanol", "SIMPLE_CHEMICAL", 94, 102], ["HFIP", "SIMPLE_CHEMICAL", 104, 108], ["lipid bilayers", "SIMPLE_CHEMICAL", 170, 184], ["HFIP", "SIMPLE_CHEMICAL", 332, 336], ["DMPC lipid bilayers", "SIMPLE_CHEMICAL", 384, 403], ["recombinant p7", "PROTEIN", 19, 33], ["recombinant p7", "PROTEIN", 296, 310], ["\u03b1-helical", "PROTEIN", 461, 470], ["methanol", "TREATMENT", 94, 102], ["HFIP", "TREATMENT", 104, 108], ["reconstitution in lipid bilayers", "TREATMENT", 152, 184], ["reconstitution protocol", "TREATMENT", 215, 238], ["HFIP", "TREATMENT", 332, 336], ["DMPC lipid bilayers", "TREATMENT", 384, 403], ["the amide I spectrum", "TEST", 405, 425], ["the protein", "TEST", 446, 457], ["lipid bilayers", "OBSERVATION", 170, 184], ["reconstitution", "OBSERVATION", 215, 229], ["trace H", "OBSERVATION_MODIFIER", 472, 479]]], ["In contrast, when recombinant p7 was solubilized first in methanol, a band centered at 1627 cm\u22121 appeared prominently, indicating an approximate 60/40% mixture of \u03b1-helix and \u03b2-strands, respectively (trace M in Fig. 3A, henceforth referred to as form B).", [["methanol", "CHEMICAL", 58, 66], ["p7", "GENE_OR_GENE_PRODUCT", 30, 32], ["methanol", "SIMPLE_CHEMICAL", 58, 66], ["\u03b1-helix", "SIMPLE_CHEMICAL", 163, 170], ["\u03b2-strands", "SIMPLE_CHEMICAL", 175, 184], ["recombinant p7", "PROTEIN", 18, 32], ["\u03b1-helix", "PROTEIN", 163, 170], ["\u03b2-strands", "PROTEIN", 175, 184], ["form B", "PROTEIN", 246, 252], ["trace M in Fig", "PROBLEM", 200, 214]]], ["Similar differences were observed using a synthetic form of p7 (not shown).", [["p7", "PROTEIN", 60, 62]]], ["Thus, regardless of the sample origin, a dramatic increase in \u03b2-structure is observed when the protein was pre-solubilized and dried from a methanol solution.", [["methanol", "CHEMICAL", 140, 148], ["methanol", "SIMPLE_CHEMICAL", 140, 148], ["a dramatic increase in \u03b2-structure", "PROBLEM", 39, 73], ["the protein", "TEST", 91, 102], ["a methanol solution", "TREATMENT", 138, 157], ["dramatic", "OBSERVATION_MODIFIER", 41, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58]]], ["For the \u03b1-helical form A, analysis of the amide I region showed that \u03b2-structure constitutes approximately 10\u201315% of the total, whereas the \u03b1-helix content was 73%, i.e., \u223c48 amino acids.", [["amino acids", "CHEMICAL", 175, 186], ["amide", "CHEMICAL", 42, 47], ["amino acids", "CHEMICAL", 175, 186], ["\u03b1-helix", "SIMPLE_CHEMICAL", 140, 147], ["amino acids", "AMINO_ACID", 175, 186], ["\u03b1-helical form A", "PROTEIN", 8, 24], ["amide I region", "PROTEIN", 42, 56], ["\u03b1-helix", "PROTEIN", 140, 147], ["analysis of the amide I region", "TEST", 26, 56], ["\u03b2-structure", "TEST", 69, 80], ["the \u03b1-helix content", "TEST", 136, 155], ["amino acids", "TEST", 175, 186]]], ["This \u03b1-helical content is consistent with the reported 62% obtained for recombinant p7 in DHPC micelles [14], the 70% obtained for synthetic p7 dissolved in 50% TFE [12], and a recent NMR structure of a p7 variant in DPC micelles [20], which is also mostly \u03b1-helical and roughly consistent with an \u03b1-helical hairpin model with two \u03b1-helical TM domains.", [["TFE", "CHEMICAL", 161, 164], ["TFE", "CHEMICAL", 161, 164], ["\u03b1-helical", "SIMPLE_CHEMICAL", 5, 14], ["DPC micelles [20]", "SIMPLE_CHEMICAL", 217, 234], ["recombinant p7", "PROTEIN", 72, 86], ["p7 variant", "PROTEIN", 203, 213], ["\u03b1-helical TM domains", "PROTEIN", 331, 351], ["synthetic p7 dissolved", "TEST", 131, 153], ["a recent NMR structure", "TEST", 175, 197], ["an \u03b1-helical hairpin model", "TREATMENT", 295, 321], ["two \u03b1-helical TM domains", "TREATMENT", 327, 351], ["consistent with", "UNCERTAINTY", 26, 41], ["consistent with", "UNCERTAINTY", 279, 294], ["hairpin model", "OBSERVATION", 308, 321]]], ["In contrast, form B obtained after methanol solubilization showed \u03b2-structure and \u03b1-helical content of 40% and 55%, respectively.", [["methanol", "CHEMICAL", 35, 43], ["methanol", "CHEMICAL", 35, 43], ["methanol", "SIMPLE_CHEMICAL", 35, 43], ["\u03b1-helical", "SIMPLE_CHEMICAL", 82, 91], ["form B", "PROTEIN", 13, 19], ["methanol solubilization", "TREATMENT", 35, 58], ["\u03b2-structure", "PROBLEM", 66, 77], ["\u03b1-helical content", "TEST", 82, 99]]], ["This corresponds to \u223c37 residues forming \u03b1-helices, too short to account for the two predicted \u03b1-helical TM domains, but too long for a single TM domain.", [["\u03b1-helices", "GENE_OR_GENE_PRODUCT", 41, 50], ["\u03b1-helices", "PROTEIN", 41, 50], ["\u03b1-helical TM domains", "PROTEIN", 95, 115], ["TM domain", "PROTEIN", 143, 152], ["\u223c37 residues forming \u03b1-helices", "PROBLEM", 20, 50], ["a single TM domain", "TREATMENT", 134, 152]]], ["Therefore, this sample is likely to contain incompletely, or incorrectly, reconstituted p7 protein.Direct method ::: Effect of reconstitution protocol on p7 secondary structure ::: Results and DiscussionWhen we used the direct method of reconstitution, i.e., without a detergent solubilization step, results were identical to the dialysis method.", [["sample", "ANATOMY", 16, 22], ["p7", "GENE_OR_GENE_PRODUCT", 88, 90], ["p7 protein", "PROTEIN", 88, 98], ["reconstitution protocol", "TREATMENT", 127, 150], ["the direct method of reconstitution", "TREATMENT", 216, 251], ["a detergent solubilization step", "TREATMENT", 267, 298], ["the dialysis method", "TREATMENT", 326, 345], ["reconstitution", "OBSERVATION", 127, 141]]], ["Specifically, samples dried from methanol (M) formed \u223c40% \u03b2-structure (Fig. 3B, curve 1), whereas those exposed to HFIP (H) were mostly \u03b1-helical (data not shown).", [["samples", "ANATOMY", 14, 21], ["methanol", "CHEMICAL", 33, 41], ["methanol", "CHEMICAL", 33, 41], ["HFIP", "CHEMICAL", 115, 119], ["H", "CHEMICAL", 121, 122], ["methanol", "SIMPLE_CHEMICAL", 33, 41], ["samples", "TEST", 14, 21]]], ["However, when that sample was subsequently vortexed, freeze-thawed, sonicated and repeatedly extruded, its \u03b2-structure content was reduced until the sample became mostly \u03b1-helical, i.e., form A (spectra 2\u20134 in Fig. 3B).", [["sample", "ANATOMY", 19, 25], ["sample", "ANATOMY", 149, 155], ["the sample", "TEST", 145, 155], ["reduced", "OBSERVATION_MODIFIER", 131, 138]]], ["This phenomenon was also observed in samples that showed initially a high content of \u03b2 structure obtained from dyalisis methods (Fig. 3A, see above) or by addition (see below).Addition method ::: Effect of reconstitution protocol on p7 secondary structure ::: Results and DiscussionThe addition method is used in dye (CF) release assays [24], where a small volume of solvent-solubilized p7 is added to preformed liposomes in aqueous buffer.", [["samples", "ANATOMY", 37, 44], ["liposomes", "SIMPLE_CHEMICAL", 412, 421], ["\u03b2 structure", "PROTEIN", 85, 96], ["This phenomenon", "PROBLEM", 0, 15], ["a high content of \u03b2 structure", "PROBLEM", 67, 96], ["reconstitution protocol", "TREATMENT", 206, 229], ["a small volume of solvent-solubilized p7", "TREATMENT", 349, 389], ["high content", "OBSERVATION", 69, 81], ["reconstitution", "OBSERVATION", 206, 220], ["small", "OBSERVATION_MODIFIER", 351, 356]]], ["In this case, p7 formed a significant (\u223c40%) proportion of \u03b2-structure (Fig. 3C, see bands at 1635 and 1629 cm\u22121) regardless of the solvent used for p7 solubilization prior addition to liposomes: methanol, HFIP or TFE.Addition method ::: Effect of reconstitution protocol on p7 secondary structure ::: Results and DiscussionThe presence of \u03b2 structure in the dyalisis and addition samples when methanol was used (Fig. 3A\u2013B) may be explained by comparison to the spectra of the dry p7 from HFIP or methanol solution (Fig. 3D).", [["methanol", "CHEMICAL", 196, 204], ["HFIP", "CHEMICAL", 206, 210], ["TFE", "CHEMICAL", 214, 217], ["methanol", "CHEMICAL", 394, 402], ["HFIP", "CHEMICAL", 489, 493], ["methanol", "CHEMICAL", 196, 204], ["HFIP", "CHEMICAL", 206, 210], ["TFE", "CHEMICAL", 214, 217], ["methanol", "CHEMICAL", 394, 402], ["HFIP", "CHEMICAL", 489, 493], ["methanol", "CHEMICAL", 497, 505], ["liposomes", "SIMPLE_CHEMICAL", 185, 194], ["methanol", "SIMPLE_CHEMICAL", 196, 204], ["HFIP", "SIMPLE_CHEMICAL", 206, 210], ["TFE", "SIMPLE_CHEMICAL", 214, 217], ["methanol", "SIMPLE_CHEMICAL", 394, 402], ["3A\u2013B", "SIMPLE_CHEMICAL", 418, 422], ["HFIP", "SIMPLE_CHEMICAL", 489, 493], ["methanol", "SIMPLE_CHEMICAL", 497, 505], ["\u03b2 structure", "PROTEIN", 340, 351], ["\u03b2-structure", "PROBLEM", 59, 70], ["the solvent", "TREATMENT", 128, 139], ["p7 solubilization", "TREATMENT", 149, 166], ["methanol", "TREATMENT", 196, 204], ["reconstitution protocol", "TREATMENT", 248, 271], ["methanol", "TREATMENT", 394, 402], ["methanol solution", "TREATMENT", 497, 514], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["reconstitution", "OBSERVATION", 248, 262], ["may be explained", "UNCERTAINTY", 424, 440]]], ["In the first case, p7 was almost completely \u03b1-helical, whereas in the second case, p7 contained more than 50% of \u03b2-structure.", [["p7", "GENE_OR_GENE_PRODUCT", 19, 21], ["p7", "PROTEIN", 19, 21], ["p7", "PROTEIN", 83, 85]]], ["However, the CD spectra of p7 in HFIP or methanol solution show no differences, with a high (\u223c70%) percentage of helical structure (data not shown).", [["HFIP", "CHEMICAL", 33, 37], ["methanol", "CHEMICAL", 41, 49], ["HFIP", "SIMPLE_CHEMICAL", 33, 37], ["methanol", "SIMPLE_CHEMICAL", 41, 49], ["the CD spectra", "TEST", 9, 23], ["methanol solution", "TREATMENT", 41, 58], ["no", "UNCERTAINTY", 64, 66], ["high", "OBSERVATION_MODIFIER", 87, 91]]], ["Therefore, we conclude that it is the drying procedure than induces \u03b2-structure formation, and not the solvent per se.", [["\u03b2-structure", "SIMPLE_CHEMICAL", 68, 79], ["the drying procedure", "TREATMENT", 34, 54], ["\u03b2-structure formation", "PROBLEM", 68, 89]]], ["This \u03b2-structure is retained even after reconstitution in lipids, unless the sample is extruded repeatedly afterwards.", [["sample", "ANATOMY", 77, 83], ["lipids", "SIMPLE_CHEMICAL", 58, 64], ["reconstitution in lipids", "TREATMENT", 40, 64], ["retained", "OBSERVATION_MODIFIER", 20, 28]]], ["This also explains that when added to preformed liposomes, p7 adopts \u03b2-structure regardless of the solvent used (Fig. 3C); while p7 is predominantly \u03b1-helical in any of these solvents, poor incorporation of p7 in the bilayers after being briefly exposed to the aqueous environment results in \u03b2-structure formation.Membrane incorporation of p7 ::: Results and DiscussionAlthough the samples shown in Fig. 3C show a high percentage of \u03b2-structure, it is possible that they are heterogeneous, and that a fraction of the p7 population inserted into membranes is well folded and \u03b1-helical.", [["Membrane", "ANATOMY", 314, 322], ["samples", "ANATOMY", 382, 389], ["membranes", "ANATOMY", 545, 554], ["liposomes", "SIMPLE_CHEMICAL", 48, 57], ["\u03b2-structure", "SIMPLE_CHEMICAL", 292, 303], ["Membrane", "CELLULAR_COMPONENT", 314, 322], ["membranes", "CELLULAR_COMPONENT", 545, 554], ["p7", "PROTEIN", 129, 131], ["p7", "PROTEIN", 207, 209], ["p7 population", "PROTEIN", 517, 530], ["\u03b1-helical", "PROTEIN", 574, 583], ["the samples", "TEST", 378, 389], ["a high percentage of \u03b2-structure", "PROBLEM", 412, 444], ["the p7 population", "TREATMENT", 513, 530], ["is possible", "UNCERTAINTY", 449, 460], ["heterogeneous", "OBSERVATION_MODIFIER", 475, 488], ["well folded", "OBSERVATION", 558, 569]]], ["Indeed, the percentage of inserted protein using this \u2018addition\u2019 method has been previously reported to range from 10 to 50% using Western blot [24], [32].", [["inserted protein", "PROTEIN", 26, 42]]], ["Thus, to compare the conformation of the fraction of p7 incorporated to liposome membranes using the dyalisis method - after extrusion -, and that using the addition method, we initially attempted to use a FLAG-p7 and detection by Western-Blot.", [["liposome membranes", "ANATOMY", 72, 90], ["FLAG", "GENE_OR_GENE_PRODUCT", 206, 210], ["p7", "PROTEIN", 53, 55], ["FLAG", "PROTEIN", 206, 210], ["p7", "PROTEIN", 211, 213], ["liposome membranes", "TREATMENT", 72, 90], ["the dyalisis method", "TREATMENT", 97, 116], ["a FLAG-p7", "TREATMENT", 204, 213], ["liposome membranes", "OBSERVATION", 72, 90]]], ["Therefore, further work to test the presence of p7 in the liposomes was performed with the non-tagged p7 protein, and the presence of p7 was directly monitored using SDS-PAGE of the pure protein.Membrane incorporation of p7 ::: Results and DiscussionThus, two methods, (i) dialysis (extruded) and (ii) addition were used in a flotation experiment to separate membrane-incorporated and non-incorporated p7 protein (Fig. 4A) and to assess its secondary structure.", [["Membrane", "ANATOMY", 195, 203], ["membrane", "ANATOMY", 359, 367], ["p7", "GENE_OR_GENE_PRODUCT", 134, 136], ["Membrane", "CELLULAR_COMPONENT", 195, 203], ["membrane", "CELLULAR_COMPONENT", 359, 367], ["p7", "PROTEIN", 48, 50], ["non-tagged p7 protein", "PROTEIN", 91, 112], ["p7", "PROTEIN", 134, 136], ["pure protein", "PROTEIN", 182, 194], ["p7 protein", "PROTEIN", 402, 412], ["4A", "PROTEIN", 419, 421], ["the non-tagged p7 protein", "TEST", 87, 112], ["SDS", "TEST", 166, 169], ["dialysis (extruded) and (ii)", "TREATMENT", 273, 301], ["a flotation experiment", "TREATMENT", 324, 346], ["secondary structure", "OBSERVATION", 441, 460]]], ["In both samples, p7 was found in both fractions LIP and PEL, and in similar proportion (Fig. 4B\u2013C), i.e., p7 is indeed incorporated in liposome membranes in both samples.", [["samples", "ANATOMY", 8, 15], ["PEL", "ANATOMY", 56, 59], ["liposome membranes", "ANATOMY", 135, 153], ["samples", "ANATOMY", 162, 169], ["p7", "GENE_OR_GENE_PRODUCT", 17, 19], ["PEL", "CANCER", 56, 59], ["liposome membranes", "CELLULAR_COMPONENT", 135, 153], ["p7", "PROTEIN", 17, 19], ["LIP", "PROTEIN", 48, 51], ["PEL", "CELL_LINE", 56, 59], ["p7", "PROTEIN", 106, 108], ["both", "ANATOMY_MODIFIER", 33, 37], ["fractions LIP", "ANATOMY", 38, 51], ["PEL", "ANATOMY", 56, 59], ["liposome membranes", "OBSERVATION", 135, 153]]], ["A substantial part of the protein appeared as aggregates, accumulated on top of the gel (white arrows) or as clearly defined p7 oligomers (black dots and arrows).", [["p7 oligomers", "PROTEIN", 125, 137], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["protein", "OBSERVATION", 26, 33], ["aggregates", "OBSERVATION", 46, 56]]], ["The presence of high oligomeric forms may be due to the TCA precipitation, prior to SDS solubilization.Membrane incorporation of p7 ::: Results and DiscussionIt is noteworthy that a considerable fraction of p7 was also found in the PEL fraction (Fig. 4C, lane PEL(20\u00d7)), despite the fact that the bulk extruded sample is \u03b1-helical (Fig. 3B).", [["Membrane", "ANATOMY", 103, 111], ["sample", "ANATOMY", 311, 317], ["TCA", "CHEMICAL", 56, 59], ["TCA", "CHEMICAL", 56, 59], ["TCA", "SIMPLE_CHEMICAL", 56, 59], ["Membrane", "CELLULAR_COMPONENT", 103, 111], ["PEL", "CANCER", 232, 235], ["p7", "PROTEIN", 207, 209], ["PEL fraction", "CELL_LINE", 232, 244], ["high oligomeric forms", "PROBLEM", 16, 37], ["the TCA precipitation", "PROBLEM", 52, 73], ["SDS solubilization", "TREATMENT", 84, 102], ["a considerable fraction of p7", "PROBLEM", 180, 209], ["the bulk extruded sample", "PROBLEM", 293, 317], ["high oligomeric forms", "OBSERVATION", 16, 37], ["may be due to", "UNCERTAINTY", 38, 51], ["PEL", "ANATOMY", 232, 235]]], ["This suggests that the PEL fraction is not merely protein precipitate, but it must also contain lipid.", [["PEL", "CANCER", 23, 26], ["lipid", "SIMPLE_CHEMICAL", 96, 101], ["PEL fraction", "CELL_LINE", 23, 35], ["the PEL fraction", "TEST", 19, 35], ["PEL", "OBSERVATION", 23, 26], ["not merely", "UNCERTAINTY", 39, 49]]], ["To test this, we analyzed by dynamic light scattering (DLS) the contents of the flotation tube, from top to bottom, in 400 \u00b5L fractions.", [["tube", "TISSUE", 90, 94], ["the flotation tube", "TREATMENT", 76, 94], ["flotation tube", "OBSERVATION", 80, 94]]], ["The results showed that liposomes were also present at the bottom of the tube in both samples (Fig. S6 in File S1).", [["tube", "ANATOMY", 73, 77], ["samples", "ANATOMY", 86, 93], ["liposomes", "SIMPLE_CHEMICAL", 24, 33], ["tube", "TISSUE", 73, 77], ["File S1", "GENE_OR_GENE_PRODUCT", 106, 113], ["S6", "PROTEIN", 100, 102], ["liposomes", "PROBLEM", 24, 33], ["liposomes", "OBSERVATION", 24, 33], ["tube", "OBSERVATION", 73, 77], ["S1", "ANATOMY", 111, 113]]], ["The latter suggests that a fraction of the liposomes contains an excessive proportion of p7 protein incorporated, and sinks to the bottom of the tube.", [["tube", "ANATOMY", 145, 149], ["liposomes", "SIMPLE_CHEMICAL", 43, 52], ["tube", "TISSUE", 145, 149], ["p7 protein", "PROTEIN", 89, 99], ["p7 protein", "TREATMENT", 89, 99], ["the tube", "TREATMENT", 141, 149], ["fraction", "OBSERVATION_MODIFIER", 27, 35], ["liposomes", "OBSERVATION_MODIFIER", 43, 52], ["excessive", "OBSERVATION_MODIFIER", 65, 74], ["proportion", "OBSERVATION_MODIFIER", 75, 85], ["p7 protein incorporated", "OBSERVATION", 89, 112], ["tube", "OBSERVATION", 145, 149]]], ["The estimated density of the lipid fraction in PAESC liposomes is 1.03 g/mL [35]\u2013[37], whereas the density of the three phases used in the sucrose gradient, 0, 10 and 20%, are 1.01548, 1.05534 and 1.09827 g/mL, respectively.", [["PAESC", "CHEMICAL", 47, 52], ["sucrose", "CHEMICAL", 139, 146], ["sucrose", "CHEMICAL", 139, 146], ["lipid", "SIMPLE_CHEMICAL", 29, 34], ["PAESC liposomes", "SIMPLE_CHEMICAL", 47, 62], ["sucrose", "SIMPLE_CHEMICAL", 139, 146], ["the lipid fraction", "TEST", 25, 43], ["PAESC liposomes", "TEST", 47, 62], ["the sucrose gradient", "TEST", 135, 155], ["density", "OBSERVATION", 14, 21], ["lipid fraction", "OBSERVATION", 29, 43], ["sucrose gradient", "OBSERVATION", 139, 155]]], ["Therefore, pure liposomes should accumulate at the interface between 0 and 10% of sucrose.", [["sucrose", "CHEMICAL", 82, 89], ["sucrose", "CHEMICAL", 82, 89], ["liposomes", "SIMPLE_CHEMICAL", 16, 25], ["sucrose", "SIMPLE_CHEMICAL", 82, 89], ["pure liposomes", "TREATMENT", 11, 25], ["sucrose", "TREATMENT", 82, 89]]], ["At the lipid-to-protein ratio molar used in the experiment (100\u22361), and assuming uniform incorporation, the density of the liposomes should be 1.0499 g/mL, therefore these liposomes should still accumulate at the 0\u201310% interface.", [["lipid", "SIMPLE_CHEMICAL", 7, 12], ["liposomes", "SIMPLE_CHEMICAL", 123, 132], ["liposomes", "SIMPLE_CHEMICAL", 172, 181], ["these liposomes", "TREATMENT", 166, 181], ["uniform", "OBSERVATION_MODIFIER", 81, 88], ["incorporation", "OBSERVATION", 89, 102], ["density", "OBSERVATION_MODIFIER", 108, 115]]], ["However, if the incorporation is not homogeneous, e.g., if the lipid to protein ratio is between 70\u22361 and 20\u22361, the liposomes would be found in the 10% section.", [["lipid", "SIMPLE_CHEMICAL", 63, 68], ["liposomes", "SIMPLE_CHEMICAL", 116, 125], ["the lipid to protein ratio", "TEST", 59, 85], ["homogeneous", "OBSERVATION_MODIFIER", 37, 48]]], ["The results observed (Fig. S6B in File S1) indicate that some liposomes contain more p7 than that corresponding to a ratio 1\u223620, as they are found at the bottom of the 20% sucrose section.Membrane incorporation of p7 ::: Results and DiscussionTo test if p7 is \u03b1-helical when incorporated to membranes, protein isolated in the two conditions from the (LIP) or (PEL) fractions were measured in an ATR-FTIR experiment.", [["Membrane", "ANATOMY", 188, 196], ["membranes", "ANATOMY", 291, 300], ["sucrose", "CHEMICAL", 172, 179], ["sucrose", "CHEMICAL", 172, 179], ["liposomes", "SIMPLE_CHEMICAL", 62, 71], ["sucrose", "SIMPLE_CHEMICAL", 172, 179], ["Membrane", "CELLULAR_COMPONENT", 188, 196], ["p7", "GENE_OR_GENE_PRODUCT", 254, 256], ["membranes", "CELLULAR_COMPONENT", 291, 300], ["p7", "PROTEIN", 254, 256], ["\u03b1-helical", "PROTEIN", 260, 269], ["some liposomes", "PROBLEM", 57, 71], ["more p7", "OBSERVATION_MODIFIER", 80, 87], ["LIP", "ANATOMY", 351, 354], ["FTIR experiment", "OBSERVATION", 399, 414]]], ["Consistent with the results shown in Fig. 3, whereas in the extrusion sample p7 (LIP fraction) adopted a clearly \u03b1-helical conformation, the LIP fraction recovered after addition contained more than 50% of \u03b2-structure (Fig. 4, D\u2013E).", [["the extrusion sample", "TEST", 56, 76], ["the LIP fraction", "TEST", 137, 153], ["LIP", "ANATOMY", 141, 144]]], ["Similar results were obtained in the PEL fraction for both conditions (not shown).", [["PEL", "CANCER", 37, 40], ["PEL fraction", "CELL_LINE", 37, 49], ["the PEL fraction", "TEST", 33, 49]]], ["Thus, although we cannot discard the possibility that, after addition, some fraction of the population inserted in liposome membranes is in the A form, it is clear that the dyalisis/extruded sample is predominantly \u03b1-helical.Form A is not responsible for CF release ::: Results and Discussionp7 has been shown previously to permeabilize liposomes and induce release of the large dye carboxyfluorescein (CF) [7].", [["liposome membranes", "ANATOMY", 115, 133], ["sample", "ANATOMY", 191, 197], ["Discussionp7", "CHEMICAL", 282, 294], ["dye carboxyfluorescein", "CHEMICAL", 379, 401], ["carboxyfluorescein", "CHEMICAL", 383, 401], ["liposome membranes", "CELLULAR_COMPONENT", 115, 133], ["liposomes", "SIMPLE_CHEMICAL", 337, 346], ["large dye carboxyfluorescein", "SIMPLE_CHEMICAL", 373, 401], ["Discussionp7", "PROTEIN", 282, 294], ["liposome membranes", "TREATMENT", 115, 133], ["the dyalisis/extruded sample", "TREATMENT", 169, 197], ["the large dye carboxyfluorescein", "TREATMENT", 369, 401], ["population", "OBSERVATION", 92, 102], ["liposome membranes", "OBSERVATION", 115, 133], ["not responsible", "UNCERTAINTY", 235, 250]]], ["We observed no significant differences in the magnitude or in the kinetics of CF release when p7 solubilized in TFE, HFIP or methanol was added to PAESC liposomes (Fig. 5A).", [["TFE", "CHEMICAL", 112, 115], ["HFIP", "CHEMICAL", 117, 121], ["methanol", "CHEMICAL", 125, 133], ["TFE", "CHEMICAL", 112, 115], ["HFIP", "CHEMICAL", 117, 121], ["methanol", "CHEMICAL", 125, 133], ["TFE", "SIMPLE_CHEMICAL", 112, 115], ["HFIP", "SIMPLE_CHEMICAL", 117, 121], ["methanol", "SIMPLE_CHEMICAL", 125, 133], ["PAESC liposomes", "SIMPLE_CHEMICAL", 147, 162], ["significant differences", "PROBLEM", 15, 38], ["HFIP", "TREATMENT", 117, 121], ["methanol", "TREATMENT", 125, 133], ["no", "UNCERTAINTY", 12, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["differences", "OBSERVATION_MODIFIER", 27, 38]]], ["This is consistent with the similar \u03b2-structure content of these preparations (Fig. 3C).Form A is not responsible for CF release ::: Results and DiscussionTo test if an incorrectly incorporated form of p7 is responsible for this CF release, we compared CF-release results from \u2018addition\u2019 experiments using p7(1-63) with its fragments, p7(27-63) and p7(1-26), that cannot form an \u03b1-helical hairpin or a native p7 structure. p7(27-63) corresponds to TM2 (more hydrophobic) and the extramembrane loop, whereas p7(1-26) corresponds to TM1 (more hydrophylic).Form A is not responsible for CF release ::: Results and DiscussionThe more hydrophobic fragment p7(27-63) was as efficient as full length p7 in releasing CF, although less than melittin (Fig. 5B), whereas p7(1-26) did not elicit CF release.", [["extramembrane loop", "ANATOMY", 479, 497], ["p7", "GENE_OR_GENE_PRODUCT", 202, 204], ["TM2", "GENE_OR_GENE_PRODUCT", 448, 451], ["TM1", "AMINO_ACID", 531, 534], ["CF", "PATHOLOGICAL_FORMATION", 709, 711], ["melittin", "SIMPLE_CHEMICAL", 732, 740], ["CF", "MULTI-TISSUE_STRUCTURE", 784, 786], ["p7", "PROTEIN", 202, 204], ["\u03b1-helical hairpin", "PROTEIN", 379, 396], ["p7 structure", "PROTEIN", 409, 421], ["TM2", "PROTEIN", 448, 451], ["extramembrane loop", "PROTEIN", 479, 497], ["TM1", "PROTEIN", 531, 534], ["p7", "PROTEIN", 693, 695], ["the extramembrane loop", "PROBLEM", 475, 497], ["hydrophobic fragment p7", "TEST", 630, 653], ["consistent with", "UNCERTAINTY", 8, 23], ["not responsible", "UNCERTAINTY", 98, 113], ["fragments", "OBSERVATION", 324, 333], ["hairpin", "OBSERVATION", 389, 396], ["extramembrane loop", "ANATOMY", 479, 497], ["TM1", "ANATOMY", 531, 534], ["not responsible", "UNCERTAINTY", 564, 579]]], ["For comparison, we used a similar hydrophobic protein with a single transmembrane (TM) domain, the peptide M2 (18-60) from influenza A, which caused only a minor CF release (Fig. S7 in File S1), suggesting that CF release may be specific for the C-terminal region of p7.", [["transmembrane", "ANATOMY", 68, 81], ["C", "CHEMICAL", 246, 247], ["File S1", "GENE_OR_GENE_PRODUCT", 185, 192], ["p7", "GENE_OR_GENE_PRODUCT", 267, 269], ["hydrophobic protein", "PROTEIN", 34, 53], ["transmembrane (TM) domain", "PROTEIN", 68, 93], ["S7", "PROTEIN", 179, 181], ["C-terminal region", "PROTEIN", 246, 263], ["p7", "PROTEIN", 267, 269], ["a single transmembrane (TM) domain", "TREATMENT", 59, 93], ["the peptide M2", "TEST", 95, 109], ["influenza A", "PROBLEM", 123, 134], ["CF release", "PROBLEM", 211, 221], ["the C-terminal region of p7", "PROBLEM", 242, 269], ["terminal", "ANATOMY_MODIFIER", 248, 256], ["region", "ANATOMY_MODIFIER", 257, 263]]], ["In summary, these results show that correct incorporation and native conformation of full length p7 is not necessary to elicit CF release, and that insertion of the TM2 fraction of p7 into lipid bilayers may be sufficient, based on the more hydrophobic nature of TM2.", [["lipid bilayers", "ANATOMY", 189, 203], ["TM2", "GENE_OR_GENE_PRODUCT", 263, 266], ["p7", "PROTEIN", 97, 99], ["p7", "PROTEIN", 181, 183], ["TM2", "PROTEIN", 263, 266], ["full length p7", "TREATMENT", 85, 99], ["the TM2 fraction", "TREATMENT", 161, 177]]], ["We note that in a recently published structural model of p7 [20], TM1 and TM2 would correspond to three helical segments H1\u2013H3, i.e., H1 and first half of H2 (TM1), and second half of H2 and H3 (TM2).", [["H2", "CHEMICAL", 155, 157], ["H2", "CHEMICAL", 184, 186], ["TM2", "CHEMICAL", 195, 198], ["p7 [20]", "GENE_OR_GENE_PRODUCT", 57, 64], ["TM1", "GENE_OR_GENE_PRODUCT", 66, 69], ["TM2", "AMINO_ACID", 74, 77], ["H1\u2013H3", "GENE_OR_GENE_PRODUCT", 121, 126], ["H3", "GENE_OR_GENE_PRODUCT", 191, 193], ["TM2", "AMINO_ACID", 195, 198], ["TM1", "PROTEIN", 66, 69], ["TM2", "PROTEIN", 74, 77], ["helical segments", "PROTEIN", 104, 120], ["H1", "PROTEIN", 121, 123], ["H3", "PROTEIN", 124, 126], ["H1", "PROTEIN", 134, 136], ["H2", "PROTEIN", 155, 157], ["TM1", "PROTEIN", 159, 162], ["H2", "PROTEIN", 184, 186], ["H3", "PROTEIN", 191, 193], ["TM2", "PROTEIN", 195, 198], ["TM1 and TM2", "TREATMENT", 66, 77], ["three", "ANATOMY_MODIFIER", 98, 103], ["helical", "ANATOMY_MODIFIER", 104, 111], ["segments", "ANATOMY_MODIFIER", 112, 120]]], ["In that model, p7(27-63) is not the pore-lining sequence and forms the \u2018lipid facing\u2019 part of the molecule.Form A is not responsible for CF release ::: Results and DiscussionTo test if form A is responsible for CF release, we incorporated p7 into CF-containing PAESC liposomes by the dyalisis method, freeze-thawing and extrusion, which should result in p7 incorporation in membranes in an \u03b1-helical form A (see Fig. 3B and Fig. 4).", [["membranes", "ANATOMY", 374, 383], ["PAESC liposomes", "SIMPLE_CHEMICAL", 261, 276], ["membranes", "CELLULAR_COMPONENT", 374, 383], ["pore-lining sequence", "PROTEIN", 36, 56], ["p7", "PROTEIN", 354, 356], ["PAESC liposomes", "TREATMENT", 261, 276], ["extrusion", "PROBLEM", 320, 329], ["p7 incorporation in membranes", "PROBLEM", 354, 383], ["not responsible", "UNCERTAINTY", 117, 132]]], ["However, after removing non incorporated CF, no significant differences in fluorescence were observed between the CF-loaded control (without p7) and sample (with p7) liposomes (Fig. 5C, white bars).", [["p7", "PROTEIN", 141, 143], ["significant differences in fluorescence", "PROBLEM", 48, 87], ["the CF-loaded control", "TREATMENT", 110, 131], ["sample", "TEST", 149, 155], ["no", "UNCERTAINTY", 45, 47], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["Most or all CF was still encapsulated, as shown by the large increase in fluorescence after Triton X-100 addition in both preparations (Fig. 5C, grey bars), and kinetics of CF release were also similar to the addition of only methanol to the liposomes (Fig. 5D).", [["Triton X-100", "CHEMICAL", 92, 104], ["Triton X-100", "CHEMICAL", 92, 104], ["methanol", "CHEMICAL", 226, 234], ["Triton X-100", "SIMPLE_CHEMICAL", 92, 104], ["methanol", "SIMPLE_CHEMICAL", 226, 234], ["liposomes", "SIMPLE_CHEMICAL", 242, 251], ["the large increase in fluorescence", "PROBLEM", 51, 85], ["Triton X", "TREATMENT", 92, 100], ["methanol to the liposomes", "TREATMENT", 226, 251], ["encapsulated", "OBSERVATION", 25, 37], ["large", "OBSERVATION_MODIFIER", 55, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69]]], ["Thus, the result of this experiment is incompatible with form A being responsible for CF release.Localization of p7 permeabilizing domain ::: Results and DiscussionCF release is affected by mutations that change p7 conformation or liposome insertion, e.g., Ala mutants in a genotype 1b J4 context K33A/R35A, H17A, G39A and P49A) [32].", [["Ala", "CHEMICAL", 257, 260], ["CF", "MULTI-TISSUE_STRUCTURE", 86, 88], ["p7 permeabilizing domain", "PROTEIN", 113, 137], ["p7", "PROTEIN", 212, 214], ["Ala mutants", "PROTEIN", 257, 268], ["CF release", "PROBLEM", 86, 96], ["liposome insertion", "TREATMENT", 231, 249]]], ["These authors showed that most of these mutants could form oligomers in detergent, and could insert in membranes.", [["membranes", "ANATOMY", 103, 112], ["membranes", "CELLULAR_COMPONENT", 103, 112]]], ["However, K33A/R35A was the least able to produce CF release, and also was the least able to insert in liposomes in a Ficoll gradient experiment.", [["liposomes", "SIMPLE_CHEMICAL", 102, 111], ["K33A", "PROTEIN", 9, 13], ["K33A", "TEST", 9, 13], ["a Ficoll gradient experiment", "TREATMENT", 115, 143], ["Ficoll gradient", "OBSERVATION", 117, 132]]], ["The basic residues K33 and R35 have been located in a loop region separating TM1 and TM2 in previous reports [12], [14].", [["K33", "GENE_OR_GENE_PRODUCT", 19, 22], ["R35", "AMINO_ACID", 27, 30], ["TM1", "AMINO_ACID", 77, 80], ["TM2", "AMINO_ACID", 85, 88], ["R35", "PROTEIN", 27, 30], ["loop region", "PROTEIN", 54, 65], ["TM1", "PROTEIN", 77, 80], ["TM2", "PROTEIN", 85, 88], ["The basic residues K33", "TEST", 0, 22], ["residues K33", "OBSERVATION", 10, 22], ["loop", "OBSERVATION_MODIFIER", 54, 58], ["TM2", "OBSERVATION_MODIFIER", 85, 88]]], ["These residues also appear between two helical segments in a recent structure of p7 in DPC micelles [20], where TM1 is proposed to line the lumen of the channel.Localization of p7 permeabilizing domain ::: Results and DiscussionThe region encompassing these residues in the interhelical loop region were predicted to be \u03b1-helical in 50% TFE, but were not \u03b1-helical in DHPC micelles [12], [14] (Fig. S8 in File S1).", [["lumen", "ANATOMY", 140, 145], ["TFE", "CHEMICAL", 337, 340], ["TM1", "AMINO_ACID", 112, 115], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 140, 145], ["TFE", "SIMPLE_CHEMICAL", 337, 340], ["\u03b1-helical", "SIMPLE_CHEMICAL", 355, 364], ["DHPC", "SIMPLE_CHEMICAL", 368, 372], ["[14]", "SIMPLE_CHEMICAL", 388, 392], ["helical segments", "PROTEIN", 39, 55], ["p7", "PROTEIN", 81, 83], ["TM1", "PROTEIN", 112, 115], ["p7 permeabilizing domain", "PROTEIN", 177, 201], ["interhelical loop region", "PROTEIN", 274, 298], ["S8", "PROTEIN", 399, 401], ["these residues in the interhelical loop region", "PROBLEM", 252, 298], ["helical", "OBSERVATION_MODIFIER", 39, 46], ["segments", "OBSERVATION_MODIFIER", 47, 55], ["lumen", "ANATOMY_MODIFIER", 140, 145], ["channel", "ANATOMY", 153, 160], ["interhelical", "ANATOMY_MODIFIER", 274, 286], ["S1", "ANATOMY", 410, 412]]], ["In another study [38], a synthetic peptide corresponding to that loop, p7(F25-Y42), produced only \u03b2-structure in presence of lipid bilayers, and this stretch of amino acids was found to be the most efficient at disrupting liposome integrity.", [["liposome", "ANATOMY", 222, 230], ["amino acids", "CHEMICAL", 161, 172], ["amino acids", "CHEMICAL", 161, 172], ["lipid bilayers", "SIMPLE_CHEMICAL", 125, 139], ["amino acids", "AMINO_ACID", 161, 172], ["liposome", "SIMPLE_CHEMICAL", 222, 230], ["another study", "TEST", 3, 16], ["a synthetic peptide", "TREATMENT", 23, 42], ["lipid bilayers", "PROBLEM", 125, 139], ["this stretch of amino acids", "TEST", 145, 172], ["lipid bilayers", "OBSERVATION", 125, 139]]], ["Regions in and around the loop contain abundant \u03b2-branched side chains (V, I), and bulky residues (Y, F,W), which disfavor \u03b1-helical conformation [39]\u2013[41].", [["\u03b2-branched side chains", "PROTEIN", 48, 70], ["bulky residues", "PROBLEM", 83, 97], ["loop", "ANATOMY_MODIFIER", 26, 30], ["abundant", "OBSERVATION_MODIFIER", 39, 47], ["\u03b2-branched", "OBSERVATION_MODIFIER", 48, 58], ["side", "OBSERVATION_MODIFIER", 59, 63], ["chains", "OBSERVATION_MODIFIER", 64, 70], ["bulky residues", "OBSERVATION", 83, 97]]], ["Thus, this small loop region is a candidate to elicit CF release, although alone does not account for the extent of \u03b2-structure found in form B (Fig. 3), which may be likely contributed by either TM1 or TM2.Localization of p7 permeabilizing domain ::: Results and DiscussionTo identify which regions form \u03b2-structure in form B, we attempted to perform native chemical ligation between a C-terminal thioester p7(1-26), encompassing TM1, and p7(27-63), encompassing TM2, with an N-terminal cysteine [42] Cys27 (Figs.", [["C", "CHEMICAL", 387, 388], ["thioester", "CHEMICAL", 398, 407], ["N", "CHEMICAL", 477, 478], ["cysteine", "CHEMICAL", 488, 496], ["TM1", "GENE_OR_GENE_PRODUCT", 196, 199], ["TM2", "GENE_OR_GENE_PRODUCT", 203, 206], ["TM1", "GENE_OR_GENE_PRODUCT", 431, 434], ["TM2", "AMINO_ACID", 464, 467], ["TM1", "PROTEIN", 196, 199], ["TM2", "PROTEIN", 203, 206], ["p7 permeabilizing domain", "PROTEIN", 223, 247], ["\u03b2-structure", "PROTEIN", 305, 316], ["form B", "PROTEIN", 320, 326], ["C-terminal thioester p7", "PROTEIN", 387, 410], ["TM1", "PROTEIN", 431, 434], ["TM2", "PROTEIN", 464, 467], ["this small loop region", "PROBLEM", 6, 28], ["CF release", "PROBLEM", 54, 64], ["\u03b2-structure", "PROBLEM", 116, 127], ["native chemical ligation", "TREATMENT", 352, 376], ["a C-terminal thioester p7", "TREATMENT", 385, 410], ["TM1", "TEST", 431, 434], ["p7", "TEST", 440, 442], ["TM2", "TEST", 464, 467], ["small", "OBSERVATION_MODIFIER", 11, 16], ["loop", "OBSERVATION", 17, 21], ["\u03b2-structure", "OBSERVATION", 116, 127], ["may be likely", "UNCERTAINTY", 160, 173], ["ligation", "OBSERVATION", 368, 376], ["terminal", "ANATOMY_MODIFIER", 389, 397], ["TM1", "ANATOMY_MODIFIER", 431, 434]]], ["S2 and S3 in File S1).", [["File S1", "GENE_OR_GENE_PRODUCT", 13, 20], ["S2", "PROTEIN", 0, 2], ["S3", "PROTEIN", 7, 9], ["S3", "ANATOMY", 7, 9], ["S1", "ANATOMY", 18, 20]]], ["A successful ligation with differentially 13C labeled fragments (roughly corresponding to TM1 and TM2 [12], [14]) would produce a hybrid sample the results of which could be easily interpreted by IR.", [["fragments", "ANATOMY", 54, 63], ["13C", "CHEMICAL", 42, 45], ["13C", "SIMPLE_CHEMICAL", 42, 45], ["TM1", "PROTEIN", 90, 93], ["A successful ligation", "TREATMENT", 0, 21], ["differentially 13C labeled fragments", "PROBLEM", 27, 63], ["TM2", "TEST", 98, 101], ["successful", "OBSERVATION_MODIFIER", 2, 12], ["ligation", "OBSERVATION", 13, 21], ["labeled fragments", "OBSERVATION", 46, 63], ["TM1", "ANATOMY_MODIFIER", 90, 93]]], ["The ligation was successful, but did not produce sufficient yield (Figs.", [["The ligation", "TREATMENT", 0, 12], ["ligation", "OBSERVATION", 4, 12]]], ["S4 and S5 in File S1).", [["File S1", "GENE_OR_GENE_PRODUCT", 13, 20], ["S4", "PROTEIN", 0, 2], ["S5", "PROTEIN", 7, 9], ["S5", "OBSERVATION_MODIFIER", 7, 9], ["S1", "ANATOMY", 18, 20]]], ["Nevertheless, these two peptides were analyzed independently by ATR-FTIR.Localization of p7 permeabilizing domain ::: Results and DiscussionThe synthetic N-terminal peptide p7(1-26) was totally insoluble in TFE or in detergent.", [["N-terminal peptide p7(1-26)", "CHEMICAL", 154, 181], ["TFE", "CHEMICAL", 207, 210], ["N", "CHEMICAL", 154, 155], ["TFE", "CHEMICAL", 207, 210], ["ATR", "SIMPLE_CHEMICAL", 64, 67], ["1-26)", "SIMPLE_CHEMICAL", 176, 181], ["TFE", "SIMPLE_CHEMICAL", 207, 210], ["p7 permeabilizing domain", "PROTEIN", 89, 113], ["The synthetic N-terminal peptide p7", "TREATMENT", 140, 175]]], ["The difficulty in handling and purification of the N-terminal fragment of p7 has been reported previously for p7(1-34) [12].", [["N", "CHEMICAL", 51, 52], ["p7", "GENE_OR_GENE_PRODUCT", 74, 76], ["N-terminal fragment", "PROTEIN", 51, 70], ["p7", "PROTEIN", 74, 76], ["The difficulty in handling", "PROBLEM", 0, 26], ["the N-terminal fragment of p7", "TREATMENT", 47, 76], ["terminal", "OBSERVATION_MODIFIER", 53, 61], ["fragment", "OBSERVATION", 62, 70]]], ["After solubilization in methanol and \u2018direct\u2019 reconstitution in DMPC liposomes, p7(1-26) produced a spectrum in the amide I consistent with \u223c100% \u03b2-structure (Fig. 6, A\u2013B, dotted line).", [["DMPC", "CHEMICAL", 64, 68], ["p7(1-26", "CHEMICAL", 80, 87], ["methanol", "CHEMICAL", 24, 32], ["DMPC", "CHEMICAL", 64, 68], ["amide I", "CHEMICAL", 116, 123], ["methanol", "SIMPLE_CHEMICAL", 24, 32], ["DMPC liposomes", "SIMPLE_CHEMICAL", 64, 78], ["amide I", "PROTEIN", 116, 123], ["solubilization in methanol", "TREATMENT", 6, 32], ["\u2018direct\u2019 reconstitution in DMPC liposomes", "TREATMENT", 37, 78], ["A\u2013B, dotted line", "TREATMENT", 167, 183]]], ["A high content (\u223c50%) in \u03b2-structure was also observed when the peptide was previously solubilized in HFIP (Fig. 6, A\u2013B, solid line).", [["HFIP", "SIMPLE_CHEMICAL", 102, 106], ["solid line", "CELL", 121, 131], ["A high content", "PROBLEM", 0, 14], ["high content", "OBSERVATION_MODIFIER", 2, 14], ["solid line", "OBSERVATION", 121, 131]]], ["The C-terminal peptide, p7(27-63) in contrast, was more \u03b1-helical in both conditions tested (Fig. 6, C\u2013D), although with more \u03b2-structure in the methanol condition.", [["C", "CHEMICAL", 4, 5], ["methanol", "CHEMICAL", 145, 153], ["methanol", "SIMPLE_CHEMICAL", 145, 153], ["The C-terminal peptide", "TEST", 0, 22], ["terminal", "ANATOMY_MODIFIER", 6, 14], ["methanol condition", "OBSERVATION", 145, 163]]], ["Nevertheless, it is remarkable that neither TM domains of p7, especially TM1, behaves like typical \u03b1-helical TM domains in similar membrane proteins.", [["membrane", "ANATOMY", 131, 139], ["p7", "GENE_OR_GENE_PRODUCT", 58, 60], ["TM1", "GENE_OR_GENE_PRODUCT", 73, 76], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["TM domains", "PROTEIN", 44, 54], ["p7", "PROTEIN", 58, 60], ["TM1", "PROTEIN", 73, 76], ["\u03b1-helical TM domains", "PROTEIN", 99, 119], ["membrane proteins", "PROTEIN", 131, 148], ["membrane proteins", "OBSERVATION", 131, 148]]], ["For example, \u03b1-helical TM domains in integrins [43], phospholamban [44], influenza A M2 [45], SARS-CoV E [29], or RSV SH [46] produce sharp amide I bands in the infrared spectrum consistent with \u223c100% \u03b1-helix.Localization of p7 permeabilizing domain ::: Results and DiscussionIn agreement with the above, it has been noted that the N-terminal half of p7 is more hydrophilic [15], and the predicted hydrophobic segment (starting at residue \u223c13) is too short to form a TM \u03b1-helix.", [["amide I", "CHEMICAL", 140, 147], ["N", "CHEMICAL", 332, 333], ["integrins", "GENE_OR_GENE_PRODUCT", 37, 46], ["phospholamban [44]", "SIMPLE_CHEMICAL", 53, 71], ["RSV", "ORGANISM", 114, 117], ["\u03b1-helix", "SIMPLE_CHEMICAL", 201, 208], ["\u03b1-helical TM domains", "PROTEIN", 13, 33], ["integrins", "PROTEIN", 37, 46], ["p7 permeabilizing domain", "PROTEIN", 225, 249], ["N-terminal half", "PROTEIN", 332, 347], ["p7", "PROTEIN", 351, 353], ["hydrophobic segment", "PROTEIN", 398, 417], ["TM \u03b1-helix", "PROTEIN", 467, 477], ["\u03b1-helical TM domains in integrins", "TEST", 13, 46], ["phospholamban", "TEST", 53, 66], ["influenza A M2", "TEST", 73, 87], ["SARS-CoV E", "TEST", 94, 104], ["RSV SH", "TEST", 114, 120], ["sharp amide I bands", "PROBLEM", 134, 153], ["the infrared spectrum", "TEST", 157, 178], ["hydrophobic", "OBSERVATION_MODIFIER", 398, 409], ["segment", "OBSERVATION_MODIFIER", 410, 417]]], ["In contrast, TM2 has the appropriate length and hydrophobicity to constitute a \u2018real\u2019 \u03b1-helical TM.", [["TM2", "GENE_OR_GENE_PRODUCT", 13, 16], ["TM2", "PROTEIN", 13, 16], ["\u03b1-helical TM", "PROTEIN", 86, 98], ["appropriate length", "OBSERVATION_MODIFIER", 25, 43]]], ["Based on the above considerations, TM1 may be more difficult to incorporate in lipid bilayers than TM2, and more likely to fold forming \u03b2-structure, presenting itself as a totally or partially exposed peptide to the aqueous solution under certain reconstitution conditions.Proton channel activity of p7 form A ::: Results and DiscussionHaving examined the conditions in which we can obtain form A, consistent with an \u03b1-helical hairpin, or a mostly helical structure [12], [20], we tested the ability of form A in transporting protons.", [["lipid bilayers", "ANATOMY", 79, 93], ["TM1", "GENE_OR_GENE_PRODUCT", 35, 38], ["TM2", "AMINO_ACID", 99, 102], ["[20]", "SIMPLE_CHEMICAL", 472, 476], ["protons", "SIMPLE_CHEMICAL", 526, 533], ["\u03b1-helical hairpin", "PROTEIN", 417, 434], ["the aqueous solution", "TREATMENT", 212, 232], ["Proton channel activity", "TREATMENT", 273, 296], ["an \u03b1-helical hairpin", "PROBLEM", 414, 434], ["more likely", "UNCERTAINTY", 108, 119], ["\u03b2-structure", "OBSERVATION", 136, 147]]], ["Proton channel activity of p7 has been observed in infected mammalian cells, acting to prevent acidification of intracellular vesicles [8], and was found to be essential for productive HCV infection.", [["cells", "ANATOMY", 70, 75], ["intracellular vesicles", "ANATOMY", 112, 134], ["HCV infection", "DISEASE", 185, 198], ["p7", "GENE_OR_GENE_PRODUCT", 27, 29], ["mammalian cells", "CELL", 60, 75], ["intracellular vesicles", "CELLULAR_COMPONENT", 112, 134], ["HCV", "ORGANISM", 185, 188], ["p7", "PROTEIN", 27, 29], ["infected mammalian cells", "CELL_TYPE", 51, 75], ["HCV", "SPECIES", 185, 188], ["Proton channel activity of p7", "TREATMENT", 0, 29], ["infected mammalian cells", "TREATMENT", 51, 75], ["acidification of intracellular vesicles", "PROBLEM", 95, 134], ["productive HCV infection", "PROBLEM", 174, 198], ["infected mammalian cells", "OBSERVATION", 51, 75], ["intracellular vesicles", "ANATOMY", 112, 134], ["productive", "OBSERVATION_MODIFIER", 174, 184], ["HCV", "OBSERVATION_MODIFIER", 185, 188], ["infection", "OBSERVATION", 189, 198]]], ["However, results from an in vitro assay using purified protein have not been reported to our knowledge.Proton channel activity of p7 form A ::: Results and DiscussionWe performed a proton transport assay where the alkalinization of the external solution is measured after generation of a pH gradient and addition of valinomycin (see Materials and Methods).", [["valinomycin", "CHEMICAL", 316, 327], ["valinomycin", "CHEMICAL", 316, 327], ["valinomycin", "SIMPLE_CHEMICAL", 316, 327], ["purified protein", "PROTEIN", 46, 62], ["an in vitro assay", "TEST", 22, 39], ["a proton transport assay", "TEST", 179, 203], ["the alkalinization of the external solution", "TREATMENT", 210, 253], ["a pH gradient", "PROBLEM", 286, 299], ["valinomycin", "TREATMENT", 316, 327]]], ["First we tested if p7 dried from HFIP (p7H) or methanol (p7M) and reconstituted by the direct method after several extrusion cycles \u2013 where form A will be obtained (Fig. 3B, curve 4) - would be equally able to transport protons.", [["HFIP", "CHEMICAL", 33, 37], ["p7H", "CHEMICAL", 39, 42], ["methanol", "CHEMICAL", 47, 55], ["p7M", "CHEMICAL", 57, 60], ["methanol", "CHEMICAL", 47, 55], ["HFIP", "SIMPLE_CHEMICAL", 33, 37], ["p7H", "SIMPLE_CHEMICAL", 39, 42], ["methanol", "SIMPLE_CHEMICAL", 47, 55], ["protons", "SIMPLE_CHEMICAL", 220, 227], ["methanol (p7M)", "TREATMENT", 47, 61], ["several extrusion cycles", "TREATMENT", 107, 131]]], ["After trying several lipid compositions, p7H (Fig. 7A) was found to be more active in the mixture PAESC (PA/PE/PS/PC 5\u22362\u22362\u22361 w/w), and similar results were obtained for p7M.", [["PAESC", "CHEMICAL", 98, 103], ["p7H", "SIMPLE_CHEMICAL", 41, 44], ["PAESC", "SIMPLE_CHEMICAL", 98, 103], ["PA", "SIMPLE_CHEMICAL", 105, 107], ["p7M", "GENE_OR_GENE_PRODUCT", 169, 172], ["p7M", "PROTEIN", 169, 172], ["PA/PE", "TEST", 105, 110], ["/PS", "TREATMENT", 110, 113], ["PC", "TEST", 114, 116], ["more", "OBSERVATION_MODIFIER", 71, 75], ["active", "OBSERVATION", 76, 82], ["PE", "OBSERVATION", 108, 110]]], ["The proton channel activity was less efficient in E. coli lipids, and completely inactive in the mixture PACC (PA/PE/PC/Chol 50\u223620\u223620\u223610 w/w) (other lipid compositions tested are not shown).", [["PACC", "CHEMICAL", 105, 109], ["Chol", "CHEMICAL", 120, 124], ["E. coli", "ORGANISM", 50, 57], ["PACC", "SIMPLE_CHEMICAL", 105, 109], ["PA", "SIMPLE_CHEMICAL", 111, 113], ["E. coli", "SPECIES", 50, 57], ["E. coli", "SPECIES", 50, 57], ["The proton channel activity", "TREATMENT", 0, 27], ["E. coli lipids", "TREATMENT", 50, 64], ["PA/PE/PC/Chol", "TREATMENT", 111, 124], ["other lipid compositions", "TEST", 143, 167], ["proton channel", "OBSERVATION_MODIFIER", 4, 18], ["coli lipids", "OBSERVATION", 53, 64], ["PE", "OBSERVATION", 114, 116]]], ["The PAESC composition was also previously found to be more suitable for storage and stability of liposomes in CF release high-throughput assays [26].", [["PAESC", "SIMPLE_CHEMICAL", 4, 9], ["liposomes", "SIMPLE_CHEMICAL", 97, 106], ["CF", "SIMPLE_CHEMICAL", 110, 112], ["liposomes in CF release", "TEST", 97, 120]]], ["The pH changes observed were significantly larger than those measured with control liposomes (trace PAESC in Fig. 7A, \u0394pH5 min = 0.03\u00b10.01).Proton channel activity of p7 form A ::: Results and DiscussionThe total pH change 5 min after valinomycin addition (Fig. 7B) was significantly larger (one-way ANOVA, P<0.05) for p7H (\u0394pH5 min = 0.22\u00b10.03) than for p7M (\u0394pH5 min = 0.20\u00b10.01), probably due to p7M incomplete conversion to form A after extrusion.", [["valinomycin", "CHEMICAL", 235, 246], ["valinomycin", "CHEMICAL", 235, 246], ["liposomes", "SIMPLE_CHEMICAL", 83, 92], ["valinomycin", "SIMPLE_CHEMICAL", 235, 246], ["p7M", "PROTEIN", 399, 402], ["The pH changes", "PROBLEM", 0, 14], ["control liposomes", "TREATMENT", 75, 92], ["trace PAESC in Fig", "PROBLEM", 94, 112], ["Proton channel activity", "TREATMENT", 140, 163], ["The total pH change", "TREATMENT", 203, 222], ["valinomycin", "TREATMENT", 235, 246], ["P", "TEST", 307, 308], ["p7H", "TEST", 319, 322], ["p7M", "TEST", 355, 358], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["larger", "OBSERVATION_MODIFIER", 43, 49]]], ["Nevertheless, both preparations were able to transport protons in a concentration dependent fashion.", [["protons", "SIMPLE_CHEMICAL", 55, 62], ["a concentration dependent fashion", "TREATMENT", 66, 99]]], ["For comparison, we used influenza A M2 fragment (18-60), a \u2018classical\u2019 proton channel, which was more efficient than p7 (\u0394pH5 min = 0.25\u00b10.03), even at a protein to lipid ratio \u223c9 times lower (see Materials and Methods).", [["influenza A M2 fragment", "PROBLEM", 24, 47], ["a \u2018classical\u2019 proton channel", "TREATMENT", 57, 85], ["lipid ratio", "TEST", 165, 176]]], ["Rimantadine (5 \u00b5M) partially inhibited the proton channel activity of p7 (Fig. 7C), consistent with previous observations [8].", [["Rimantadine", "CHEMICAL", 0, 11], ["Rimantadine", "CHEMICAL", 0, 11], ["Rimantadine", "SIMPLE_CHEMICAL", 0, 11], ["p7", "PROTEIN", 70, 72], ["Rimantadine", "TREATMENT", 0, 11], ["the proton channel activity", "TREATMENT", 39, 66]]], ["Overall, these results show that form A, consistent with an \u03b1-helical hairpin, is responsible for proton transport.", [["proton", "SIMPLE_CHEMICAL", 98, 104], ["an \u03b1-helical hairpin", "TREATMENT", 57, 77], ["proton transport", "TREATMENT", 98, 114], ["consistent with", "UNCERTAINTY", 41, 56], ["hairpin", "OBSERVATION", 70, 77]]], ["We could not test if form B can also transport protons because the proton transport assay requires extrusion to produce unilamellar liposomes, and this inevitably converts form B to A (Fig. 3B).Proton channel activity of p7 form A ::: Results and DiscussionThen we tested if fragments encompassing TM1 and TM2 can transport protons (Fig. 8).", [["fragments", "ANATOMY", 275, 284], ["protons", "SIMPLE_CHEMICAL", 47, 54], ["proton", "SIMPLE_CHEMICAL", 67, 73], ["unilamellar liposomes", "SIMPLE_CHEMICAL", 120, 141], ["TM1", "GENE_OR_GENE_PRODUCT", 298, 301], ["TM2", "AMINO_ACID", 306, 309], ["form B", "PROTEIN", 21, 27], ["TM1", "PROTEIN", 298, 301], ["TM2", "PROTEIN", 306, 309], ["the proton transport assay", "TEST", 63, 89], ["unilamellar liposomes", "TREATMENT", 120, 141], ["Proton channel activity", "TREATMENT", 194, 217], ["fragments", "PROBLEM", 275, 284]]], ["Both fragments were able to transport protons to some extent, although the linear plot suggests that this permeability may not be specific.", [["fragments", "ANATOMY", 5, 14], ["protons", "SIMPLE_CHEMICAL", 38, 45], ["Both fragments", "PROBLEM", 0, 14], ["the linear plot", "TEST", 71, 86], ["fragments", "OBSERVATION", 5, 14], ["may not be", "UNCERTAINTY", 119, 129]]], ["The total pH change 5 min after valinomycin addition was still significantly larger (one-way ANOVA, P<0.05) for TM2 p7(27-63) (\u0394pH5 min = 0.15\u00b10.01) than for TM1 p7(1-26) (\u0394pH5 min = 0.1\u00b10.01).", [["valinomycin", "CHEMICAL", 32, 43], ["valinomycin", "CHEMICAL", 32, 43], ["valinomycin", "SIMPLE_CHEMICAL", 32, 43], ["The total pH change", "PROBLEM", 0, 19], ["valinomycin", "TREATMENT", 32, 43], ["TM2 p7(", "TEST", 112, 119], ["TM1 p7(1", "TEST", 158, 166], ["larger", "OBSERVATION_MODIFIER", 77, 83]]], ["However, this may simply reflect a more difficult incorporation of TM1 in lipid bilayers.Model for A and B forms of p7 ::: Results and DiscussionThe conclusion of these experiments are summarized in a cartoon representation (Fig. 9), where form B has only one TM inserted in the lipid bilayer (TM2), whereas interhelical loop and TM1 form predominantly \u03b2-structure that may be partially inserted in the membrane.", [["lipid bilayers", "ANATOMY", 74, 88], ["lipid bilayer", "ANATOMY", 279, 292], ["membrane", "ANATOMY", 403, 411], ["TM1", "GENE_OR_GENE_PRODUCT", 67, 70], ["lipid bilayers", "CELLULAR_COMPONENT", 74, 88], ["lipid bilayer", "CELLULAR_COMPONENT", 279, 292], ["TM2", "AMINO_ACID", 294, 297], ["TM1", "AMINO_ACID", 330, 333], ["membrane", "CELLULAR_COMPONENT", 403, 411], ["TM1", "PROTEIN", 67, 70], ["TM", "PROTEIN", 260, 262], ["interhelical loop", "PROTEIN", 308, 325], ["TM1", "PROTEIN", 330, 333], ["\u03b2-structure", "PROTEIN", 353, 364], ["TM1 in lipid bilayers", "TREATMENT", 67, 88], ["interhelical loop and TM1 form predominantly \u03b2-structure", "PROBLEM", 308, 364], ["may simply reflect", "UNCERTAINTY", 14, 32], ["lipid bilayers", "OBSERVATION", 74, 88], ["interhelical loop", "OBSERVATION", 308, 325], ["predominantly", "OBSERVATION_MODIFIER", 339, 352], ["\u03b2-structure", "OBSERVATION", 353, 364], ["may be", "UNCERTAINTY", 370, 376], ["membrane", "ANATOMY_MODIFIER", 403, 411]]], ["Form A, in contrast, is not able to allow CF release, although it is able to transport protons (grey arrow).Model for A and B forms of p7 ::: Results and DiscussionThese models assume that TM2 is the site for inhibition.", [["protons", "SIMPLE_CHEMICAL", 87, 94], ["TM2", "GENE_OR_GENE_PRODUCT", 189, 192], ["TM2", "DNA", 189, 192]]], ["This is supported by the observed direct interaction between the inhibitor amantadine and TM2 leucines 51\u201357, which have been shown unequivocally to be part of a membrane inserted \u03b1-helix [20], [47], and Leu to Ala mutations at this region of TM2 produced an amantadine resistant p7 mutant [32].", [["membrane", "ANATOMY", 162, 170], ["amantadine", "CHEMICAL", 75, 85], ["Leu", "CHEMICAL", 204, 207], ["amantadine", "CHEMICAL", 259, 269], ["amantadine", "CHEMICAL", 75, 85], ["Leu", "CHEMICAL", 204, 207], ["Ala", "CHEMICAL", 211, 214], ["amantadine", "CHEMICAL", 259, 269], ["amantadine", "SIMPLE_CHEMICAL", 75, 85], ["TM2 leucines 51\u201357", "SIMPLE_CHEMICAL", 90, 108], ["membrane", "CELLULAR_COMPONENT", 162, 170], ["[47]", "SIMPLE_CHEMICAL", 194, 198], ["Leu", "AMINO_ACID", 204, 207], ["Ala", "AMINO_ACID", 211, 214], ["TM2", "AMINO_ACID", 243, 246], ["amantadine", "SIMPLE_CHEMICAL", 259, 269], ["TM2", "PROTEIN", 243, 246], ["the inhibitor amantadine", "TREATMENT", 61, 85], ["TM2 leucines", "TEST", 90, 102], ["Leu to Ala mutations", "TREATMENT", 204, 224], ["an amantadine resistant p7 mutant", "PROBLEM", 256, 289]]], ["However, amantadine and rimantadine have also been reported to interact with some residues in TM1 when forming an \u03b1-helical hairpin [20], [32], [47].", [["amantadine", "CHEMICAL", 9, 19], ["rimantadine", "CHEMICAL", 24, 35], ["amantadine", "CHEMICAL", 9, 19], ["rimantadine", "CHEMICAL", 24, 35], ["amantadine", "SIMPLE_CHEMICAL", 9, 19], ["rimantadine", "SIMPLE_CHEMICAL", 24, 35], ["TM1", "AMINO_ACID", 94, 97], ["amantadine", "TREATMENT", 9, 19], ["rimantadine", "TREATMENT", 24, 35]]], ["Thus we propose that these drugs interact with membrane-inserted TM2, possibly increasing its rigidity (and preventing CF release) when form B is present, and interact with both TM1 and TM2 (inhibiting proton channel activity) when form A is present.", [["membrane", "ANATOMY", 47, 55], ["rigidity", "DISEASE", 94, 102], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["TM2", "AMINO_ACID", 65, 68], ["TM1", "GENE_OR_GENE_PRODUCT", 178, 181], ["TM2", "AMINO_ACID", 186, 189], ["TM2", "PROTEIN", 65, 68], ["form B", "PROTEIN", 136, 142], ["TM1", "PROTEIN", 178, 181], ["TM2", "PROTEIN", 186, 189], ["these drugs", "TREATMENT", 21, 32], ["membrane-inserted TM2", "TREATMENT", 47, 68], ["increasing its rigidity", "PROBLEM", 79, 102], ["proton channel activity", "TREATMENT", 202, 225], ["possibly", "UNCERTAINTY", 70, 78], ["increasing", "OBSERVATION_MODIFIER", 79, 89], ["rigidity", "OBSERVATION_MODIFIER", 94, 102]]], ["Indeed, that amantadine is able to interact with both TM1 and TM2 has been recently confirmed experimentally using p7 in DPC micelles, although the strain used is quite different from ours [20].", [["amantadine", "CHEMICAL", 13, 23], ["amantadine", "CHEMICAL", 13, 23], ["amantadine", "SIMPLE_CHEMICAL", 13, 23], ["TM1", "GENE_OR_GENE_PRODUCT", 54, 57], ["TM2", "GENE_OR_GENE_PRODUCT", 62, 65], ["DPC micelles", "SIMPLE_CHEMICAL", 121, 133], ["TM1", "PROTEIN", 54, 57], ["TM2", "PROTEIN", 62, 65], ["amantadine", "TREATMENT", 13, 23], ["DPC micelles", "TREATMENT", 121, 133]]], ["The p7 sequence (subtype 5a, strain EUH1480) in that report is less than 50% identical to the sequence used here (1a, H77).", [["p7 sequence", "DNA", 4, 15], ["The p7 sequence", "TEST", 0, 15]]], ["Overall, our results suggest that, although a CF release assay may be able to detect p7 channel inhibitors because of the proposed dependency of CF release on membrane-inserted TM2, a proton or ion transport assay is more relevant to discover channel blockers.Model for A and B forms of p7 ::: Results and DiscussionFrom the model shown in Fig. 9, once could argue that form B cannot transport protons or ions because TM2 is not lining the chanel in p7.", [["membrane", "ANATOMY", 159, 167], ["TM2", "CHEMICAL", 418, 421], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["TM2", "AMINO_ACID", 177, 180], ["proton", "SIMPLE_CHEMICAL", 184, 190], ["ion", "SIMPLE_CHEMICAL", 194, 197], ["protons", "SIMPLE_CHEMICAL", 394, 401], ["TM2", "AMINO_ACID", 418, 421], ["p7", "PROTEIN", 85, 87], ["TM2", "PROTEIN", 177, 180], ["p7", "PROTEIN", 450, 452], ["a CF release assay", "TEST", 44, 62], ["p7 channel inhibitors", "TREATMENT", 85, 106], ["CF release", "PROBLEM", 145, 155], ["a proton", "TREATMENT", 182, 190], ["ion transport assay", "TREATMENT", 194, 213], ["channel blockers", "TREATMENT", 243, 259]]], ["However, although a recent NMR based model places TM1 as lining the lumen [20], this is still a controversial point.", [["lumen", "ANATOMY", 68, 73], ["TM1", "GENE_OR_GENE_PRODUCT", 50, 53], ["TM1", "PROTEIN", 50, 53], ["a recent NMR based model places TM1", "TREATMENT", 18, 53], ["lumen", "ANATOMY_MODIFIER", 68, 73]]], ["Support for this arrangement is found in the physico-chemical properties of TM1 and molecular dynamics simulations [16], [19], and the observed partial inhibition of p7 channel activity by Cu2+, but not by Mg2+[17].", [["Cu2", "CHEMICAL", 189, 192], ["Mg2", "CHEMICAL", 206, 209], ["Cu2+", "CHEMICAL", 189, 193], ["Mg2+", "CHEMICAL", 206, 210], ["TM1", "SIMPLE_CHEMICAL", 76, 79], ["[19]", "SIMPLE_CHEMICAL", 121, 125], ["Cu2+", "SIMPLE_CHEMICAL", 189, 193], ["Mg2+[17]", "SIMPLE_CHEMICAL", 206, 214], ["p7 channel", "PROTEIN", 166, 176], ["Cu2", "PROTEIN", 189, 192], ["Mg2", "PROTEIN", 206, 209], ["Mg2", "TEST", 206, 209]]], ["Peptides corresponding to TM2 or TM1, e.g., p7(35-63) or p7(1-34) easily aggregate, so that individual channel activity of TM1 or TM2 cannot be properly measured [12].", [["TM2", "GENE_OR_GENE_PRODUCT", 26, 29], ["TM1", "GENE_OR_GENE_PRODUCT", 33, 36], ["TM1", "GENE_OR_GENE_PRODUCT", 123, 126], ["TM2", "AMINO_ACID", 130, 133], ["TM2", "PROTEIN", 26, 29], ["TM1", "PROTEIN", 33, 36], ["TM1", "PROTEIN", 123, 126], ["TM2", "PROTEIN", 130, 133], ["Peptides", "TEST", 0, 8], ["TM2", "TEST", 26, 29], ["TM1", "TEST", 33, 36], ["TM2", "ANATOMY_MODIFIER", 26, 29], ["TM1", "ANATOMY_MODIFIER", 33, 36]]], ["In the latter paper, peptide TM1 p7(1-34) showed some channel activity that was probably non-specific, because inhibition data was not reported, and the peptide had not been purified [12].", [["1-34", "CHEMICAL", 36, 40], ["peptide TM1 p7", "TEST", 21, 35], ["some channel activity", "PROBLEM", 49, 70], ["inhibition data", "TEST", 111, 126], ["channel activity", "OBSERVATION", 54, 70], ["probably", "UNCERTAINTY", 80, 88], ["non-specific", "OBSERVATION_MODIFIER", 89, 101]]], ["Other reports were unable to measure channel activity for this peptide [5], and we show that purified peptide p7(1-26) is not even \u03b1-helical in presence of lipid bilayers after methanol exposure, and it is only partially helical after HFIP exposure.Possible relevance of forms A and B in vivo::: Results and DiscussionAlthough we propose that form B is simply an artifact, it is possible that when the p7 polypeptide is cleaved during processing, an equilibrium is established between form A and B, where TM1 is totally or partially exposed to the aqueous domain, leading to a coexistence between these two conformations, and this may explain different topologies reported in the literature.", [["lipid bilayers", "ANATOMY", 156, 170], ["methanol", "CHEMICAL", 177, 185], ["HFIP", "CHEMICAL", 235, 239], ["methanol", "CHEMICAL", 177, 185], ["HFIP", "CHEMICAL", 235, 239], ["lipid bilayers", "SIMPLE_CHEMICAL", 156, 170], ["methanol", "SIMPLE_CHEMICAL", 177, 185], ["HFIP", "SIMPLE_CHEMICAL", 235, 239], ["B", "GENE_OR_GENE_PRODUCT", 348, 349], ["B", "GENE_OR_GENE_PRODUCT", 496, 497], ["TM1", "GENE_OR_GENE_PRODUCT", 505, 508], ["form B", "PROTEIN", 343, 349], ["p7 polypeptide", "PROTEIN", 402, 416], ["B", "PROTEIN", 496, 497], ["TM1", "PROTEIN", 505, 508], ["aqueous domain", "PROTEIN", 548, 562], ["this peptide", "TEST", 58, 70], ["purified peptide p7", "TEST", 93, 112], ["an artifact", "PROBLEM", 360, 371], ["the p7 polypeptide", "PROBLEM", 398, 416], ["different topologies", "PROBLEM", 643, 663], ["artifact", "OBSERVATION", 363, 371]]], ["This is not rare in viral proteins; the N terminus of HCV NS4B has been reported to assume dual TM topology, with possible distinct functions, on each side of the ER membrane [48].", [["ER membrane", "ANATOMY", 163, 174], ["N", "CHEMICAL", 40, 41], ["HCV NS4B", "ORGANISM", 54, 62], ["ER", "GENE_OR_GENE_PRODUCT", 163, 165], ["viral proteins", "PROTEIN", 20, 34], ["N terminus", "PROTEIN", 40, 50], ["HCV NS4B", "PROTEIN", 54, 62], ["ER", "PROTEIN", 163, 165], ["HCV", "SPECIES", 54, 57], ["rare in viral proteins", "PROBLEM", 12, 34], ["HCV NS4B", "PROBLEM", 54, 62], ["dual TM topology", "TEST", 91, 107], ["distinct functions", "PROBLEM", 123, 141], ["not", "UNCERTAINTY", 8, 11], ["rare", "OBSERVATION_MODIFIER", 12, 16], ["viral proteins", "OBSERVATION", 20, 34], ["possible", "UNCERTAINTY", 114, 122], ["distinct", "OBSERVATION_MODIFIER", 123, 131], ["functions", "OBSERVATION", 132, 141]]], ["In addition, the hepatitis B virus surface L-glycoprotein also adopts different TM topologies, acting during virus assembly as a matrix-like protein, and in virus entry as a receptor-binding protein [49].", [["hepatitis B", "DISEASE", 17, 28], ["hepatitis B virus", "ORGANISM", 17, 34], ["L-glycoprotein", "GENE_OR_GENE_PRODUCT", 43, 57], ["matrix", "CELLULAR_COMPONENT", 129, 135], ["hepatitis B virus surface L-glycoprotein", "PROTEIN", 17, 57], ["TM topologies", "PROTEIN", 80, 93], ["matrix-like protein", "PROTEIN", 129, 148], ["receptor-binding protein", "PROTEIN", 174, 198], ["hepatitis B virus", "SPECIES", 17, 34], ["hepatitis B virus", "SPECIES", 17, 34], ["the hepatitis B virus surface L-glycoprotein", "TREATMENT", 13, 57], ["different TM topologies", "TREATMENT", 70, 93], ["a matrix-like protein", "TEST", 127, 148], ["hepatitis", "OBSERVATION", 17, 26]]], ["Lastly, the Newcastle disease virus fusion protein exists in two topological forms with respect to membranes, one of which has been proposed to be involved in fusion [50].Possible relevance of forms A and B in vivo::: Results and DiscussionIndeed, some functions of p7 are independent from its ion or proton channel activity because they are not affected by either channel inactivating mutations, or treatment with rimantadine [8].", [["membranes", "ANATOMY", 99, 108], ["Newcastle disease", "DISEASE", 12, 29], ["rimantadine", "CHEMICAL", 415, 426], ["rimantadine", "CHEMICAL", 415, 426], ["Newcastle disease virus", "ORGANISM", 12, 35], ["membranes", "CELLULAR_COMPONENT", 99, 108], ["p7", "GENE_OR_GENE_PRODUCT", 266, 268], ["rimantadine", "SIMPLE_CHEMICAL", 415, 426], ["Newcastle disease virus fusion protein", "PROTEIN", 12, 50], ["p7", "PROTEIN", 266, 268], ["Newcastle disease virus", "SPECIES", 12, 35], ["the Newcastle disease virus fusion protein", "PROBLEM", 8, 50], ["proton channel activity", "TREATMENT", 301, 324], ["rimantadine", "TREATMENT", 415, 426], ["virus fusion", "OBSERVATION", 30, 42]]], ["For example, p7-mediated localization of NS2 protein to sites of viral replication in lipid raft regions [9], or the transfer of HCV core protein from lipid droplets to the ER, which depends on interaction between p7 and NS2 [10].", [["lipid raft", "ANATOMY", 86, 96], ["lipid droplets", "ANATOMY", 151, 165], ["ER", "ANATOMY", 173, 175], ["p7", "GENE_OR_GENE_PRODUCT", 13, 15], ["NS2", "GENE_OR_GENE_PRODUCT", 41, 44], ["lipid raft", "CELLULAR_COMPONENT", 86, 96], ["lipid droplets", "CELLULAR_COMPONENT", 151, 165], ["ER", "GENE_OR_GENE_PRODUCT", 173, 175], ["p7", "PROTEIN", 13, 15], ["NS2 protein", "PROTEIN", 41, 52], ["HCV core protein", "PROTEIN", 129, 145], ["ER", "PROTEIN", 173, 175], ["p7", "PROTEIN", 214, 216], ["NS2", "PROTEIN", 221, 224], ["HCV", "SPECIES", 129, 132], ["NS2 protein", "TREATMENT", 41, 52], ["viral replication in lipid raft regions", "TREATMENT", 65, 104], ["HCV core protein from lipid droplets", "TREATMENT", 129, 165], ["viral replication", "OBSERVATION", 65, 82]]], ["Incidentally, in this role, the interaction between p7 TM2 and NS2 TM1 was proposed as specially important. p7 also interacts with other viral structural and non-structural proteins that are important to promote virus assembly and release [2], [51]\u2013[53].", [["p7 TM2", "GENE_OR_GENE_PRODUCT", 52, 58], ["NS2 TM1", "GENE_OR_GENE_PRODUCT", 63, 70], ["p7", "GENE_OR_GENE_PRODUCT", 108, 110], ["[51]\u2013[53]", "SIMPLE_CHEMICAL", 244, 253], ["p7 TM2", "PROTEIN", 52, 58], ["NS2 TM1", "PROTEIN", 63, 70], ["p7", "PROTEIN", 108, 110], ["viral structural and non-structural proteins", "PROTEIN", 137, 181], ["p7 TM2 and NS2 TM1", "TREATMENT", 52, 70], ["other viral structural and non-structural proteins", "PROBLEM", 131, 181]]], ["Lastly, although the present results have been obtained with p7 from subtype 1a, it is likely that these results can be extrapolated to other studies that used different subtypes of HCV p7 because of the >80% identity between sequences of subtypes 1a, 1b and 2a.Possible relevance of forms A and B in vivo::: Results and DiscussionViruses are economical in their use of resources and it is often encountered that a single protein performs a variety of tasks, being involved in invasion of the host cell to evasion from the host defense system, and conformational flexibility has been recognized as one of the features necessary to provide these functionalities [54].", [["cell", "ANATOMY", 498, 502], ["HCV p7", "ORGANISM", 182, 188], ["b", "GENE_OR_GENE_PRODUCT", 253, 254], ["2a", "GENE_OR_GENE_PRODUCT", 259, 261], ["host cell", "CELL", 493, 502], ["p7", "PROTEIN", 61, 63], ["HCV", "SPECIES", 182, 185], ["other studies", "TEST", 136, 149], ["HCV p7", "PROBLEM", 182, 188], ["host cell", "OBSERVATION", 493, 502]]]], "50c1a6b8ece0433ff3b65fc15a1f1bb62a13095f": [["INTRODUCTIONFacing an unprecedented pandemic, intensive care clinicians feel obligated to intervene in order to prevent, modulate, or reverse COVID-19 disease and avert death.", [["death", "DISEASE", 169, 174], ["reverse COVID-19 disease", "PROBLEM", 134, 158], ["avert death", "PROBLEM", 163, 174]]], ["Human nature is to err in favor of intervention rather than thoughtful inaction, commission over omission.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["intervention", "TREATMENT", 35, 47]]], ["As a result, we have seen widespread adoption of a variety of (primarily pharmacologic) interventions with little or no supportive evidence.", [["pharmacologic) interventions", "TREATMENT", 73, 101]]], ["The temptation of bioplausibility has again emerged in critical care medicine (CCM), despite a negative track record of results for pharmacologic therapies in multicenter trials (1) .", [["pharmacologic therapies", "TREATMENT", 132, 155]]], ["Given limitations in resources as well as evidence, we need to tread lightly in the intensive care unit more than ever.INTRODUCTIONOver the past year, a common theme of care has emerged in social media discussions under the hashtag #zentensivist, describing a combination of Zen-like philosophy with intensive care medicine.", [["intensive care medicine", "TREATMENT", 300, 323]]], ["Intensive care conjures images of invasiveness and aggressive care.", [["aggressive care", "TREATMENT", 51, 66]]], ["In combination, the #zentensivist approach focuses on minimally burdensome ICU care that is grounded in pragmatism, humanism, and tolerance of risk in facing the abnormal and unknown.", [["the #zentensivist approach", "TREATMENT", 16, 42], ["minimally burdensome ICU care", "TREATMENT", 54, 83], ["the abnormal", "PROBLEM", 158, 170]]], ["Here we describe how this perspective can best be applied to the care of the critically-ill COVID-19 patient.MINIMALLY INVASIVE, MAXIMALLY ATTENTIVEEarly guidance on hypoxemic respiratory failure during the COVID-19 outbreak has been largely based on expert opinion and has mostly advocated early consideration of invasive mechanical ventilation (IMV).", [["respiratory", "ANATOMY", 176, 187], ["critically-ill", "DISEASE", 77, 91], ["hypoxemic respiratory failure", "DISEASE", 166, 195], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["IMV", "SPECIES", 347, 350], ["hypoxemic respiratory failure", "PROBLEM", 166, 195], ["the COVID", "TEST", 203, 212], ["invasive mechanical ventilation", "TREATMENT", 314, 345], ["INVASIVE", "OBSERVATION_MODIFIER", 119, 127], ["hypoxemic", "OBSERVATION_MODIFIER", 166, 175], ["respiratory failure", "OBSERVATION", 176, 195], ["mechanical ventilation", "OBSERVATION", 323, 345]]], ["These recommendations, at least in part, are due to observation of rapid clinical deterioration, high reported rates of IMV in this population(2,3), as well as concerns for aerosol generation with high flow nasal cannula (HFNC) or non-invasive positive pressure ventilation (NIV).", [["nasal", "ANATOMY", 207, 212], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 207, 220], ["rapid clinical deterioration", "PROBLEM", 67, 95], ["IMV", "TREATMENT", 120, 123], ["aerosol generation", "TREATMENT", 173, 191], ["high flow nasal cannula (HFNC", "TREATMENT", 197, 226], ["non-invasive positive pressure ventilation", "TREATMENT", 231, 273], ["pressure ventilation", "OBSERVATION", 253, 273]]], ["A lower threshold than normal to initiate IMV creates two potential issues:MINIMALLY INVASIVE, MAXIMALLY ATTENTIVEiatrogenic harms and depletion of finite resources, namely ventilators.MINIMALLY INVASIVE, MAXIMALLY ATTENTIVEConsider a patient with the commonly-seen \"silent hypoxemia\" phenotype of COVID-19, who does not otherwise show signs of respiratory failure.", [["respiratory", "ANATOMY", 345, 356], ["hypoxemia", "DISEASE", 274, 283], ["respiratory failure", "DISEASE", 345, 364], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["A lower threshold", "PROBLEM", 0, 17], ["IMV", "TREATMENT", 42, 45], ["MINIMALLY INVASIVE", "PROBLEM", 75, 93], ["ventilators", "TREATMENT", 173, 184], ["silent hypoxemia", "PROBLEM", 267, 283], ["COVID", "TEST", 298, 303], ["respiratory failure", "PROBLEM", 345, 364], ["lower threshold", "OBSERVATION_MODIFIER", 2, 17], ["MINIMALLY", "OBSERVATION_MODIFIER", 75, 84], ["INVASIVE", "OBSERVATION_MODIFIER", 85, 93], ["INVASIVE", "OBSERVATION_MODIFIER", 195, 203], ["hypoxemia", "OBSERVATION", 274, 283], ["respiratory failure", "OBSERVATION", 345, 364]]], ["A minimally invasive, yet maximally attentive approach could involve placement of HFNC, with consideration of awake prone positioning(4) to attempt to reduce likelihood of requiring IMV which are physiological, supported by studies and at minimal risk to patients.", [["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["A minimally invasive", "PROBLEM", 0, 20], ["placement of HFNC", "TREATMENT", 69, 86], ["awake prone positioning", "TREATMENT", 110, 133], ["IMV", "TREATMENT", 182, 185], ["minimally", "OBSERVATION_MODIFIER", 2, 11], ["invasive", "OBSERVATION", 12, 20]]], ["In this scenario, the awake patient can participate in many aspects of their care and bond with the care team(5), without experiencing potentially deleterious effects of IMV and sedation.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["IMV", "TREATMENT", 170, 173], ["sedation", "TREATMENT", 178, 186]]], ["Meanwhile, the zentensive care team maintains high vigilance in case of deterioration, but otherwise allows restitution to unfold.MINIMALLY INVASIVE, MAXIMALLY ATTENTIVEFinally, patient-specific characteristics need to be carefully considered.", [["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["deterioration", "PROBLEM", 72, 85], ["INVASIVE", "OBSERVATION_MODIFIER", 140, 148]]], ["In COVID-19 as well as other causes of respiratory failure requiring IMV, there is an increasing mortality burden with increasing age (6) .", [["respiratory", "ANATOMY", 39, 50], ["respiratory failure", "DISEASE", 39, 58], ["respiratory failure", "PROBLEM", 39, 58], ["IMV", "TREATMENT", 69, 72], ["an increasing mortality burden", "PROBLEM", 83, 113], ["respiratory", "ANATOMY", 39, 50], ["failure", "OBSERVATION", 51, 58], ["increasing", "OBSERVATION_MODIFIER", 86, 96], ["mortality", "OBSERVATION_MODIFIER", 97, 106], ["burden", "OBSERVATION_MODIFIER", 107, 113], ["increasing", "OBSERVATION_MODIFIER", 119, 129]]], ["With increasing frailty and burden of comorbidities across the population, sometimes the best course of action is \"early goal-directed palliation\", focusing on symptom management, appropriate expectations, and goals of care based on patient values and likelihood of benefit from our interventions.PRAGMATISM OVER NEOPHILIAThe history of CCM does not support magic bullets.", [["CCM", "DISEASE", 337, 340], ["CCM", "CHEMICAL", 337, 340], ["patient", "ORGANISM", 233, 240], ["patient", "SPECIES", 233, 240], ["increasing frailty", "PROBLEM", 5, 23], ["burden of comorbidities", "PROBLEM", 28, 51], ["directed palliation", "TREATMENT", 126, 145], ["symptom management", "TREATMENT", 160, 178], ["patient values", "TEST", 233, 247], ["our interventions", "TREATMENT", 279, 296], ["CCM", "PROBLEM", 337, 340], ["magic bullets", "PROBLEM", 358, 371], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["frailty", "OBSERVATION", 16, 23], ["burden", "OBSERVATION_MODIFIER", 28, 34], ["comorbidities", "OBSERVATION", 38, 51], ["CCM", "OBSERVATION", 337, 340], ["magic bullets", "OBSERVATION", 358, 371]]], ["In fact, clinical trialists are quick to note that medications with strong bioplausible foundations have not yielded positive results in phase III randomized controlled trials (RCTs).", [["medications", "TREATMENT", 51, 62], ["phase III randomized controlled trials (RCTs", "TREATMENT", 137, 181]]], ["Early reports of medications directed at COVID-19 have often been small, non-randomized, and retrospective with questionable benefit.", [["medications", "TREATMENT", 17, 28], ["small", "OBSERVATION_MODIFIER", 66, 71]]], ["Before we rush to each \"new exciting treatment\" for COVID-19, we have to remember our history, and execute well-designed RCTs.PRAGMATISM OVER NEOPHILIAWhat is the bedside clinician to do, given intense desire to help a growing number of critically-ill patients in this pandemic?", [["critically-ill", "DISEASE", 237, 251], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260]]], ["Understandably, many of us feel compelled to act, which introduces temptation to broadly apply unproven interventions.", [["unproven interventions", "TREATMENT", 95, 117]]], ["In the short term, the answer is not to be found in off-label therapies or unvalidated biomarkers.", [["unvalidated biomarkers", "TEST", 75, 97], ["short term", "OBSERVATION_MODIFIER", 7, 17]]], ["The zentensivist mindfully attends to the core group of interventions with proven impact on patient outcomes, for instance, lungprotective ventilation, conservative fluid management, and the ABCDEF bundle (8) .", [["fluid", "ANATOMY", 165, 170], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["interventions", "TREATMENT", 56, 69], ["lungprotective ventilation", "TREATMENT", 124, 150], ["conservative fluid management", "TREATMENT", 152, 181]]], ["While additional data is gathered on this admittedly novel condition, we must concentrate on timetested tools to liberate patients from the burdens of our environment.CONCLUSIONCOVID-19 presents unique clinical and logistical challenges to CCM practitioners as well as health systems.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["CONCLUSIONCOVID", "TEST", 167, 182], ["CCM practitioners", "TREATMENT", 240, 257]]], ["From all angles, the pressure to add interventions to change the course of illness is heaped upon the bedside clinician.", [["illness", "DISEASE", 75, 82], ["the pressure", "TEST", 17, 29], ["interventions", "TREATMENT", 37, 50]]], ["This inertia unfortunately puts us and our patients at high risk for future medical reversal(9), whereby current practices will be shown to be ineffective or even harmful by future studies.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["future medical reversal", "TREATMENT", 69, 92]]], ["The key message of the #zentensivist to those on the front lines against COVID-19 is not novel: less is more.", [["front lines", "ANATOMY", 53, 64], ["COVID-19", "CHEMICAL", 73, 81], ["front lines", "CELL", 53, 64], ["COVID-19", "CELL", 73, 81], ["COVID-19", "DNA", 73, 81], ["COVID", "TEST", 73, 78]]], ["Less is likely to work for more patients, however more may be needed in fewer patients who have the reserve to survive extraordinary intensive care support and to thrive once they survive their critical illness.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 78, 86], ["extraordinary intensive care support", "TREATMENT", 119, 155]]], ["If we devote our efforts to humanistic, minimally invasive care that is focused on core interventions, we can create an environment that facilitates ICU liberation and recovery.", [["minimally invasive care", "TREATMENT", 40, 63], ["core interventions", "TREATMENT", 83, 101], ["ICU liberation", "TREATMENT", 149, 163]]]], "PMC4177793": [["IntroductionPublic influenza surveillance systems are important for early detection and rapid response to an epidemic.", [["IntroductionPublic influenza surveillance systems", "PROBLEM", 0, 49], ["an epidemic", "PROBLEM", 106, 117]]], ["In Korea, the two separate national surveillance networks that report on the circulation of influenza are the outpatient influenza-like illness (ILI) surveillance network (Korean Influenza Surveillance System, KISS) and the laboratory virus surveillance system (Korean Influenza and Respiratory Viruses Surveillance Scheme, KINRESS).", [["influenza", "DISEASE", 92, 101], ["influenza-like illness", "DISEASE", 121, 143], ["ILI", "DISEASE", 145, 148], ["Influenza", "DISEASE", 179, 188], ["Influenza and Respiratory Viruses", "DISEASE", 269, 302], ["influenza", "PROBLEM", 92, 101], ["the laboratory virus surveillance system", "TEST", 220, 260], ["Korean Influenza", "PROBLEM", 262, 278]]], ["In 2011, the Trans-government Enterprise of Pandemic Influenza in Korea (TEPIK) developed another hospital-based influenza surveillance system, named \u201cHospital-based Influenza Morbidity and Mortality\u201d (HIMM).", [["Influenza", "DISEASE", 53, 62], ["Influenza Morbidity", "DISEASE", 166, 185], ["Influenza Morbidity", "PROBLEM", 166, 185]]], ["The HIMM consists of an integrated clinical and laboratory surveillance system, in which seven nationwide tertiary teaching hospitals collect data of patients who visit the emergency room with ILI.", [["ILI", "DISEASE", 193, 196], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["ILI", "PROBLEM", 193, 196]]], ["This system aims to monitor not only influenza activity but also influenza severity, such as hospitalization, complication and mortality, which cannot be reflected by national surveillance systems.", [["influenza", "DISEASE", 65, 74], ["influenza activity", "PROBLEM", 37, 55], ["influenza severity", "PROBLEM", 65, 83], ["complication", "PROBLEM", 110, 122]]], ["The objective of this study was to compare the surveillance data of HIMM with KISS and KINRESS in its first year of operation during the 2011\u20132012 influenza season.MethodsAnalyses were performed according to the week of the year with week 1 defined as starting with the week (from Monday through Sunday) in which the January 1 is allocated.", [["influenza", "DISEASE", 147, 156], ["this study", "TEST", 17, 27], ["the surveillance data", "TEST", 43, 64], ["KINRESS", "TREATMENT", 87, 94], ["MethodsAnalyses", "TEST", 164, 179]]], ["The study period was from October 2, 2011, through June 30, 2012.", [["The study", "TEST", 0, 9]]], ["We restricted our analysis to the period during which HIMM surveillance was initiated, from week 41 of 2011 through week 26 of 2012.MethodsIn the HIMM surveillance network, participating sites prospectively entered the data of patients who visited the emergency room with an ILI (defined as sudden onset of fever \u226537\u00b78\u00b0C accompanied by \u22651 respiratory symptoms such as cough, sore throat, or rhinorrhea) into the Internet database.", [["respiratory", "ANATOMY", 339, 350], ["ILI", "DISEASE", 275, 278], ["fever", "DISEASE", 307, 312], ["cough", "DISEASE", 368, 373], ["sore throat", "DISEASE", 375, 386], ["rhinorrhea", "DISEASE", 391, 401], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["HIMM surveillance", "TEST", 54, 71], ["fever", "PROBLEM", 307, 312], ["\u22651 respiratory symptoms", "PROBLEM", 336, 359], ["cough", "PROBLEM", 368, 373], ["sore throat", "PROBLEM", 375, 386], ["rhinorrhea", "PROBLEM", 391, 401]]], ["The weekly incidence of ILI per 1000 patients who visited the ER was calculated from the database.", [["ILI", "DISEASE", 24, 27], ["patients", "ORGANISM", 37, 45], ["ER", "GENE_OR_GENE_PRODUCT", 62, 64], ["ER", "PROTEIN", 62, 64], ["patients", "SPECIES", 37, 45]]], ["A rapid antigen test (SD Bioline rapid influenza test, Standard Diagnostics, Inc., Yongin City, Korea ) for influenza virus was performed using the respiratory samples that were collected by nasopharyngeal swab or aspirate, and throat swab if the patient consented to the test.", [["respiratory samples", "ANATOMY", 148, 167], ["nasopharyngeal swab", "ANATOMY", 191, 210], ["aspirate", "ANATOMY", 214, 222], ["throat swab", "ANATOMY", 228, 239], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 191, 210], ["throat swab", "ORGANISM_SUBDIVISION", 228, 239], ["patient", "ORGANISM", 247, 254], ["influenza virus", "SPECIES", 108, 123], ["patient", "SPECIES", 247, 254], ["influenza virus", "SPECIES", 108, 123], ["A rapid antigen test", "TEST", 0, 20], ["SD Bioline rapid influenza test", "TEST", 22, 53], ["influenza virus", "PROBLEM", 108, 123], ["the respiratory samples", "TEST", 144, 167], ["nasopharyngeal swab", "TEST", 191, 210], ["aspirate", "TEST", 214, 222], ["throat swab", "TEST", 228, 239], ["the test", "TEST", 268, 276]]], ["During the study period, samples were taken from 41\u00b73% of 10 872 patients presenting with ILI.", [["samples", "ANATOMY", 25, 32], ["ILI", "DISEASE", 90, 93], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the study", "TEST", 7, 16], ["samples", "TEST", 25, 32], ["ILI", "PROBLEM", 90, 93]]], ["The influenza test positivity was defined as the ratio of the number of positive cases divided by the total number of tests.", [["The influenza test positivity", "TEST", 0, 29], ["tests", "TEST", 118, 123]]], ["RAT positivity was reported weekly.MethodsTo compare the HIMM data, the data from the two national influenza surveillance systems were obtained from the Korean National Institute of Health (KNIH).", [["influenza", "DISEASE", 99, 108], ["RAT positivity", "TEST", 0, 14], ["the HIMM data", "TEST", 53, 66], ["the data", "TEST", 68, 76]]], ["Both HIMM and KINH use same definition of ILI.", [["ILI", "DISEASE", 42, 45], ["ILI", "PROBLEM", 42, 45]]], ["KISS surveillance consists of a network of about 800 public health centers and private clinics that record the weekly proportion of patients who have ILI symptoms.1 KISS reports the weekly incidence of ILI per 1000 outpatients.", [["ILI", "DISEASE", 150, 153], ["ILI", "DISEASE", 202, 205], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["ILI symptoms", "PROBLEM", 150, 162], ["ILI", "PROBLEM", 202, 205]]], ["KINRESS surveillance consists of about 100 hospitals that obtain the respiratory specimens by nasopharyngeal swab, nasopharyngeal aspirate, or throat swab from patients presenting with ILI.", [["respiratory specimens", "ANATOMY", 69, 90], ["nasopharyngeal swab", "ANATOMY", 94, 113], ["nasopharyngeal aspirate", "ANATOMY", 115, 138], ["throat swab", "ANATOMY", 143, 154], ["ILI", "DISEASE", 185, 188], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 94, 113], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 115, 138], ["throat", "ORGANISM_SUBDIVISION", 143, 149], ["swab", "ORGANISM_SUBSTANCE", 150, 154], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["KINRESS surveillance", "TEST", 0, 20], ["the respiratory specimens", "TEST", 65, 90], ["nasopharyngeal swab", "TEST", 94, 113], ["nasopharyngeal aspirate", "TEST", 115, 138], ["throat swab", "TEST", 143, 154], ["ILI", "PROBLEM", 185, 188], ["nasopharyngeal", "ANATOMY", 94, 108], ["nasopharyngeal", "ANATOMY", 115, 129]]], ["Samples are forwarded to KNIH, where viruses are characterized by self-developed multiplex reverse-transcriptase polymerase chain reaction (RT-PCR).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["viruses", "PROBLEM", 37, 44], ["multiplex reverse-transcriptase polymerase chain reaction", "PROBLEM", 81, 138]]], ["The KINRESS reports weekly positivity of influenza tests along with other respiratory viruses, including respiratory syncytial virus, parainfluenza virus, adenovirus, human rhinovirus, human metapneumovirus, human coronavirus and human bocavirus.MethodsThe influenza epidemic period was defined as the week in which the ILI rate crossed a certain value based on a seasonal threshold set by the KNIH.", [["respiratory viruses", "DISEASE", 74, 93], ["respiratory syncytial virus", "DISEASE", 105, 132], ["parainfluenza virus", "DISEASE", 134, 153], ["human metapneumovirus", "DISEASE", 185, 206], ["human coronavirus", "DISEASE", 208, 225], ["respiratory syncytial virus", "ORGANISM", 105, 132], ["parainfluenza virus", "ORGANISM", 134, 153], ["adenovirus", "ORGANISM", 155, 165], ["human", "ORGANISM", 167, 172], ["rhinovirus", "ORGANISM", 173, 183], ["human", "ORGANISM", 185, 190], ["metapneumovirus", "ORGANISM", 191, 206], ["human", "ORGANISM", 208, 213], ["coronavirus", "ORGANISM", 214, 225], ["human", "ORGANISM", 230, 235], ["bocavirus", "ORGANISM", 236, 245], ["respiratory syncytial virus", "SPECIES", 105, 132], ["parainfluenza virus", "SPECIES", 134, 153], ["human", "SPECIES", 167, 172], ["rhinovirus", "SPECIES", 173, 183], ["human", "SPECIES", 185, 190], ["metapneumovirus", "SPECIES", 191, 206], ["human", "SPECIES", 208, 213], ["coronavirus", "SPECIES", 214, 225], ["human", "SPECIES", 230, 235], ["respiratory syncytial virus", "SPECIES", 105, 132], ["parainfluenza virus", "SPECIES", 134, 153], ["adenovirus", "SPECIES", 155, 165], ["human rhinovirus", "SPECIES", 167, 183], ["human metapneumovirus", "SPECIES", 185, 206], ["human coronavirus", "SPECIES", 208, 225], ["human", "SPECIES", 230, 235], ["influenza tests", "PROBLEM", 41, 56], ["other respiratory viruses", "PROBLEM", 68, 93], ["respiratory syncytial virus", "PROBLEM", 105, 132], ["parainfluenza virus", "PROBLEM", 134, 153], ["adenovirus", "PROBLEM", 155, 165], ["human rhinovirus", "PROBLEM", 167, 183], ["human metapneumovirus", "PROBLEM", 185, 206], ["human coronavirus", "PROBLEM", 208, 225], ["human bocavirus", "PROBLEM", 230, 245], ["the ILI rate", "TEST", 316, 328], ["respiratory", "ANATOMY", 74, 85], ["viruses", "OBSERVATION", 86, 93], ["respiratory", "ANATOMY", 105, 116], ["syncytial virus", "OBSERVATION", 117, 132], ["parainfluenza virus", "OBSERVATION", 134, 153]]], ["Baseline ILI rate was calculated as the average of the values of the ILI rate during the pre-epidemic period.", [["Baseline ILI rate", "TEST", 0, 17]]], ["Scatter plots were constructed to compare HIMM ILI surveillance data with KISS surveillance data.", [["Scatter plots", "TEST", 0, 13], ["HIMM ILI surveillance data", "TEST", 42, 68], ["KISS surveillance data", "TEST", 74, 96]]], ["From these comparisons, Pearson's correlation coefficients (R) were calculated, and a relationship is reported as significant at P < 0\u00b705.", [["Pearson's correlation coefficients", "TEST", 24, 58]]], ["Correlation coefficients were subsequently calculated for regional HIMM and KISS surveillance data to monitor regional influenza trends.", [["Correlation coefficients", "TEST", 0, 24], ["regional HIMM", "TEST", 58, 71], ["KISS surveillance data", "TEST", 76, 98], ["regional influenza trends", "PROBLEM", 110, 135]]], ["We undertook an additional correlation analysis to determine whether HIMM RAT surveillance was correlated with KINRESS RT-PCR surveillance.", [["an additional correlation analysis", "TEST", 13, 47], ["HIMM RAT surveillance", "TEST", 69, 90], ["KINRESS RT", "TEST", 111, 121], ["PCR surveillance", "TEST", 122, 138]]], ["Data analysis was performed using spss, version 10\u00b70 (SPSS Inc., Chicago, IL, USA).", [["Data analysis", "TEST", 0, 13]]], ["The study was approved by the ethics committee of each institution involved and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.ResultsDuring the study period, HIMM ILI surveillance showed a strong temporal correlation with KISS surveillance.", [["The study", "TEST", 0, 9], ["the study", "TEST", 182, 191], ["HIMM ILI surveillance", "TEST", 200, 221], ["KISS surveillance", "TEST", 264, 281]]], ["Simple inspection revealed broad similarity in terms of timing of seasonal peaks (Figure 1).", [["Simple inspection", "TEST", 0, 17], ["broad similarity", "PROBLEM", 27, 43], ["seasonal peaks", "PROBLEM", 66, 80], ["broad", "OBSERVATION_MODIFIER", 27, 32]]], ["The correlation between HIMM ILI surveillance and KISS surveillance was 0\u00b7886.", [["HIMM ILI surveillance", "TEST", 24, 45], ["KISS surveillance", "TEST", 50, 67]]], ["Although the weekly ILI rate patterns of the two surveillance systems closely resembled each other, the HIMM surveillance showed a higher baseline rate of ILI.", [["ILI", "DISEASE", 155, 158], ["the weekly ILI rate", "TEST", 9, 28], ["the HIMM surveillance", "TEST", 100, 121], ["ILI", "PROBLEM", 155, 158]]], ["The mean baseline rate of ILI before the influenza epidemic was 77\u00b74 of 1000 emergency patients in the hospital-based influenza morbidity and mortality and 2\u00b79 of 1000 outpatients in the Korean influenza surveillance.ResultsWhen compared by region, a high correlation was found in the regions in which HIMM hospitals were located.", [["ILI", "DISEASE", 26, 29], ["influenza", "DISEASE", 41, 50], ["influenza", "DISEASE", 118, 127], ["influenza", "DISEASE", 194, 203], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["ILI", "PROBLEM", 26, 29], ["the influenza epidemic", "PROBLEM", 37, 59], ["the Korean influenza surveillance", "TREATMENT", 183, 216]]], ["The correlation between regional HIMM ILI and KISS surveillance ranged from 0\u00b7717 in Gyeonggi to 0\u00b7894 in Seoul (Table 1).", [["KISS surveillance", "TEST", 46, 63]]], ["The mean correlation for these comparisons was 0\u00b7814.", [["these comparisons", "TEST", 25, 42]]], ["Each site showed a relatively stable contribution to the total ILI cases each week.ResultsThe weekly influenza cases detected by HIMM RAT and KINRESS RT-PCR surveillance during the study period are shown in Figure 1.", [["ILI", "DISEASE", 63, 66], ["influenza", "DISEASE", 101, 110], ["The weekly influenza cases", "TEST", 90, 116], ["PCR surveillance", "TEST", 153, 169], ["the study", "TEST", 177, 186], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["stable", "OBSERVATION", 30, 36]]], ["Two epidemic peaks were noted.", [["Two epidemic peaks", "PROBLEM", 0, 18], ["epidemic", "OBSERVATION_MODIFIER", 4, 12], ["peaks", "OBSERVATION_MODIFIER", 13, 18]]], ["Influenza A was predominant during the first epidemic peak, while influenza B was predominant during the second peak.", [["Influenza A", "ORGANISM", 0, 11], ["Influenza A", "SPECIES", 0, 11], ["Influenza A", "PROBLEM", 0, 11], ["influenza B", "PROBLEM", 66, 77]]], ["The initial rise occurred earlier in KINRESS surveillance from week 51 and in HIMM from week 52.", [["KINRESS surveillance", "TEST", 37, 57], ["rise", "OBSERVATION_MODIFIER", 12, 16]]], ["In addition, HIMM RAT surveillance and KINRESS RT-PCR surveillance, respectively, showed strong correlation with HIMM ILI surveillance and KISS ILI surveillance (HIMM ILI versus HIMM RAT, R = 0\u00b7742; KISS ILI versus KINRESS RT-PCR, R = 0\u00b7935).DiscussionHIMM ILI and HIMM RAT surveillance systems were established under the assumption that effective influenza surveillance could be performed easily and rapidly at the tertiary hospital emergency room level.", [["HIMM RAT surveillance", "TEST", 13, 34], ["KINRESS RT-PCR surveillance", "TEST", 39, 66], ["surveillance", "TEST", 148, 160], ["HIMM", "TEST", 178, 182], ["RAT", "TEST", 183, 186], ["R", "TEST", 188, 189], ["KISS ILI", "TEST", 199, 207], ["KINRESS", "TEST", 215, 222], ["RT", "TEST", 223, 225], ["PCR", "TEST", 226, 229], ["effective influenza surveillance", "TEST", 338, 370]]], ["This study provided a report of the first year of HIMM surveillance and assessed the correlation with the two Korean national influenza surveillance systems.DiscussionThe comparison between HIMM ILI and national ILI surveillance demonstrated the reliability of tertiary hospitals' ER-based surveillance to monitor influenza activity.", [["influenza", "DISEASE", 126, 135], ["influenza", "DISEASE", 314, 323], ["ER", "GENE_OR_GENE_PRODUCT", 281, 283], ["ER", "PROTEIN", 281, 283], ["This study", "TEST", 0, 10], ["HIMM surveillance", "TEST", 50, 67], ["national ILI surveillance", "TEST", 203, 228], ["surveillance", "TEST", 290, 302], ["influenza activity", "PROBLEM", 314, 332]]], ["However, HIMM could achieve daily analysis of ILI rates by asking sentinel sites, and this suggests that HIMM could identify the daily influenza activity.", [["influenza", "DISEASE", 135, 144], ["ILI rates", "TREATMENT", 46, 55], ["sentinel sites", "TEST", 66, 80], ["HIMM", "PROBLEM", 105, 109], ["the daily influenza activity", "PROBLEM", 125, 153]]], ["This may provide an advantage of HIMM ILI surveillance compared with other established small-scale influenza networks.2,3DiscussionIt is interesting that HIMM surveillance showed a higher baseline ILI rate than national ILI surveillance.", [["HIMM ILI surveillance", "TEST", 33, 54], ["HIMM surveillance", "TEST", 154, 171], ["a higher baseline ILI rate", "PROBLEM", 179, 205], ["national ILI surveillance", "TEST", 211, 236]]], ["Because the cost of ER care in Korea is not as expensive as in other countries and over-the-counter drugs are not available in supermarkets, many patients tend to visit the ER when local clinics are closed, regardless of the severity of the disease.", [["ER", "GENE_OR_GENE_PRODUCT", 20, 22], ["patients", "ORGANISM", 146, 154], ["ER", "GENE_OR_GENE_PRODUCT", 173, 175], ["ER", "PROTEIN", 20, 22], ["ER", "PROTEIN", 173, 175], ["patients", "SPECIES", 146, 154], ["drugs", "TREATMENT", 100, 105], ["the disease", "PROBLEM", 237, 248], ["disease", "OBSERVATION", 241, 248]]], ["Therefore, patients with ILI are always found visiting the ER.DiscussionThe ILI rates need to be interpreted with caution because they may not represent true cases of influenza.", [["ILI", "DISEASE", 25, 28], ["influenza", "DISEASE", 167, 176], ["patients", "ORGANISM", 11, 19], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["ER", "PROTEIN", 59, 61], ["patients", "SPECIES", 11, 19], ["ILI", "PROBLEM", 25, 28], ["The ILI rates", "TREATMENT", 72, 85], ["influenza", "PROBLEM", 167, 176], ["influenza", "OBSERVATION", 167, 176]]], ["Additional laboratory surveillance is important to initiate proper preventive measures with confidence.", [["Additional laboratory surveillance", "TEST", 0, 34]]], ["For this reason, the results produced by virologic surveillance should be available with as little delay as possible.", [["virologic surveillance", "TEST", 41, 63]]], ["Although virologic surveillance can be carried out by various techniques, RT-PCR is commonly used in most influenza surveillance systems.", [["virologic surveillance", "TEST", 9, 31], ["RT-PCR", "TEST", 74, 80]]], ["However, it is labor-intensive and time-consuming.", [["labor", "PROBLEM", 15, 20], ["labor", "OBSERVATION", 15, 20]]], ["The strong correlation between RAT-confirmed positivity by HIMM and RT-PCRs by KINRSS supports the use of RATs for evaluating real-time confirmed influenza activity.", [["influenza", "DISEASE", 146, 155], ["KINRSS", "DNA", 79, 85], ["RAT", "TEST", 31, 34], ["HIMM", "TEST", 59, 63], ["RT-PCRs", "TEST", 68, 75], ["influenza activity", "PROBLEM", 146, 164], ["influenza", "OBSERVATION", 146, 155]]], ["Previous studies revealed the simplicity and reliability of RAT for surveillance of influenza epidemics, and our study supports these results.4,5DiscussionEarly detection of an epidemic is important to prepare for the potentially serious threat to public health.", [["influenza", "DISEASE", 84, 93], ["Previous studies", "TEST", 0, 16], ["influenza epidemics", "PROBLEM", 84, 103], ["our study", "TEST", 109, 118], ["epidemic", "OBSERVATION", 177, 185]]], ["Although few studies have evaluated the timeliness of ILI surveillance compared with laboratory surveillance, ILI surveillance has been reported to detect the onset of seasonal influenza before an increase in laboratory notification.6,7 However, surveillance systems for early detection may be affected differently by geography and methodology.", [["influenza", "DISEASE", 177, 186], ["few studies", "TEST", 9, 20], ["ILI surveillance", "TEST", 54, 70], ["laboratory surveillance", "TEST", 85, 108], ["ILI surveillance", "TEST", 110, 126], ["seasonal influenza", "PROBLEM", 168, 186], ["surveillance systems", "TEST", 246, 266], ["early detection", "TEST", 271, 286], ["influenza", "OBSERVATION", 177, 186], ["increase", "OBSERVATION_MODIFIER", 197, 205]]], ["In our analysis, an upswing of HIMM RAT-based surveillance occurred at least one week earlier than in the national ILI surveillance.", [["our analysis", "TEST", 3, 15], ["HIMM RAT", "TEST", 31, 39]]], ["This finding suggests that HIMM RAT surveillance could be useful to detect the early signs of an influenza epidemic.DiscussionWe note that our study had several limitations.", [["influenza", "DISEASE", 97, 106], ["HIMM RAT surveillance", "TEST", 27, 48], ["an influenza epidemic", "PROBLEM", 94, 115], ["our study", "TEST", 139, 148], ["influenza", "OBSERVATION", 97, 106]]], ["Compared with KISS surveillance, the baseline ILI rates of HIMM surveillance showed fluctuation during the initial operating period, and this may have affected the results.", [["KISS surveillance", "TEST", 14, 31], ["HIMM surveillance", "TEST", 59, 76], ["fluctuation", "OBSERVATION_MODIFIER", 84, 95]]], ["This fluctuation may be due to the immaturity of data collection at that time.", [["the immaturity of data collection", "PROBLEM", 31, 64], ["may be due to", "UNCERTAINTY", 17, 30], ["immaturity", "OBSERVATION", 35, 45]]], ["Another limitation was the limited information of epidemiological features in national surveillance systems, so comparison along with age, sex, influenza vaccination, and comorbidities was not available.DiscussionIn conclusion, the HIMM surveillance system has some strengths compared with national influenza surveillance.", [["influenza", "DISEASE", 144, 153], ["national surveillance systems", "TEST", 78, 107], ["influenza vaccination", "TREATMENT", 144, 165], ["comorbidities", "PROBLEM", 171, 184], ["national influenza surveillance", "TEST", 290, 321]]], ["HIMM surveillance can monitor influenza circulation based on a small number of nationwide tertiary institutions, so more rapid data processing and reporting are possible.", [["HIMM surveillance", "TEST", 0, 17], ["influenza circulation", "PROBLEM", 30, 51], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["Moreover, it demonstrated the possibility of detecting early signals of influenza epidemics by using simple and quick RATs.", [["influenza", "DISEASE", 72, 81], ["influenza epidemics", "PROBLEM", 72, 91], ["influenza", "OBSERVATION", 72, 81]]], ["HIMM surveillance can also monitor severity of influenza infection by collecting the data of the hospitalization, intensive care unit admission, complications, and mortality, which cannot be reflected by national surveillance system.", [["influenza infection", "DISEASE", 47, 66], ["HIMM surveillance", "TEST", 0, 17], ["influenza infection", "PROBLEM", 47, 66], ["complications", "PROBLEM", 145, 158], ["influenza", "OBSERVATION", 47, 56]]], ["We hope that HIMM surveillance will prove to be an excellent complementary tool to national influenza surveillance systems in the future.", [["HIMM surveillance", "TEST", 13, 30]]]], "a7e35b95fd9ae87cdde455093d564ccc1d3ede7b": [["BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent of coronavirus disease 2019 .", [["acute respiratory syndrome coronavirus", "DISEASE", 17, 55], ["coronavirus disease", "DISEASE", 98, 117], ["BackgroundSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 57], ["SARS-CoV-2", "ORGANISM", 59, 69], ["coronavirus", "ORGANISM", 98, 109], ["BackgroundSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS-CoV-2", "SPECIES", 59, 69], ["BackgroundSevere acute respiratory syndrome coronavirus", "PROBLEM", 0, 55], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["coronavirus disease", "PROBLEM", 98, 117], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["coronavirus disease", "OBSERVATION", 98, 117]]], ["Starting from the first case recorded in Wuhan (China) in December 2019, SARS-CoV-2 quickly spread around the world, leading the World Health Organization to declare pandemic [1] .", [["SARS", "DISEASE", 73, 77], ["SARS-CoV", "SPECIES", 73, 81]]], ["To date, June 6th, 2020, the confirmed cases in the world are around 6.6 million and more than 390,000 deaths [2] .BackgroundCOVID-19 is a systemic infection that usually presents with fatigue and fever.", [["deaths", "DISEASE", 103, 109], ["systemic infection", "DISEASE", 139, 157], ["fatigue", "DISEASE", 185, 192], ["fever", "DISEASE", 197, 202], ["BackgroundCOVID", "TEST", 115, 130], ["a systemic infection", "PROBLEM", 137, 157], ["fatigue", "PROBLEM", 185, 192], ["fever", "PROBLEM", 197, 202], ["systemic", "ANATOMY", 139, 147], ["infection", "OBSERVATION", 148, 157], ["fever", "OBSERVATION", 197, 202]]], ["The most frequent symptoms described are respiratory and gastrointestinal [3] .", [["respiratory", "ANATOMY", 41, 52], ["gastrointestinal", "ANATOMY", 57, 73], ["The most frequent symptoms", "PROBLEM", 0, 26], ["gastrointestinal", "ANATOMY", 57, 73]]], ["However, neurological complications have recently been reported, including dizziness, headache, febrile seizures, myalgia, encephalopathy, encephalitis, stroke, and acute peripheral nerve diseases [4, 5] .BackgroundSome cases of Acute Motor and Sensory Axonal Neuropathy (AMSAN) and acute inflammatory demyelinating polyradiculoneuropathy (AIDP) subtypes of Guillain-Barr\u00e9 syndrome (GBS) have recently been described.", [["neurological", "ANATOMY", 9, 21], ["peripheral nerve", "ANATOMY", 171, 187], ["neurological complications", "DISEASE", 9, 35], ["dizziness", "DISEASE", 75, 84], ["headache", "DISEASE", 86, 94], ["febrile seizures", "DISEASE", 96, 112], ["myalgia", "DISEASE", 114, 121], ["encephalopathy", "DISEASE", 123, 137], ["encephalitis", "DISEASE", 139, 151], ["stroke", "DISEASE", 153, 159], ["peripheral nerve diseases", "DISEASE", 171, 196], ["Acute Motor and Sensory Axonal Neuropathy", "DISEASE", 229, 270], ["AMSAN", "DISEASE", 272, 277], ["acute inflammatory demyelinating polyradiculoneuropathy", "DISEASE", 283, 338], ["AIDP", "DISEASE", 340, 344], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 358, 381], ["GBS", "DISEASE", 383, 386], ["peripheral nerve", "MULTI-TISSUE_STRUCTURE", 171, 187], ["Guillain-Barr\u00e9", "ORGANISM", 358, 372], ["neurological complications", "PROBLEM", 9, 35], ["dizziness", "PROBLEM", 75, 84], ["headache", "PROBLEM", 86, 94], ["febrile seizures", "PROBLEM", 96, 112], ["myalgia", "PROBLEM", 114, 121], ["encephalopathy", "PROBLEM", 123, 137], ["encephalitis", "PROBLEM", 139, 151], ["stroke", "PROBLEM", 153, 159], ["acute peripheral nerve diseases", "PROBLEM", 165, 196], ["Acute Motor", "PROBLEM", 229, 240], ["Sensory Axonal Neuropathy", "PROBLEM", 245, 270], ["acute inflammatory demyelinating polyradiculoneuropathy", "PROBLEM", 283, 338], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 358, 381], ["GBS", "PROBLEM", 383, 386], ["myalgia", "OBSERVATION", 114, 121], ["encephalopathy", "OBSERVATION", 123, 137], ["encephalitis", "OBSERVATION", 139, 151], ["stroke", "OBSERVATION", 153, 159], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["peripheral", "ANATOMY_MODIFIER", 171, 181], ["nerve", "ANATOMY", 182, 187], ["diseases", "OBSERVATION", 188, 196], ["Acute", "OBSERVATION_MODIFIER", 229, 234], ["Motor", "OBSERVATION_MODIFIER", 235, 240], ["Sensory Axonal Neuropathy", "OBSERVATION", 245, 270], ["acute", "OBSERVATION_MODIFIER", 283, 288], ["inflammatory", "OBSERVATION_MODIFIER", 289, 301], ["demyelinating polyradiculoneuropathy", "OBSERVATION", 302, 338], ["Barr\u00e9 syndrome", "OBSERVATION", 367, 381]]], ["GBS is an acute immune-mediated polyradiculoneuropathy often related to previous infectious exposure [6] [7] [8] .", [["GBS", "DISEASE", 0, 3], ["polyradiculoneuropathy", "DISEASE", 32, 54], ["GBS", "PROBLEM", 0, 3], ["an acute immune-mediated polyradiculoneuropathy", "PROBLEM", 7, 54], ["previous infectious exposure", "PROBLEM", 72, 100], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["immune", "OBSERVATION", 16, 22], ["polyradiculoneuropathy", "OBSERVATION", 32, 54], ["infectious", "OBSERVATION", 81, 91]]], ["Clinically, GBS is characterized by limbs or cranial-nerve weakness, loss of deep tendon reflexes, sensory, and dysautonomic symptoms due to peripheral nerves and root demyelination and/or axonal damage [9] .", [["limbs", "ANATOMY", 36, 41], ["cranial-nerve", "ANATOMY", 45, 58], ["tendon", "ANATOMY", 82, 88], ["peripheral nerves", "ANATOMY", 141, 158], ["root", "ANATOMY", 163, 167], ["axonal", "ANATOMY", 189, 195], ["GBS", "DISEASE", 12, 15], ["cranial-nerve weakness", "DISEASE", 45, 67], ["demyelination", "DISEASE", 168, 181], ["axonal damage", "DISEASE", 189, 202], ["limbs", "ORGANISM_SUBDIVISION", 36, 41], ["nerve", "MULTI-TISSUE_STRUCTURE", 53, 58], ["tendon", "ORGANISM_SUBDIVISION", 82, 88], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 141, 158], ["root", "TISSUE", 163, 167], ["GBS", "PROBLEM", 12, 15], ["cranial-nerve weakness", "PROBLEM", 45, 67], ["loss of deep tendon reflexes", "PROBLEM", 69, 97], ["sensory, and dysautonomic symptoms", "PROBLEM", 99, 133], ["peripheral nerves", "PROBLEM", 141, 158], ["root demyelination", "PROBLEM", 163, 181], ["axonal damage", "PROBLEM", 189, 202], ["GBS", "OBSERVATION", 12, 15], ["limbs", "ANATOMY", 36, 41], ["cranial", "ANATOMY", 45, 52], ["nerve", "ANATOMY", 53, 58], ["weakness", "OBSERVATION", 59, 67], ["deep tendon", "ANATOMY", 77, 88], ["peripheral", "ANATOMY_MODIFIER", 141, 151], ["nerves", "ANATOMY", 152, 158], ["root", "ANATOMY", 163, 167], ["demyelination", "OBSERVATION", 168, 181]]], ["About 60% of all GBS are preceded by respiratory or a gastrointestinal [10] .BackgroundWe reported a case of COVID-19 patient with AIDP subtype of GBS, associating a literature review on the SARS-CoV-2 and GBS etiological correlation.Case descriptionOn April 26th, 2020, a 68-year-old man presented to the emergency department with symptoms of acute progressive symmetric ascending flaccid tetraparesis.", [["respiratory", "ANATOMY", 37, 48], ["gastrointestinal", "ANATOMY", 54, 70], ["flaccid", "ANATOMY", 382, 389], ["GBS", "DISEASE", 17, 20], ["GBS", "DISEASE", 147, 150], ["tetraparesis", "DISEASE", 390, 402], ["patient", "ORGANISM", 118, 125], ["man", "ORGANISM", 285, 288], ["patient", "SPECIES", 118, 125], ["man", "SPECIES", 285, 288], ["all GBS", "TEST", 13, 20], ["COVID", "TEST", 109, 114], ["AIDP subtype of GBS", "PROBLEM", 131, 150], ["the SARS", "TEST", 187, 195], ["CoV", "TEST", 196, 199], ["GBS etiological correlation", "TEST", 206, 233], ["symptoms", "PROBLEM", 332, 340], ["acute progressive symmetric ascending flaccid tetraparesis", "PROBLEM", 344, 402], ["gastrointestinal", "ANATOMY", 54, 70], ["GBS", "OBSERVATION", 147, 150], ["acute", "OBSERVATION_MODIFIER", 344, 349], ["progressive", "OBSERVATION_MODIFIER", 350, 361], ["symmetric", "OBSERVATION_MODIFIER", 362, 371], ["ascending", "ANATOMY_MODIFIER", 372, 381], ["flaccid tetraparesis", "OBSERVATION", 382, 402]]], ["Patient medical history included dyslipidemia, benign prostatic hypertrophy, hypertension, and abdominal aortic aneurysm in follow-up.", [["benign prostatic", "ANATOMY", 47, 63], ["abdominal aortic aneurysm", "ANATOMY", 95, 120], ["dyslipidemia", "DISEASE", 33, 45], ["benign prostatic hypertrophy", "DISEASE", 47, 75], ["hypertension", "DISEASE", 77, 89], ["abdominal aortic aneurysm", "DISEASE", 95, 120], ["prostatic", "MULTI-TISSUE_STRUCTURE", 54, 63], ["aortic", "ORGAN", 105, 111], ["Patient", "SPECIES", 0, 7], ["dyslipidemia", "PROBLEM", 33, 45], ["benign prostatic hypertrophy", "PROBLEM", 47, 75], ["hypertension", "PROBLEM", 77, 89], ["abdominal aortic aneurysm", "PROBLEM", 95, 120], ["dyslipidemia", "OBSERVATION", 33, 45], ["benign", "OBSERVATION_MODIFIER", 47, 53], ["prostatic", "ANATOMY", 54, 63], ["hypertrophy", "OBSERVATION", 64, 75], ["hypertension", "OBSERVATION", 77, 89], ["abdominal aortic", "ANATOMY", 95, 111], ["aneurysm", "OBSERVATION", 112, 120]]], ["Ten days before admission, dry cough associated with fever, dysgeusia, and hyposmia appeared.", [["dry cough", "DISEASE", 27, 36], ["fever", "DISEASE", 53, 58], ["dysgeusia", "DISEASE", 60, 69], ["hyposmia", "DISEASE", 75, 83], ["dry cough", "PROBLEM", 27, 36], ["fever", "PROBLEM", 53, 58], ["dysgeusia", "PROBLEM", 60, 69], ["hyposmia", "PROBLEM", 75, 83], ["cough", "OBSERVATION", 31, 36], ["fever", "OBSERVATION", 53, 58], ["dysgeusia", "OBSERVATION", 60, 69], ["hyposmia", "OBSERVATION", 75, 83]]], ["Neurological manifestations started 5 days later with progressive acute weakness of distal lower extremities.Case descriptionOn admission, oxygen saturation was 96% on room air, with a respiratory rate of 17 breaths/min, and the body temperature was 37.2\u00b0C. Chest computed tomography highlighted a bilateral basilar ground glass opacity, with oropharyngeal swab positive for SARS-CoV-2 on reverse transcriptasepolymerase chain reaction (RT-PCR) assay.", [["Neurological", "ANATOMY", 0, 12], ["distal lower extremities", "ANATOMY", 84, 108], ["body", "ANATOMY", 229, 233], ["oropharyngeal swab", "ANATOMY", 343, 361], ["oxygen", "CHEMICAL", 139, 145], ["oxygen", "CHEMICAL", 139, 145], ["lower extremities", "ORGANISM_SUBDIVISION", 91, 108], ["oxygen", "SIMPLE_CHEMICAL", 139, 145], ["body", "ORGANISM_SUBDIVISION", 229, 233], ["SARS-CoV", "SPECIES", 375, 383], ["Neurological manifestations", "PROBLEM", 0, 27], ["progressive acute weakness of distal lower extremities", "PROBLEM", 54, 108], ["oxygen saturation", "TEST", 139, 156], ["a respiratory rate", "TEST", 183, 201], ["the body temperature", "TEST", 225, 245], ["Chest computed tomography", "TEST", 258, 283], ["a bilateral basilar ground glass opacity", "PROBLEM", 296, 336], ["oropharyngeal swab", "TEST", 343, 361], ["SARS", "PROBLEM", 375, 379], ["CoV", "TEST", 380, 383], ["reverse transcriptasepolymerase chain reaction", "TREATMENT", 389, 435], ["progressive", "OBSERVATION_MODIFIER", 54, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["weakness", "OBSERVATION", 72, 80], ["distal", "ANATOMY_MODIFIER", 84, 90], ["lower extremities", "ANATOMY", 91, 108], ["Chest", "ANATOMY", 258, 263], ["bilateral", "ANATOMY_MODIFIER", 298, 307], ["basilar", "ANATOMY_MODIFIER", 308, 315], ["ground glass opacity", "OBSERVATION", 316, 336], ["oropharyngeal", "ANATOMY", 343, 356]]], ["No pathological findings were auscultated on pulmonary objective examination.Case descriptionThe patient was then isolated and antiviral drugs have been started.", [["pulmonary", "ANATOMY", 45, 54], ["pulmonary", "ORGAN", 45, 54], ["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["pathological findings", "PROBLEM", 3, 24], ["pulmonary objective examination", "TEST", 45, 76], ["antiviral drugs", "TREATMENT", 127, 142], ["pathological", "OBSERVATION", 3, 15], ["pulmonary", "ANATOMY", 45, 54]]], ["Neurological examination showed bifacial nerve palsy (House-Brackmann grade 3) and muscular weakness, with a Medical Research Council scale of 1/5 in proximal and 2/5 in distal of the lower limbs.", [["bifacial nerve", "ANATOMY", 32, 46], ["muscular", "ANATOMY", 83, 91], ["lower limbs", "ANATOMY", 184, 195], ["bifacial nerve palsy", "DISEASE", 32, 52], ["muscular weakness", "DISEASE", 83, 100], ["bifacial nerve", "MULTI-TISSUE_STRUCTURE", 32, 46], ["muscular", "ORGAN", 83, 91], ["lower limbs", "ORGANISM_SUBDIVISION", 184, 195], ["Neurological examination", "TEST", 0, 24], ["bifacial nerve palsy", "PROBLEM", 32, 52], ["muscular weakness", "PROBLEM", 83, 100], ["a Medical Research Council scale", "TEST", 107, 139], ["bifacial nerve", "ANATOMY", 32, 46], ["palsy", "OBSERVATION", 47, 52], ["muscular", "ANATOMY", 83, 91], ["weakness", "OBSERVATION", 92, 100], ["proximal", "ANATOMY_MODIFIER", 150, 158], ["2/5", "ANATOMY_MODIFIER", 163, 166], ["distal", "ANATOMY_MODIFIER", 170, 176], ["lower limbs", "ANATOMY", 184, 195]]], ["The osteo-tendon reflexes were hypoactive with bilateral areflexia to the Achilles tendons.", [["osteo-tendon", "ANATOMY", 4, 16], ["Achilles tendons", "ANATOMY", 74, 90], ["areflexia", "DISEASE", 57, 66], ["osteo-tendon", "TISSUE", 4, 16], ["Achilles tendons", "TISSUE", 74, 90], ["The osteo-tendon reflexes", "TEST", 0, 25], ["hypoactive", "PROBLEM", 31, 41], ["bilateral areflexia to the Achilles tendons", "PROBLEM", 47, 90], ["osteo", "OBSERVATION", 4, 9], ["tendon", "ANATOMY", 10, 16], ["hypoactive", "OBSERVATION", 31, 41], ["bilateral", "ANATOMY_MODIFIER", 47, 56], ["areflexia", "OBSERVATION", 57, 66], ["Achilles tendons", "ANATOMY", 74, 90]]], ["No sensory deficit was recorded.", [["sensory deficit", "PROBLEM", 3, 18], ["sensory deficit", "OBSERVATION", 3, 18]]], ["Upper motor neuron disorder or meningeal irritation signs have not been found.Case descriptionBaseline laboratoristic analysis showed thrombocytopenia (101 \u00d7 10 9 /L, reference value: 125-300 \u00d7 10 9 /L) and lymphocytopenia (0.48 \u00d7 10 9 /L, reference value: 1.1-3.2 \u00d7 10 9 /L).", [["Upper motor neuron", "ANATOMY", 0, 18], ["meningeal", "ANATOMY", 31, 40], ["Upper motor neuron disorder", "DISEASE", 0, 27], ["meningeal irritation", "DISEASE", 31, 51], ["thrombocytopenia", "DISEASE", 134, 150], ["lymphocytopenia", "DISEASE", 207, 222], ["meningeal", "PATHOLOGICAL_FORMATION", 31, 40], ["Upper motor neuron disorder", "PROBLEM", 0, 27], ["meningeal irritation signs", "PROBLEM", 31, 57], ["Case descriptionBaseline laboratoristic analysis", "TEST", 78, 126], ["thrombocytopenia", "PROBLEM", 134, 150], ["lymphocytopenia", "TEST", 207, 222], ["value", "TEST", 250, 255], ["motor neuron disorder", "OBSERVATION", 6, 27], ["meningeal", "ANATOMY", 31, 40], ["irritation", "OBSERVATION", 41, 51], ["thrombocytopenia", "OBSERVATION", 134, 150], ["lymphocytopenia", "OBSERVATION", 207, 222]]], ["Cerebrospinal fluid assessment showed an albuminocytologic dissociation with increased protein level (98 mg/dL, reference value: 8-43 mg/dL) and normal cell count (2 \u00d7 10 6 /L, reference value: 0-8 \u00d7 10 6 /L).", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["cell", "ANATOMY", 152, 156], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["cell", "CELL", 152, 156], ["Cerebrospinal fluid assessment", "TEST", 0, 30], ["an albuminocytologic dissociation", "PROBLEM", 38, 71], ["increased protein level", "PROBLEM", 77, 100], ["reference value", "TEST", 112, 127], ["reference value", "TEST", 177, 192], ["fluid", "OBSERVATION", 14, 19], ["albuminocytologic dissociation", "OBSERVATION", 41, 71], ["cell count", "OBSERVATION", 152, 162]]], ["Additional serological tests (i.e., ANA, anti-DNA, c-ANCA, p-ANCA, Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, Cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, Varicella-Zoster virus, influenza virus A and B, human immunodeficiency virus) were negative.", [["Campylobacter jejuni", "DISEASE", 67, 87], ["herpes simplex virus", "DISEASE", 170, 190], ["Varicella-Zoster virus", "DISEASE", 200, 222], ["human immunodeficiency virus", "DISEASE", 249, 277], ["anti-DNA", "GENE_OR_GENE_PRODUCT", 41, 49], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 51, 57], ["p-ANCA", "GENE_OR_GENE_PRODUCT", 59, 65], ["Campylobacter jejuni", "ORGANISM", 67, 87], ["Mycoplasma pneumoniae", "ORGANISM", 89, 110], ["Salmonella enterica", "ORGANISM", 112, 131], ["Cytomegalovirus,", "ORGANISM", 133, 149], ["Epstein-Barr virus", "ORGANISM", 150, 168], ["herpes simplex virus 1", "ORGANISM", 170, 192], ["2,", "ORGANISM", 197, 199], ["Varicella-Zoster virus", "ORGANISM", 200, 222], ["influenza virus A", "ORGANISM", 224, 241], ["B", "GENE_OR_GENE_PRODUCT", 246, 247], ["human immunodeficiency virus", "ORGANISM", 249, 277], ["anti-DNA", "PROTEIN", 41, 49], ["ANCA", "PROTEIN", 53, 57], ["ANCA", "PROTEIN", 61, 65], ["Campylobacter jejuni", "SPECIES", 67, 87], ["Mycoplasma pneumoniae", "SPECIES", 89, 110], ["Salmonella enterica", "SPECIES", 112, 131], ["herpes simplex virus", "SPECIES", 170, 190], ["Varicella-Zoster virus", "SPECIES", 200, 222], ["influenza virus", "SPECIES", 224, 239], ["human", "SPECIES", 249, 254], ["immunodeficiency virus", "SPECIES", 255, 277], ["Campylobacter jejuni", "SPECIES", 67, 87], ["Mycoplasma pneumoniae", "SPECIES", 89, 110], ["Salmonella enterica", "SPECIES", 112, 131], ["Epstein-Barr virus", "SPECIES", 150, 168], ["herpes simplex virus 1", "SPECIES", 170, 192], ["Varicella-Zoster virus", "SPECIES", 200, 222], ["human immunodeficiency virus", "SPECIES", 249, 277], ["Additional serological tests", "TEST", 0, 28], ["ANA", "TEST", 36, 39], ["anti-DNA", "TEST", 41, 49], ["c", "TEST", 51, 52], ["ANCA", "TEST", 53, 57], ["p", "TEST", 59, 60], ["ANCA", "TEST", 61, 65], ["Campylobacter jejuni", "PROBLEM", 67, 87], ["Mycoplasma pneumoniae", "PROBLEM", 89, 110], ["Salmonella enterica", "PROBLEM", 112, 131], ["Cytomegalovirus", "PROBLEM", 133, 148], ["Epstein", "TEST", 150, 157], ["Barr virus", "PROBLEM", 158, 168], ["herpes simplex virus", "PROBLEM", 170, 190], ["Varicella", "TEST", 200, 209], ["Zoster virus", "PROBLEM", 210, 222], ["influenza virus A", "PROBLEM", 224, 241], ["human immunodeficiency virus", "PROBLEM", 249, 277], ["Campylobacter jejuni", "ANATOMY", 67, 87], ["Mycoplasma pneumoniae", "OBSERVATION", 89, 110], ["Zoster virus", "ANATOMY", 210, 222]]], ["Normal serum vitamin B12 level and serum protein electrophoresis were found.Case descriptionFour days after neurological symptoms and signs onset, motor nerve conduction studies showed delayed distal latencies and absent F waves in early course, supporting demyelinating pattern in accordance with GBS diagnostic criteria (Table 1) .", [["serum", "ANATOMY", 7, 12], ["serum", "ANATOMY", 35, 40], ["neurological", "ANATOMY", 108, 120], ["nerve", "ANATOMY", 153, 158], ["vitamin B12", "CHEMICAL", 13, 24], ["neurological symptoms", "DISEASE", 108, 129], ["GBS", "DISEASE", 298, 301], ["vitamin B12", "CHEMICAL", 13, 24], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["vitamin", "SIMPLE_CHEMICAL", 13, 20], ["B12", "SIMPLE_CHEMICAL", 21, 24], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["serum vitamin B12 level", "TEST", 7, 30], ["serum protein electrophoresis", "TEST", 35, 64], ["neurological symptoms", "PROBLEM", 108, 129], ["signs onset", "PROBLEM", 134, 145], ["motor nerve conduction studies", "TEST", 147, 177], ["delayed distal latencies", "PROBLEM", 185, 209], ["absent F waves in early course", "PROBLEM", 214, 244], ["demyelinating pattern", "PROBLEM", 257, 278], ["motor nerve", "ANATOMY", 147, 158], ["distal", "OBSERVATION_MODIFIER", 193, 199], ["latencies", "OBSERVATION", 200, 209], ["F waves", "OBSERVATION_MODIFIER", 221, 228], ["early course", "OBSERVATION_MODIFIER", 232, 244], ["demyelinating pattern", "OBSERVATION", 257, 278]]], ["Sensory nerve conduction showed nerve action potentials; the recorded values were all in range, in line with the patient clinic.Case descriptionA diagnosis of Guillain-Barr\u00e9 syndrome was then made.", [["Sensory nerve", "ANATOMY", 0, 13], ["nerve", "ANATOMY", 32, 37], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 159, 182], ["Sensory nerve", "MULTI-TISSUE_STRUCTURE", 0, 13], ["nerve", "MULTI-TISSUE_STRUCTURE", 32, 37], ["patient", "ORGANISM", 113, 120], ["Guillain-Barr\u00e9", "ORGANISM", 159, 173], ["patient", "SPECIES", 113, 120], ["Sensory nerve conduction", "TEST", 0, 24], ["nerve action potentials", "PROBLEM", 32, 55], ["the recorded values", "TEST", 57, 76], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 159, 182], ["nerve", "ANATOMY", 8, 13], ["nerve", "ANATOMY", 32, 37], ["Barr\u00e9 syndrome", "OBSERVATION", 168, 182]]], ["Intravenous immunoglobulin was administered at a dose of 0.4 g/kg for 5 days.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 12, 26], ["immunoglobulin", "PROTEIN", 12, 26], ["Intravenous immunoglobulin", "TREATMENT", 0, 26]]], ["Thrombocytopenia and lymphocytopenia progressively returned in the following days, with complete resolution of the admission radiological pulmonary findings.", [["pulmonary", "ANATOMY", 138, 147], ["Thrombocytopenia", "DISEASE", 0, 16], ["lymphocytopenia", "DISEASE", 21, 36], ["pulmonary", "ORGAN", 138, 147], ["Thrombocytopenia", "PROBLEM", 0, 16], ["lymphocytopenia", "PROBLEM", 21, 36], ["the admission radiological pulmonary findings", "PROBLEM", 111, 156], ["lymphocytopenia", "OBSERVATION", 21, 36], ["pulmonary", "ANATOMY", 138, 147]]], ["The improvement of the respiratory and laboratory clinic was followed by a progressive recovery of limb strength and a return to osteo-tendon normoreflexia.", [["respiratory", "ANATOMY", 23, 34], ["limb", "ANATOMY", 99, 103], ["tendon", "ANATOMY", 135, 141], ["normoreflexia", "DISEASE", 142, 155], ["limb", "ORGANISM_SUBDIVISION", 99, 103], ["a progressive recovery of limb strength", "PROBLEM", 73, 112], ["osteo-tendon normoreflexia", "PROBLEM", 129, 155], ["improvement", "OBSERVATION_MODIFIER", 4, 15], ["respiratory", "ANATOMY", 23, 34], ["limb strength", "OBSERVATION", 99, 112], ["osteo", "OBSERVATION", 129, 134], ["tendon", "ANATOMY", 135, 141], ["normoreflexia", "OBSERVATION", 142, 155]]], ["Thirty days after hospitalization, following the negative result of the oropharyngeal swab for SARS-CoV-2, the patient was discharged to continue the rehabilitation program at home.DiscussionWe described a case of acute progressive symmetric ascending flaccid tetraparesis in a COVID-19 patient with diagnosis of AIDP subtype of GBS.", [["oropharyngeal swab", "ANATOMY", 72, 90], ["SARS", "DISEASE", 95, 99], ["tetraparesis", "DISEASE", 260, 272], ["AIDP", "DISEASE", 313, 317], ["GBS", "DISEASE", 329, 332], ["oropharyngeal swab", "MULTI-TISSUE_STRUCTURE", 72, 90], ["patient", "ORGANISM", 111, 118], ["patient", "ORGANISM", 287, 294], ["AIDP", "CANCER", 313, 317], ["patient", "SPECIES", 111, 118], ["patient", "SPECIES", 287, 294], ["SARS-CoV", "SPECIES", 95, 103], ["the oropharyngeal swab", "TEST", 68, 90], ["SARS", "PROBLEM", 95, 99], ["the rehabilitation program", "TREATMENT", 146, 172], ["acute progressive symmetric ascending flaccid tetraparesis", "PROBLEM", 214, 272], ["a COVID", "TEST", 276, 283], ["AIDP subtype of GBS", "PROBLEM", 313, 332], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["progressive", "OBSERVATION_MODIFIER", 220, 231], ["symmetric", "OBSERVATION_MODIFIER", 232, 241], ["ascending", "OBSERVATION_MODIFIER", 242, 251], ["flaccid", "OBSERVATION_MODIFIER", 252, 259], ["tetraparesis", "OBSERVATION", 260, 272], ["GBS", "OBSERVATION", 329, 332]]], ["The anamnestic, clinical, electrophysiological, and laboratory evidence leads to a likely causal association with SARS-CoV-2.DiscussionStarting from the first case of GBS SARS-CoV-2 infectionrelated described by Zhao H. et al. [11] , a series of cases have been reported in the literature, supporting the post-infectious and para-infectious etiopathological correlation between SARS-CoV-2 and this acute polyradiculoneuropathy ( Table 2) .", [["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 171, 175], ["polyradiculoneuropathy", "DISEASE", 404, 426], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 114, 124], ["SARS-CoV-2", "ORGANISM", 378, 388], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 378, 386], ["GBS SARS", "PROBLEM", 167, 175], ["CoV", "PROBLEM", 176, 179], ["the post-infectious and para-infectious etiopathological correlation", "PROBLEM", 301, 369], ["SARS", "TEST", 378, 382], ["CoV", "TEST", 383, 386], ["this acute polyradiculoneuropathy", "PROBLEM", 393, 426], ["post-infectious", "OBSERVATION", 305, 320], ["acute", "OBSERVATION_MODIFIER", 398, 403], ["polyradiculoneuropathy", "OBSERVATION", 404, 426]]], ["A systematic review of the literature on GBS and its correlation with SARS-CoV-2 infection was performed.", [["GBS", "DISEASE", 41, 44], ["SARS-CoV-2 infection", "DISEASE", 70, 90], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["GBS", "TEST", 41, 44], ["SARS", "PROBLEM", 70, 74], ["CoV-2 infection", "PROBLEM", 75, 90], ["infection", "OBSERVATION", 81, 90]]], ["Multiple searches were made on PubMed and Scopus by cross-referencing the following keywords: \"Guillan-Barr\u00e8\", \"Guillan-Barr\u00e8 syndrome\", \"COVID-19\", \"SARS-CoV-2\", \"para-infectious\", \"post-infectious\", \"molecular mimicry\", \"neuropathy\", \"flaccid\", \"polyradiculoneuropathy\", \"ACE-2\", \"pathogenesis\".", [["flaccid", "ANATOMY", 237, 244], ["Guillan-Barr\u00e8 syndrome", "DISEASE", 112, 134], ["SARS", "DISEASE", 150, 154], ["neuropathy", "DISEASE", 223, 233], ["polyradiculoneuropathy", "DISEASE", 248, 270], ["neuropathy\"", "PROBLEM", 223, 234], ["flaccid\"", "PROBLEM", 237, 245], ["polyradiculoneuropathy", "PROBLEM", 248, 270], ["infectious", "OBSERVATION", 188, 198], ["neuropathy", "OBSERVATION", 223, 233], ["polyradiculoneuropathy", "OBSERVATION", 248, 270]]], ["Other pertinent articles were retrieved through reference analysis.", [["reference analysis", "TEST", 48, 66]]], ["Inclusion criteria were the report of GBS clinical manifestation in COVID-19 patients.", [["GBS", "DISEASE", 38, 41], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 68, 73]]], ["To date, June 6th, 2020, 16 papers have been published regarding the GBS-SARS-CoV-2 correlation.", [["SARS", "DISEASE", 73, 77], ["the GBS", "TEST", 65, 72]]], ["Adding up all the cases reported in the literature, 23 COVID-19 patients with GBS have been described, including our case report.", [["GBS", "DISEASE", 78, 81], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["GBS", "PROBLEM", 78, 81]]], ["There was no gender prevalence, and the average age of the patients was 61 years.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["no", "UNCERTAINTY", 10, 12]]], ["A slight prevalence of AIDP over AMSAN subtype was observed.", [["AIDP", "DISEASE", 23, 27], ["AIDP", "CANCER", 23, 27], ["AMSAN", "CANCER", 33, 38], ["AIDP", "PROBLEM", 23, 27], ["AMSAN subtype", "PROBLEM", 33, 46], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["prevalence", "OBSERVATION_MODIFIER", 9, 19], ["AIDP", "OBSERVATION", 23, 27]]], ["Post-infectious cases were predominant over para-infectious cases.DiscussionGBS is an acute flaccid paralytic disease that most commonly presents with progressive symmetric weakness and areflexia.", [["flaccid paralytic disease", "DISEASE", 92, 117], ["areflexia", "DISEASE", 186, 195], ["an acute flaccid paralytic disease", "PROBLEM", 83, 117], ["progressive symmetric weakness", "PROBLEM", 151, 181], ["areflexia", "PROBLEM", 186, 195], ["infectious", "OBSERVATION", 5, 15], ["predominant", "OBSERVATION_MODIFIER", 27, 38], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["flaccid", "OBSERVATION_MODIFIER", 92, 99], ["paralytic disease", "OBSERVATION", 100, 117], ["progressive", "OBSERVATION_MODIFIER", 151, 162], ["symmetric", "OBSERVATION_MODIFIER", 163, 172], ["weakness", "OBSERVATION", 173, 181], ["areflexia", "OBSERVATION", 186, 195]]], ["GBS usually occurs following a respiratory or gastrointestinal infection, with a presentation latency varying between 3 days and 6 weeks [9] .", [["respiratory", "ANATOMY", 31, 42], ["gastrointestinal", "ANATOMY", 46, 62], ["GBS", "DISEASE", 0, 3], ["respiratory or gastrointestinal infection", "DISEASE", 31, 72], ["gastrointestinal", "ORGAN", 46, 62], ["GBS", "PROBLEM", 0, 3], ["a respiratory or gastrointestinal infection", "PROBLEM", 29, 72], ["gastrointestinal", "ANATOMY", 46, 62], ["infection", "OBSERVATION", 63, 72]]], ["The supposed pathophysiological mechanism is the \"molecular mimicry\", an aberrant autoimmune response to a preceding infection which evokes a cross-reaction against the peripheral nerve antigens (e.g. production of anti-ganglioside antibodies in AMSAN GBS subtype preceded by Campylobacter jejuni infection) [9] .", [["peripheral nerve", "ANATOMY", 169, 185], ["infection", "DISEASE", 117, 126], ["GBS", "DISEASE", 252, 255], ["Campylobacter jejuni infection", "DISEASE", 276, 306], ["anti-ganglioside antibodies", "GENE_OR_GENE_PRODUCT", 215, 242], ["Campylobacter jejuni", "ORGANISM", 276, 296], ["peripheral nerve antigens", "PROTEIN", 169, 194], ["anti-ganglioside antibodies", "PROTEIN", 215, 242], ["Campylobacter jejuni", "SPECIES", 276, 296], ["Campylobacter jejuni", "SPECIES", 276, 296], ["an aberrant autoimmune response", "PROBLEM", 70, 101], ["a preceding infection", "PROBLEM", 105, 126], ["the peripheral nerve antigens", "PROBLEM", 165, 194], ["anti-ganglioside antibodies", "PROBLEM", 215, 242], ["GBS subtype", "PROBLEM", 252, 263], ["Campylobacter jejuni infection", "PROBLEM", 276, 306], ["aberrant", "OBSERVATION_MODIFIER", 73, 81], ["autoimmune", "OBSERVATION", 82, 92], ["infection", "OBSERVATION", 117, 126], ["peripheral", "ANATOMY_MODIFIER", 169, 179], ["nerve", "ANATOMY", 180, 185], ["Campylobacter jejuni infection", "OBSERVATION", 276, 306]]], ["For this NR not reported reason, GBS can be defined as para-infectious neurological disease [4] .", [["neurological", "ANATOMY", 71, 83], ["GBS", "DISEASE", 33, 36], ["neurological disease", "DISEASE", 71, 91], ["GBS", "PROBLEM", 33, 36], ["para-infectious neurological disease", "PROBLEM", 55, 91]]], ["SARS-CoV-2 nervous tissue damage can be both related to the direct neuroinvasive action (through direct binding with ACE-2 receptors) [24] and to an indirect injury of the immune system.", [["nervous tissue", "ANATOMY", 11, 25], ["immune system", "ANATOMY", 172, 185], ["SARS", "DISEASE", 0, 4], ["nervous tissue", "TISSUE", 11, 25], ["ACE-2 receptors", "GENE_OR_GENE_PRODUCT", 117, 132], ["ACE-2 receptors", "PROTEIN", 117, 132], ["SARS", "PROBLEM", 0, 4], ["CoV-2 nervous tissue damage", "PROBLEM", 5, 32], ["ACE-2 receptors", "TREATMENT", 117, 132], ["an indirect injury of the immune system", "PROBLEM", 146, 185], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["nervous tissue", "OBSERVATION_MODIFIER", 11, 25], ["damage", "OBSERVATION", 26, 32], ["injury", "OBSERVATION", 158, 164]]], ["In the latter case, the mechanism of immunemediated damage can be due both to an overactivation of the immune system with hyperproduction of interleukin-6, and to the generation of an autoimmune reaction [18] .", [["immune system", "ANATOMY", 103, 116], ["autoimmune reaction", "DISEASE", 184, 203], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 141, 154], ["interleukin-6", "PROTEIN", 141, 154], ["immunemediated damage", "PROBLEM", 37, 58], ["an overactivation of the immune system", "PROBLEM", 78, 116], ["hyperproduction of interleukin", "PROBLEM", 122, 152], ["an autoimmune reaction", "PROBLEM", 181, 203]]], ["The infectious bacterial agents classically associated with GBS are Campylobacter jejuni, which is the most frequent, Mycoplasma pneumoniae, and Haemophilus influenzae; Cytomegalovirus, Epstein-Barr virus, and Influenza-A virus are the most involved viral pathogens [9] .", [["GBS", "DISEASE", 60, 63], ["Campylobacter jejuni", "DISEASE", 68, 88], ["Mycoplasma pneumoniae", "DISEASE", 118, 139], ["Haemophilus influenzae", "DISEASE", 145, 167], ["Epstein-Barr virus", "DISEASE", 186, 204], ["Influenza-A virus", "DISEASE", 210, 227], ["Campylobacter jejuni", "ORGANISM", 68, 88], ["Mycoplasma pneumoniae", "ORGANISM", 118, 139], ["Haemophilus influenzae", "ORGANISM", 145, 167], ["Cytomegalovirus", "ORGANISM", 169, 184], ["Epstein-Barr virus", "ORGANISM", 186, 204], ["Influenza-A virus", "ORGANISM", 210, 227], ["Campylobacter jejuni", "SPECIES", 68, 88], ["Mycoplasma pneumoniae", "SPECIES", 118, 139], ["Haemophilus influenzae", "SPECIES", 145, 167], ["Influenza-A virus", "SPECIES", 210, 227], ["Campylobacter jejuni", "SPECIES", 68, 88], ["Mycoplasma pneumoniae", "SPECIES", 118, 139], ["Haemophilus influenzae", "SPECIES", 145, 167], ["Epstein-Barr virus", "SPECIES", 186, 204], ["Influenza-A virus", "SPECIES", 210, 227], ["The infectious bacterial agents", "PROBLEM", 0, 31], ["GBS", "PROBLEM", 60, 63], ["Campylobacter jejuni", "PROBLEM", 68, 88], ["Mycoplasma pneumoniae", "PROBLEM", 118, 139], ["Haemophilus influenzae", "PROBLEM", 145, 167], ["Cytomegalovirus", "PROBLEM", 169, 184], ["Epstein-Barr virus", "PROBLEM", 186, 204], ["Influenza", "PROBLEM", 210, 219], ["A virus", "PROBLEM", 220, 227], ["viral pathogens", "PROBLEM", 250, 265], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["GBS", "OBSERVATION", 60, 63], ["Campylobacter jejuni", "OBSERVATION", 68, 88], ["Mycoplasma pneumoniae", "OBSERVATION", 118, 139], ["Barr virus", "OBSERVATION", 194, 204]]], ["Cases associated with hepatitis E virus infection and measle infection have also rarely been found [25, 26] .", [["hepatitis E virus infection", "DISEASE", 22, 49], ["measle infection", "DISEASE", 54, 70], ["hepatitis E virus", "ORGANISM", 22, 39], ["hepatitis E virus", "SPECIES", 22, 39], ["hepatitis E virus", "SPECIES", 22, 39], ["hepatitis E virus infection", "PROBLEM", 22, 49], ["measle infection", "PROBLEM", 54, 70], ["hepatitis", "OBSERVATION", 22, 31], ["virus infection", "OBSERVATION", 34, 49], ["infection", "OBSERVATION", 61, 70]]], ["In 2015 and 2016, cases of GBS related to the Zika virus were also reported [10, 27] .", [["GBS", "DISEASE", 27, 30], ["Zika virus", "ORGANISM", 46, 56], ["Zika virus", "SPECIES", 46, 56], ["GBS", "PROBLEM", 27, 30], ["the Zika virus", "PROBLEM", 42, 56]]], ["In addition, recent evidence reported some cases of GBS in COVID-19 patients, to the point of speculating a possible association between the acute polyradiculopathy and SARS-CoV-2 infection [10-23, 28, 29] .DiscussionPost-infectious refers to patients with GBS arisen once the SARS-CoV-2 infection has resolved, while para-infectious if GBS occurred during COVID-19 [14] .", [["GBS", "DISEASE", 52, 55], ["polyradiculopathy", "DISEASE", 147, 164], ["SARS-CoV-2 infection", "DISEASE", 169, 189], ["GBS", "DISEASE", 257, 260], ["SARS", "DISEASE", 277, 281], ["infection", "DISEASE", 288, 297], ["GBS", "DISEASE", 337, 340], ["COVID-19", "CHEMICAL", 357, 365], ["patients", "ORGANISM", 68, 76], ["SARS-CoV-2", "ORGANISM", 169, 179], ["patients", "ORGANISM", 243, 251], ["SARS-CoV-2", "ORGANISM", 277, 287], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 243, 251], ["SARS-CoV", "SPECIES", 169, 177], ["SARS-CoV", "SPECIES", 277, 285], ["GBS", "PROBLEM", 52, 55], ["COVID", "TEST", 59, 64], ["the acute polyradiculopathy", "PROBLEM", 137, 164], ["SARS", "PROBLEM", 169, 173], ["CoV-2 infection", "PROBLEM", 174, 189], ["GBS", "PROBLEM", 257, 260], ["the SARS", "TEST", 273, 281], ["CoV", "PROBLEM", 282, 285], ["2 infection", "PROBLEM", 286, 297], ["GBS", "PROBLEM", 337, 340], ["COVID", "TEST", 357, 362], ["GBS", "OBSERVATION", 52, 55], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["polyradiculopathy", "OBSERVATION", 147, 164], ["infection", "OBSERVATION", 288, 297]]], ["In our case, the respiratory clinic slightly preceded the appearance of neurological symptoms, while the pulmonary, laboratory and radiological positivity to SARS-CoV-2 accompanied the whole clinical course of GBS, to have an almost parallel resolution.", [["respiratory", "ANATOMY", 17, 28], ["neurological", "ANATOMY", 72, 84], ["pulmonary", "ANATOMY", 105, 114], ["neurological symptoms", "DISEASE", 72, 93], ["SARS", "DISEASE", 158, 162], ["GBS", "DISEASE", 210, 213], ["pulmonary", "ORGAN", 105, 114], ["neurological symptoms", "PROBLEM", 72, 93], ["radiological positivity", "TEST", 131, 154], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["GBS", "PROBLEM", 210, 213], ["pulmonary", "ANATOMY", 105, 114], ["GBS", "OBSERVATION", 210, 213]]], ["These data are suggestive for a para-infectious mechanism.DiscussionAs well described in the literature, GBS is an immunemediated disorder due to a molecular mimicry mechanism [9] .", [["GBS", "DISEASE", 105, 108], ["These data", "TEST", 0, 10], ["a para-infectious mechanism", "PROBLEM", 30, 57], ["GBS", "PROBLEM", 105, 108], ["an immunemediated disorder", "PROBLEM", 112, 138], ["suggestive for", "UNCERTAINTY", 15, 29]]], ["However, a real verification of the production of specific antibodies against gangliosides present on the surface of the nerve myelin sheaths is still lacking [12] .", [["surface", "ANATOMY", 106, 113], ["nerve myelin sheaths", "ANATOMY", 121, 141], ["antibodies against gangliosides", "GENE_OR_GENE_PRODUCT", 59, 90], ["surface", "CELLULAR_COMPONENT", 106, 113], ["nerve myelin sheaths", "CELLULAR_COMPONENT", 121, 141], ["antibodies", "PROTEIN", 59, 69], ["specific antibodies against gangliosides", "PROBLEM", 50, 90], ["the nerve myelin sheaths", "TREATMENT", 117, 141], ["nerve myelin", "ANATOMY", 121, 133]]], ["For this reason, further studies are needed to better clarify the pathophysiological mechanism of GBS in patients with COVID-19.DiscussionThe diagnosis of SARS-CoV-2-related GBS in our patient was supported by a series of laboratory findings associated with the incipient clinic and electrophysiological data.", [["GBS", "DISEASE", 98, 101], ["SARS", "DISEASE", 155, 159], ["GBS", "DISEASE", 174, 177], ["patients", "ORGANISM", 105, 113], ["SARS-CoV-2", "ORGANISM", 155, 165], ["patient", "ORGANISM", 185, 192], ["patients", "SPECIES", 105, 113], ["patient", "SPECIES", 185, 192], ["further studies", "TEST", 17, 32], ["GBS", "PROBLEM", 98, 101], ["COVID", "TEST", 119, 124], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163], ["GBS", "PROBLEM", 174, 177], ["laboratory findings", "TEST", 222, 241], ["electrophysiological data", "TEST", 283, 308], ["GBS", "OBSERVATION", 98, 101], ["GBS", "OBSERVATION", 174, 177]]], ["In particular, the serologies of the most common pathogens associated with GBS, such as Campylobacter jejuni, Mycoplasma pneumoniae, Salmonella enterica, Cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, Varicella-Zoster virus, influenza virus A and B, and human immunodeficiency virus, were negative.", [["GBS", "DISEASE", 75, 78], ["Campylobacter jejuni", "DISEASE", 88, 108], ["Mycoplasma pneumoniae", "DISEASE", 110, 131], ["herpes simplex virus", "DISEASE", 191, 211], ["Varicella-Zoster virus", "DISEASE", 221, 243], ["human immunodeficiency virus", "DISEASE", 274, 302], ["Campylobacter jejuni", "ORGANISM", 88, 108], ["Mycoplasma pneumoniae", "ORGANISM", 110, 131], ["Salmonella enterica", "ORGANISM", 133, 152], ["Cytomegalovirus", "ORGANISM", 154, 169], ["Epstein-Barr virus", "ORGANISM", 171, 189], ["herpes simplex virus 1", "ORGANISM", 191, 213], ["2,", "ORGANISM", 218, 220], ["Varicella-Zoster virus", "ORGANISM", 221, 243], ["influenza virus A", "ORGANISM", 245, 262], ["B", "GENE_OR_GENE_PRODUCT", 267, 268], ["human immunodeficiency virus", "ORGANISM", 274, 302], ["Campylobacter jejuni", "SPECIES", 88, 108], ["Mycoplasma pneumoniae", "SPECIES", 110, 131], ["Salmonella enterica", "SPECIES", 133, 152], ["Epstein-Barr virus", "SPECIES", 171, 189], ["herpes simplex virus 1", "SPECIES", 191, 213], ["Varicella-Zoster virus", "SPECIES", 221, 243], ["influenza virus", "SPECIES", 245, 260], ["human", "SPECIES", 274, 279], ["immunodeficiency virus", "SPECIES", 280, 302], ["Campylobacter jejuni", "SPECIES", 88, 108], ["Mycoplasma pneumoniae", "SPECIES", 110, 131], ["Salmonella enterica", "SPECIES", 133, 152], ["Epstein-Barr virus", "SPECIES", 171, 189], ["herpes simplex virus 1", "SPECIES", 191, 213], ["Varicella-Zoster virus", "SPECIES", 221, 243], ["influenza virus A", "SPECIES", 245, 262], ["human immunodeficiency virus", "SPECIES", 274, 302], ["the serologies", "TEST", 15, 29], ["the most common pathogens", "PROBLEM", 33, 58], ["GBS", "PROBLEM", 75, 78], ["Campylobacter jejuni", "PROBLEM", 88, 108], ["Mycoplasma pneumoniae", "PROBLEM", 110, 131], ["Salmonella enterica", "PROBLEM", 133, 152], ["Cytomegalovirus", "PROBLEM", 154, 169], ["Epstein-Barr virus", "PROBLEM", 171, 189], ["herpes simplex virus", "PROBLEM", 191, 211], ["Varicella", "TEST", 221, 230], ["Zoster virus", "PROBLEM", 231, 243], ["influenza virus A and B", "PROBLEM", 245, 268], ["human immunodeficiency virus", "PROBLEM", 274, 302], ["GBS", "OBSERVATION", 75, 78], ["Campylobacter jejuni", "ANATOMY", 88, 108], ["Mycoplasma pneumoniae", "OBSERVATION", 110, 131], ["Barr virus", "OBSERVATION", 179, 189], ["Zoster virus", "ANATOMY", 231, 243], ["influenza virus", "OBSERVATION", 245, 260]]], ["Antibody tests for GBS-associated autoimmune diseases (e.g., ANA, anti-DNA, c-ANCA, p-ANCA) were also negative.", [["GBS", "DISEASE", 19, 22], ["autoimmune diseases", "DISEASE", 34, 53], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 76, 82], ["p-ANCA", "GENE_OR_GENE_PRODUCT", 84, 90], ["ANA", "PROTEIN", 61, 64], ["anti-DNA", "PROTEIN", 66, 74], ["c", "PROTEIN", 76, 77], ["ANCA", "PROTEIN", 78, 82], ["p", "PROTEIN", 84, 85], ["ANCA", "PROTEIN", 86, 90], ["Antibody tests", "TEST", 0, 14], ["GBS", "PROBLEM", 19, 22], ["autoimmune diseases", "PROBLEM", 34, 53], ["ANA", "TEST", 61, 64], ["anti-DNA", "TEST", 66, 74], ["c", "TEST", 76, 77], ["ANCA", "TEST", 78, 82], ["ANCA", "TEST", 86, 90]]], ["Furthermore, in support of GBS diagnosis, we observed a marked albuminocytologic dissociation.", [["GBS diagnosis", "TEST", 27, 40], ["a marked albuminocytologic dissociation", "PROBLEM", 54, 93], ["marked", "OBSERVATION_MODIFIER", 56, 62], ["albuminocytologic dissociation", "OBSERVATION", 63, 93]]], ["However, we cannot prove with certainty that a COVID-19 para-infectious AIDP subtype of GBS has occurred, as the sensitivity RT-PCR test of the oropharyngeal swab is suboptimal [14] .", [["oropharyngeal swab", "ANATOMY", 144, 162], ["AIDP", "DISEASE", 72, 76], ["GBS", "DISEASE", 88, 91], ["AIDP", "CANCER", 72, 76], ["oropharyngeal swab", "ORGAN", 144, 162], ["a COVID", "TEST", 45, 52], ["GBS", "PROBLEM", 88, 91], ["the sensitivity RT-PCR test", "TEST", 109, 136], ["the oropharyngeal swab", "TEST", 140, 162], ["GBS", "OBSERVATION", 88, 91], ["oropharyngeal", "ANATOMY", 144, 157]]], ["Furthermore, some rarer but endemic Northern Italy infectious agents that can be related to para-infectious GBS, such as West Nile virus and Toscana Virus, have not rv reference value been tested [14] .", [["GBS", "DISEASE", 108, 111], ["West Nile virus", "ORGANISM", 121, 136], ["Toscana Virus", "ORGANISM", 141, 154], ["West Nile virus", "SPECIES", 121, 136], ["Toscana Virus", "SPECIES", 141, 154], ["West Nile virus", "SPECIES", 121, 136], ["Toscana Virus", "SPECIES", 141, 154], ["para-infectious GBS", "PROBLEM", 92, 111], ["West Nile virus and Toscana Virus", "PROBLEM", 121, 154], ["endemic", "OBSERVATION_MODIFIER", 28, 35]]], ["Besides, adequate paraneoplastic screening was not performed, and antiganglioside antibodies were not studied.", [["paraneoplastic", "DISEASE", 18, 32], ["antiganglioside antibodies", "GENE_OR_GENE_PRODUCT", 66, 92], ["antiganglioside antibodies", "PROTEIN", 66, 92], ["adequate paraneoplastic screening", "TEST", 9, 42], ["antiganglioside antibodies", "TEST", 66, 92], ["adequate", "OBSERVATION_MODIFIER", 9, 17], ["paraneoplastic", "OBSERVATION", 18, 32]]], ["Despite this, based on the anamnestic, laboratory, neurophysiological, and clinical data collected, we can support the correlation between the onset of GBS and COVID-19, in line with emerged data of the literature review.ConclusionWhile it is well known that SARS-CoV-2 correlates with respiratory and gastrointestinal manifestations, systemic and neurological involvement is still being studied.", [["respiratory", "ANATOMY", 286, 297], ["gastrointestinal", "ANATOMY", 302, 318], ["neurological", "ANATOMY", 348, 360], ["GBS", "DISEASE", 152, 155], ["respiratory and gastrointestinal manifestations", "DISEASE", 286, 333], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 259, 269], ["gastrointestinal", "ORGAN", 302, 318], ["clinical data", "TEST", 75, 88], ["GBS", "PROBLEM", 152, 155], ["COVID", "TEST", 160, 165], ["SARS", "PROBLEM", 259, 263], ["respiratory and gastrointestinal manifestations", "PROBLEM", 286, 333], ["systemic and neurological involvement", "PROBLEM", 335, 372], ["gastrointestinal", "ANATOMY", 302, 318]]], ["The case we described of GBS in a COVID-19 patient adds to those already reported in the literature, in support of SARS-CoV-2 triggering of GBS.ConclusionThe aim of this work is to shed more light on the neurological manifestations of COVID-19, not as a corollary of classic respiratory and gastrointestinal symptoms, but as SARS-CoV-2-related standalone clinical entities.", [["neurological", "ANATOMY", 204, 216], ["respiratory", "ANATOMY", 275, 286], ["gastrointestinal", "ANATOMY", 291, 307], ["GBS", "DISEASE", 25, 28], ["GBS", "DISEASE", 140, 143], ["COVID", "DISEASE", 235, 240], ["respiratory and gastrointestinal symptoms", "DISEASE", 275, 316], ["patient", "ORGANISM", 43, 50], ["CoV-2", "ORGANISM", 120, 125], ["gastrointestinal", "ORGAN", 291, 307], ["CoV-2", "ORGANISM", 330, 335], ["patient", "SPECIES", 43, 50], ["GBS", "PROBLEM", 25, 28], ["a COVID", "TEST", 32, 39], ["SARS", "PROBLEM", 115, 119], ["CoV", "TEST", 120, 123], ["GBS", "PROBLEM", 140, 143], ["COVID", "TEST", 235, 240], ["classic respiratory and gastrointestinal symptoms", "PROBLEM", 267, 316], ["SARS", "TEST", 325, 329], ["CoV", "TEST", 330, 333], ["GBS", "OBSERVATION", 140, 143], ["gastrointestinal", "ANATOMY", 291, 307]]], ["To date, it is essential for all specialists, clinicians, and surgeons, to direct attention towards the study of this virus, in order to clarify the spectrum of its neurological manifestations.ConclusionAcknowledgements Open access funding provided by Universit\u00e0 degli Studi dell'Insubria within the CRUI-CARE Agreement.Compliance with ethical standardsConflict of Interest The authors declare that they have no conflict of interest.Compliance with ethical standardsEthical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Compliance with ethical standardsInstitutional review board approval Informed consent was obtained from all individual participants included in the study.Compliance with ethical standardsConsent for publication Consent for publication was obtained for every individual person's data included in the study.Compliance with ethical standardsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["neurological", "ANATOMY", 165, 177], ["human", "ORGANISM", 529, 534], ["human", "SPECIES", 529, 534], ["participants", "SPECIES", 535, 547], ["participants", "SPECIES", 865, 877], ["person", "SPECIES", 1015, 1021], ["human", "SPECIES", 529, 534], ["the study", "TEST", 100, 109], ["this virus", "TREATMENT", 113, 123], ["its neurological manifestations", "PROBLEM", 161, 192], ["Insubria", "PROBLEM", 280, 288], ["ethical standards", "TREATMENT", 336, 353], ["ethical standards", "TREATMENT", 449, 466], ["Ethical approval", "TREATMENT", 466, 482], ["All procedures", "TREATMENT", 483, 497], ["ethical standards", "TREATMENT", 762, 779], ["the study", "TEST", 890, 899], ["ethical standards", "TREATMENT", 916, 933], ["the study", "TEST", 1041, 1050], ["ethical standards", "TREATMENT", 1067, 1084], ["Open Access", "TREATMENT", 1084, 1095]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "894f98dcfe5044e6eeed84e9fd59cc4082e62bb9": [["Thus we have to look at previous experience to allow an informed estimate to be made of the risk of holding the Olympic Games at the same time as an ongoing epidemic of a vector-borne viral infection.IntroductionAt the other end of the scale are unintentional 'mass gatherings' such as refugees taking shelter in huge camps, often in cramped conditions with poor hygiene.", [["viral infection", "DISEASE", 184, 199], ["a vector-borne viral infection", "PROBLEM", 169, 199], ["IntroductionAt", "TREATMENT", 200, 214], ["infection", "OBSERVATION", 190, 199]]], ["These are not usually regarded as mass gathering events, but nevertheless they pose the same problem in terms of the transmission of pathogens in the situation of a large number of people in a limited space.", [["people", "ORGANISM", 181, 187], ["people", "SPECIES", 181, 187], ["mass gathering events", "PROBLEM", 34, 55], ["pathogens", "PROBLEM", 133, 142], ["not usually regarded", "UNCERTAINTY", 10, 30], ["mass", "OBSERVATION", 34, 38], ["pathogens", "OBSERVATION", 133, 142], ["large", "OBSERVATION_MODIFIER", 165, 170], ["number", "OBSERVATION_MODIFIER", 171, 177]]], ["Currently the civil war in Syria has displaced many people, and diseases like tuberculosis, cutaneous leishmaniasis, measles, and polio are a risk.", [["tuberculosis", "DISEASE", 78, 90], ["cutaneous leishmaniasis", "DISEASE", 92, 115], ["measles", "DISEASE", 117, 124], ["polio", "DISEASE", 130, 135], ["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["diseases", "PROBLEM", 64, 72], ["tuberculosis", "PROBLEM", 78, 90], ["cutaneous leishmaniasis", "PROBLEM", 92, 115], ["measles", "PROBLEM", 117, 124], ["displaced", "OBSERVATION_MODIFIER", 37, 46], ["many", "OBSERVATION_MODIFIER", 47, 51], ["tuberculosis", "OBSERVATION", 78, 90], ["cutaneous", "OBSERVATION_MODIFIER", 92, 101], ["leishmaniasis", "OBSERVATION", 102, 115]]], ["1 Such conditions also increase the risk of transmission of zoonoses, with expected closer contact to rodents compared to normal conditions.", [["zoonoses", "DISEASE", 60, 68], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["zoonoses", "OBSERVATION", 60, 68]]], ["2 Mass gathering events are theoretically ideal situations for the spread of infections between people from very different and widespread geographical localities, with potentially different immune responses.", [["infections", "DISEASE", 77, 87], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["2 Mass gathering events", "PROBLEM", 0, 23], ["infections", "PROBLEM", 77, 87], ["Mass", "OBSERVATION", 2, 6], ["infections", "OBSERVATION", 77, 87], ["very different", "OBSERVATION_MODIFIER", 108, 122], ["widespread", "OBSERVATION_MODIFIER", 127, 137], ["geographical localities", "OBSERVATION", 138, 161]]], ["One of the first events that focused the international health community on mass gathering events was the outbreak of meningitis in 2000-2001 after the Hajj.", [["meningitis", "DISEASE", 117, 127], ["meningitis", "PROBLEM", 117, 127], ["mass", "OBSERVATION", 75, 79], ["meningitis", "OBSERVATION", 117, 127]]], ["3, 4 However, the spread of infections is rarely caused by mass gathering sports events.", [["infections", "DISEASE", 28, 38], ["infections", "PROBLEM", 28, 38], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["infections", "OBSERVATION", 28, 38], ["mass", "OBSERVATION", 59, 63]]], ["5 All previous experiences from different mass gathering show that vaccine preventable diseases is the most important infections like influenza, hepatitis A, polio and meningitis.", [["infections", "DISEASE", 118, 128], ["influenza", "DISEASE", 134, 143], ["hepatitis A", "DISEASE", 145, 156], ["polio", "DISEASE", 158, 163], ["meningitis", "DISEASE", 168, 178], ["hepatitis A", "ORGANISM", 145, 156], ["hepatitis A", "SPECIES", 145, 156], ["different mass", "PROBLEM", 32, 46], ["vaccine preventable diseases", "PROBLEM", 67, 95], ["influenza", "PROBLEM", 134, 143], ["hepatitis A", "PROBLEM", 145, 156], ["polio", "PROBLEM", 158, 163], ["meningitis", "PROBLEM", 168, 178], ["mass", "OBSERVATION", 42, 46], ["influenza", "OBSERVATION", 134, 143], ["hepatitis", "OBSERVATION", 145, 154], ["meningitis", "OBSERVATION", 168, 178]]], ["Three mass gathering held in Africa during the Ebola outbreak accepted participants from West Africa and was able to handle the theoretical risk without any incident.", [["Ebola", "DISEASE", 47, 52], ["Ebola", "ORGANISM", 47, 52], ["participants", "SPECIES", 71, 83], ["Three mass", "PROBLEM", 0, 10], ["mass", "OBSERVATION", 6, 10]]], ["The number of visitors to the games is a tiny fraction (1%) of other visitors to Zika endemic countries and it will have no measurable effect on the risk of spreading Zika virus, if the games was cancelled.", [["Zika virus", "ORGANISM", 167, 177], ["Zika virus", "SPECIES", 167, 177], ["spreading Zika virus", "PROBLEM", 157, 177]]], ["The spread of severe acute respiratory syndrome coronavirus (SARS-CoV) from China to Hong Kong and further to Canada was not due to a mass gathering, but to infected individuals travelling late in the incubation period or just after the onset of symptoms.", [["acute respiratory syndrome coronavirus", "DISEASE", 21, 59], ["SARS-CoV)", "DISEASE", 61, 70], ["severe acute respiratory syndrome coronavirus", "SPECIES", 14, 59], ["SARS-CoV", "SPECIES", 61, 69], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 14, 59], ["a mass", "PROBLEM", 132, 138], ["symptoms", "PROBLEM", 246, 254], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["respiratory syndrome coronavirus", "OBSERVATION", 27, 59], ["mass", "OBSERVATION", 134, 138]]], ["6, 7 The introduction of West Nile virus to North America was probably through wild birds crossing the Atlantic, and it could not have been predicted.", [["West Nile virus", "ORGANISM", 25, 40], ["West Nile virus", "SPECIES", 25, 40]]], ["Lastly, the outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) in Korea was caused by a single traveller waiting in an overcrowded hospital emergency room in South Korea.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 24, 68], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 24, 68], ["MERS-CoV", "ORGANISM", 70, 78], ["Middle East respiratory syndrome coronavirus", "SPECIES", 24, 68], ["MERS-CoV", "SPECIES", 70, 78], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 24, 68], ["Middle", "ANATOMY_MODIFIER", 24, 30], ["respiratory syndrome", "OBSERVATION", 36, 56]]], ["8 The Korean MERS-CoV outbreak illustrates how difficult it is to predict the future.", [["Korean MERS-CoV", "SPECIES", 6, 21]]], ["MERS was estimated to have a low epidemic potential, 9 and it was pointed out in this Journal that the outbreak was identified as being caused by MERS-CoV because it happened in a country with the resources (knowledge and laboratory facilities) to rapidly identify the virus.", [["MERS-CoV", "ORGANISM", 146, 154], ["MERS-CoV", "SPECIES", 146, 154], ["a low epidemic potential", "PROBLEM", 27, 51], ["the virus", "PROBLEM", 265, 274]]], ["The Sendai Framework has an emphasis on health and gives a clear mandate, emphasizing the need for more integrated DRR that incorporates bottom-up as well as top-down approaches, local scientific and technical knowledge, and draws attention to synergies with other critical policy arenas including health, climate change, and sustainable development.", [["Sendai", "ORGANISM", 4, 10], ["DRR", "DNA", 115, 118]]], ["Over the next 15 years, the Sendai Framework has set out to achieve ''the substantial reduction of disaster risk and losses in lives, livelihoods and health and in the economic, physical, social, cultural and environmental assets of persons, businesses, communities and countries'' -including risk reduction at mass gatherings.", [["Sendai", "ORGANISM", 28, 34], ["persons", "SPECIES", 233, 240], ["mass", "OBSERVATION", 311, 315]]], ["11 The use of science to inform decisions, an integral part of the Sendai Framework, must also be applied to mass gatherings.Spread of pathogens between healthy, asymptomatic individualsSome infections like tuberculosis have a long incubation period of several years, and exposure at a mass gathering will not be apparent and may easily be overlooked.", [["infections", "DISEASE", 191, 201], ["tuberculosis", "DISEASE", 207, 219], ["the Sendai Framework", "TREATMENT", 63, 83], ["Some infections", "PROBLEM", 186, 201], ["tuberculosis", "PROBLEM", 207, 219], ["a mass", "PROBLEM", 284, 290], ["mass", "OBSERVATION", 109, 113], ["pathogens", "OBSERVATION", 135, 144], ["infections", "OBSERVATION", 191, 201], ["tuberculosis", "OBSERVATION", 207, 219], ["long incubation", "OBSERVATION_MODIFIER", 227, 242], ["mass", "OBSERVATION", 286, 290]]], ["12 The transmission of multidrug-resistant bacteria, for instance Gram-negative bacteria hosted in the intestine, is another concern that has not been well studied.", [["intestine", "ANATOMY", 103, 112], ["intestine", "ORGAN", 103, 112], ["multidrug-resistant bacteria", "PROBLEM", 23, 51], ["instance Gram", "TEST", 57, 70], ["negative bacteria", "PROBLEM", 71, 88], ["resistant bacteria", "OBSERVATION", 33, 51], ["negative bacteria", "OBSERVATION", 71, 88], ["intestine", "ANATOMY", 103, 112]]], ["Asymptomatic individuals are colonized with local bacteria and may be carriers for months.", [["individuals", "ORGANISM", 13, 24], ["Asymptomatic individuals", "PROBLEM", 0, 24], ["local bacteria", "PROBLEM", 44, 58]]], ["14 The events all accepted participants from West Africa.Kumbh Mela, IndiaThe Hindu Kumbh Mela is a 3-month long religious conglomeration held every 3 years in four different cities of North India by rotation, the most famous being held in Allahabad.", [["participants", "SPECIES", 27, 39]]], ["This is considered to be the largest human gathering on earth.", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["considered to be", "UNCERTAINTY", 8, 24], ["largest", "OBSERVATION_MODIFIER", 29, 36]]], ["Kumbh Mela does not involve a fixed human settlement, but the creation of temporary settlements of canvas, corrugated metal sheets, bamboo, nails, and rope in the flood plains of the rivers to house and feed millions of people for 3 months every 3 years.", [["human", "ORGANISM", 36, 41], ["canvas", "ORGANISM_SUBDIVISION", 99, 105], ["nails", "ORGANISM_SUBDIVISION", 140, 145], ["people", "ORGANISM", 220, 226], ["human", "SPECIES", 36, 41], ["people", "SPECIES", 220, 226], ["human", "SPECIES", 36, 41], ["a fixed human settlement", "TREATMENT", 28, 52], ["temporary settlements of canvas", "TREATMENT", 74, 105], ["corrugated metal sheets", "TREATMENT", 107, 130], ["nails", "ANATOMY", 140, 145]]], ["For Kumbh Mela people come by air, road, rail, and foot from within India, making it almost impossible to maintain detailed records of people movements.", [["foot", "ORGANISM_SUBDIVISION", 51, 55], ["people", "ORGANISM", 135, 141], ["people", "SPECIES", 15, 21], ["people", "SPECIES", 135, 141], ["air", "OBSERVATION", 30, 33], ["foot", "ANATOMY", 51, 55]]], ["Studies and reviews of surveillance data from returning pilgrims have shown that influenza, rhinovirus, and non-MERS coronavirus are the most common pathogens, and suggest that influenza immunization before departure may be justified.", [["influenza, rhinovirus", "DISEASE", 81, 102], ["non-MERS coronavirus", "DISEASE", 108, 128], ["influenza", "DISEASE", 177, 186], ["rhinovirus", "ORGANISM", 92, 102], ["non-MERS coronavirus", "ORGANISM", 108, 128], ["non-MERS coronavirus", "SPECIES", 108, 128], ["non-MERS coronavirus", "SPECIES", 108, 128], ["surveillance data", "TEST", 23, 40], ["influenza", "PROBLEM", 81, 90], ["rhinovirus", "PROBLEM", 92, 102], ["non-MERS coronavirus", "PROBLEM", 108, 128], ["influenza immunization", "TREATMENT", 177, 199], ["influenza", "OBSERVATION", 81, 90]]], ["[16] [17] [18] General screening for infections in pilgrims visiting the Hajj has been reported in two other studies, 17, 19 which found influenza to be the most common respiratory pathogen.", [["infections", "DISEASE", 37, 47], ["influenza", "DISEASE", 137, 146], ["pilgrims", "ORGANISM", 51, 59], ["General screening", "TEST", 15, 32], ["infections", "PROBLEM", 37, 47], ["influenza", "PROBLEM", 137, 146], ["the most common respiratory pathogen", "PROBLEM", 153, 189]]], ["Meningococcal disease is now rarely recorded.", [["Meningococcal disease", "DISEASE", 0, 21], ["Meningococcal disease", "PROBLEM", 0, 21], ["disease", "OBSERVATION", 14, 21]]], ["They also noted that gastroenteritis was common, but this is most probably due to lack of hygiene at the event.Kumbh Mela, IndiaA study from Australia looking at pre-travel prevention among pilgrims found that 80% were immunized against influenza, 30% against pneumococcus, and 30% against pertussis.", [["gastroenteritis", "DISEASE", 21, 36], ["influenza", "DISEASE", 237, 246], ["pneumococcus", "DISEASE", 260, 272], ["pertussis", "DISEASE", 290, 299], ["pilgrims", "ORGANISM", 190, 198], ["pertussis", "ORGANISM", 290, 299], ["gastroenteritis", "PROBLEM", 21, 36], ["IndiaA study", "TEST", 123, 135], ["influenza", "PROBLEM", 237, 246], ["pneumococcus", "PROBLEM", 260, 272], ["pertussis", "PROBLEM", 290, 299], ["gastroenteritis", "OBSERVATION", 21, 36]]], ["Concern about contracting disease at Hajj was the most cited reason for vaccination (73.4%).", [["contracting disease", "PROBLEM", 14, 33], ["vaccination", "TEST", 72, 83], ["disease", "OBSERVATION", 26, 33]]], ["20 Since the 2000 and 2001 outbreak, bacterial meningitis has been a high priority for the Kingdom of Saudi Arabia.", [["bacterial meningitis", "DISEASE", 37, 57], ["bacterial meningitis", "PROBLEM", 37, 57], ["bacterial", "OBSERVATION_MODIFIER", 37, 46], ["meningitis", "OBSERVATION", 47, 57]]], ["Several studies have looked at carrier rates of Neisseria meningitidis in Hajj pilgrims, and overall carriage rates of 5-10% were found, comparable to the rate found in populations in non-epidemic settings.", [["Neisseria meningitidis", "DISEASE", 48, 70], ["Neisseria meningitidis", "ORGANISM", 48, 70], ["Neisseria meningitidis", "SPECIES", 48, 70], ["Neisseria meningitidis", "SPECIES", 48, 70], ["Several studies", "TEST", 0, 15], ["Neisseria meningitidis", "PROBLEM", 48, 70], ["overall carriage rates", "TEST", 93, 115], ["the rate", "TEST", 151, 159], ["Neisseria", "OBSERVATION_MODIFIER", 48, 57], ["meningitidis", "OBSERVATION", 58, 70]]], ["21 In 2000 and 2001, 338 and 316 cases of laboratoryverified Neisseria meningitidis were reported; this fell dramatically to 2-4 cases per year (2013-2015) following the introduction of mandatory immunization with the quadrivalent vaccine.", [["Neisseria meningitidis", "DISEASE", 61, 83], ["Neisseria meningitidis", "ORGANISM", 61, 83], ["Neisseria meningitidis", "SPECIES", 61, 83], ["Neisseria meningitidis", "SPECIES", 61, 83], ["laboratoryverified Neisseria meningitidis", "PROBLEM", 42, 83], ["mandatory immunization", "TREATMENT", 186, 208], ["the quadrivalent vaccine", "TREATMENT", 214, 238], ["Neisseria meningitidis", "OBSERVATION", 61, 83]]], ["22 The quadrivalent ACWY polysaccharide meningococcal vaccine has been a visa requirement for Hajj and Umrah since 2002.", [["ACWY polysaccharide", "CHEMICAL", 20, 39], ["ACWY polysaccharide", "ORGANISM", 20, 39], ["The quadrivalent ACWY polysaccharide meningococcal vaccine", "TREATMENT", 3, 61]]], ["At the same time the Saudi authorities introduced a vaccination programme for children and adults living in Mecca and Medina, healthcare workers, and government personnel serving the pilgrims.", [["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["a vaccination programme", "TREATMENT", 50, 73]]], ["23 A recent study of bacterial infections and resistance to antibiotics in hospitalized Hajj pilgrims in Mecca found that Escherichia coli was the most common bacterium (28%), followed by Klebsiella pneumoniae and Pseudomonas.", [["bacterial infections", "DISEASE", 21, 41], ["Klebsiella pneumoniae", "DISEASE", 188, 209], ["Escherichia coli", "ORGANISM", 122, 138], ["Klebsiella pneumoniae", "ORGANISM", 188, 209], ["Escherichia coli", "SPECIES", 122, 138], ["Klebsiella pneumoniae", "SPECIES", 188, 209], ["Escherichia coli", "SPECIES", 122, 138], ["Klebsiella pneumoniae", "SPECIES", 188, 209], ["A recent study", "TEST", 3, 17], ["bacterial infections", "PROBLEM", 21, 41], ["antibiotics", "TREATMENT", 60, 71], ["Escherichia coli", "PROBLEM", 122, 138], ["Klebsiella pneumoniae", "PROBLEM", 188, 209], ["Pseudomonas", "PROBLEM", 214, 225], ["bacterial", "OBSERVATION_MODIFIER", 21, 30], ["infections", "OBSERVATION", 31, 41], ["Escherichia coli", "OBSERVATION", 122, 138], ["Klebsiella pneumoniae", "OBSERVATION", 188, 209], ["Pseudomonas", "OBSERVATION", 214, 225]]], ["Methicillin-resistant Staphylococcus aureus (MRSA) was found in 9.6%.", [["Methicillin", "CHEMICAL", 0, 11], ["Staphylococcus aureus", "DISEASE", 22, 43], ["Methicillin", "CHEMICAL", 0, 11], ["Methicillin-resistant Staphylococcus aureus", "ORGANISM", 0, 43], ["MRSA", "CANCER", 45, 49], ["Staphylococcus aureus", "SPECIES", 22, 43], ["MRSA", "SPECIES", 45, 49], ["Staphylococcus aureus", "SPECIES", 22, 43], ["MRSA", "SPECIES", 45, 49], ["Methicillin", "TEST", 0, 11], ["resistant Staphylococcus aureus", "PROBLEM", 12, 43], ["MRSA", "PROBLEM", 45, 49], ["resistant", "OBSERVATION_MODIFIER", 12, 21], ["Staphylococcus aureus", "OBSERVATION", 22, 43]]], ["24 The potential spread of bacterial infections between Hajj pilgrims -whether symptomatic or not -is also a concern because of the unrestricted prescription of antibiotics by local pharmacies to the pilgrims.", [["bacterial infections", "DISEASE", 27, 47], ["bacterial infections", "PROBLEM", 27, 47], ["antibiotics", "TREATMENT", 161, 172], ["potential", "UNCERTAINTY", 7, 16], ["spread", "OBSERVATION_MODIFIER", 17, 23], ["bacterial", "OBSERVATION_MODIFIER", 27, 36], ["infections", "OBSERVATION", 37, 47]]], ["25Other mass gatheringsThe most common outbreaks at mass gatherings, including religious mass gatherings other than Hajj, sports events, and outdoor festivals, have involved vaccine-preventable infections, mainly measles and influenza, but also mumps and hepatitis A. 16 The psychology of individuals participating in mass gatheringsOther mass gatheringsThe individual participant behaves in the context of their understanding of the norms associated with the group, and the relationships between group members become more trusting and supportive.", [["infections", "DISEASE", 194, 204], ["measles", "DISEASE", 213, 220], ["influenza", "DISEASE", 225, 234], ["mumps", "DISEASE", 245, 250], ["hepatitis", "DISEASE", 255, 264], ["individuals", "ORGANISM", 289, 300], ["participant", "SPECIES", 369, 380], ["preventable infections", "PROBLEM", 182, 204], ["measles", "PROBLEM", 213, 220], ["influenza", "PROBLEM", 225, 234], ["hepatitis A.", "PROBLEM", 255, 267], ["Other mass gatherings", "PROBLEM", 333, 354], ["mass", "OBSERVATION", 8, 12], ["most common", "OBSERVATION_MODIFIER", 27, 38], ["mass", "OBSERVATION", 52, 56], ["infections", "OBSERVATION", 194, 204], ["mass", "OBSERVATION", 339, 343]]], ["Understanding these two behavioural changes is key to understanding how and why mass gathering participants may behave in ways that make them more or less vulnerable to the transmission of infection.", [["infection", "DISEASE", 189, 198], ["participants", "SPECIES", 95, 107], ["infection", "PROBLEM", 189, 198], ["infection", "OBSERVATION", 189, 198]]], ["26Tools for the control of infections at mass gatheringsVaccines are an important preventive tool for mass gatherings and should include the basic coverage provided by childhood immunization programmes, supplemented where appropriate with protection against meningitis and influenza, and yellow fever for mass gathering participants coming from yellow fever endemic countries.", [["infections", "DISEASE", 27, 37], ["meningitis", "DISEASE", 258, 268], ["influenza", "DISEASE", 273, 282], ["yellow fever", "DISEASE", 288, 300], ["fever", "DISEASE", 352, 357], ["participants", "SPECIES", 320, 332], ["infections at mass", "PROBLEM", 27, 45], ["Vaccines", "TREATMENT", 56, 64], ["mass gatherings", "PROBLEM", 102, 117], ["the basic coverage", "TREATMENT", 137, 155], ["childhood immunization programmes", "TREATMENT", 168, 201], ["protection", "TREATMENT", 239, 249], ["meningitis", "PROBLEM", 258, 268], ["influenza", "PROBLEM", 273, 282], ["yellow fever", "PROBLEM", 288, 300], ["mass", "PROBLEM", 305, 309], ["yellow fever endemic countries", "PROBLEM", 345, 375], ["infections", "OBSERVATION", 27, 37]]], ["A review in this issue discusses the need for vaccines for mass gatherings and draws attention to immunization against pneumococcal infections in elderly pilgrims and highlights that polio may be a risk.", [["pneumococcal infections", "DISEASE", 119, 142], ["polio", "DISEASE", 183, 188], ["pneumococcal", "ORGANISM", 119, 131], ["polio", "ORGANISM", 183, 188], ["pneumococcal", "SPECIES", 119, 131], ["vaccines", "TREATMENT", 46, 54], ["mass gatherings", "PROBLEM", 59, 74], ["immunization", "TREATMENT", 98, 110], ["pneumococcal infections", "PROBLEM", 119, 142]]], ["27 An important vaccine for Hajj pilgrims, and the Arabian Peninsula in general, is one against MERS-CoV.", [["MERS-CoV", "ORGANISM", 96, 104], ["MERS-CoV", "SPECIES", 96, 104]]], ["The engineering of live attenuated vaccines has been facilitated by the development of reverse genetics.", [["live attenuated vaccines", "TREATMENT", 19, 43]]], ["Using one of these methodologies, viruses deleted in the small envelope (E) protein have been developed.", [["small envelope (E)", "GENE_OR_GENE_PRODUCT", 57, 75], ["small envelope (E) protein", "PROTEIN", 57, 83], ["these methodologies", "TREATMENT", 13, 32], ["viruses", "TREATMENT", 34, 41], ["the small envelope (E) protein", "TREATMENT", 53, 83], ["small", "OBSERVATION_MODIFIER", 57, 62]]], ["These viruses have been attenuated and have induced protective humoral and cell-based immune responses in hamsters and mice after SARS-CoV challenge.", [["cell", "ANATOMY", 75, 79], ["cell", "CELL", 75, 79], ["hamsters", "ORGANISM", 106, 114], ["mice", "ORGANISM", 119, 123], ["SARS-CoV", "ORGANISM", 130, 138], ["hamsters", "SPECIES", 106, 114], ["mice", "SPECIES", 119, 123], ["hamsters", "SPECIES", 106, 114], ["mice", "SPECIES", 119, 123], ["SARS-CoV", "SPECIES", 130, 138], ["These viruses", "PROBLEM", 0, 13], ["CoV challenge", "TREATMENT", 135, 148], ["viruses", "OBSERVATION", 6, 13], ["cell", "OBSERVATION", 75, 79], ["immune responses", "OBSERVATION", 86, 102]]], ["28 A meta-analysis on the use of face masks and the reduction in risk of upper respiratory infections found a modest effect.", [["respiratory", "ANATOMY", 79, 90], ["respiratory infections", "DISEASE", 79, 101], ["upper respiratory", "ORGANISM_SUBDIVISION", 73, 90], ["face masks", "TREATMENT", 33, 43], ["the reduction", "TREATMENT", 48, 61], ["upper respiratory infections", "PROBLEM", 73, 101], ["reduction", "OBSERVATION_MODIFIER", 52, 61], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory", "ANATOMY", 79, 90], ["infections", "OBSERVATION", 91, 101], ["modest", "OBSERVATION_MODIFIER", 110, 116], ["effect", "OBSERVATION_MODIFIER", 117, 123]]], ["29 Compliance is always higher during a study than in the real-life situation, and making face masks mandatory at mass gatherings is not presently recommended.From all this experience, what are the implications for the August Olympics in Rio de Janeiro?Clearly there is a risk of Zika virus (ZKV) infection, but ZKV is already present in more than 60 countries and the risk of spread already exists with or without the Olympics.", [["Zika virus (ZKV) infection", "DISEASE", 280, 306], ["Zika virus", "ORGANISM", 280, 290], ["ZKV", "GENE_OR_GENE_PRODUCT", 312, 315], ["Zika virus", "SPECIES", 280, 290], ["ZKV", "SPECIES", 292, 295], ["ZKV", "SPECIES", 312, 315], ["a study", "TEST", 38, 45], ["face masks mandatory", "TREATMENT", 90, 110], ["Zika virus (ZKV) infection", "PROBLEM", 280, 306], ["Zika virus", "OBSERVATION", 280, 290], ["infection", "OBSERVATION", 297, 306]]], ["ZIKV spread from Africa to Southeast Asia without any mass gathering event being involved, as far as we know, and its further spread to South America and between countries in South America has not been linked definitively to any mass gathering event.From all this experience, what are the implications for the August Olympics in Rio de Janeiro?From the review of mass gathering experience in this special issue of the Journal, vector-borne infections have not previously appeared as a particular risk, but experience also shows that potential health risks at a mass gathering can be mitigated effectively if they are recognized and planned for.", [["infections", "DISEASE", 440, 450], ["ZIKV", "SPECIES", 0, 4], ["ZIKV spread", "PROBLEM", 0, 11], ["any mass", "PROBLEM", 50, 58], ["mass", "PROBLEM", 363, 367], ["borne infections", "PROBLEM", 434, 450], ["a mass", "PROBLEM", 559, 565], ["mass", "OBSERVATION", 54, 58], ["mass", "OBSERVATION", 229, 233], ["mass", "OBSERVATION", 363, 367]]], ["The health authorities in Brazil are aware of the vector-borne risks and have already managed several mass gatherings without evidence of significant international spread (e.g. annual Rio Carnival, World Cup 2014).", [["several mass gatherings", "PROBLEM", 94, 117], ["significant international spread", "PROBLEM", 138, 170], ["mass", "OBSERVATION", 102, 106], ["without evidence of", "UNCERTAINTY", 118, 137], ["significant", "OBSERVATION_MODIFIER", 138, 149]]], ["The estimated 500 000 visitors to The Olympic Games constitute less than 1% of visitors to the ZKV endemic countries (and many of these travellers will come from countries already affected by ZKV), so limiting travel to the Olympics will not substantially affect the risk of ZKV spread.", [["ZKV", "GENE_OR_GENE_PRODUCT", 275, 278], ["ZKV", "SPECIES", 192, 195], ["ZKV", "SPECIES", 275, 278], ["ZKV spread", "PROBLEM", 275, 285], ["ZKV spread", "OBSERVATION", 275, 285]]], ["30 Pregnant women should avoid visiting the Olympics and those at risk of pregnancy should use contraception.From all this experience, what are the implications for the August Olympics in Rio de Janeiro?For the individual non-pregnant traveller, ZKV is a short febrile illness that leaves no sequelae.", [["febrile illness", "DISEASE", 261, 276], ["women", "ORGANISM", 12, 17], ["ZKV", "ORGANISM", 246, 249], ["women", "SPECIES", 12, 17], ["ZKV", "SPECIES", 246, 249], ["contraception", "TREATMENT", 95, 108], ["a short febrile illness", "PROBLEM", 253, 276], ["sequelae", "PROBLEM", 292, 300], ["no", "UNCERTAINTY", 289, 291], ["sequelae", "OBSERVATION", 292, 300]]], ["There is a small risk of complications like Guillain-Barr\u00e9 syndrome, but there is also a risk of ordinary influenza turning into severe double pneumonia requiring ventilator treatment, but we do not routinely immunize travellers to the tropics with year-round influenza transmission.", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 44, 67], ["influenza", "DISEASE", 106, 115], ["pneumonia", "DISEASE", 143, 152], ["influenza", "DISEASE", 260, 269], ["Guillain-Barr\u00e9", "ORGANISM", 44, 58], ["a small risk of complications", "PROBLEM", 9, 38], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 44, 67], ["ordinary influenza", "PROBLEM", 97, 115], ["severe double pneumonia", "PROBLEM", 129, 152], ["ventilator treatment", "TREATMENT", 163, 183], ["round influenza transmission", "PROBLEM", 254, 282], ["small", "OBSERVATION_MODIFIER", 11, 16], ["complications", "OBSERVATION", 25, 38], ["Barr\u00e9 syndrome", "OBSERVATION", 53, 67], ["influenza", "OBSERVATION", 106, 115], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["double", "OBSERVATION_MODIFIER", 136, 142], ["pneumonia", "OBSERVATION", 143, 152], ["ventilator treatment", "OBSERVATION", 163, 183], ["influenza", "OBSERVATION", 260, 269]]], ["Travellers should be advised to follow standard precautions against insect bites, including applying repellent, wearing impregnated clothes, and using bed nets if they do not sleep in an airconditioned room.From all this experience, what are the implications for the August Olympics in Rio de Janeiro?The available evidence does not support cancelling, postponing, or moving the 2016 Olympic Games and we hope that the Games in Rio de Janeiro will be successful for the athletes and enjoyable for the public.From all this experience, what are the implications for the August Olympics in Rio de Janeiro?Conflict of interest: The authors declare no conflict of interest.", [["insect bites", "DISEASE", 68, 80]]]], "1894cac8794748c11482c059bc5a2c6d4f1e9527": [["INTRODUCTIONPrimary immunodeficiency disorders (PIDs) are monogenic defects affecting the innate and/or adaptive immune systems (1) .", [["INTRODUCTIONPrimary immunodeficiency disorders", "DISEASE", 0, 46], ["PIDs", "DISEASE", 48, 52], ["monogenic defects", "DISEASE", 58, 75], ["INTRODUCTIONPrimary immunodeficiency disorders", "PROBLEM", 0, 46], ["monogenic defects", "PROBLEM", 58, 75]]], ["Patients are at increased risk of a wide range of manifestations including autoimmunity, immune dysregulation, and malignancies, but infectious complications are the commonest (2) (3) (4) .", [["malignancies", "ANATOMY", 115, 127], ["autoimmunity", "DISEASE", 75, 87], ["immune dysregulation", "DISEASE", 89, 109], ["malignancies", "DISEASE", 115, 127], ["Patients", "ORGANISM", 0, 8], ["malignancies", "CANCER", 115, 127], ["Patients", "SPECIES", 0, 8], ["autoimmunity", "PROBLEM", 75, 87], ["immune dysregulation", "PROBLEM", 89, 109], ["malignancies", "PROBLEM", 115, 127], ["infectious complications", "PROBLEM", 133, 157], ["wide range", "OBSERVATION_MODIFIER", 36, 46], ["malignancies", "OBSERVATION", 115, 127], ["infectious", "OBSERVATION_MODIFIER", 133, 143]]], ["Historically, PID patients used to die before recognition because of infections due to the lack of effective measures to either prevent or treat them.", [["PID", "DISEASE", 14, 17], ["infections", "DISEASE", 69, 79], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["infections", "PROBLEM", 69, 79], ["effective measures", "TREATMENT", 99, 117], ["infections", "OBSERVATION", 69, 79]]], ["Advances in public health and the discovery of antimicrobial agents made the diagnosis of PIDs possible (5) .INTRODUCTIONAlthough therapeutic interventions like intravenous immunoglobulins and hematopoietic stem cell transplants have helped to decrease morbidity and mortality, physicians caring for PID patients frequently struggle with treating infections which are usually recurrent or chronic, severe and are frequently caused by opportunistic organisms.", [["intravenous", "ANATOMY", 161, 172], ["hematopoietic stem cell", "ANATOMY", 193, 216], ["PIDs", "DISEASE", 90, 94], ["PID", "DISEASE", 300, 303], ["infections", "DISEASE", 347, 357], ["intravenous immunoglobulins", "SIMPLE_CHEMICAL", 161, 188], ["hematopoietic stem cell", "CELL", 193, 216], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 304, 312], ["antimicrobial agents", "TREATMENT", 47, 67], ["PIDs", "PROBLEM", 90, 94], ["therapeutic interventions", "TREATMENT", 130, 155], ["intravenous immunoglobulins", "TREATMENT", 161, 188], ["hematopoietic stem cell transplants", "TREATMENT", 193, 228], ["PID", "PROBLEM", 300, 303], ["treating infections", "PROBLEM", 338, 357], ["opportunistic organisms", "PROBLEM", 434, 457], ["hematopoietic stem cell transplants", "OBSERVATION", 193, 228], ["chronic", "OBSERVATION_MODIFIER", 389, 396], ["severe", "OBSERVATION_MODIFIER", 398, 404]]], ["Among these microbes are viruses that in PID patients can be challenging with an increased risk of mortality and may predispose to malignancies (6) (7) (8) .", [["malignancies", "ANATOMY", 131, 143], ["PID", "DISEASE", 41, 44], ["malignancies", "DISEASE", 131, 143], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["viruses", "PROBLEM", 25, 32], ["malignancies", "PROBLEM", 131, 143], ["microbes", "OBSERVATION", 12, 20], ["viruses", "OBSERVATION", 25, 32], ["malignancies", "OBSERVATION", 131, 143]]], ["PIDs may also lead to reduced clearance and prolonged shedding of certain viruses like rhinovirus and poliovirus (9, 10) .", [["PIDs", "DISEASE", 0, 4], ["PIDs", "SIMPLE_CHEMICAL", 0, 4], ["rhinovirus", "ORGANISM", 87, 97], ["PIDs", "PROBLEM", 0, 4], ["reduced clearance", "PROBLEM", 22, 39], ["prolonged shedding of certain viruses", "PROBLEM", 44, 81], ["rhinovirus", "PROBLEM", 87, 97], ["poliovirus", "PROBLEM", 102, 112], ["rhinovirus", "OBSERVATION", 87, 97], ["poliovirus", "OBSERVATION", 102, 112]]], ["While most PIDs predispose to a wide spectrum of viral infections, certain diseases enhance vulnerability to specific viral infections (11) .INTRODUCTIONWhereas, the risk of viral infections in PIDs is well-established and was recently reviewed (12, 13) , we are not aware of any report that characterizes such infections in a large cohort of patients with different types of PIDs.", [["PIDs", "DISEASE", 11, 15], ["viral infections", "DISEASE", 49, 65], ["viral infections", "DISEASE", 118, 134], ["viral infections", "DISEASE", 174, 190], ["PIDs", "DISEASE", 194, 198], ["infections", "DISEASE", 311, 321], ["PIDs", "DISEASE", 376, 380], ["PIDs", "CANCER", 11, 15], ["PIDs", "CANCER", 194, 198], ["patients", "ORGANISM", 343, 351], ["PIDs", "CANCER", 376, 380], ["patients", "SPECIES", 343, 351], ["viral infections", "PROBLEM", 49, 65], ["certain diseases enhance vulnerability", "PROBLEM", 67, 105], ["specific viral infections", "PROBLEM", 109, 134], ["viral infections in PIDs", "PROBLEM", 174, 198], ["such infections", "PROBLEM", 306, 321], ["PIDs", "PROBLEM", 376, 380], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 55, 65], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infections", "OBSERVATION", 124, 134], ["viral", "OBSERVATION_MODIFIER", 174, 179], ["infections", "OBSERVATION", 180, 190], ["infections", "OBSERVATION", 311, 321], ["large", "OBSERVATION_MODIFIER", 327, 332]]], ["In this report, we present the frequency and spectrum of viral infections in primary immunodeficient children from Kuwait between January 2004 and December 2018.Patients DataThe data was obtained from the Kuwait National Primary Immunodeficiency Disorders Registry (KNPIDR) which was approved by The Research and Ethics Committee of the Ministry of Health in Kuwait and the Kuwait University Health Sciences Center Ethical Committee in accordance with the Declaration of Helsinki.", [["viral infections", "DISEASE", 57, 73], ["primary immunodeficient", "DISEASE", 77, 100], ["Primary Immunodeficiency Disorders", "DISEASE", 221, 255], ["children", "ORGANISM", 101, 109], ["Patients", "ORGANISM", 161, 169], ["children", "SPECIES", 101, 109], ["Patients", "SPECIES", 161, 169], ["viral infections", "PROBLEM", 57, 73], ["viral infections", "OBSERVATION", 57, 73]]], ["The patients were followed prospectively and classified according to the International Union of Immunological Societies, Primary Immunodeficiency Diseases Committee report on Inborn Errors of Immunity (2017) (1).", [["Primary Immunodeficiency Diseases", "DISEASE", 121, 154], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Secondary immunodeficiencies (drug induced, HIV induced, and immunodeficiency associated with metabolic disorders... etc.), were ruled out by obtaining a detailed history and by performing appropriate testing when these disorders were suspected.Diagnosis of Viral InfectionsThe clinical diagnosis was based on the standard of care depending on the patient's signs and symptoms supported by laboratory and/or radiologic findings.", [["Secondary immunodeficiencies", "DISEASE", 0, 28], ["drug induced, HIV induced, and immunodeficiency", "DISEASE", 30, 77], ["metabolic disorders", "DISEASE", 94, 113], ["Viral Infections", "DISEASE", 258, 274], ["patient", "ORGANISM", 348, 355], ["HIV", "SPECIES", 44, 47], ["patient", "SPECIES", 348, 355], ["HIV", "SPECIES", 44, 47], ["Secondary immunodeficiencies", "PROBLEM", 0, 28], ["HIV", "PROBLEM", 44, 47], ["immunodeficiency", "PROBLEM", 61, 77], ["metabolic disorders", "PROBLEM", 94, 113], ["appropriate testing", "TEST", 189, 208], ["these disorders", "PROBLEM", 214, 229], ["Viral Infections", "PROBLEM", 258, 274], ["the patient's signs", "TEST", 344, 363], ["symptoms", "PROBLEM", 368, 376], ["radiologic findings", "TEST", 408, 427], ["immunodeficiencies", "OBSERVATION", 10, 28], ["Viral", "OBSERVATION_MODIFIER", 258, 263], ["Infections", "OBSERVATION", 264, 274]]], ["For example, patients who were diagnosed with pneumonia presented with respiratory signs and symptoms associated with radiologic findings.", [["respiratory", "ANATOMY", 71, 82], ["pneumonia", "DISEASE", 46, 55], ["respiratory signs", "DISEASE", 71, 88], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["pneumonia", "PROBLEM", 46, 55], ["respiratory signs", "PROBLEM", 71, 88], ["symptoms", "PROBLEM", 93, 101], ["radiologic findings", "TEST", 118, 137], ["pneumonia", "OBSERVATION", 46, 55], ["respiratory", "ANATOMY", 71, 82]]], ["The diagnosis of herpes simplex virus (HSV) keratitis and stomatitis, warts caused by human papilloma virus (HPV), varicella-zoster virus (VZV) and molluscum contagiosum infections was based on clinical evaluation.", [["warts", "ANATOMY", 70, 75], ["herpes simplex virus (HSV) keratitis", "DISEASE", 17, 53], ["stomatitis", "DISEASE", 58, 68], ["warts", "DISEASE", 70, 75], ["human papilloma virus (HPV)", "DISEASE", 86, 113], ["varicella-zoster", "DISEASE", 115, 131], ["VZV", "DISEASE", 139, 142], ["molluscum contagiosum infections", "DISEASE", 148, 180], ["herpes simplex virus", "ORGANISM", 17, 37], ["HSV", "ORGANISM", 39, 42], ["human papilloma virus", "ORGANISM", 86, 107], ["HPV", "ORGANISM", 109, 112], ["varicella-zoster virus", "ORGANISM", 115, 137], ["VZV", "ORGANISM", 139, 142], ["molluscum contagiosum", "ORGANISM", 148, 169], ["herpes simplex virus", "SPECIES", 17, 37], ["human", "SPECIES", 86, 91], ["papilloma virus", "SPECIES", 92, 107], ["varicella-zoster virus", "SPECIES", 115, 137], ["herpes simplex virus", "SPECIES", 17, 37], ["HSV", "SPECIES", 39, 42], ["human papilloma virus", "SPECIES", 86, 107], ["HPV", "SPECIES", 109, 112], ["varicella-zoster virus", "SPECIES", 115, 137], ["VZV", "SPECIES", 139, 142], ["herpes simplex virus (HSV) keratitis", "PROBLEM", 17, 53], ["stomatitis", "PROBLEM", 58, 68], ["warts", "PROBLEM", 70, 75], ["human papilloma virus", "PROBLEM", 86, 107], ["varicella-zoster virus", "PROBLEM", 115, 137], ["VZV", "PROBLEM", 139, 142], ["molluscum contagiosum infections", "PROBLEM", 148, 180], ["clinical evaluation", "TEST", 194, 213], ["herpes simplex virus", "OBSERVATION", 17, 37], ["keratitis", "OBSERVATION", 44, 53], ["papilloma virus", "OBSERVATION", 92, 107], ["zoster virus", "OBSERVATION", 125, 137], ["molluscum", "OBSERVATION_MODIFIER", 148, 157]]], ["In-house Polymerase Chain Reaction (PCR) was used initially to test for Cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpesvirus 6 (HHV-6), adenovirus, respiratory and gastrointestinal viruses.", [["respiratory", "ANATOMY", 156, 167], ["gastrointestinal", "ANATOMY", 172, 188], ["Cytomegalovirus (CMV), Epstein-Barr virus (EBV)", "DISEASE", 72, 119], ["respiratory and gastrointestinal viruses", "DISEASE", 156, 196], ["Cytomegalovirus", "ORGANISM", 72, 87], ["CMV", "ORGANISM", 89, 92], ["Epstein-Barr virus", "ORGANISM", 95, 113], ["EBV", "ORGANISM", 115, 118], ["herpesvirus 6", "ORGANISM", 121, 134], ["HHV-6", "ORGANISM", 136, 141], ["adenovirus", "ORGANISM", 144, 154], ["gastrointestinal viruses", "ORGANISM", 172, 196], ["Barr virus", "SPECIES", 103, 113], ["HHV-6", "SPECIES", 136, 141], ["CMV", "SPECIES", 89, 92], ["Epstein-Barr virus", "SPECIES", 95, 113], ["EBV", "SPECIES", 115, 118], ["HHV-6", "SPECIES", 136, 141], ["adenovirus", "SPECIES", 144, 154], ["PCR", "TEST", 36, 39], ["Cytomegalovirus", "PROBLEM", 72, 87], ["CMV", "TEST", 89, 92], ["Epstein", "TEST", 95, 102], ["Barr virus (EBV", "TEST", 103, 118], ["herpesvirus", "TEST", 121, 132], ["HHV", "TEST", 136, 139], ["adenovirus", "PROBLEM", 144, 154], ["respiratory and gastrointestinal viruses", "PROBLEM", 156, 196], ["respiratory", "ANATOMY", 156, 167], ["gastrointestinal", "ANATOMY", 172, 188], ["viruses", "OBSERVATION", 189, 196]]], ["This was replaced later by commercial kits as indicated below.Sample Collection and TransportationFor patients with gastrointestinal manifestations stool or colonic samples were collected.", [["gastrointestinal", "ANATOMY", 116, 132], ["stool", "ANATOMY", 148, 153], ["colonic samples", "ANATOMY", 157, 172], ["patients", "ORGANISM", 102, 110], ["gastrointestinal", "ORGANISM_SUBDIVISION", 116, 132], ["stool", "ORGANISM_SUBSTANCE", 148, 153], ["colonic samples", "CANCER", 157, 172], ["patients", "SPECIES", 102, 110], ["Sample Collection", "TEST", 62, 79], ["gastrointestinal manifestations stool", "PROBLEM", 116, 153], ["colonic samples", "PROBLEM", 157, 172], ["Collection", "OBSERVATION", 69, 79], ["gastrointestinal", "ANATOMY", 116, 132], ["colonic", "ANATOMY", 157, 164]]], ["Deep nasopharyngeal aspirate or bronchoalveolar lavage samples were collected from patients with respiratory manifestations using sterile nylon flocked swab or by bronchoscopy and placed in viral transport medium.", [["nasopharyngeal aspirate", "ANATOMY", 5, 28], ["bronchoalveolar lavage samples", "ANATOMY", 32, 62], ["respiratory", "ANATOMY", 97, 108], ["swab", "ANATOMY", 152, 156], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 5, 28], ["bronchoalveolar lavage samples", "ORGANISM_SUBSTANCE", 32, 62], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Deep nasopharyngeal aspirate", "TEST", 0, 28], ["bronchoalveolar lavage samples", "TEST", 32, 62], ["respiratory manifestations", "PROBLEM", 97, 123], ["sterile nylon flocked swab", "TREATMENT", 130, 156], ["bronchoscopy", "TEST", 163, 175], ["viral transport medium", "TREATMENT", 190, 212], ["nasopharyngeal", "ANATOMY", 5, 19], ["aspirate", "OBSERVATION", 20, 28], ["bronchoalveolar lavage", "OBSERVATION", 32, 54]]], ["Serum and cerebrospinal fluid samples were collected for viral infections as required.", [["Serum", "ANATOMY", 0, 5], ["cerebrospinal fluid samples", "ANATOMY", 10, 37], ["viral infections", "DISEASE", 57, 73], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cerebrospinal fluid samples", "ORGANISM_SUBSTANCE", 10, 37], ["Serum and cerebrospinal fluid samples", "TEST", 0, 37], ["viral infections", "PROBLEM", 57, 73], ["cerebrospinal", "ANATOMY", 10, 23], ["fluid", "OBSERVATION", 24, 29]]], ["All samples were labeled and transported the earliest to Virology Laboratory, Faculty of Medicine, Kuwait University for day-to-day routine screening for viral infections and storage.Nucleic Acid ExtractionViral nucleic acid from samples was extracted using an automated MagNa Pure LC 2.0 system (Roche Diagnostic Systems, Branchburg, NJ).", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 230, 237], ["viral infections", "DISEASE", 154, 170], ["nucleic acid", "CHEMICAL", 212, 224], ["Nucleic Acid", "SIMPLE_CHEMICAL", 183, 195], ["routine screening", "TEST", 132, 149], ["viral infections", "PROBLEM", 154, 170], ["Nucleic Acid ExtractionViral nucleic acid", "TEST", 183, 224], ["infections", "OBSERVATION", 160, 170]]], ["HSV (2) Keratitis (2) HPV (2) Warts (2) CMV (8) Viremia (4), Pneumonia (6) Adenovirus (3) Viremia (2), Pneumonia (1)Poliovirus-1 (1) Shedding in the stoolEnterovirus (3) Hemophagocytosis (1), Viremia (1), Pneumonia (1) Norovirus (1)ManifestationsImmunodeficiency with centromeric instability and facial anomalies (2) Sapovirus (2) Enteritis (2) Adenovirus (2) Enteritis (1), Viremia (1) PREDOMINANTLY ANTIBODY DEFICIENCIES (n = 6)ManifestationsBTK deficiency (1) Enterovirus (1) Meningo-encephalitis \u00b5 Heavy chain deficiency (1) Enterovirus (1) (1) VZV (1) ChickenpoxDISEASES OF IMMUNE DYSREGULATION (n = 10)LYST deficiency (1) EBV (1) HemophagocytosisDISEASES OF IMMUNE DYSREGULATION (n = 10)CMV (2) Colitis (1), Viremia (2) EBV (2) Stool samples were homogenized.", [["centromeric", "ANATOMY", 268, 279], ["facial", "ANATOMY", 296, 302], ["samples", "ANATOMY", 740, 747], ["CMV (8) Viremia", "DISEASE", 40, 55], ["Pneumonia", "DISEASE", 61, 70], ["Pneumonia", "DISEASE", 103, 112], ["Enterovirus", "DISEASE", 154, 165], ["Hemophagocytosis", "DISEASE", 170, 186], ["Pneumonia", "DISEASE", 205, 214], ["Norovirus", "DISEASE", 219, 228], ["Immunodeficiency with centromeric instability", "DISEASE", 246, 291], ["facial anomalies", "DISEASE", 296, 312], ["Enteritis", "DISEASE", 331, 340], ["Adenovirus (2) Enteritis", "DISEASE", 345, 369], ["Viremia", "DISEASE", 375, 382], ["ManifestationsBTK deficiency", "DISEASE", 430, 458], ["Enterovirus", "DISEASE", 463, 474], ["Meningo-encephalitis", "DISEASE", 479, 499], ["Colitis", "DISEASE", 701, 708], ["HSV", "ORGANISM", 0, 3], ["CMV", "ORGANISM", 40, 43], ["Adenovirus", "ORGANISM", 75, 85], ["Adenovirus", "ORGANISM", 345, 355], ["VZV", "ORGANISM", 549, 552], ["EBV", "ORGANISM", 628, 631], ["CMV", "ORGANISM", 693, 696], ["EBV", "ORGANISM", 726, 729], ["Stool samples", "CANCER", 734, 747], ["Poliovirus-1", "SPECIES", 116, 128], ["HSV", "SPECIES", 0, 3], ["Poliovirus-1", "SPECIES", 116, 128], ["HSV", "PROBLEM", 0, 3], ["Keratitis", "PROBLEM", 8, 17], ["HPV (2) Warts", "PROBLEM", 22, 35], ["CMV", "TEST", 40, 43], ["Viremia", "PROBLEM", 48, 55], ["Pneumonia", "PROBLEM", 61, 70], ["Adenovirus", "PROBLEM", 75, 85], ["Viremia", "PROBLEM", 90, 97], ["Pneumonia", "PROBLEM", 103, 112], ["Poliovirus", "PROBLEM", 116, 126], ["Shedding in the stoolEnterovirus", "PROBLEM", 133, 165], ["Hemophagocytosis", "PROBLEM", 170, 186], ["Viremia", "PROBLEM", 192, 199], ["Pneumonia", "PROBLEM", 205, 214], ["Norovirus", "PROBLEM", 219, 228], ["ManifestationsImmunodeficiency", "PROBLEM", 232, 262], ["centromeric instability", "PROBLEM", 268, 291], ["facial anomalies", "PROBLEM", 296, 312], ["Sapovirus (2) Enteritis (2) Adenovirus (2) Enteritis", "PROBLEM", 317, 369], ["Viremia", "PROBLEM", 375, 382], ["PREDOMINANTLY ANTIBODY DEFICIENCIES (n = 6)ManifestationsBTK deficiency", "PROBLEM", 387, 458], ["Enterovirus", "PROBLEM", 463, 474], ["Meningo-encephalitis", "PROBLEM", 479, 499], ["Heavy chain deficiency", "PROBLEM", 502, 524], ["Enterovirus", "PROBLEM", 529, 540], ["VZV", "PROBLEM", 549, 552], ["IMMUNE DYSREGULATION", "PROBLEM", 579, 599], ["LYST deficiency", "PROBLEM", 608, 623], ["EBV (1) HemophagocytosisDISEASES OF IMMUNE DYSREGULATION", "PROBLEM", 628, 684], ["CMV (2) Colitis", "PROBLEM", 693, 708], ["Viremia (2) EBV", "PROBLEM", 714, 729], ["Stool samples", "TEST", 734, 747], ["Keratitis", "OBSERVATION", 8, 17], ["Pneumonia", "OBSERVATION", 61, 70], ["Pneumonia", "OBSERVATION", 103, 112], ["stool", "ANATOMY", 149, 154], ["Viremia", "OBSERVATION", 192, 199], ["Pneumonia", "OBSERVATION", 205, 214], ["centromeric instability", "OBSERVATION", 268, 291], ["facial", "ANATOMY", 296, 302], ["anomalies", "OBSERVATION", 303, 312], ["Enteritis", "OBSERVATION", 331, 340], ["Enteritis", "OBSERVATION", 360, 369], ["Viremia", "OBSERVATION", 375, 382], ["ANTIBODY DEFICIENCIES", "OBSERVATION", 401, 422], ["chain deficiency", "OBSERVATION", 508, 524], ["IMMUNE DYSREGULATION", "OBSERVATION", 664, 684], ["Colitis", "OBSERVATION", 701, 708]]], ["Prior to extraction, a 200 mg aliquot was suspended in 1 ml of nuclease-free water or 1 ml of stool transport and recovery buffer (Roche Diagnostics, Meylan, France).", [["stool", "ANATOMY", 94, 99], ["stool", "ORGANISM_SUBSTANCE", 94, 99], ["nuclease", "PROTEIN", 63, 71], ["extraction", "TREATMENT", 9, 19], ["a 200 mg aliquot", "TREATMENT", 21, 37], ["nuclease-free water", "TREATMENT", 63, 82], ["stool transport", "TREATMENT", 94, 109]]], ["Then the suspension was immediately clarified by centrifugation at 11,000 g for 5 min.", [["the suspension", "TREATMENT", 5, 19]]], ["According to the manufacturer's instructions RT-PCRs was performed on 10 \u00b5l of nucleic acid by using LightCycler 480 RT-PCR thermocycler (Roche, Meylan, France).DISEASES OF IMMUNE DYSREGULATION (n = 10)CMV, EBV, enterovirus, HAdV, and HHV-6 detection were performed on serum, stool/colonic, respiratory or CSF samples by LightMix R Kits (TIB Molbiol, Berlin, Germany).", [["serum", "ANATOMY", 269, 274], ["stool", "ANATOMY", 276, 281], ["colonic", "ANATOMY", 282, 289], ["respiratory", "ANATOMY", 291, 302], ["samples", "ANATOMY", 310, 317], ["nucleic acid", "CHEMICAL", 79, 91], ["CMV", "ORGANISM", 202, 205], ["EBV", "ORGANISM", 207, 210], ["enterovirus", "ORGANISM", 212, 223], ["HAdV", "ORGANISM", 225, 229], ["HHV-6", "ORGANISM", 235, 240], ["serum", "ORGANISM_SUBSTANCE", 269, 274], ["stool", "ORGANISM_SUBSTANCE", 276, 281], ["colonic", "MULTI-TISSUE_STRUCTURE", 282, 289], ["CSF samples", "ORGANISM_SUBSTANCE", 306, 317], ["CMV", "SPECIES", 202, 205], ["EBV", "SPECIES", 207, 210], ["HAdV", "SPECIES", 225, 229], ["HHV-6", "SPECIES", 235, 240], ["nucleic acid", "TEST", 79, 91], ["LightCycler", "TEST", 101, 112], ["IMMUNE DYSREGULATION", "PROBLEM", 173, 193], ["CMV", "PROBLEM", 202, 205], ["EBV", "PROBLEM", 207, 210], ["enterovirus", "PROBLEM", 212, 223], ["HAdV", "PROBLEM", 225, 229], ["HHV", "PROBLEM", 235, 238], ["serum, stool/colonic", "TEST", 269, 289], ["CSF samples", "TEST", 306, 317], ["LightMix R Kits", "TEST", 321, 336], ["IMMUNE DYSREGULATION", "OBSERVATION", 173, 193], ["colonic", "ANATOMY", 282, 289], ["respiratory", "ANATOMY", 291, 302], ["TIB", "ANATOMY", 338, 341]]], ["Amplifications were performed according to the manufacturer's instructions on LightCycler 480 RT-PCR thermocycler (Roche, Meylan, France).", [["LightCycler", "TEST", 78, 89]]], ["The presence of poliovirus RNA in clinical samples was confirmed by one-step reverse transcription-PCR, followed by a direct sequencing of PCR products, as described previously (14) .Statistical AnalysisData were processed using IBM SPSS, version 25 (IBM Corporation, Armonk, NY, USA 2017).", [["samples", "ANATOMY", 43, 50], ["poliovirus", "ORGANISM", 16, 26], ["samples", "CANCER", 43, 50], ["poliovirus RNA", "RNA", 16, 30], ["PCR products", "DNA", 139, 151], ["poliovirus", "SPECIES", 16, 26], ["poliovirus RNA", "PROBLEM", 16, 30], ["PCR", "TEST", 99, 102], ["PCR products", "TREATMENT", 139, 151], ["Statistical AnalysisData", "TEST", 183, 207], ["poliovirus RNA", "OBSERVATION", 16, 30]]], ["Pearson's Chi-square test was used to assess the association between two categorical variables.", [["Pearson's Chi-square test", "TEST", 0, 25]]], ["The non-parametric Mann-Whitney U-test was applied to assess whether the patients' ages at onset of a symptom of PID have a significant effect on the risk of viral infection.", [["PID", "DISEASE", 113, 116], ["viral infection", "DISEASE", 158, 173], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Whitney U-test", "TEST", 24, 38], ["a symptom of PID", "PROBLEM", 100, 116], ["viral infection", "PROBLEM", 158, 173], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 164, 173]]], ["The p \u2264 0.05 was used as the cut-off level for statistical significance.RESULTSA total of 274 PID children (142 males and 132 females) were registered in KNPIDR during the study period.", [["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106], ["The p \u2264 0.05", "TREATMENT", 0, 12]]], ["The distribution of these patients according to PID categories is: immunodeficiencies affecting cellular and humoral immunity, 97 patients (35.4%); combined immunodeficiencies with associated syndromic features, 67 patients (24.5%); predominantly antibody deficiencies, 34 patients (12.4%); diseases of immune dysregulation, 47 patients (17.2%); congenital defects of phagocyte number or function, 17 patients (6.2%); autoinflammatory disorders, 1 patient (0.3%); and complement deficiencies, 11 patients (4%).", [["cellular", "ANATOMY", 96, 104], ["phagocyte", "ANATOMY", 368, 377], ["immunodeficiencies", "DISEASE", 67, 85], ["immunodeficiencies", "DISEASE", 157, 175], ["antibody deficiencies", "DISEASE", 247, 268], ["immune dysregulation", "DISEASE", 303, 323], ["congenital defects of phagocyte number", "DISEASE", 346, 384], ["autoinflammatory disorders", "DISEASE", 418, 444], ["complement deficiencies", "DISEASE", 468, 491], ["patients", "ORGANISM", 26, 34], ["cellular", "CELL", 96, 104], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 273, 281], ["patients", "ORGANISM", 328, 336], ["phagocyte", "CELL", 368, 377], ["patients", "ORGANISM", 401, 409], ["patient", "ORGANISM", 448, 455], ["patients", "ORGANISM", 496, 504], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 273, 281], ["patients", "SPECIES", 328, 336], ["patients", "SPECIES", 401, 409], ["patient", "SPECIES", 448, 455], ["patients", "SPECIES", 496, 504], ["immunodeficiencies", "PROBLEM", 67, 85], ["humoral immunity", "TEST", 109, 125], ["combined immunodeficiencies", "PROBLEM", 148, 175], ["associated syndromic features", "PROBLEM", 181, 210], ["predominantly antibody deficiencies", "PROBLEM", 233, 268], ["diseases of immune dysregulation", "PROBLEM", 291, 323], ["congenital defects of phagocyte number", "PROBLEM", 346, 384], ["autoinflammatory disorders", "PROBLEM", 418, 444], ["complement deficiencies", "PROBLEM", 468, 491], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["antibody deficiencies", "OBSERVATION", 247, 268], ["immune dysregulation", "OBSERVATION", 303, 323], ["congenital", "OBSERVATION_MODIFIER", 346, 356], ["defects", "OBSERVATION", 357, 364], ["phagocyte number", "OBSERVATION", 368, 384]]], ["No patients with defects in innate immunity were registered.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["defects in innate immunity", "PROBLEM", 17, 43], ["defects", "OBSERVATION", 17, 24]]], ["Seventy-one patients were treated with hematopoietic stem cell transplant (HSCT) and 141 received intravenous immunoglobulins.", [["hematopoietic stem cell", "ANATOMY", 39, 62], ["intravenous", "ANATOMY", 98, 109], ["patients", "ORGANISM", 12, 20], ["hematopoietic stem cell", "CELL", 39, 62], ["patients", "SPECIES", 12, 20], ["hematopoietic stem cell transplant", "TREATMENT", 39, 73], ["HSCT", "TEST", 75, 79], ["intravenous immunoglobulins", "TREATMENT", 98, 125], ["hematopoietic stem cell transplant", "OBSERVATION", 39, 73]]], ["It is important to mention that of the reported viral infections occurred prior to HSCT in patients who received such treatment.RESULTSOverall infectious complications affected 226 patients (82.4%), and viral infections affected 87 patients (31.7% of the registered patients).", [["viral infections", "DISEASE", 48, 64], ["viral infections", "DISEASE", 203, 219], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 266, 274], ["the reported viral infections", "PROBLEM", 35, 64], ["such treatment", "TREATMENT", 113, 127], ["RESULTSOverall infectious complications", "PROBLEM", 128, 167], ["viral infections", "PROBLEM", 203, 219], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["infections", "OBSERVATION", 54, 64], ["infectious", "OBSERVATION_MODIFIER", 143, 153], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["infections", "OBSERVATION", 209, 219]]], ["Forty-five patients (16.4%) developed viral infections caused by at least 2 organisms, mostly in the category of immunodeficiencies affecting cellular and humoral immunity (31 patients).", [["cellular", "ANATOMY", 142, 150], ["viral infections", "DISEASE", 38, 54], ["immunodeficiencies", "DISEASE", 113, 131], ["patients", "ORGANISM", 11, 19], ["cellular", "CELL", 142, 150], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 176, 184], ["viral infections", "PROBLEM", 38, 54], ["immunodeficiencies", "PROBLEM", 113, 131], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infections", "OBSERVATION", 44, 54], ["immunodeficiencies", "OBSERVATION", 113, 131]]], ["Among those, 20 patients were affected by three or more viral infections.", [["viral infections", "DISEASE", 56, 72], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["more viral infections", "PROBLEM", 51, 72], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infections", "OBSERVATION", 62, 72]]], ["There was a statistically significant association between viral infections and PID category after excluding patients who belong to congenital defects of phagocyte number or function, autoinflammatory disorders and complement deficiencies due to low numbers (p < 0.001) ( Table 1) .", [["phagocyte", "ANATOMY", 153, 162], ["viral infections", "DISEASE", 58, 74], ["PID", "DISEASE", 79, 82], ["congenital defects of phagocyte number", "DISEASE", 131, 169], ["autoinflammatory disorders", "DISEASE", 183, 209], ["complement deficiencies", "DISEASE", 214, 237], ["patients", "ORGANISM", 108, 116], ["phagocyte", "CELL", 153, 162], ["patients", "SPECIES", 108, 116], ["viral infections", "PROBLEM", 58, 74], ["PID category", "TREATMENT", 79, 91], ["congenital defects of phagocyte number", "PROBLEM", 131, 169], ["autoinflammatory disorders", "PROBLEM", 183, 209], ["complement deficiencies", "PROBLEM", 214, 237], ["low numbers", "PROBLEM", 245, 256], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infections", "OBSERVATION", 64, 74], ["congenital", "OBSERVATION_MODIFIER", 131, 141], ["defects", "OBSERVATION", 142, 149], ["phagocyte", "OBSERVATION", 153, 162]]], ["However, there was no statistically significant association between viral infections and gender (p = 0.488), or the patients' onset age when assessed both as quantitative and qualitative variables (p-values 0.23 and 0.655, respectively).RESULTSThere was a total of 170 viral infections during the study period, 33% were detected at the time of PID diagnosis while 67% were documented after establishing the diagnosis.", [["viral infections", "DISEASE", 68, 84], ["viral infections", "DISEASE", 269, 285], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["viral infections", "PROBLEM", 68, 84], ["p-values", "TEST", 198, 206], ["170 viral infections", "PROBLEM", 265, 285], ["the study", "TEST", 293, 302], ["PID diagnosis", "TEST", 344, 357], ["no", "UNCERTAINTY", 19, 21], ["statistically", "OBSERVATION_MODIFIER", 22, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infections", "OBSERVATION", 74, 84], ["viral", "OBSERVATION_MODIFIER", 269, 274], ["infections", "OBSERVATION", 275, 285]]], ["The causes of these infections were: CMV (22.2%); adenovirus (11.7%); EBV (11.1%); enteroviruses (7.4%), HSV and HPV (6.8% each); VZV and rhinovirus (6.2% each); Molluscum contagiosum (5.5%) (Figure 1) ; norovirus and parainfluenza virus (3% each); H1N1 virus (1.85%); rotavirus, RSV, sapovirus, HHV-6 and corona virus (1.2% each).", [["infections", "DISEASE", 20, 30], ["enteroviruses", "DISEASE", 83, 96], ["HSV and HPV", "DISEASE", 105, 116], ["VZV and rhinovirus", "DISEASE", 130, 148], ["Molluscum contagiosum", "DISEASE", 162, 183], ["norovirus and parainfluenza virus", "DISEASE", 204, 237], ["H1N1 virus", "DISEASE", 249, 259], ["rotavirus, RSV", "DISEASE", 269, 283], ["CMV", "ORGANISM", 37, 40], ["adenovirus", "ORGANISM", 50, 60], ["EBV", "ORGANISM", 70, 73], ["HSV", "ORGANISM", 105, 108], ["HPV", "ORGANISM", 113, 116], ["VZV", "ORGANISM", 130, 133], ["rhinovirus", "ORGANISM", 138, 148], ["Molluscum contagiosum", "ORGANISM", 162, 183], ["norovirus", "ORGANISM", 204, 213], ["parainfluenza virus", "ORGANISM", 218, 237], ["H1N1 virus", "ORGANISM", 249, 259], ["rotavirus", "ORGANISM", 269, 278], ["RSV", "ORGANISM", 280, 283], ["HHV-6", "ORGANISM", 296, 301], ["corona virus", "ORGANISM", 306, 318], ["VZV and rhinovirus", "SPECIES", 130, 148], ["Molluscum contagiosum", "SPECIES", 162, 183], ["parainfluenza virus", "SPECIES", 218, 237], ["H1N1 virus", "SPECIES", 249, 259], ["rotavirus", "SPECIES", 269, 278], ["RSV", "SPECIES", 280, 283], ["HHV-6", "SPECIES", 296, 301], ["CMV", "SPECIES", 37, 40], ["EBV", "SPECIES", 70, 73], ["HSV", "SPECIES", 105, 108], ["HPV", "SPECIES", 113, 116], ["VZV", "SPECIES", 130, 133], ["Molluscum contagiosum", "SPECIES", 162, 183], ["parainfluenza virus", "SPECIES", 218, 237], ["H1N1 virus", "SPECIES", 249, 259], ["rotavirus", "SPECIES", 269, 278], ["RSV", "SPECIES", 280, 283], ["HHV-6", "SPECIES", 296, 301], ["these infections", "PROBLEM", 14, 30], ["CMV", "TEST", 37, 40], ["adenovirus", "TEST", 50, 60], ["EBV", "TEST", 70, 73], ["enteroviruses", "TEST", 83, 96], ["HSV", "TEST", 105, 108], ["HPV", "TEST", 113, 116], ["VZV", "TEST", 130, 133], ["rhinovirus", "TEST", 138, 148], ["Molluscum contagiosum", "TEST", 162, 183], ["Figure", "TEST", 192, 198], ["norovirus", "PROBLEM", 204, 213], ["parainfluenza virus", "PROBLEM", 218, 237], ["H1N1 virus", "PROBLEM", 249, 259], ["rotavirus", "PROBLEM", 269, 278], ["RSV", "PROBLEM", 280, 283], ["sapovirus", "PROBLEM", 285, 294], ["HHV", "TEST", 296, 299], ["corona virus", "PROBLEM", 306, 318], ["infections", "OBSERVATION", 20, 30], ["RSV", "ANATOMY", 280, 283]]], ["A patient with severe combined immunodeficiency presented with myocarditis caused by poliovirus type 2.", [["immunodeficiency", "DISEASE", 31, 47], ["myocarditis", "DISEASE", 63, 74], ["patient", "ORGANISM", 2, 9], ["poliovirus type 2", "ORGANISM", 85, 102], ["patient", "SPECIES", 2, 9], ["severe combined immunodeficiency", "PROBLEM", 15, 47], ["myocarditis", "PROBLEM", 63, 74], ["poliovirus type 2", "PROBLEM", 85, 102], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["immunodeficiency", "OBSERVATION", 31, 47], ["myocarditis", "OBSERVATION", 63, 74], ["poliovirus type", "OBSERVATION", 85, 100]]], ["Two patients (1 with severe combined immunodeficiency and 1 with MHC II deficiency) had prolonged excretion of poliovirus type 1 in the stool.", [["stool", "ANATOMY", 136, 141], ["immunodeficiency", "DISEASE", 37, 53], ["MHC II deficiency", "DISEASE", 65, 82], ["patients", "ORGANISM", 4, 12], ["poliovirus type 1", "GENE_OR_GENE_PRODUCT", 111, 128], ["stool", "ORGANISM_SUBSTANCE", 136, 141], ["MHC II", "PROTEIN", 65, 71], ["patients", "SPECIES", 4, 12], ["poliovirus type 1", "SPECIES", 111, 128], ["severe combined immunodeficiency", "PROBLEM", 21, 53], ["MHC II deficiency", "PROBLEM", 65, 82], ["poliovirus type 1", "PROBLEM", 111, 128], ["poliovirus type", "OBSERVATION", 111, 126], ["stool", "ANATOMY", 136, 141]]], ["The details of the viral infections are presented in Table 2 .", [["viral infections", "DISEASE", 19, 35], ["the viral infections", "PROBLEM", 15, 35], ["viral", "OBSERVATION_MODIFIER", 19, 24], ["infections", "OBSERVATION", 25, 35]]], ["Figure 2 shows the number of patients affected by different viruses according to PID categories.", [["PID", "DISEASE", 81, 84], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["different viruses", "PROBLEM", 50, 67], ["viruses", "OBSERVATION", 60, 67]]], ["The most prominent findings are that CMV and parainfluenza infections are more common in the group of immunodeficiencies affecting cellular and humoral immunity while EBV and HPV are more common in the immune dysregulation group and combined immunodeficiencies with associated syndromic features, respectively.", [["cellular", "ANATOMY", 131, 139], ["parainfluenza infections", "DISEASE", 45, 69], ["immunodeficiencies", "DISEASE", 102, 120], ["immunodeficiencies", "DISEASE", 242, 260], ["CMV", "ORGANISM", 37, 40], ["parainfluenza", "ORGANISM", 45, 58], ["cellular", "CELL", 131, 139], ["EBV", "ORGANISM", 167, 170], ["HPV", "ORGANISM", 175, 178], ["parainfluenza", "SPECIES", 45, 58], ["CMV", "SPECIES", 37, 40], ["EBV", "SPECIES", 167, 170], ["HPV", "SPECIES", 175, 178], ["CMV", "PROBLEM", 37, 40], ["parainfluenza infections", "PROBLEM", 45, 69], ["immunodeficiencies", "PROBLEM", 102, 120], ["EBV", "PROBLEM", 167, 170], ["HPV", "PROBLEM", 175, 178], ["the immune dysregulation group", "PROBLEM", 198, 228], ["combined immunodeficiencies", "PROBLEM", 233, 260], ["associated syndromic features", "PROBLEM", 266, 295], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["CMV", "OBSERVATION", 37, 40], ["parainfluenza infections", "OBSERVATION", 45, 69], ["humoral immunity", "OBSERVATION", 144, 160], ["more common", "OBSERVATION_MODIFIER", 183, 194]]], ["The most common presentation was viremia (28.8%) followed by pneumonia (28.2%) and skin infections (17.6%) ( Table 3) .", [["skin", "ANATOMY", 83, 87], ["viremia", "DISEASE", 33, 40], ["pneumonia", "DISEASE", 61, 70], ["skin infections", "DISEASE", 83, 98], ["skin", "ORGAN", 83, 87], ["viremia", "PROBLEM", 33, 40], ["pneumonia", "PROBLEM", 61, 70], ["skin infections", "PROBLEM", 83, 98], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["viremia", "OBSERVATION", 33, 40], ["pneumonia", "OBSERVATION", 61, 70], ["skin", "ANATOMY", 83, 87], ["infections", "OBSERVATION", 88, 98]]], ["The most common causes of viremia were CMV followed by adenovirus and EBV, while the most common organisms causing pneumonia were CMV followed by rhinovirus and parainfluenza ( Table 3) .DISCUSSIONIn the current study, we present the characteristics of viral infections in a large cohort of PID children who were followed prospectively over a period of 15 years.", [["viremia", "DISEASE", 26, 33], ["CMV followed by adenovirus and EBV", "DISEASE", 39, 73], ["pneumonia", "DISEASE", 115, 124], ["CMV followed by rhinovirus and parainfluenza", "DISEASE", 130, 174], ["viral infections", "DISEASE", 253, 269], ["CMV", "ORGANISM", 39, 42], ["adenovirus", "ORGANISM", 55, 65], ["EBV", "ORGANISM", 70, 73], ["CMV", "ORGANISM", 130, 133], ["rhinovirus", "ORGANISM", 146, 156], ["parainfluenza", "ORGANISM", 161, 174], ["children", "ORGANISM", 295, 303], ["rhinovirus", "SPECIES", 146, 156], ["parainfluenza", "SPECIES", 161, 174], ["children", "SPECIES", 295, 303], ["CMV", "SPECIES", 39, 42], ["adenovirus", "SPECIES", 55, 65], ["EBV", "SPECIES", 70, 73], ["CMV", "SPECIES", 130, 133], ["viremia", "PROBLEM", 26, 33], ["CMV", "PROBLEM", 39, 42], ["adenovirus", "PROBLEM", 55, 65], ["EBV", "PROBLEM", 70, 73], ["pneumonia", "PROBLEM", 115, 124], ["CMV", "PROBLEM", 130, 133], ["rhinovirus", "PROBLEM", 146, 156], ["parainfluenza", "PROBLEM", 161, 174], ["the current study", "TEST", 200, 217], ["viral infections", "PROBLEM", 253, 269], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["viremia", "OBSERVATION", 26, 33], ["pneumonia", "OBSERVATION", 115, 124], ["viral", "OBSERVATION_MODIFIER", 253, 258], ["infections", "OBSERVATION", 259, 269], ["large", "OBSERVATION_MODIFIER", 275, 280]]], ["Viral infections affected more than 1/3 of the registered patients, many of whom were affected by more than 1 virus.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Viral infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16]]], ["The patients were affected by a range of viral organisms but CMV, adenovirus and EBV were the culprits in almost half of the cases.", [["patients", "ORGANISM", 4, 12], ["CMV", "ORGANISM", 61, 64], ["adenovirus", "ORGANISM", 66, 76], ["EBV", "ORGANISM", 81, 84], ["patients", "SPECIES", 4, 12], ["CMV", "SPECIES", 61, 64], ["adenovirus", "SPECIES", 66, 76], ["EBV", "SPECIES", 81, 84], ["viral organisms", "PROBLEM", 41, 56], ["CMV", "PROBLEM", 61, 64], ["adenovirus", "PROBLEM", 66, 76], ["EBV", "PROBLEM", 81, 84]]], ["The high frequency of CMV infections (>20%) in our cohort can be explained by the fact that most of the cases are affected by combined immunodeficiencies.", [["CMV infections", "DISEASE", 22, 36], ["immunodeficiencies", "DISEASE", 135, 153], ["CMV", "ORGANISM", 22, 25], ["CMV", "SPECIES", 22, 25], ["CMV infections", "PROBLEM", 22, 36], ["combined immunodeficiencies", "PROBLEM", 126, 153], ["high", "OBSERVATION_MODIFIER", 4, 8], ["frequency", "OBSERVATION_MODIFIER", 9, 18], ["CMV infections", "OBSERVATION", 22, 36], ["immunodeficiencies", "OBSERVATION", 135, 153]]], ["Patients with such defects are extremely susceptible to progressive infection with CMV (12) .", [["infection", "DISEASE", 68, 77], ["Patients", "ORGANISM", 0, 8], ["CMV", "ORGANISM", 83, 86], ["Patients", "SPECIES", 0, 8], ["CMV", "SPECIES", 83, 86], ["such defects", "PROBLEM", 14, 26], ["progressive infection", "PROBLEM", 56, 77], ["CMV", "TEST", 83, 86], ["defects", "OBSERVATION", 19, 26], ["progressive", "OBSERVATION_MODIFIER", 56, 67], ["infection", "OBSERVATION", 68, 77], ["CMV", "OBSERVATION", 83, 86]]], ["Our finding that CMV and parainfluenza infections are more common in the group of immunodeficiencies affecting cellular and humoral immunity has been documented previously (7, 15) .", [["cellular", "ANATOMY", 111, 119], ["CMV and parainfluenza infections", "DISEASE", 17, 49], ["immunodeficiencies", "DISEASE", 82, 100], ["CMV", "ORGANISM", 17, 20], ["parainfluenza", "ORGANISM", 25, 38], ["cellular", "CELL", 111, 119], ["parainfluenza", "SPECIES", 25, 38], ["CMV", "SPECIES", 17, 20], ["CMV", "PROBLEM", 17, 20], ["parainfluenza infections", "PROBLEM", 25, 49], ["immunodeficiencies", "PROBLEM", 82, 100], ["CMV", "OBSERVATION", 17, 20], ["parainfluenza infections", "OBSERVATION", 25, 49], ["humoral immunity", "OBSERVATION", 124, 140]]], ["The observation that EBV is more common in the immune dysregulation group specifically triggering HLH is also welldocumented (8, 12) .", [["HLH", "DISEASE", 98, 101], ["EBV", "ORGANISM", 21, 24], ["EBV", "PROBLEM", 21, 24], ["HLH", "PROBLEM", 98, 101], ["more common", "OBSERVATION_MODIFIER", 28, 39], ["HLH", "OBSERVATION", 98, 101]]], ["We have found that patients with DOCK8 deficiency are particularly predisposed to mucocutaneous viral infections like molluscum contagiosum and HSV infections.", [["DOCK8 deficiency", "DISEASE", 33, 49], ["viral infections", "DISEASE", 96, 112], ["molluscum contagiosum", "DISEASE", 118, 139], ["HSV infections", "DISEASE", 144, 158], ["patients", "ORGANISM", 19, 27], ["DOCK8", "GENE_OR_GENE_PRODUCT", 33, 38], ["molluscum contagiosum", "ORGANISM", 118, 139], ["HSV", "ORGANISM", 144, 147], ["patients", "SPECIES", 19, 27], ["HSV", "SPECIES", 144, 147], ["DOCK8 deficiency", "PROBLEM", 33, 49], ["mucocutaneous viral infections", "PROBLEM", 82, 112], ["molluscum contagiosum", "PROBLEM", 118, 139], ["HSV infections", "PROBLEM", 144, 158], ["particularly predisposed to", "UNCERTAINTY", 54, 81], ["mucocutaneous viral infections", "OBSERVATION", 82, 112], ["molluscum contagiosum", "OBSERVATION", 118, 139], ["HSV", "OBSERVATION_MODIFIER", 144, 147], ["infections", "OBSERVATION", 148, 158]]], ["This is probably since DOCK8 is an important regulator of the actin cytoskeleton that is critical for cell migration through collagendense tissue, hence playing an important antiviral immunity in the skin (16) .DISCUSSIONThe presented cohort of patients are characterized by the high frequency of combined immunodeficiencies which are more severe with a higher predisposition to viral infections compared to other PID categories.", [["cytoskeleton", "ANATOMY", 68, 80], ["cell", "ANATOMY", 102, 106], ["collagendense tissue", "ANATOMY", 125, 145], ["skin", "ANATOMY", 200, 204], ["immunodeficiencies", "DISEASE", 306, 324], ["viral infections", "DISEASE", 379, 395], ["DOCK8", "GENE_OR_GENE_PRODUCT", 23, 28], ["actin", "GENE_OR_GENE_PRODUCT", 62, 67], ["cytoskeleton", "CELLULAR_COMPONENT", 68, 80], ["cell", "CELL", 102, 106], ["collagendense tissue", "TISSUE", 125, 145], ["skin", "ORGAN", 200, 204], ["patients", "ORGANISM", 245, 253], ["DOCK8", "PROTEIN", 23, 28], ["actin", "PROTEIN", 62, 67], ["patients", "SPECIES", 245, 253], ["cell migration through collagendense tissue", "PROBLEM", 102, 145], ["combined immunodeficiencies", "PROBLEM", 297, 324], ["viral infections", "PROBLEM", 379, 395], ["probably", "UNCERTAINTY", 8, 16], ["actin cytoskeleton", "OBSERVATION", 62, 80], ["cell migration", "OBSERVATION", 102, 116], ["collagendense tissue", "OBSERVATION", 125, 145], ["antiviral immunity", "OBSERVATION", 174, 192], ["skin", "ANATOMY", 200, 204], ["immunodeficiencies", "OBSERVATION", 306, 324], ["more severe", "OBSERVATION_MODIFIER", 335, 346], ["viral", "OBSERVATION_MODIFIER", 379, 384], ["infections", "OBSERVATION", 385, 395]]], ["Another prominent feature of our cohort is that none of the registered patients suffer from Adenovirus (12) EBV (10) Enteroviruses (6) HHV-6 (2)DISCUSSIONPneumonia 28.2DISCUSSIONCMV (18) Rhinovirus (9) Parainfluenza (5) Adenovirus (4) H1N1 (3) Coronavirus (2) RSV (2) EBV (2) Enterovirus (1) Skin infections 17.6DISCUSSIONHPV (11) VZV (10) Molluscum contagiosum (9) Gastrointestinal infections 9.4DISCUSSIONNorovirus (5) Enteroviruses (4) Adenovirus (2) CMV (2) Sapovirus (2) Rotavirus ( increased susceptibility to specific viral infections.", [["Parainfluenza", "CHEMICAL", 202, 215], ["Enterovirus", "DISEASE", 276, 287], ["Skin infections", "DISEASE", 292, 307], ["Molluscum contagiosum", "DISEASE", 340, 361], ["Gastrointestinal infections", "DISEASE", 366, 393], ["Rotavirus", "DISEASE", 476, 485], ["viral infections", "DISEASE", 525, 541], ["patients", "ORGANISM", 71, 79], ["Adenovirus", "ORGANISM", 92, 102], ["EBV", "ORGANISM", 108, 111], ["Adenovirus", "ORGANISM", 220, 230], ["RSV", "ORGANISM", 260, 263], ["EBV", "ORGANISM", 268, 271], ["Skin", "ORGAN", 292, 296], ["VZV", "ORGANISM", 331, 334], ["Molluscum contagiosum", "ORGANISM", 340, 361], ["Adenovirus", "ORGANISM", 439, 449], ["CMV", "ORGANISM", 454, 457], ["Rotavirus", "ORGANISM", 476, 485], ["patients", "SPECIES", 71, 79], ["Molluscum contagiosum", "SPECIES", 340, 361], ["RSV", "SPECIES", 260, 263], ["Adenovirus", "PROBLEM", 92, 102], ["EBV", "TEST", 108, 111], ["Enteroviruses", "PROBLEM", 117, 130], ["HHV", "TEST", 135, 138], ["DISCUSSIONPneumonia", "TEST", 144, 163], ["DISCUSSIONCMV", "TEST", 168, 181], ["Rhinovirus", "TEST", 187, 197], ["Parainfluenza (5) Adenovirus (4) H1N1 (3) Coronavirus (2) RSV (2) EBV (2) Enterovirus", "PROBLEM", 202, 287], ["Skin infections", "TEST", 292, 307], ["DISCUSSIONHPV", "TEST", 312, 325], ["VZV", "TEST", 331, 334], ["Molluscum contagiosum", "PROBLEM", 340, 361], ["Gastrointestinal infections", "PROBLEM", 366, 393], ["DISCUSSIONNorovirus (5) Enteroviruses (4) Adenovirus (2) CMV (2) Sapovirus", "PROBLEM", 397, 471], ["Rotavirus ( increased susceptibility to specific viral infections", "PROBLEM", 476, 541], ["prominent", "OBSERVATION_MODIFIER", 8, 17], ["Skin", "ANATOMY", 292, 296], ["infections", "OBSERVATION", 297, 307], ["Gastrointestinal", "ANATOMY", 366, 382], ["viral infections", "OBSERVATION", 525, 541]]], ["Examples of such diseases are TLR3, TRIF, or UNC93B1 deficiencies which predispose to HSV-1 encephalitis and epidermodysplasia verruciformis or CXCR4 deficiencies which predispose to HPV.DISCUSSIONIt is important to stress that physicians should be aware of PIDs and consider them in patients with severe or recurrent viral infections.", [["HSV-1 encephalitis", "DISEASE", 86, 104], ["epidermodysplasia verruciformis", "DISEASE", 109, 140], ["PIDs", "DISEASE", 258, 262], ["viral infections", "DISEASE", 318, 334], ["TLR3", "GENE_OR_GENE_PRODUCT", 30, 34], ["TRIF", "GENE_OR_GENE_PRODUCT", 36, 40], ["UNC93B1", "GENE_OR_GENE_PRODUCT", 45, 52], ["HSV-1 encephalitis", "ORGANISM", 86, 104], ["epidermodysplasia verruciformis", "ORGANISM", 109, 140], ["CXCR4", "GENE_OR_GENE_PRODUCT", 144, 149], ["HPV", "ORGANISM", 183, 186], ["PIDs", "CANCER", 258, 262], ["patients", "ORGANISM", 284, 292], ["TLR3", "PROTEIN", 30, 34], ["TRIF", "PROTEIN", 36, 40], ["UNC93B1", "PROTEIN", 45, 52], ["CXCR4", "PROTEIN", 144, 149], ["HSV-1", "SPECIES", 86, 91], ["patients", "SPECIES", 284, 292], ["HSV-1", "SPECIES", 86, 91], ["epidermodysplasia verruciformis", "SPECIES", 109, 140], ["HPV", "SPECIES", 183, 186], ["such diseases", "PROBLEM", 12, 25], ["TLR3", "PROBLEM", 30, 34], ["TRIF", "PROBLEM", 36, 40], ["UNC93B1 deficiencies", "PROBLEM", 45, 65], ["HSV", "PROBLEM", 86, 89], ["1 encephalitis", "PROBLEM", 90, 104], ["epidermodysplasia verruciformis", "PROBLEM", 109, 140], ["CXCR4 deficiencies", "PROBLEM", 144, 162], ["HPV", "PROBLEM", 183, 186], ["PIDs", "PROBLEM", 258, 262], ["recurrent viral infections", "PROBLEM", 308, 334], ["encephalitis", "OBSERVATION", 92, 104], ["epidermodysplasia", "OBSERVATION", 109, 126], ["CXCR4 deficiencies", "OBSERVATION", 144, 162], ["recurrent", "OBSERVATION_MODIFIER", 308, 317], ["viral", "OBSERVATION_MODIFIER", 318, 323], ["infections", "OBSERVATION", 324, 334]]], ["Importantly, they should be aware that many PIDs result in poor antibody response, hence serologic testing should be avoided while testing a patient for infectious complications and antigenic detection method should be used instead.", [["PIDs", "CANCER", 44, 48], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["many PIDs", "PROBLEM", 39, 48], ["poor antibody response", "PROBLEM", 59, 81], ["serologic testing", "TEST", 89, 106], ["infectious complications", "PROBLEM", 153, 177], ["antigenic detection method", "TREATMENT", 182, 208]]], ["Health care providers should also be aware of the recommendations for live viral vaccines in immunodeficient patients and their close contacts (17) .", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["live viral vaccines", "TREATMENT", 70, 89]]], ["Live vaccines, such as the chicken pox, measles, mumps, rubella (MMR), rotavirus, yellow fever, oral polio, and the influenza nasal spray should be avoided in certain types of PIDs.", [["oral", "ANATOMY", 96, 100], ["nasal", "ANATOMY", 126, 131], ["measles, mumps, rubella (MMR)", "DISEASE", 40, 69], ["rotavirus", "DISEASE", 71, 80], ["yellow fever", "DISEASE", 82, 94], ["oral polio", "DISEASE", 96, 106], ["PIDs", "DISEASE", 176, 180], ["chicken", "ORGANISM", 27, 34], ["pox", "ORGANISM", 35, 38], ["measles", "ORGANISM", 40, 47], ["mumps", "ORGANISM", 49, 54], ["rubella", "ORGANISM", 56, 63], ["rotavirus", "ORGANISM", 71, 80], ["yellow fever", "ORGANISM", 82, 94], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["polio", "ORGANISM", 101, 106], ["PIDs", "CANCER", 176, 180], ["chicken", "SPECIES", 27, 34], ["pox", "SPECIES", 35, 38], ["rotavirus", "SPECIES", 71, 80], ["yellow fever", "SPECIES", 82, 94], ["chicken pox", "SPECIES", 27, 38], ["Live vaccines", "TREATMENT", 0, 13], ["the chicken pox", "PROBLEM", 23, 38], ["measles", "PROBLEM", 40, 47], ["mumps", "PROBLEM", 49, 54], ["rubella", "PROBLEM", 56, 63], ["rotavirus", "PROBLEM", 71, 80], ["yellow fever", "PROBLEM", 82, 94], ["oral polio", "PROBLEM", 96, 106], ["the influenza nasal spray", "TREATMENT", 112, 137], ["PIDs", "PROBLEM", 176, 180]]], ["Furthermore, any infants born into a family with a suspicious history of PID should avoid all live viral and bacterial vaccines until PIDs is ruled out.DISCUSSIONHistorically, oral polio vaccine (OPV) was the only form used in the vaccination schedule in Kuwait.", [["oral", "ANATOMY", 176, 180], ["PID", "DISEASE", 73, 76], ["PIDs", "DISEASE", 134, 138], ["infants", "ORGANISM", 17, 24], ["oral polio", "ORGANISM", 176, 186], ["infants", "SPECIES", 17, 24], ["OPV", "SPECIES", 196, 199], ["PID", "PROBLEM", 73, 76], ["all live viral", "TREATMENT", 90, 104], ["bacterial vaccines", "TREATMENT", 109, 127], ["PIDs", "PROBLEM", 134, 138], ["oral polio vaccine (OPV", "TREATMENT", 176, 199]]], ["Since 2008 the first dose of OPV given at the age of 2 months was replaced with the inactivated formulation.", [["OPV", "CHEMICAL", 29, 32], ["OPV", "CHEMICAL", 29, 32], ["OPV", "TREATMENT", 29, 32], ["the inactivated formulation", "TREATMENT", 80, 107]]], ["Fortunately, only 1 patient from our cohort who was diagnosed with RAG1 deficiency developed OPV related complication (i.e., myocarditis).", [["RAG1 deficiency", "DISEASE", 67, 82], ["OPV", "DISEASE", 93, 96], ["myocarditis", "DISEASE", 125, 136], ["patient", "ORGANISM", 20, 27], ["RAG1", "GENE_OR_GENE_PRODUCT", 67, 71], ["RAG1", "PROTEIN", 67, 71], ["patient", "SPECIES", 20, 27], ["RAG1 deficiency", "PROBLEM", 67, 82], ["OPV related complication", "PROBLEM", 93, 117], ["myocarditis", "PROBLEM", 125, 136], ["RAG1 deficiency", "OBSERVATION", 67, 82], ["complication", "OBSERVATION", 105, 117], ["myocarditis", "OBSERVATION", 125, 136]]], ["Two more patients with CID had prolonged excretion of poliovirus type 1 in the stool.", [["stool", "ANATOMY", 79, 84], ["CID", "DISEASE", 23, 26], ["patients", "ORGANISM", 9, 17], ["poliovirus type 1", "GENE_OR_GENE_PRODUCT", 54, 71], ["stool", "ORGANISM_SUBSTANCE", 79, 84], ["patients", "SPECIES", 9, 17], ["poliovirus type 1", "SPECIES", 54, 71], ["poliovirus type 1", "PROBLEM", 54, 71], ["poliovirus type", "OBSERVATION", 54, 69], ["stool", "ANATOMY", 79, 84]]], ["Unfortunately, stool surveillance program of PID patients for vaccine derived polio virus is not available in the country.DISCUSSIONThe present study has some limitations since we did not determine the true burden of viral infections in PIDs.", [["PID", "DISEASE", 45, 48], ["polio virus", "DISEASE", 78, 89], ["viral infections", "DISEASE", 217, 233], ["PIDs", "DISEASE", 237, 241], ["patients", "ORGANISM", 49, 57], ["vaccine derived polio virus", "ORGANISM", 62, 89], ["PIDs", "PATHOLOGICAL_FORMATION", 237, 241], ["patients", "SPECIES", 49, 57], ["polio virus", "SPECIES", 78, 89], ["PID patients", "TREATMENT", 45, 57], ["vaccine derived polio virus", "TREATMENT", 62, 89], ["The present study", "TEST", 132, 149], ["viral infections in PIDs", "PROBLEM", 217, 241], ["viral", "OBSERVATION_MODIFIER", 217, 222], ["infections", "OBSERVATION", 223, 233]]], ["This could be established by documenting the number of admissions to the intensive care unit and the type of care provided like mechanical ventilation and the use of inotropes during these admissions.", [["mechanical ventilation", "TREATMENT", 128, 150], ["inotropes", "TREATMENT", 166, 175], ["mechanical ventilation", "OBSERVATION", 128, 150]]], ["Other important variables that can be considered are the number of viral infection reactivations, the number of admissions to the hospital, the length of stay, and duration of using antiviral treatments.", [["infection", "DISEASE", 73, 82], ["viral infection reactivations", "PROBLEM", 67, 96], ["antiviral treatments", "TREATMENT", 182, 202], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infection", "OBSERVATION", 73, 82]]], ["However, an important strength of the study is that the patients were followed prospectively by the same clinical immunologist.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["the study", "TEST", 34, 43]]], ["Another important strength of the study is that most patients were diagnosed at the molecular level.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["the study", "TEST", 30, 39]]], ["Yet, collaborative efforts will be needed to collect a bigger number of patients.DISCUSSIONViral infections in PIDs should be treated aggressively with appropriate antiviral medications and definitive treatments like HSCT when possible since failure to eradicate viral pathogens creates an inflammatory environment that promotes cell survival and proliferation and may predispose to malignancy (18) .", [["cell", "ANATOMY", 329, 333], ["infections", "DISEASE", 97, 107], ["PIDs", "DISEASE", 111, 115], ["malignancy", "DISEASE", 383, 393], ["patients", "ORGANISM", 72, 80], ["PIDs", "CANCER", 111, 115], ["cell", "CELL", 329, 333], ["patients", "SPECIES", 72, 80], ["DISCUSSIONViral infections in PIDs", "PROBLEM", 81, 115], ["appropriate antiviral medications", "TREATMENT", 152, 185], ["definitive treatments", "TREATMENT", 190, 211], ["HSCT", "TREATMENT", 217, 221], ["failure to eradicate viral pathogens", "PROBLEM", 242, 278], ["an inflammatory environment", "PROBLEM", 287, 314], ["proliferation", "PROBLEM", 347, 360], ["malignancy", "PROBLEM", 383, 393], ["infections", "OBSERVATION", 97, 107], ["inflammatory", "OBSERVATION_MODIFIER", 290, 302], ["cell survival", "OBSERVATION", 329, 342], ["may predispose to", "UNCERTAINTY", 365, 382], ["malignancy", "OBSERVATION", 383, 393]]], ["Innovative treatments like virus-specific T cells should be explored to improve clinical outcomes for this group of patients (19) .DATA AVAILABILITYAll datasets generated for this study are included in the manuscript and/or the supplementary files.ETHICS STATEMENTThe data was obtained from the Kuwait National Primary Immunodeficiency Disorders Registry (KNPIDR) which was approved by The Research and Ethics Committee of the Ministry of Health in Kuwait and the Kuwait University Health Sciences Center Ethical Committee in accordance with the Declaration of Helsinki.AUTHOR CONTRIBUTIONSWA-H: development of the research concept and goals, design of methodology, data collection and analysis, writing the initial manuscript draft, approval of the submitted manuscript, and agreement to be accountable for the content of the work.", [["T cells", "ANATOMY", 42, 49], ["Primary Immunodeficiency Disorders", "DISEASE", 311, 345], ["T cells", "CELL", 42, 49], ["patients", "ORGANISM", 116, 124], ["T cells", "CELL_TYPE", 42, 49], ["patients", "SPECIES", 116, 124], ["Innovative treatments", "TREATMENT", 0, 21], ["virus", "PROBLEM", 27, 32], ["specific T cells", "TREATMENT", 33, 49], ["this study", "TEST", 175, 185], ["data collection", "TEST", 666, 681], ["analysis", "TEST", 686, 694]]], ["SE: contributed to the research idea, writing of the manuscript and approval of the submitted manuscript and agreement to be accountable for the content of the work.FUNDINGKNPIDR was funded by Kuwait Foundation for the Advancement of Sciences.", [["SE", "DISEASE", 0, 2]]]], "PMC7107947": [["Notably, destinations include many low- and middle-income plus a few high-income countries.", [["middle", "ANATOMY_MODIFIER", 44, 50]]], ["Patients often seek treatment in their World Health Organization (WHO) region of residence, but the diaspora population may combine medical treatment with family visits [8].", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["treatment", "TREATMENT", 20, 29]]], ["Seventy percent of patients going to Singapore and Malaysia are from countries in the Association of Southeast Asian Nations; those going to Cuba are mainly from the Caribbean and Central America, and those going to Jordan are mostly from Middle Eastern countries [8].", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["Central", "ANATOMY_MODIFIER", 180, 187]]], ["The main constraint on medical tourism is the challenge of insurance portability.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["constraint", "OBSERVATION_MODIFIER", 9, 19]]], ["Meanwhile, lower costs of services, including labor, provide developing countries a substantial cost advantage [8].MAGNITUDE/OVERALL VOLUMEComplete and accurate data on medical tourism volume, destinations, services, and procedures are unavailable.", [["labor", "PROBLEM", 46, 51], ["a substantial cost advantage", "TREATMENT", 82, 110]]], ["One source estimated 4 million international patients annually [8].", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Thailand attracted 1.28 million international patients in 2005, [9] with India, Singapore, and Malaysia each approaching this number by 2012 [8].", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["Singapore has launched an initiative to develop new areas, such as stem cell treatment and transplant.", [["stem cell", "ANATOMY", 67, 76], ["stem cell", "CELL", 67, 76], ["new areas", "PROBLEM", 48, 57], ["stem cell treatment", "TREATMENT", 67, 86], ["transplant", "TREATMENT", 91, 101], ["new", "OBSERVATION_MODIFIER", 48, 51], ["areas", "OBSERVATION", 52, 57], ["stem cell treatment", "OBSERVATION", 67, 86]]], ["In 2005, an estimated 55 000 Americans received care at Bumrungrad Hospital (Bangkok), a hospital that currently estimates treating 420 000 international patients annually [13].REASONS FOR SEEKING CARE ABROAD AND PROBLEMS ASSOCIATED WITH MEDICAL TOURISMAmong the motivations for medical tourism (Table 1) are lower cost, avoidance of long waits, legal or cultural restrictions at home, privacy and opportunity to recover away from home, incentives offered by employers or insurers, and interest in combining an exotic vacation with a medical procedure [1, 2, 7, 14].", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["a medical procedure", "TREATMENT", 532, 551]]], ["Common procedures include dental work; arthroplasty; cataract, bariatric, cosmetic, and cardiac surgery; reproductive care; and tissue and organ transplant.", [["cardiac", "ANATOMY", 88, 95], ["tissue", "ANATOMY", 128, 134], ["organ", "ANATOMY", 139, 144], ["cataract", "DISEASE", 53, 61], ["tissue", "TISSUE", 128, 134], ["organ", "ORGAN", 139, 144], ["Common procedures", "TREATMENT", 0, 17], ["dental work", "TREATMENT", 26, 37], ["arthroplasty", "TREATMENT", 39, 51], ["cataract", "PROBLEM", 53, 61], ["bariatric, cosmetic", "TREATMENT", 63, 82], ["cardiac surgery", "TREATMENT", 88, 103], ["reproductive care", "TREATMENT", 105, 122], ["tissue and organ transplant", "TREATMENT", 128, 155], ["arthroplasty", "OBSERVATION", 39, 51], ["cataract", "OBSERVATION", 53, 61], ["cardiac", "ANATOMY", 88, 95], ["surgery", "OBSERVATION", 96, 103], ["organ", "ANATOMY", 139, 144], ["transplant", "OBSERVATION", 145, 155]]], ["More than 40% of unrelated stem cell transplants worldwide involve donors from a different country [15].", [["stem cell", "ANATOMY", 27, 36], ["stem cell", "CELL", 27, 36], ["donors", "ORGANISM", 67, 73], ["unrelated stem cell transplants", "TREATMENT", 17, 48], ["stem cell transplants", "OBSERVATION", 27, 48]]], ["Vast cost differences exist: a hip replacement may cost $7000\u2013$12 000 (India) or $6500\u2013$14 000 (Thailand) versus $43 000\u2013100 000 (United States) [12].", [["hip", "ORGANISM_SUBDIVISION", 31, 34], ["a hip replacement", "TREATMENT", 29, 46], ["hip", "ANATOMY", 31, 34]]], ["Medical tourism is sufficiently common that the Centers for Disease Control and Prevention and professional societies have developed patient guidelines (Table 2).", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["Disease Control", "TREATMENT", 60, 75]]]], "81e0cb0e2997c47f583f9fdb8b7d62b14e7d3b31": [["Biodegradable organic carbon 463 Biodegradation 351, 405, 499, 793, 971, 1110 , 2801 , 2927 , 2999 , 5151 Biodegradation kinetics 3838, 5151 Biofi lm control 229, 417, 433, 933, 1775 , 2549 , 4461, 4780, 5005, 5252 Biofi lm development 2699 , 4461, 4780, 5005 Biofi lm formation 3469, 4461, 4780, 5005 Biofi lm matrix 63, 117, 417, 433, 933, 1775 , 2549 , 1993 , 2169 , 3902, 4381 Degradation pathway 441, 573, 1303 , 1993 , 2169 , 3902, 4381 Degradation products 733, 1303 , 1993 , 2169 , 2865 1237 , 4676 Disinfection 47, 463, 481, 643, 1370 , 2233 , 3037, 3559, 5225 Disinfection by-products 463, 481, 643, 1370 , 1541 , 2057 , 2201 , 2233 , 3009, 3037, 3057, 3453, 3559, 4177, 4698, 5225 Disinfection byproduct (DBP) 2750 , 3037, 3559, 5225 Disinfection byproduct 971, 1370 , 1597 , 2233 , 3037, 3559, 5225 Disinfection byproducts 2093 , 2233 , 3037, 3047, 3559, 5225 Disinfection model 2916 117, 211, 583, 643, 2011 , 2093 , 2317 , 2647 , 2829 , 4698, 4707, 5005, 5119 Drinking water biofi lm 3375, 4698, 4707, 5005, 5119 Drinking water production 182, 211, 583, 643, 2011 , 2093 , 2317 , 2647 , 2829 , 4698, 4707, 5005, 5119 Drinking water quality 989, 2011 , 2093 , 2317 , 2647 , 2829 , 4698, 4707, 5005, 5119 Drinking water research priorities 3453, 4698, 4707, 5005, 5119 Drinking water safety 2057 , 2093 , 2317 , 2647 , 2829 , 3227, 4698, 4707, 5005, 5119 Drinking water system 1641 , 2011 , 2093 , 2317 , 2647 , 2829 , 4698, 4707, 5005, 5119 Drinking water treatment 331, 395, 583, 643, 2011 , 2093 , 2317 , 2647 , 2829 635, 895, 1831 635, 895, , 1968 635, 895, , 3992, 4347 Hydroxyl radicals 1005 635, 895, , 1766 635, 895, , 1831 635, 895, , 1924 635, 895, , 1968 NF 583 Nickel 853, 1935 Nicotine 4187 Nitrate 47, 173, 1159 , 3047, 4225, 4430, 4652 Nitrate effects 4507, 4652 Nitric oxide 4093 Nitrifi cation 77, 182, 535, 822, 1265 , 1403 , 1680 , 1879 , 2363 , 2449 , 2623 , 3301, 3622, 4093, 4149, 5097, 5129 Nitritation 563, 2699 Nitrite 546, 1680 , 1993 , 3047 Nitrite oxidation 1680 , 1993 , 784, 1448 , 1471 , 3838, 4441, 4707 PFGE 1441 PFOA 1150 , 2399 , 2811 , 4760 PFOS 1150 , 2399 , 4760 pH 490, 2431 , 2549 Pharmaceutical compounds 3751, 3992 Pharmaceutical wastewater 4010 Pharmaceutically active compounds 613, 3992 Pharmaceuticals 351, 831, 903, 951, 1005 , 1513 , 1766 , 2349 , 2493 , 3407, 3849, 3922, 3992, 4707 Pharmaceuticals 363, 831, 903, 951, 1005 , 1513 , 1766 , 2349 , 2493 , 4707 Pharmaceuticals and personal care products (PPCPs) 4019, 4707 Pharmaceuticals removal 3270, 3407, 3849, 3922, 3992, 4707 Phenol degradation 1295 , 1303 , 1313 , 4063 Phenol removal 313, 1303 , 4063 Phenyl-ureas 267 Phenylureas 1471 Phosphate 1088 , 2907 , 3891, 4421 Phosphorus 277, 773, 1654 , 1667 , 1740 , 2739 , 4207, 4316 Phosphorus and nitrogen removal 3743, 4207, 4316 Phosphorus balance 1788 , 2739 , 4207, 4316 Phosphorus recovery 1887 , 2739 , 3493, 4207, 4316 Photo catalysis 3932 Photo-Fenton 441, 653, 661, 784, 3922, 3984, 4050, 4441 Photo-Fenton oxidation 2471 , 3922, 3984, 4050, 4441 Photo-Fenton reaction 1313 , 3922, 3984, 4050, 4441 Photocatalysis 47, 979, 1513 , 1597", [["organic carbon", "CHEMICAL", 14, 28], ["Hydroxyl", "CHEMICAL", 1587, 1595], ["Nicotine", "CHEMICAL", 1702, 1710], ["Nitrate", "CHEMICAL", 1716, 1723], ["Nitrate", "CHEMICAL", 1763, 1770], ["Nitric oxide", "CHEMICAL", 1790, 1802], ["Nitrifi cation", "CHEMICAL", 1808, 1822], ["Nitrite", "CHEMICAL", 1948, 1955], ["Nitrite", "CHEMICAL", 1980, 1987], ["PFOA", "CHEMICAL", 2058, 2062], ["PFOS", "CHEMICAL", 2089, 2093], ["Phenol", "CHEMICAL", 2541, 2547], ["Phenol", "CHEMICAL", 2586, 2592], ["Phenyl-ureas", "CHEMICAL", 2618, 2630], ["2739 , 4207, 4316 Phosphorus", "CHEMICAL", 2729, 2757], ["carbon", "CHEMICAL", 22, 28], ["Hydroxyl", "CHEMICAL", 1587, 1595], ["Nicotine", "CHEMICAL", 1702, 1710], ["Nitrate", "CHEMICAL", 1716, 1723], ["Nitrate", "CHEMICAL", 1763, 1770], ["Nitric oxide", "CHEMICAL", 1790, 1802], ["Nitrite", "CHEMICAL", 1948, 1955], ["Nitrite", "CHEMICAL", 1980, 1987], ["PFOA", "CHEMICAL", 2058, 2062], ["PFOS", "CHEMICAL", 2089, 2093], ["Phenol", "CHEMICAL", 2541, 2547], ["Phenol", "CHEMICAL", 2586, 2592], ["Phenyl-ureas", "CHEMICAL", 2618, 2630], ["Phenylureas", "CHEMICAL", 2635, 2646], ["Phosphate", "CHEMICAL", 2652, 2661], ["Phosphorus", "CHEMICAL", 2687, 2697], ["Phosphorus", "CHEMICAL", 2747, 2757], ["nitrogen", "CHEMICAL", 2762, 2770], ["Phosphorus", "CHEMICAL", 2796, 2806], ["Phosphorus", "CHEMICAL", 2840, 2850], ["Nitrate", "SIMPLE_CHEMICAL", 1763, 1770], ["Nitric oxide", "SIMPLE_CHEMICAL", 1790, 1802], ["Nitrite", "SIMPLE_CHEMICAL", 1980, 1987], ["Phenyl-ureas", "SIMPLE_CHEMICAL", 2618, 2630], ["Biodegradation kinetics", "TEST", 106, 129], ["Degradation products", "TEST", 443, 463], ["Disinfection", "TEST", 507, 519], ["Disinfection by-products", "TEST", 570, 594], ["Disinfection byproduct", "TEST", 692, 714], ["DBP", "TEST", 716, 719], ["Disinfection byproduct", "TEST", 745, 767], ["Disinfection byproducts", "TEST", 811, 834], ["Disinfection model", "TEST", 872, 890], ["Hydroxyl radicals", "TEST", 1587, 1604], ["Nicotine", "TEST", 1702, 1710], ["Nitrate effects", "TEST", 1763, 1778], ["Nitric oxide", "TEST", 1790, 1802], ["Nitrifi cation", "TEST", 1808, 1822], ["Nitritation", "TEST", 1926, 1937], ["Nitrite", "TEST", 1948, 1955], ["Nitrite oxidation", "TEST", 1980, 1997], ["PFGE", "TEST", 2048, 2052], ["PFOA", "TEST", 2058, 2062], ["PFOS", "TEST", 2089, 2093], ["pH", "TEST", 2113, 2115], ["Pharmaceutical compounds", "TEST", 2133, 2157], ["Pharmaceutical wastewater", "TEST", 2169, 2194], ["Pharmaceuticals", "TEST", 2244, 2259], ["Pharmaceuticals", "TEST", 2344, 2359], ["Pharmaceuticals removal", "TREATMENT", 2482, 2505], ["Phenol degradation", "TEST", 2541, 2559], ["Phenol removal", "TEST", 2586, 2600], ["Phenyl-ureas", "TEST", 2618, 2630], ["Phenylureas", "TEST", 2635, 2646], ["Phosphate", "TEST", 2652, 2661], ["Phosphorus", "TEST", 2687, 2697], ["Phosphorus", "TEST", 2747, 2757], ["nitrogen removal", "TEST", 2762, 2778], ["Phosphorus balance", "TEST", 2796, 2814], ["Phosphorus recovery", "TEST", 2840, 2859], ["Photo catalysis", "TEST", 2891, 2906], ["Fenton oxidation", "TEST", 2974, 2990]]]], "1f6281398667f0f9e2695ed85e88d261b0c775c1": [["DiscussionSince the beginning of 2020, an increasing number of works related to the COVID-19 disease and the SARS-CoV-2 coronavirus have been published.", [["SARS-CoV-2 coronavirus", "DISEASE", 109, 131], ["SARS-CoV-2 coronavirus", "ORGANISM", 109, 131], ["CoV-2 coronavirus", "SPECIES", 114, 131], ["SARS-CoV-2 coronavirus", "SPECIES", 109, 131], ["the COVID-19 disease", "PROBLEM", 80, 100], ["the SARS", "TEST", 105, 113], ["coronavirus", "PROBLEM", 120, 131]]], ["Some of them are papers covering different aspects referred to the virus and the disease in relation to environmental compartments and environmental parameters.DiscussionIn a previous paper, N\u00fa\u00f1ez-Delgado (2020) commented on SARS-CoV-2 and the environment, but at this moment many other relevant works have been published focusing on certain environmental and public health aspects such as:Discussion(A) Detection and quantification of SARS-CoV-2 in water (mainly in wastewater), and its potential use as early warning, to report on the situation of current and eventual future outbreaks, most of these works taking into account precepts of the so called \"wastewater based epidemiology\" (WBE).", [["SARS", "DISEASE", 436, 440], ["water", "SIMPLE_CHEMICAL", 450, 455], ["SARS-CoV", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 436, 444], ["the virus", "PROBLEM", 63, 72], ["the disease", "PROBLEM", 77, 88], ["SARS", "PROBLEM", 436, 440], ["disease", "OBSERVATION", 81, 88]]], ["Some papers in this category are those by Bofill-Mas and Rusi\u00f1ol (2020), Bowser (2020), Daughton (2020) , Farkas et al. (2020) , Mao et al. (2020) , Nabi et al. (2020) , Orive et al. (2020) , Race et al. (2020) , Sims et al. (2020), and Venugopal et al. (2020) .Discussion(B) Relations among atmospheric variables (mostly those informing on weather condition) and incidence/evolution of COVID-19, with special relevance for studies focusing on suspended particulate matter and overall pollution in the atmosphere (for example, Bahir et al., 2020; Bontempi, 2020; Chauhan and Singh, 2020; Domingo and Rovira, 2020; Holtmann et al., 2020; Setti et al., 2020; Zhu et al., 2020) .DiscussionHowever, regarding sewage sludge in relation to SARS-CoV-2, as per the scientific searching tools web of science (WOS) and Scopus (SP), few peer-reviewed papers have been published up to now (specifically, WOS found 2, and SP found 1, at date July 4, 2020).", [["SARS", "DISEASE", 734, 738], ["SARS-CoV", "SPECIES", 734, 742], ["COVID", "TEST", 387, 392], ["studies", "TEST", 424, 431], ["sewage sludge", "PROBLEM", 705, 718], ["SARS", "PROBLEM", 734, 738], ["sludge", "OBSERVATION", 712, 718]]], ["When carrying out the search in Google Scholar (GS) using the same searching string as in WOS and SP (\"SARS-Cov-2 AND sewage-sludge\"), a total of 49 results is shown, including various papers presented in repositories but not yet peer-reviewed.", [["SARS", "DISEASE", 103, 107], ["Cov", "TEST", 108, 111]]], ["In addition, some of these papers do not really have a clear relation with environmental aspects, or even do not really fit simultaneously with the SARS-CoV-2 virus and sewage sludge, which is due to limitations of searching tools.DiscussionFor soil, the numbers resulting from an equivalent search with the same tools are higher (15 on WOS, 3 on SP, and 851 on GS) but most of the papers are not really related to environmental aspects of soils and this virus.", [["SARS", "DISEASE", 148, 152], ["SARS-CoV-2 virus", "ORGANISM", 148, 164], ["SARS-CoV-2 virus", "SPECIES", 148, 164], ["the SARS", "TEST", 144, 152], ["CoV", "TEST", 153, 156], ["virus", "PROBLEM", 159, 164], ["sewage sludge", "PROBLEM", 169, 182], ["searching tools", "PROBLEM", 215, 230], ["this virus", "PROBLEM", 450, 460], ["sludge", "OBSERVATION", 176, 182]]], ["Refining the search string to \"SARS-Cov-2-detection AND soil\", no results are found by WOS and by SP, and 16 results are provided by GS, most of them being manuscript not peer-reviewed at that moment, and they are not really related to the detection of the SARS-CoV-2 virus in soils.DiscussionBut, in fact, would it really needed to study soils in relation to SARS-CoV-2?DiscussionTo have an answer, some aspects should be taken into consideration:DiscussionIn certain cases, wastewater may be directly applied on soils.", [["SARS", "DISEASE", 31, 35], ["SARS", "DISEASE", 257, 261], ["SARS", "DISEASE", 360, 364], ["SARS-CoV-2 virus", "ORGANISM", 257, 273], ["SARS-CoV-2 virus", "SPECIES", 257, 273], ["SARS-CoV", "SPECIES", 360, 368], ["the SARS", "PROBLEM", 253, 261], ["CoV", "PROBLEM", 262, 265], ["SARS", "TEST", 360, 364], ["CoV", "TEST", 365, 368]]], ["This could be treated wastewater that is recycled for irrigation purposes, or could be raw wastewater, more probably in areas where wastewater treatment facilities are scarce or absent, and where that water is really needed for irrigating/feeding crops, or where water streams are not near, promoting a direct spreading on soils.", [["irrigation purposes", "TREATMENT", 54, 73], ["irrigating/feeding crops", "TREATMENT", 228, 252]]], ["In these situations, not only soils, but also plants, may receive the application of wastewater, and in certain cases some of these plants may be exposed to grazing by cattle and/or wild fauna.", [["cattle", "ORGANISM", 168, 174], ["cattle", "SPECIES", 168, 174], ["cattle", "SPECIES", 168, 174], ["the application of wastewater", "TREATMENT", 66, 95], ["soils", "OBSERVATION", 30, 35]]], ["In the medium term, some crops can become food for humans, although at that time virus most probably would be deactivated and not infective.", [["humans", "ORGANISM", 51, 57], ["humans", "SPECIES", 51, 57], ["humans", "SPECIES", 51, 57], ["infective", "PROBLEM", 130, 139], ["medium term", "OBSERVATION_MODIFIER", 7, 18], ["infective", "OBSERVATION", 130, 139]]], ["To be noted that the survival of various coronavirus E-mail address: avelino.nunez@usc.es. has been shown to be variable in raw wastewaters, in a range going from few days to various weeks, depending on temperature (with more extended survival at low temperature), and other factors, while in treated wastewater is mostly dependent on the fact of suffering an effective tertiary treatment with disinfectants.DiscussionJust for comparison, dealing with diluted feces spread as slurry fertilizer, and just counting fecal bacteria (not viruses) N\u00fa\u00f1ez-Delgado et al. (2002) detected a prolonged persistence of viable fecal microorganisms in runoff samples generated in a pastureland.", [["feces", "ANATOMY", 460, 465], ["runoff samples", "ANATOMY", 637, 651], ["coronavirus", "ORGANISM", 41, 52], ["feces", "ORGANISM_SUBSTANCE", 460, 465], ["an effective tertiary treatment", "TREATMENT", 357, 388], ["disinfectants", "TREATMENT", 394, 407], ["diluted feces", "PROBLEM", 452, 465], ["slurry fertilizer", "TREATMENT", 476, 493], ["fecal bacteria", "PROBLEM", 513, 527], ["viable fecal microorganisms", "PROBLEM", 606, 633], ["variable", "OBSERVATION_MODIFIER", 112, 120], ["mostly dependent", "OBSERVATION_MODIFIER", 315, 331], ["viable", "OBSERVATION_MODIFIER", 606, 612], ["fecal microorganisms", "OBSERVATION", 613, 633]]], ["Also, fecal bacteria remained viable in leachates after passing through 70 cm of soil in column experiments (N\u00fa\u00f1ez-Delgado et al., 1996) and through up to 90 cm of soil in field experiments .DiscussionIn addition, sewage sludge is a waste material very usually recycled as organic amendment on crop soils (and sometimes on forest soils).", [["fecal bacteria", "PROBLEM", 6, 20], ["soil in column experiments", "TREATMENT", 81, 107], ["sewage sludge", "PROBLEM", 214, 227], ["a waste material", "PROBLEM", 231, 247], ["fecal", "ANATOMY", 6, 11], ["bacteria", "OBSERVATION", 12, 20], ["viable", "OBSERVATION_MODIFIER", 30, 36], ["leachates", "OBSERVATION", 40, 49], ["70 cm", "OBSERVATION_MODIFIER", 72, 77], ["sludge", "OBSERVATION", 221, 227]]], ["Once again just for comparison, Pousada-Ferrad\u00e1s et al. (2012) quantified fecal bacteria in leachates generated from treated sludge in laboratory columns, finding viable bacteria 4 weeks after the start of the experiment, as previously found in solid samples of treated sludge (Pousada-Ferrad\u00e1s et al., 2011) .", [["solid samples", "ANATOMY", 245, 258], ["Pousada", "TEST", 32, 39], ["fecal bacteria in leachates", "PROBLEM", 74, 101], ["treated sludge in laboratory columns", "PROBLEM", 117, 153], ["viable bacteria", "PROBLEM", 163, 178], ["treated sludge", "PROBLEM", 262, 276], ["fecal", "ANATOMY", 74, 79], ["bacteria", "OBSERVATION", 80, 88], ["sludge", "OBSERVATION", 125, 131], ["viable", "OBSERVATION_MODIFIER", 163, 169], ["bacteria", "OBSERVATION", 170, 178], ["sludge", "OBSERVATION", 270, 276]]], ["Focusing on viruses in sewage sludge, some selected references are the papers by Nag et al. (2020) and by Mart\u00ednez-Puchol et al. (2020) .DiscussionSpecifically for viruses in soils, there are also several papers that can be considered a reference, such as those by Kimura et al. (2008) , Williamson et al. (2017) , or Kuzyakov and Mason-Jones (2018) .", [["viruses", "PROBLEM", 164, 171], ["sewage sludge", "OBSERVATION", 23, 36]]], ["And there are even some of them focusing on epidemic viruses, such as that by Guti\u00e9rrez and Buchy (2012) .DiscussionEven if to date no peer-reviewed published papers have focused on SARS-CoV-2 in soils, the procedures that are being considered for eventual future use on samples of sewage sludge (or other more specific), could be used on soil samples in the coming future.", [["SARS", "DISEASE", 182, 186], ["SARS-CoV-2", "ORGANISM", 182, 192], ["epidemic viruses", "PROBLEM", 44, 60], ["the procedures", "TREATMENT", 203, 217], ["sewage sludge", "PROBLEM", 282, 295]]], ["In fact, previous papers have already studied other viruses in sewage sludge (Bibby and Peccia, 2013) .", [["viruses", "OBSERVATION", 52, 59], ["sewage sludge", "OBSERVATION", 63, 76]]], ["As in the case of water and wastewater, these eventual procedures and techniques would have to report on the presence of the virus, its quantification, and/or its infectivity.", [["water", "SIMPLE_CHEMICAL", 18, 23], ["these eventual procedures", "TREATMENT", 40, 65], ["the virus", "PROBLEM", 121, 130], ["its infectivity", "PROBLEM", 159, 174], ["virus", "OBSERVATION", 125, 130]]], ["Currently, there are techniques that allow achieving these goals for different liquid and solid substrates, and it could be also possible for soil samples.", [["samples", "ANATOMY", 147, 154], ["different liquid and solid substrates", "TREATMENT", 69, 106], ["soil samples", "TEST", 142, 154]]], ["It is sure that detailed studies specific for soils could take into account many specific particularities of the edaphic environment, such as the variable distribution of a porous system constituting a certain kind of net with porous channels of a variety of sizes, subject of convective and diffusive transport for liquids containing abiotic and microscopic biotic components, as well as containing its own biome, its own \"climate\" (mainly at a certain depth, where the influence of the atmospheric weather is attenuated), and so on.DiscussionSome microclimates into soil could favor the survival of infective SARS-CoV-2?", [["SARS", "DISEASE", 611, 615], ["SARS-CoV", "SPECIES", 611, 619], ["detailed studies", "TEST", 16, 32], ["a porous system", "PROBLEM", 171, 186], ["convective and diffusive transport for liquids", "TREATMENT", 277, 323], ["abiotic and microscopic biotic components", "TREATMENT", 335, 376], ["infective SARS", "PROBLEM", 601, 615], ["CoV", "TEST", 616, 619], ["sizes", "OBSERVATION_MODIFIER", 259, 264], ["biotic components", "OBSERVATION", 359, 376], ["infective", "OBSERVATION", 601, 610]]], ["Some protozoa, fungus or other microorganisms could fight these viruses (for example, by means of some exudates)?DiscussionAll this would merit more exhaustive comments, in case of going ahead in this kind of studies.DiscussionIn addition, direct and individualized sampling of plants (for example, grasses, or different crops) growing on soils receiving wastewater and sewage sludge would be clearly interesting, and the appropriate procedures for eventual concentration and further detection/ quantification of the viruses would be applied.", [["Some protozoa", "PROBLEM", 0, 13], ["fungus", "PROBLEM", 15, 21], ["other microorganisms", "PROBLEM", 25, 45], ["these viruses", "PROBLEM", 58, 71], ["some exudates", "PROBLEM", 98, 111], ["grasses", "PROBLEM", 299, 306], ["wastewater", "TREATMENT", 355, 365], ["sewage sludge", "TREATMENT", 370, 383], ["eventual concentration", "PROBLEM", 449, 471], ["further detection", "TEST", 476, 493], ["the viruses", "PROBLEM", 513, 524], ["protozoa", "OBSERVATION", 5, 13], ["fungus", "OBSERVATION", 15, 21], ["exudates", "OBSERVATION", 103, 111], ["viruses", "OBSERVATION", 517, 524]]], ["Fig. 1 shows a pictographic illustration of the specific problems, and also of the starting points for the proposed workflow corresponding to the various aspects covered in this piece.DiscussionAs in the previous discussion piece by N\u00fa\u00f1ez-Delgado (2020) , it would be noted that it is obvious that during the peaks of a pandemic situation, most effort should be directed to fight the pandemic, assisting people affected, and searching for medical treatments to cure and/or palliate the disease.", [["people", "ORGANISM", 404, 410], ["people", "SPECIES", 404, 410], ["medical treatments", "TREATMENT", 439, 457], ["palliate the disease", "PROBLEM", 473, 493], ["disease", "OBSERVATION", 486, 493]]], ["However, in the medium and long term, thinking on eventual future outbreaks or on eventual future pandemics, many other aspects involving different environmental compartments, and the whole environment, should be considered to reach sustainable solutions.DiscussionRegarding soils and plants affected by the spreading of solid and/or liquid wastes containing SARS-CoV-2 and other pathogens with epidemic potential, future directions of the research would focus on the establishment of appropriate procedures for sampling of the materials, as well as on specific procedures for concentration, quantification and assessment of viability (and infectivity) of the pathogens in these kinds of samples.DiscussionIn addition, with a broad view, maintaining biodiversity has been signaled as an overall way of promoting protection against pandemics (Everard et al., 2020) , which otherwise, can be enunciated as \"Pandemics such as Corona are an immediate consequence of destruction of nature\" (Goymann, 2020) , or as \"There is strong evidence that ecological changes have led to increased rates of emerging and re-emerging diseases such as malaria, hantavirus lung syndrome, Nipah virus, and Ebola virus disease\" (O'Callaghan-Gordo and Ant\u00f3, 2020).DiscussionMore specifically, soil biodiversity would be an aid in protecting against microorganism that are pathogenic for humans and have the potential for causing epidemic outbreaks (Wall et al., 2015) .", [["samples", "ANATOMY", 688, 695], ["lung", "ANATOMY", 1152, 1156], ["pandemics", "DISEASE", 98, 107], ["SARS", "DISEASE", 359, 363], ["pandemics", "DISEASE", 831, 840], ["malaria", "DISEASE", 1132, 1139], ["hantavirus lung syndrome", "DISEASE", 1141, 1165], ["Nipah virus", "DISEASE", 1167, 1178], ["Ebola virus disease", "DISEASE", 1184, 1203], ["CoV-2", "ORGANISM", 364, 369], ["hantavirus", "ORGANISM", 1141, 1151], ["lung", "ORGAN", 1152, 1156], ["Nipah virus", "ORGANISM", 1167, 1178], ["Ebola virus", "ORGANISM", 1184, 1195], ["humans", "ORGANISM", 1363, 1369], ["Nipah virus", "SPECIES", 1167, 1178], ["Ebola virus", "SPECIES", 1184, 1195], ["humans", "SPECIES", 1363, 1369], ["SARS-CoV", "SPECIES", 359, 367], ["Nipah virus", "SPECIES", 1167, 1178], ["Ebola virus", "SPECIES", 1184, 1195], ["humans", "SPECIES", 1363, 1369], ["solid and/or liquid wastes", "TREATMENT", 321, 347], ["appropriate procedures", "TREATMENT", 485, 507], ["sampling of the materials", "TREATMENT", 512, 537], ["quantification", "TEST", 592, 606], ["assessment", "TEST", 611, 621], ["viability", "PROBLEM", 625, 634], ["infectivity", "PROBLEM", 640, 651], ["the pathogens", "PROBLEM", 656, 669], ["pandemics", "PROBLEM", 831, 840], ["re-emerging diseases", "PROBLEM", 1103, 1123], ["malaria", "PROBLEM", 1132, 1139], ["hantavirus lung syndrome", "PROBLEM", 1141, 1165], ["Nipah virus", "PROBLEM", 1167, 1178], ["Ebola virus disease", "PROBLEM", 1184, 1203], ["soil biodiversity", "TREATMENT", 1269, 1286], ["microorganism", "PROBLEM", 1325, 1338], ["hantavirus lung syndrome", "OBSERVATION", 1141, 1165]]], ["Soil biodiversity should be preserved (Geisen et al., 2019) , as, among other beneficial effects, it would also aid to diminish the proliferation of antibiotic-resistant bacteria, considered another heavy threat for human health now and in the coming decades.", [["human", "ORGANISM", 216, 221], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["Soil biodiversity", "TREATMENT", 0, 17], ["antibiotic", "TREATMENT", 149, 159], ["resistant bacteria", "PROBLEM", 160, 178]]]], "d1c0a03982601bfd3076e50c71cc53bc62e9cb4d": [["AbsTrACTThe COVID-19 pandemic is a reminder that insufficient income security in periods of ill health leads to economic hardship for individuals and hampers disease control efforts as people struggle to stay home when sick or advised to observe quarantine.", [["people", "ORGANISM", 185, 191], ["people", "SPECIES", 185, 191]]], ["We performed a scoping review to map the range, features, coverage, protective effects and equity of policies that aim to provide income security for adults whose ill health prevents them from participating in gainful work.", [["a scoping review", "TEST", 13, 29]]], ["Collectively the included studies demonstrate that coverage of contributory incomesecurity schemes is low, especially for informal and lowincome workers.", [["the included studies", "TEST", 13, 33]]], ["Meanwhile, non-contributory schemes targeting low-income groups are often not explicitly designed to provide income support in periods of ill health, they can be difficult to access and rarely provide sufficient income support to cover the needs of eligible recipients.", [["recipients", "ORGANISM", 258, 268], ["eligible recipients", "TREATMENT", 249, 268]]], ["While identifying an urgent need for more research on illness-related income security in LMICs, this review concludes that scaling up and diversifying the range of income security interventions is crucial for improving coverage and equity.", [["illness", "DISEASE", 54, 61], ["income security interventions", "TREATMENT", 164, 193]]], ["To achieve these outcomes, illnessrelated income protection must receive greater recognition in health policy and health financing circles, expanding our understanding of financial hardship beyond direct medical costs.InTroduCTIonThe advent of the United Nations Sustainable Development Goals (SDGs) has placed holistic, multisectoral development strategies in mainstream policy-making spaces.", [["InTroduCTIon", "CHEMICAL", 218, 230], ["illnessrelated income protection", "TREATMENT", 27, 59]]], ["3 As such, SDG 3 'Good Health and Well-being' aims to reduce a range of adverse health outcomes and the associated financial burden of them, primarily through the realisation of Universal Health Coverage (UHC).", [["Universal Health Coverage", "TREATMENT", 178, 203]]], ["1 4 5 However, while UHC has the potential to minimise impoverishment due to high out-of-pocket healthcare costs, it does not inherently protect against income loss for individuals who cannot participate in gainful work due to ill health.", [["UHC", "CHEMICAL", 21, 24], ["income loss", "DISEASE", 153, 164], ["UHC", "CANCER", 21, 24]]], ["[6] [7] [8] [9] ThisKey questionsWhat is already known? \u25ba Financial protection through reduction of out-ofpocket medical expenditures is already a prominent element of universal health coverage (UHC) within Sustainable Development Goal 3.", [["[6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 14], ["Financial protection", "TREATMENT", 58, 78], ["universal health coverage", "TREATMENT", 168, 193], ["prominent element", "OBSERVATION_MODIFIER", 147, 164]]], ["However, UHC does not include mechanisms to compensate for income loss due to ill health. \u25ba Income security during periods of ill health is severely under-researched, especially in low-income and middle-income countries (LMICs).What are the new findings?\u25ba This scoping review demonstrates that while most LMICs have policies in place for income security during periods of ill health, effective coverage is very low and existing schemes often exclude those who have the greatest need. \u25ba There are several prominent access barriers, particularly for those with short-term to medium-term illnesses who are not in the formal workforce.", [["income loss", "DISEASE", 59, 70], ["ill", "DISEASE", 78, 81], ["income loss", "PROBLEM", 59, 70], ["This scoping review", "TEST", 256, 275], ["ill health", "TREATMENT", 372, 382], ["effective coverage", "TREATMENT", 384, 402], ["very low", "PROBLEM", 406, 414], ["several", "OBSERVATION_MODIFIER", 496, 503], ["prominent", "OBSERVATION_MODIFIER", 504, 513], ["access barriers", "OBSERVATION", 514, 529]]], ["However, firm conclusions about coverage, equity and effects cannot be drawn due to the dearth of published studies on the topic.What are the new findings?What do the new findings imply?What are the new findings?\u25ba Income security during periods of ill health needs to become a more prominent part of global health research and action. \u25ba With income security contributing to better health outcomes, illness-related social protection needs to be integrated into health policies beyond UHC, allowing for a more nuanced understanding of indirect medical costs. relationship has become apparent in the current context of the COVID-19 pandemic, which has seen a staggering number of illness-related unpaid leaves of absence.", [["illness", "DISEASE", 398, 405], ["illness", "DISEASE", 677, 684], ["published studies", "TEST", 98, 115], ["illness", "PROBLEM", 398, 405], ["firm", "OBSERVATION_MODIFIER", 9, 13], ["new", "OBSERVATION_MODIFIER", 142, 145]]], ["10 Indeed, a cursory exploration of the SDGs and broader policies from WHO demonstrates a lack of analysis on income loss due to short-term and long-term illness.", [["income loss", "DISEASE", 110, 121], ["a cursory exploration", "TEST", 11, 32], ["income loss", "PROBLEM", 110, 121], ["short-term and long-term illness", "PROBLEM", 129, 161]]], ["12 As such, this study aims to refocus the attention on this topic, by consolidating the range of existing policies and practices which protect income during periods of ill health, specifically in low-income and middleincome countries (LMICs). defining income security According to the International Labour Organization (ILO) guidelines, income security denotes 'adequate income, either earned or in the form of social security and other benefits (which also) encompasses the level of income (absolute and relative to needs), assurance of receipt, and expectation of current and future income, both during working life and in old age or disability retirement'.", [["disability", "DISEASE", 637, 647], ["this study", "TEST", 12, 22]]], ["13 Expanding on this definition, the ILO highlights that income security requires a 'replacement of income which has been lost temporarily as a result of injury, disability or sickness', among other reasons.", [["injury", "DISEASE", 154, 160], ["disability", "DISEASE", 162, 172], ["sickness", "DISEASE", 176, 184], ["a 'replacement of income", "TREATMENT", 82, 106], ["injury", "PROBLEM", 154, 160], ["disability", "PROBLEM", 162, 172], ["sickness'", "PROBLEM", 176, 185], ["injury", "OBSERVATION", 154, 160]]], ["14 defining ill health While seemingly straightforward, the language surrounding income-reducing health conditions is vague and inconsistent.", [["vague", "PROBLEM", 118, 123]]], ["15 Indeed, the above definition of income security references 'injury, disability or sickness', all of which can be non-discrete and, by definition, overlap.", [["injury", "DISEASE", 63, 69], ["disability", "DISEASE", 71, 81], ["sickness", "DISEASE", 85, 93], ["'injury", "PROBLEM", 62, 69], ["disability", "PROBLEM", 71, 81], ["sickness'", "PROBLEM", 85, 94]]], ["12 15 The term 'ill health' is used in this study as an umbrella descriptor for these terms and is defined as: 'a condition of inferior health in which some disease or impairment of function is present'.", [["this study", "TEST", 39, 49], ["some disease", "PROBLEM", 152, 164], ["impairment of function", "PROBLEM", 168, 190], ["disease", "OBSERVATION", 157, 164]]], ["16 Further, periods of ill health can lead to income loss when impaired function reduces ability to participate in gainful work, or when opportunity to work is lost for other health-related reasons, such as limitations caused by infectious disease legislation 6 or when work time is lost due to healthcare utilisation.", [["income loss", "PROBLEM", 46, 57], ["impaired function", "PROBLEM", 63, 80]]], ["Therefore, within the context of this study, the term 'ill health' specifically refers to any condition, short or long term, which reduces a person's ability to participate in gainful work.", [["person", "SPECIES", 141, 147], ["this study", "TEST", 33, 43]]], ["[17] [18] [19] The health benefits of income security during periods of ill health Income loss during periods of ill health can greatly reduce an individual's resilience to health shocks.", [["Income loss", "DISEASE", 83, 94]]], ["First, income loss can reduce access to healthcare by diminishing financial capacity to cover health-related expenses.", [["diminishing financial capacity", "PROBLEM", 54, 84]]], ["[20] [21] [22] Second, income loss can increase future health vulnerability for the individual and the household by hindering a nutritionally balanced diet, 23 maintaining healthy living conditions 12 and sustaining adequate resources for household dependents (figure 1) 21 24 .", [["income loss", "DISEASE", 23, 34]]], ["While UHC can reduce these costs, it does not eliminate insecurity.", [["insecurity", "PROBLEM", 56, 66]]], ["[8] [9] [10]BMJ Global HealthIncome security has the potential to complement UHC in improving the efficacy of healthcare interventions by helping people pay for costs associated with repeat health visits, prescriptions and assistive devices.", [["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["healthcare interventions", "TREATMENT", 110, 134], ["assistive devices", "TREATMENT", 223, 240]]], ["This ensures that their condition can be treated effectively and may prevent a more severe illness from developing.", [["a more severe illness", "PROBLEM", 77, 98], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["illness", "OBSERVATION", 91, 98]]], ["25 26 It can also reduce the need to return to work when sick (presenteeism), promoting recovery, while also reducing the risk of transmitting infectious diseases.", [["infectious diseases", "DISEASE", 143, 162], ["transmitting infectious diseases", "PROBLEM", 130, 162], ["infectious", "OBSERVATION", 143, 153]]], ["6 25 Moreover, a stable income allows the maintenance of healthy living conditions, helping to maintain the social, mental and physical health of the household.", [["stable", "OBSERVATION_MODIFIER", 17, 23]]], ["Broadly, these interventions can be divided into two categories; contributory and non-contributory.Contributory schemesContributory schemes require payment as a prerequisite to receiving support, either in the form of labour hours or monetary contributions.", [["these interventions", "TREATMENT", 9, 28], ["support", "TREATMENT", 187, 194]]], ["In means-tested schemes, only recipients with a certain income are eligible.", [["recipients", "ORGANISM", 30, 40]]], ["Non-means tested schemes, on the other hand, can be accessed by anyone, regardless of income (universal schemes), and instead depend on a predetermined category, such as disability (categorical schemes).", [["disability", "DISEASE", 170, 180]]], ["29 The difference between CCTs and UCTs refers to the responsibility placed on the recipient.", [["The difference between CCTs and UCTs", "PROBLEM", 3, 39], ["the recipient", "TREATMENT", 79, 92], ["difference", "OBSERVATION_MODIFIER", 7, 17]]], ["33 CCTs offer cash payments to households with the expectation that they comply with certain requirements, such as school enrolment or health check-ups.", [["cash payments", "TREATMENT", 14, 27]]], ["[32] [33] [34] UCTs, however, do not require anything in return.", [["[32] [33] [34] UCTs", "CHEMICAL", 0, 19], ["[32] [33] [34] UCTs", "SIMPLE_CHEMICAL", 0, 19], ["34] UCTs", "TEST", 11, 19]]], ["35 Several studies have reported that the conditions associated with CCTs were impractical for people who are experiencing ill health, resulting in considerably lower enrolment rates for people with disabilities.", [["people", "ORGANISM", 95, 101], ["people", "ORGANISM", 187, 193], ["people", "SPECIES", 95, 101], ["people", "SPECIES", 187, 193], ["Several studies", "TEST", 3, 18], ["the conditions", "PROBLEM", 38, 52]]], ["36 37 As a result of these findings, CCTs were not included in this study.study purposeThis study aimed to map the range, features, coverage, protective effects and equity of formal policies in LMICs, which provide income security for adults whose ill health prevents them from participating in gainful work.", [["CCTs", "CANCER", 37, 41], ["CCTs", "TEST", 37, 41], ["this study", "TEST", 63, 73], ["study purpose", "TEST", 74, 87], ["This study", "TEST", 87, 97]]], ["How equitable are income protection schemes in LMICs, in terms of the level of coverage in different populations?MeTHodsA scoping review was conducted, which included all relevant literature on social protection and income security in LMICs.", [["MeTHodsA scoping review", "TEST", 113, 136], ["social protection", "TREATMENT", 194, 211]]], ["This method was chosen owing to the exploratory, broad and heterogeneous nature of the topic at hand.", [["hand", "ORGANISM_SUBDIVISION", 96, 100], ["This method", "TREATMENT", 0, 11], ["heterogeneous", "OBSERVATION_MODIFIER", 59, 72]]], ["39 The final design was cross referenced with the more concise Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews checklist to ensure that all reporting requirements have been met.", [["Systematic Reviews", "TEST", 93, 111]]], ["The search included all full-text sources that discussed sickness and disability-specific income security, with the exception of CCTs.", [["sickness and disability", "DISEASE", 57, 80], ["sickness", "PROBLEM", 57, 65], ["CCTs", "TEST", 129, 133]]], ["Further, the eligibility criteria specifically included articles published in English between 2009 and 2019, including grey literature.", [["the eligibility criteria", "TEST", 9, 33]]], ["Finally, the full text of each record was appraised, and ineligible records were excluded.selection of search resultsBMJ Global Health data extraction and charting of results Data from the included papers were charted into a table where the specific characteristics of each study were recorded.", [["each study", "TEST", 269, 279]]], ["These characteristics included: authorship, year of publication, study design, study location, study objectives, study population, type of intervention, name of intervention and major findings.", [["study location", "TEST", 79, 93], ["study objectives", "TEST", 95, 111], ["intervention", "TREATMENT", 139, 151], ["intervention", "TREATMENT", 161, 173]]], ["After a review of the titles, abstracts and then fulltext review, papers that met the eligibility criteria were included.Critical appraisalThis study did not employ a systematic critical appraisal of each study.", [["This study", "TEST", 139, 149], ["each study", "TEST", 200, 210]]], ["[41] [42] [43] synthesis of results Following the charting process, the data were synthesised using an inductive content analysis approach.", [["an inductive content analysis approach", "TREATMENT", 100, 138]]], ["This involved an appraisal of each study's main findings to then stratify into a series of themes and subthemes (see online supplementary table 1 ).", [["each study", "TEST", 30, 40]]], ["The volume of quantitative data was too small to analyse using statistical methods, but a discussion of descriptive quantitative results was included in the final analysis. (online supplementary table 2) .Conceptualising ill healthThe included studies demonstrate a lack of practical consensus on what constitutes 'too ill to work', 45 particularly when considering short-term illnesses.", [["quantitative data", "TEST", 14, 31], ["statistical methods", "TEST", 63, 82], ["the final analysis", "TEST", 153, 171], ["The included studies", "TEST", 231, 251], ["short-term illnesses", "PROBLEM", 366, 386], ["volume", "OBSERVATION_MODIFIER", 4, 10]]], ["While 11 studies loosely described policies for short-term illnesses, none described what specifically constituted a short-term illness.", [["short-term illnesses", "PROBLEM", 48, 68], ["a short-term illness", "PROBLEM", 115, 135]]], ["Three studies addressed the length of time that an individual could receive payments, 25 46 47 yet failed to elaborate on what happens if their illness exceeds the timeframe.", [["illness", "DISEASE", 144, 151], ["Three studies", "TEST", 0, 13]]], ["Long-term illnesses were more clearly defined, with studies collectively demonstrating a general shift towards using the ICF model when determining the eligibility of applicants.", [["Long-term illnesses", "PROBLEM", 0, 19], ["studies", "TEST", 52, 59], ["a general shift", "PROBLEM", 87, 102], ["the ICF model", "TREATMENT", 117, 130]]], ["[48] [49] [50] However, 27 studies showed that degrees of incapacity remain challenging to categorise objectively, stating that criteria were often inconsistent and unclear.", [["incapacity", "PROBLEM", 58, 68]]], ["22 51 legal protections against illness-induced poverty The majority of LMICs have policies stipulating varying levels of illness-related income protection for sickness, work-related injury or disability .", [["illness", "DISEASE", 32, 39], ["illness", "DISEASE", 122, 129], ["sickness", "DISEASE", 160, 168], ["disability", "DISEASE", 193, 203], ["illness", "PROBLEM", 32, 39], ["illness", "PROBLEM", 122, 129], ["sickness", "PROBLEM", 160, 168], ["injury", "PROBLEM", 183, 189], ["disability", "PROBLEM", 193, 203], ["majority", "OBSERVATION_MODIFIER", 60, 68]]], ["14 In addition, the regional distribution of legal protections varies significantly ( figure 3 ).", [["regional", "OBSERVATION_MODIFIER", 20, 28], ["distribution", "OBSERVATION_MODIFIER", 29, 41], ["legal protections", "OBSERVATION", 45, 62]]], ["While all forms of protection are legally mandated in all European and Central Asian countries, only 17% of countries in sub-Saharan Africa offer the same scope of legal coverage.", [["legal coverage", "TREATMENT", 164, 178]]], ["14 Legal coverage is consistently low across most of Asia, the Pacific and Africa, 14 and does not reflect actual coverage.", [["Legal coverage", "TREATMENT", 3, 17]]], ["For instance, population coverage of injury compensation and 'severe' disability benefits range between 4.8%-100% and 0.1%-100%, respectively.", [["injury", "DISEASE", 37, 43], ["injury compensation", "PROBLEM", 37, 56], ["'severe' disability benefits", "PROBLEM", 61, 89], ["injury", "OBSERVATION", 37, 43], ["severe", "OBSERVATION_MODIFIER", 62, 68]]], ["14 Insufficient financing, ineffective legal enforcement, inadequate health assessments, social inequalities, exclusion of informal workers, a lack of political will and ineffective monitoring or measurement tools were reported as contributing factors towards gaps in coverage.", [["ineffective monitoring", "TEST", 170, 192], ["measurement tools", "TEST", 196, 213]]], ["14 29 However, the level of protection varies significantly across LMICs, both in terms of the benefits offered and the scope of legal coverage.", [["legal coverage", "TREATMENT", 129, 143]]], ["Further, there are discrepancies in coverage even in countries where injury compensation is grounded in national legislation.", [["discrepancies in coverage", "PROBLEM", 19, 44], ["injury compensation", "PROBLEM", 69, 88], ["discrepancies", "OBSERVATION", 19, 32], ["injury", "OBSERVATION", 69, 75]]], ["The protective capacity of social insurance Little data has been identified on the amount paid to people who are sick, injured or have a disability, or if these benefits meet basic needs.", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104], ["protective", "OBSERVATION_MODIFIER", 4, 14], ["capacity", "OBSERVATION_MODIFIER", 15, 23]]], ["Six studies discussed the BMJ Global Health Figure 2 Flow diagram to show each stage of the scoping search process, adapted from the PRISMA statement by Liberati et al. 44 CCT, conditional cash transfer; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; LMIC, low-income and middle-income countries level of pay, stating that replacement rates vary between 'lump sums' and 100% of wages.", [["Six studies", "TEST", 0, 11], ["CCT", "TEST", 172, 175], ["Systematic Reviews", "TEST", 242, 260], ["LMIC", "TEST", 280, 284], ["replacement rates", "TREATMENT", 352, 369]]], ["25 46 47 54 70 Four studies highlighted issues of non-compliance, demonstrating that legal provision does not necessarily reflect real benefits.", [["Four studies", "TEST", 15, 27]]], ["A second factor influencing the protective capacity of social insurance pertains to the length of time that benefits are available for.", [["A second factor", "PROBLEM", 0, 15]]], ["Only two studies report this feature, explaining that payments can span anywhere from a maximum of 7 days to 2 years.", [["two studies", "TEST", 5, 16]]], ["46 Following this, however, there is no information on the support given to those whose illness persists after their insurance entitlements expire.", [["illness", "DISEASE", 88, 95]]], ["The degree of equity in social insurance schemes Results highlight large disparities in the populations that are adequately covered by social insurance.", [["degree", "OBSERVATION_MODIFIER", 4, 10], ["equity", "OBSERVATION_MODIFIER", 14, 20], ["large", "OBSERVATION_MODIFIER", 67, 72], ["disparities", "OBSERVATION_MODIFIER", 73, 84]]], ["52 Injury insurance claimants in Colombia were reported to have claims rejected if the aetiology of their injury was not correctly identified.", [["their injury", "PROBLEM", 100, 112]]], ["69 Additionally, Thailand's system offers greater financial support to those who are able to contribute more towards their insurance, while those who contribute less are only entitled to a small lump sum payment, in place of a sustained income.", [["small", "OBSERVATION_MODIFIER", 189, 194], ["lump", "OBSERVATION", 195, 199]]], ["53 Further, four studies report that employees must have contributed a certain number of work hours, within a specific timeframe, in order to meet the qualifying conditions.Conceptualising ill healthWhile there are differences in entitlements for those who do have legal access to social insurance, there are even greater disparities between those who are, and are not, included in social insurance schemes.", [["four studies", "TEST", 12, 24]]], ["India, 68 Vietnam, 63 China, 62 Thailand, 66 Colombia 69BMJ Global HealthFurther, migrant workers and people with disabilities are more likely to engage in informal work and thus face higher levels of exclusion from social insurance.", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108]]], ["14 27 72-74 Finally, five studies discuss the availability of voluntary insurance schemes for informal workers.", [["five studies", "TEST", 21, 33]]], ["76 This is largely attributed to a lack of awareness of these schemes and the difficulties in raising a surplus income to pay for insurance.", [["these schemes", "PROBLEM", 56, 69]]], ["53 66 77 Contributory schemes: microfinance The features of microfinance Nine studies discussed microfinance schemes which specifically include people who are sick or have a disability in their targeting criteria.", [["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150], ["Nine studies", "TEST", 73, 85]]], ["45 75 78-84 The aim of these schemes is to provide low-interest loans to promote income generating activities for those who cannot participate in full-time employment but still have the capacity to generate an income.", [["the capacity", "PROBLEM", 182, 194]]], ["84 Recipients can choose how their loan is spent, empowering people to start their own business and produce a sustainable income.BMJ Global HealthThe protective capacity of microfinance All included studies viewed microfinance favourably, identifying it as an effective tool in protecting income during periods of ill health.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["microfinance", "TREATMENT", 173, 185]]], ["Three studies reported that access to credit through microfinance schemes was able to smooth consumption in labour-contained households that experienced health shocks.", [["Three studies", "TEST", 0, 13], ["microfinance schemes", "TREATMENT", 53, 73]]], ["45 75 83 Further, microfinance was shown to empower people with disabilities, both economically and socially.", [["disabilities", "DISEASE", 64, 76], ["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["79 The degree of equity of microfinance From a policy perspective, the design of microfinance schemes aims to expand financial protection to underrepresented groups, particularly those with low income, disabilities or who work in informal employment.", [["microfinance schemes", "TREATMENT", 81, 101], ["degree", "OBSERVATION_MODIFIER", 7, 13], ["equity", "OBSERVATION_MODIFIER", 17, 23]]], ["83 While results demonstrate the BMJ Global Health overall positive impacts of microfinance, other studies highlight several factors which contribute towards the exclusion of people with disabilities.", [["people", "ORGANISM", 175, 181], ["people", "SPECIES", 175, 181], ["other studies", "TEST", 93, 106], ["several factors", "PROBLEM", 117, 132]]], ["82 Beisland and Mersland suggest improving the design of microfinance schemes, introducing more flexibility to loan conditions and repayment plans.", [["microfinance schemes", "TREATMENT", 57, 77], ["repayment plans", "TREATMENT", 131, 146]]], ["85 However, microfinance schemes may not be accessible for those with severe impairments.non-contributory schemes: uCTs Features of UCTsThe UCT schemes identified in this review can be divided into two categories: means-tested and non-means-tested schemes (online supplementary figure 1 ).", [["microfinance schemes", "TREATMENT", 12, 32], ["severe impairments", "PROBLEM", 70, 88], ["means", "TEST", 214, 219]]], ["A total of 91 studies identified 70 individual UCTs schemes across 54 countries, finding that 31 (44%) of these schemes targeted general poverty alleviation using a means-tested approach, with disability as a proxy for vulnerability.", [["disability", "DISEASE", 193, 203], ["91 studies", "TEST", 11, 21], ["vulnerability", "PROBLEM", 219, 232]]], ["Meanwhile, the remaining 39 (56%) of schemes were tailored specifically for people with disabilities (online supplementary table 1).", [["disabilities", "DISEASE", 88, 100], ["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82]]], ["A second difference between UCT schemes pertains to the types of assessments used.", [["A second difference between UCT schemes", "PROBLEM", 0, 39], ["assessments", "TEST", 65, 76], ["second", "OBSERVATION_MODIFIER", 2, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["Means-tested schemes generally relied on decentralised assessment protocols, using local community members to determine the eligible individuals and households in the community (online supplementary table 1 ).The protective capacity of UCTsUCTs were reported to reduce financial pressure on households, which in turn, reduced stress levels and improved food security and access to household amenities (table 2) .", [["decentralised assessment protocols", "TREATMENT", 41, 75], ["financial pressure on households", "TREATMENT", 269, 301], ["reduced stress levels", "PROBLEM", 318, 339], ["protective", "OBSERVATION_MODIFIER", 213, 223], ["capacity", "OBSERVATION_MODIFIER", 224, 232]]], ["As such, studies indicate that UCTs could encourage dependency and fail to lift people out of chronic poverty (table 2) .Equity in UCT schemesWhen comparing the entitlements afforded to UCT recipients to the income of the average population, those who receive UCTs receive an income 10 times lower than the average per capita income ( figure 4) .", [["chronic poverty", "DISEASE", 94, 109], ["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["studies", "TEST", 9, 16], ["UCTs", "TREATMENT", 260, 264]]], ["Furthermore, there are significant variations in equity within populations who cannot work due to ill health.", [["significant", "OBSERVATION_MODIFIER", 23, 34], ["variations", "OBSERVATION_MODIFIER", 35, 45]]], ["Severe disability benefits cover from as little as 0.1% up to 100% of the population who have disabilities.", [["disability", "DISEASE", 7, 17], ["Severe disability benefits", "PROBLEM", 0, 26], ["disability", "OBSERVATION", 7, 17]]], ["More significantly, however, the ILO does not have sufficient data on disability benefits in 73% of LMICs, and an absence of data on those with less severe disabilities.", [["disability", "DISEASE", 70, 80], ["less severe disabilities", "PROBLEM", 144, 168]]], ["14 There are many factors which contribute towards poor coverage within populations, and primarily stem from the incorrect inclusion or exclusion of people who experience ill health (online supplementary table 3) .Inclusion errorsSeven studies provided results on inclusion errors, which is a phenomenon whereby income support is provided to individuals who are not eligible for the scheme.", [["people", "ORGANISM", 149, 155], ["people", "SPECIES", 149, 155], ["Inclusion errorsSeven studies", "TEST", 214, 243]]], ["20 104 122-126 BMJ Global Health Figure 4 Maximum amount of disability/sickness benefits available to eligible unconditional cash transfer (UCT) recipients per month, compared with the National average monthly per capita income (GDP per capita PPP) in selected low-income and middle-income countries (presented using a logarithmic scale 120 121 LICs, low-income countries; MICs, middle-income countries; GDP, gross domestic product; PPP, purchasing power parity Mitra 109 reported a 34% inclusion error rate in South Africa, attributing this to the wrongful inclusion of persons without disabilities during the assessment process.", [["disability/sickness", "DISEASE", 60, 79], ["persons", "ORGANISM", 571, 578], ["persons", "SPECIES", 571, 578], ["sickness", "PROBLEM", 71, 79], ["a logarithmic scale", "TEST", 317, 336], ["the assessment process", "TEST", 607, 629]]], ["109 Two studies report that some healthcare workers believe that they encounter large numbers of people who fabricate or exaggerate symptoms.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103], ["Two studies", "TEST", 4, 15], ["exaggerate symptoms", "PROBLEM", 121, 140]]], ["[123] [124] [125] [126] Exclusion errors Exclusion errors featured more prominently in the results of this review, with 46 studies discussing the circumstances in cases where eligible individuals were not in receipt of income support (online supplementary table 3) .", [["individuals", "ORGANISM", 184, 195], ["Exclusion errors", "PROBLEM", 24, 40]]], ["Sixty-one studies identified that 24 factors, reported in 29 countries, contributed towards high exclusion errors (online supplementary table 3 ).", [["high exclusion errors", "PROBLEM", 92, 113]]], ["These errors were attributed to stigma, costs in applying for income protection, failures in the assessment process and the complexity of applying.", [["stigma", "PROBLEM", 32, 38], ["income protection", "TREATMENT", 62, 79], ["failures", "PROBLEM", 81, 89], ["the assessment process", "TEST", 93, 115], ["attributed to", "UNCERTAINTY", 18, 31], ["stigma", "OBSERVATION", 32, 38]]], ["Further, structural barriers also contributed toward exclusion errors, including problems of underfunding, poorly organised administration, corruption and the systemic exclusion of marginalised groups (online supplementary table 3) .Moral hazardIndividuals may be less likely to safeguard against risks when protected from their consequences.", [["exclusion errors", "PROBLEM", 53, 69], ["Moral hazardIndividuals", "PROBLEM", 233, 256]]], ["128 129 Several studies speculate that recipients of South Africa's Disability Grant alter their behaviour when insured, leading to moral hazard.", [["Several studies", "TEST", 8, 23]]], ["One study hypothesised that financial support impacted adherence to antiretroviral therapy (ART), leading people to 'stay sick' in order to receive an income.", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["One study", "TEST", 0, 9], ["antiretroviral therapy", "TREATMENT", 68, 90]]], ["98 However, Woolgar and Mayers 23 found that recipients would remain adherent to ART despite the risk of losing a grant.", [["recipients", "ORGANISM", 45, 55]]], ["22 23 Additionally, M\u00f8ller's investigation of this 'perverse incentive' for youth to contract tuberculosis was inconclusive.", [["tuberculosis", "DISEASE", 94, 106], ["tuberculosis", "PROBLEM", 94, 106], ["tuberculosis", "OBSERVATION", 94, 106]]], ["96 Lastly, respondents in South Africa stated that finding work was considered preferable to receiving a social grant, 107 112 with Goudge and Ngoma 93 adding that, while people can get sick after losing the grant, poverty and malnourishment may instead be the cause of ex-recipients' deterioration in health.", [["poverty", "DISEASE", 215, 222], ["malnourishment", "DISEASE", 227, 241], ["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177], ["ex-recipients' deterioration in health", "PROBLEM", 270, 308]]], ["However, a significant number of limitations remain.", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["number", "OBSERVATION_MODIFIER", 23, 29]]], ["Indeed, while a number of weaknesses are associated with specific policies, the patterns and themes uncovered in this review provide a collective insight into the landscape of social protection and reveal systemic barriers that inhibit the efficacy and equity of protective interventions.Protective capacity of income securityThere is very limited evidence on whether income support in its present form meets the needs of the claimant.", [["social protection", "TREATMENT", 176, 193], ["systemic barriers", "TREATMENT", 205, 222], ["protective interventions", "TREATMENT", 263, 287]]], ["125 Research on UCTs and microfinance has garnered the most research, indicating strengths and weaknesses in the level of income support provided.", [["microfinance", "TREATMENT", 25, 37]]], ["Nine studies on 10 countries reported that UCT programmes were underfunded and resulted in inadequate support and long delays in payments (online supplementary table 3 ).", [["Nine studies", "TEST", 0, 12]]], ["Studies on microfinance demonstrated that it can protect against financial shocks.", [["Studies on microfinance", "TEST", 0, 23]]], ["81 83 However, this draws on a small sample of nine studies, and cannot be reflective of all schemes.Protective capacity of income securityResearch on sickness benefits, injury compensation and general social insurance is even more inconclusive, largely owing to the absence of data on the subject.", [["nine studies", "TEST", 47, 59], ["injury compensation", "PROBLEM", 170, 189]]], ["While the ILO present data on legal coverage, little is known on the level of payments that are made, and whether payments meet the level of need.", [["legal coverage", "TREATMENT", 30, 44]]], ["Indeed, the ILO concede that there is no effective monitoring in place to see for example if injured workers are effectively compensated by their employers.", [["no", "UNCERTAINTY", 38, 40], ["effective", "OBSERVATION_MODIFIER", 41, 50]]], ["Ultimately, therefore, further research is needed to understand the sufficiency of protective measures relating to sickness benefits, injury compensation, social insurance in general and UCTs.equity in income securityBeginning from a policy perspective, the eligibility criteria establishes a fragmented picture, leaving gaps in coverage for those in need.", [["protective measures", "TREATMENT", 83, 102], ["sickness benefits", "PROBLEM", 115, 132], ["injury compensation", "PROBLEM", 134, 153], ["a fragmented picture", "PROBLEM", 291, 311], ["fragmented", "OBSERVATION_MODIFIER", 293, 303]]], ["For instance, those suffering from short-term illnesses are heavily reliant on social insurance schemes, yet those who are informally employed cannot always access these privileges.", [["short-term illnesses", "PROBLEM", 35, 55]]], ["Herein lies the first gap, which separates the short-term health entitlements of those with and without basic workers\u2032 rights.equity in income securityBuilding on this, the distinction between short-term and long-term illness seems to have been universally ignored in policy-making spaces, leaving an absence of any universal standard that defines these states of being.", [["illness", "DISEASE", 218, 225], ["long-term illness", "PROBLEM", 208, 225]]], ["This conclusion does not mean to negate the value of the ICF model, 19 yet, in practice, the fragmented nature of income security policies has ruptured the spectrum on which ill health occurs, boxing short-term and long-term illnesses into separate, yet blurred, policy spaces.", [["long-term illnesses", "PROBLEM", 215, 234], ["fragmented", "OBSERVATION_MODIFIER", 93, 103], ["long-term", "OBSERVATION_MODIFIER", 215, 224], ["blurred", "OBSERVATION", 254, 261]]], ["This is most evident in the context of UCTs, which primarily aim to protect the most vulnerable in society.", [["most evident", "UNCERTAINTY", 8, 20], ["most", "OBSERVATION_MODIFIER", 80, 84], ["vulnerable", "OBSERVATION_MODIFIER", 85, 95], ["society", "OBSERVATION", 99, 106]]], ["However, this review has shown the application process of obtaining income support can be a slow, confusing and time-consuming process, with conflicting interpretations made by healthcare professionals on who is eligible for support.", [["income support", "TREATMENT", 68, 82], ["a slow, confusing", "PROBLEM", 90, 107]]], ["Those who have short-term illnesses, work informally, are typically poorer and in greater need of income support, are, in practice, ineligible for UCTs owing to the time it takes to apply.", [["short-term illnesses", "PROBLEM", 15, 35]]], ["Within this time, they may have recovered from their illness but are left burdened financially, owing to lost wages in the time it has taken to recover.equity in income securityThe third gap pertains exclusively to long-term illnesses, which in many contexts, remains equally fragmented.", [["long-term illnesses", "PROBLEM", 215, 234], ["left", "ANATOMY_MODIFIER", 69, 73], ["third", "OBSERVATION_MODIFIER", 181, 186], ["gap", "OBSERVATION", 187, 190], ["long-term", "OBSERVATION_MODIFIER", 215, 224], ["illnesses", "OBSERVATION", 225, 234], ["equally", "OBSERVATION_MODIFIER", 268, 275], ["fragmented", "OBSERVATION", 276, 286]]], ["For instance, some UCTs require a minimum length of time before a person is deemed to have a disability, regardless of their medical diagnosis.", [["disability", "DISEASE", 93, 103], ["UCTs", "CANCER", 19, 23], ["person", "SPECIES", 66, 72]]], ["14 47 Other schemes have what is effectively an 'expiry date' whereby individuals lose their welfare entitlements after a certain number of years.", [["individuals", "ORGANISM", 70, 81]]], ["66 Further, many countries exclude potential recipients, either on the basis of the type of illness or the severity.", [["illness", "DISEASE", 92, 99], ["recipients", "ORGANISM", 45, 55], ["illness", "PROBLEM", 92, 99], ["the severity", "PROBLEM", 103, 115], ["illness", "OBSERVATION", 92, 99]]], ["14 36 114 115 130 Lastly, of the 70 UCT schemes identified in this review, 49 (70%) stipulated that a claimant with a disability must already live in poverty (online supplementary material 1; 113-115 131 132 ).", [["disability", "DISEASE", 118, 128]]], ["Here again, gaps emerge, with people experiencing a moderate degree of incapacity and those vulnerable to poverty, being excluded from income security schemes.", [["poverty", "DISEASE", 106, 113], ["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["a moderate degree of incapacity", "PROBLEM", 50, 81], ["moderate degree", "OBSERVATION_MODIFIER", 52, 67], ["incapacity", "OBSERVATION", 71, 81]]], ["Consequently, several studies highlight the importance of diversifying income security programmes, to offer a range of incomesupporting and income-generating options, which meet the needs of a broader pool of recipients.", [["recipients", "ORGANISM", 209, 219], ["several studies", "TEST", 14, 29]]], ["22 23 99 133 134 This study presents several limitations.", [["This study", "TEST", 17, 27]]], ["First, by excluding studies that are not published in English, this study cannot claim to include all relevant literature on this topic.", [["studies", "TEST", 20, 27], ["this study", "TEST", 63, 73]]], ["Second, manually reviewing the data increases the risk of human error, meaning that relevant literature may have been overlooked.", [["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["human error", "PROBLEM", 58, 69], ["human error", "OBSERVATION", 58, 69]]], ["39 The use of a formalised scoping review aimed to mitigate this risk and the iterative nature of a scoping review allows for the expansion of the search parameters.", [["a formalised scoping", "TREATMENT", 14, 34], ["a scoping review", "TEST", 98, 114]]], ["Although this investigation has included non-peer-reviewed studies, any unqualified statements have been noted and compared with similar studies, to illustrate inconsistencies.", [["this investigation", "TEST", 9, 27], ["similar studies", "TEST", 129, 144]]], ["Lastly, the data extracted from this body of research derive from a variety of contexts.", [["the data", "TEST", 8, 16]]], ["Therefore, the data in this review are not standardised in nature, nor can individual studies provide exact answers to our research questions.", [["the data", "TEST", 11, 19]]], ["In doing so, it has identified significant inequalities in the level of income support and coverage across and within LMICs, specifically in regard to sickness benefits, injury compensation, social insurance, microfinance and UCTs.", [["UCTs", "DISEASE", 226, 230], ["income support", "TREATMENT", 72, 86], ["injury compensation", "PROBLEM", 170, 189], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["inequalities", "OBSERVATION", 43, 55]]], ["14 This review demonstrates the BMJ Global Health need for a greater understanding of the circumstances of those who cannot work due to ill heath, to improve the equity and coverage of income security in LMICs.ConClusIonThe small number of studies in LMICs is in itself a significant finding, showing that the topic has received very limited attention in countries where it is of major importance.", [["ill heath", "PROBLEM", 136, 145], ["small", "OBSERVATION_MODIFIER", 224, 229], ["number", "OBSERVATION_MODIFIER", 230, 236], ["significant", "OBSERVATION_MODIFIER", 272, 283]]], ["Moving forward, further research is crucial in contributing towards a better understanding of how to reach the SDGs, particularly goals 1, 3, 8 and 10, which advocate for the eradication of poverty, good health and well-being, decent work and reduced inequalities.", [["poverty", "DISEASE", 190, 197]]], ["1 More specifically, further investigation into coverage, protective effects, equity and operational challenges must involve the study of all forms of sickness-related income loss and account for the changing landscape of global health and labour market transition.", [["sickness", "DISEASE", 151, 159], ["income loss", "DISEASE", 168, 179], ["further investigation", "TEST", 21, 42], ["operational challenges", "TREATMENT", 89, 111], ["the study", "TEST", 125, 134], ["sickness", "PROBLEM", 151, 159], ["income loss", "PROBLEM", 168, 179]]], ["135 In order to foster intersectoral approaches for financial risk protection for people struck by ill health, research on income security needs to become a more visible part of the UHC research and policy agenda.", [["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88], ["financial risk protection", "TREATMENT", 52, 77]]], ["Without valuable input from the health sector, the true understanding of illness-related costs and the corresponding scalability, equity and fiscal space to develop protective interventions will remain limited.ConClusIonUltimately, more research in this field could inform a number of evidence-based interventions, including better enforcement of labour regulations, improving access to social insurance, developing more diverse or integrated contributory and non-contributory schemes, and improving rehabilitation and work opportunities for people with disabilities.", [["illness", "DISEASE", 73, 80], ["people", "ORGANISM", 542, 548], ["people", "SPECIES", 542, 548], ["illness", "PROBLEM", 73, 80], ["the corresponding scalability", "PROBLEM", 99, 128], ["protective interventions", "TREATMENT", 165, 189], ["based interventions", "TREATMENT", 294, 313], ["labour regulations", "TREATMENT", 347, 365]]]]}